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Abstract 
 
In 2015, an estimated 46.8 million people were living with dementia, a number predicted to increase to 
74.7 million by 2030 and 131.5 million by 2050.  Whilst there are numerous causes for the development 
of dementia, Alzheimer’s disease is by far the most common, accounting for approximately 50-70% of all 
cases. Current therapeutic agents against Alzheimer’s disease are palliative in nature, managing 
symptoms without addressing the underlying cause and thus disease progression and patient death 
remain a certainty. Whilst the main underlying cause for the development of Alzheimer’s disease was 
originally thought to be an abnormal deposition of insoluble amyloid-β peptide derived plaques within 
the brain, the failure of several high-profile therapeutic agents, which were shown to reduce the plaque 
burden without improving cognition, has recently prompted a shift in focus to soluble oligomeric forms 
of amyloid-β peptide. Such soluble oligomers have been shown to be toxic in their own right and to 
precede plaque deposition. Soluble amyloid-β oligomers have been identified in various subcellular 
compartments, including the mitochondria, where they form a complex with the 17β-HSD10 enzyme 
resulting in cytotoxicity. Interestingly, hallmarks of this toxicity have been shown to be dependent on the 
catalytic activity of the 17β-HSD10 enzyme, suggesting two therapeutic approaches may hold merit in 
treating Alzheimer’s disease: disrupting the interaction between the 17β-HSD10 enzyme and amyloid-β 
peptide, or directly inhibiting the catalytic activity of the 17β-HSD10 enzyme. In 2006, Frentizole was 
identified as a small molecule capable of disrupting the 17β-HSD10/amyloid interaction.  
The work described herein details the generation of a robust screening assay allowing the catalytic activity 
of the 17β-HSD10 enzyme to be measured in vitro. This assay was subsequently employed for small 
molecule screening using two methodologies; first in a targeted approach using compounds derived from 
the Frentizole core scaffold, and second in an explorative manner using a diverse library of compounds 
supplied by the National Cancer Institute. As a result, a range of novel small molecule inhibitors of the 
17β-HSD10 enzyme have been identified and the most promising characterised in terms of potency and 
mechanism of action. De-selection assays were developed to allow the efficient triage of hit compounds 
and work was begun on a cellular based assay which would allow the ability of compounds of interest to 
reverse a disease relevant phenotype to be assessed in a cellular environment. 
As such, we now have a number of hit compounds which will form the basis for the generation of 
subsequent series of derivatives with improved potency and specificity, as well as the robust assays 
required to measure such criteria, potentially leading to the generation of novel therapeutic agents 
against Alzheimer’s disease. 
  
 8 
 
 
 
  
Table of Contents 
9 
 
 
Acknowledgements ...................................................................................................................................... 5 
Abstract ........................................................................................................................................................ 7 
Abbreviations ............................................................................................................................................. 15 
Chapter 1: Introduction .............................................................................................................................. 19 
1.1 Neuropathology of Alzheimer’s Disease .......................................................................................... 20 
Amyloid Beta-Peptide: ....................................................................................................................... 22 
Tau Protein ........................................................................................................................................ 26 
1.2 The Genetics of Alzheimer’s Disease ............................................................................................... 27 
Early-Onset Alzheimer’s Disease (EOAD) ........................................................................................... 27 
Late-Onset Alzheimer’s Disease (LOAD) ............................................................................................ 28 
1.3 The Amyloid Cascade Hypothesis and Therapeutic Intervention .................................................... 32 
1.31 Approved Therapeutic Agents: .................................................................................................. 34 
NMDA Receptor Antagonists: ....................................................................................................... 34 
Acetylcholinesterase Inhibitors: .................................................................................................... 37 
1.32 Non-approved Therapeutic Agents............................................................................................ 40 
β-secretase and γ-secretase Inhibitors.......................................................................................... 40 
Aβ Aggregation Inhibitors ............................................................................................................. 42 
Aβ Directed Immunotherapy......................................................................................................... 43 
1.4 Soluble Aβ and 17β-Hydroxysteroid Dehydrogenase Type 10 ......................................................... 46 
1.41 Soluble Aβ .................................................................................................................................. 46 
1.42 17β-HSD10 ................................................................................................................................. 47 
Summary: ............................................................................................................................................... 62 
Project Aims: .......................................................................................................................................... 64 
Chapter 2: Materials and Methods ............................................................................................................ 65 
Section 1: Molecular Cloning ................................................................................................................. 66 
1.01 Competent Cell Generation: ...................................................................................................... 66 
1.02 Heat-Shock Transformation: ...................................................................................................... 66 
1.03 Glycerol Stock Preparation: ....................................................................................................... 67 
1.04 Plasmid DNA Isolation:............................................................................................................... 67 
1.05 Restriction Digest: ...................................................................................................................... 67 
1.06 Agarose Gel Electrophoresis: ..................................................................................................... 67 
1.07 DNA Gel Extraction: ................................................................................................................... 67 
1.08 Ligation: ..................................................................................................................................... 68 
1.09 Diagnostic Digest: ...................................................................................................................... 68 
1.10 General PCR: .............................................................................................................................. 68 
1.11 Site Directed Mutagenesis: ........................................................................................................ 68 
1.12 Ligation Independent Cloning (LIC): ........................................................................................... 69 
Table of Contents 
10 
 
1.13 cDNA Cloning: ............................................................................................................................ 69 
M-MLV Reverse-Transcriptase: ..................................................................................................... 69 
AMV Reverse-Transcriptase: ......................................................................................................... 69 
Section 2: Protein Purification ............................................................................................................... 71 
2.1 SDS-PAGE: .................................................................................................................................... 71 
2.2 Coomassie Blue Staining: ............................................................................................................. 71 
2.3 Small-Scale Expression Optimisation: .......................................................................................... 71 
2.4 Tobacco Etch Virus Protease (S219V) Purification: ...................................................................... 72 
2.5 17β-HSD8, 17β-HSD10 and 17β-HSD14 Purification:................................................................... 73 
Section 3: Recombinant Enzyme Assays ................................................................................................ 75 
3.1 17β-HSD10 ................................................................................................................................... 75 
3.11 Michaelis-Menten Kinetics: ................................................................................................... 75 
3.12 DMSO Titration: ..................................................................................................................... 75 
3.13 Small Molecule Screening: .................................................................................................... 76 
3.14 Dose Response Experiments: ................................................................................................ 76 
3.15 Mechanism of Inhibition Experiments: ................................................................................. 76 
3.16 Small Molecule Aggregation Test: ......................................................................................... 77 
3.17 Reversible/Irreversible Inhibition Test: ................................................................................. 77 
3.18 NCI Diversity IV Screening Assay: .......................................................................................... 77 
3.2 17β-HSD8 and 17β-HSD14 ........................................................................................................... 77 
3.21 17β-HSD8 Activity Test: ......................................................................................................... 77 
3.22 17β-HSD14 Activity Test: ....................................................................................................... 78 
3.23 17β-HSD8 Michaelis-Menten Kinetics: .................................................................................. 78 
3.24 17β-HSD14 Michaelis-Menten Kinetics: ................................................................................ 78 
3.25 17β-HSD8 Small Molecule Screening: ................................................................................... 79 
3.26 17β-HSD14 Small Molecule Screening: ................................................................................. 79 
Section 4: Differential Scanning Fluorimetry ......................................................................................... 80 
4.1 Differential Scanning Fluorimetry Assay Optimisation: ............................................................... 80 
4.2 NADH Titration:............................................................................................................................ 80 
4.3 NAD+ Titration: ............................................................................................................................. 80 
4.4 Acetoacetyl-CoA Titrations: ......................................................................................................... 81 
4.5 Small Molecule Screening: ........................................................................................................... 81 
4.6 Amyloid-beta Peptide: ................................................................................................................. 81 
4.7 17β-HSD10/Aβ Interaction Western Blot .................................................................................... 81 
Section 5: Cell Culture ............................................................................................................................ 83 
5.01 Culture Media: ........................................................................................................................... 83 
5.02 Foetal Bovine Serum (FBS) Heat Inactivation: ........................................................................... 83 
Table of Contents 
11 
 
5.03 Cryogenic Storage of Cell Lines: ................................................................................................. 83 
5.04 Thawing of Cryogenically Stored Cell Lines: .............................................................................. 83 
5.05 Lactate Dehydrogenase (LDH) Assay: ........................................................................................ 84 
5.06 HEK293 Polyethylenimine (PEI) Transfection: ........................................................................... 84 
5.07 SH-SY5Y Nucelofection: ............................................................................................................. 84 
5.08 Enzyme Activity in Cell Lysates: ................................................................................................. 85 
5.09 Stable Cell Line Generation:....................................................................................................... 85 
5.10 Cell Lysate Generation: .............................................................................................................. 85 
5.11 Generalised Western Blot: ......................................................................................................... 86 
Chapter 3: 17β-HSD10 Assay Development and Small Molecule Screening .............................................. 87 
3.01 Protein Purification: ....................................................................................................................... 89 
3.02 Activity Assay Development: .......................................................................................................... 94 
3.03 Michaelis-Menten Kinetics: ............................................................................................................ 97 
3.04 DMSO Titration: ............................................................................................................................. 98 
3.05 Assay Validation: AG18051 Dose-Response and Z-Factor calculation ........................................... 99 
3.06 Frentizole Derivatives - Initial Screens: ........................................................................................ 101 
3.07 K690, K691 and K801 Dose-Response Curves: ............................................................................. 108 
3.08 K690 and K691 Mechanism of Inhibition: .................................................................................... 111 
3.09 K690 and K691 Small Molecule Aggregation Test: ....................................................................... 116 
3.10 K690, K691 and AG18051 - Reversible/Irreversible Inhibition ..................................................... 117 
3.11 Frentizole Derivatives - Differential Scanning Fluorimetry .......................................................... 118 
3.12 Quantifying The 17β-HSD10-Aβ Interaction ................................................................................ 125 
3.13 NCI Diversity IV Initial Screen: ...................................................................................................... 128 
17796 Analogues .................................................................................................................................. 131 
88402 Analogues .................................................................................................................................. 136 
Chapter 3 - Discussion .......................................................................................................................... 137 
Chapter 4: Inhibitor Specificity - Molecular Cloning and Purification of 17β-HSD8 and 17β-HSD14 ....... 145 
4.1: 17β-HSD8 and 17β-HSD14 cDNA Cloning ..................................................................................... 147 
4.11 peHISTEV-HSD8 ........................................................................................................................ 147 
4.12 peHISTEV-HSD14 ...................................................................................................................... 152 
4.2: 17β-HSD8 and 17β-HSD14 Protein Expression ............................................................................. 156 
4.21 Whole Cell Lysates: .................................................................................................................. 156 
4.22 Optimisation of E. coli Cell Lysis: ............................................................................................. 157 
4.23 Recombinant 17β-HSD8 and 17β-HSD14 Solubility Assessment ............................................. 159 
4.24 17β-HSD8-Maltose Binding Protein Fusion ............................................................................. 161 
4.25 17β-HSD14: Large-Scale Purification ....................................................................................... 165 
4.26 17β-HSD8: Large-Scale Purification: ........................................................................................ 168 
4.27 Purified Protein Concentration Check: .................................................................................... 172 
Table of Contents 
12 
 
4.3 17β-HSD8 and 17β-HSD14 Recombinant Enzyme Assays: ............................................................. 173 
4.31 Initial Activity Tests .................................................................................................................. 173 
4.32 Michaelis-Menten Kinetics ...................................................................................................... 175 
4.33 Inhibitor Screening 17β-HSD10, 17β-HSD8 and 17β-HSD14 .................................................... 177 
Chapter 4 - Discussion: ......................................................................................................................... 178 
Chapter 5: Development of a 17β-HSD10 Driven Cellular AD Model ....................................................... 183 
5.1 Mammalian 17β-HSD10 Inhibition ................................................................................................. 185 
5.2 Inhibitor Toxicity ............................................................................................................................ 186 
5.3 17β-HSD10 Site-Directed Mutagenesis: ......................................................................................... 188 
Q165H Mutant ................................................................................................................................. 189 
Y168G Mutant .................................................................................................................................. 189 
5.4:  17β-HSD10 Mutant Characterisation ........................................................................................... 190 
5.41 Mutant 17β-HSD10 Expression ................................................................................................ 190 
5.42 Mutant 17β-HSD10 Enzymatic Activity .................................................................................... 191 
5.5 APP Transfection Optimisation ...................................................................................................... 193 
5.6 HEK293 ........................................................................................................................................... 194 
5.61 HEK293 17β-HSD10 Stable Cell Line Generation ..................................................................... 194 
5.62 HEK293 17β-HSD10 Stable Cell Lines + APP - 4-HNE Western Blot: ........................................ 195 
5.7 SH-SY5Y Dual Stable Cell Line Generation ...................................................................................... 196 
Chapter 5 - Discussion: ......................................................................................................................... 201 
Chapter 6 - Final Discussion and Future Perspectives .............................................................................. 205 
References ................................................................................................................................................ 210 
Appendix: ................................................................................................................................................. 227 
Appendix A: Protein Mass Spectrometry ............................................................................................. 227 
17β-HSD10 Mass Spectrometry ....................................................................................................... 227 
17β-HSD8 Mass Spectrometry ......................................................................................................... 228 
17β-HSD14 Mass Spectrometry ....................................................................................................... 229 
Appendix B: DNA Construct Sequencing .............................................................................................. 230 
pcDNA3-HSD10: ............................................................................................................................... 230 
pcDNA3-HSD10: Q165H Mutation ................................................................................................... 232 
pcDNA3-HSD10: Y168G Mutation.................................................................................................... 234 
pcDNA4-APPswe .............................................................................................................................. 236 
peHISTEV-HSD10 .............................................................................................................................. 241 
peHISTEV-HSD14 .............................................................................................................................. 243 
pET-MBP-HSD8 (Codon Optimised) ................................................................................................. 245 
Appendix C: Compound Synthesis and NMR ....................................................................................... 247 
Synthesis Methodology ................................................................................................................... 247 
Series 1: K684-K711 ......................................................................................................................... 248 
Table of Contents 
13 
 
Series 2: K795-K805 ......................................................................................................................... 255 
Appendix D: NCI Diversity IV Hits ......................................................................................................... 258 
Appendix E: 17β-HSD14 Rare-Codons .................................................................................................. 261 
Appendix F: Publications ...................................................................................................................... 262 
  
 14 
 
 
 
  
Abbreviations 
15 
 
Abbreviations 
 
17β-HSD10 = 17β-Hydroxysteroid dehydrogenase type 10 
17β-HSD14 = 17β-Hydroxysteroid dehydrogenase type 14 
17β-HSD8 = 17β-Hydroxysteroid dehydrogenase type 8 
4-HNE = 4-hydroxynoneal 
ABAD = Amyloid-binding alcohol dehydrogenase 
ABAD-DP = Amyloid-binding alcohol dehydrogenase decoy peptide 
ABAD-RP = Amyloid-binding alcohol dehydrogenase reverse peptide 
AChE = Acetylcholinesterase 
AD = Alzheimer’s disease 
ADAS-cog = Alzheimer’s Disease Assessment Scale - Cognitive Subscale 
ADDL = Amyloid-beta derived diffusible ligands 
ADSC-ADL = Alzheimer’s Disease Cooperative Study - Activity of Daily Living Inventory  
AICD = Amyloid intracellular domain 
AMPA receptor = α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
AMV Reverse Transcriptase = Avian myeloblastosis virus reverse transcriptase  
Apo-E = Apolipoprotein E 
APP = Amyloid precursor protein 
APPswe = Swedish mutation of the amyloid precursor protein 
Aβ = Amyloid beta-peptide 
BCA Assay = Bicinchoninic acid assay 
bp = Basepair 
BSA = Bovine serum albumin 
CAT = Choline acetyltransferase  
cDNA = Complementary DNA 
CNS = Central nervous system 
COX8 = Cytochrome c oxidase subunit VIII 
CSF = Cerebrospinal fluid 
dCTP/dGTP = Deoxycytidine triphosphate/ deoxyguanosine triphosphate 
DMSO = Dimethyl sulfoxide 
DSF = Differential scanning fluorimetry  
DTT = Dithiothreitol 
Abbreviations 
16 
 
E. coli = Escherichia coli 
ECM = Extracellular matrix 
EDTA = Ethylenediaminetetraacetic acid 
ELISA = Enzyme-linked immunosorbent assay 
EOAD = Early-onset Alzheimer’s disease 
FAD = Familial Alzheimer’s disease 
FBS = Foetal bovine serum 
FDA = Food and Drug Administration 
GST-tag = Glutathione S-transferase-tag 
HFIP = Hexafluoroisopropanol 
His-tag = Histidine-tag 
HSD10 = 17β-HSD10 
HSD14 = 17β-HSD14 
HSD8 = 17β-HSD8 
IC50 = Concentration required for 50% inhibition of target 
IPTG = Isopropyl β-D-1-thiogalactopyranoside 
kb = Kilobase 
kDa = Kilodalton 
Km = Substrate concentration for half-maximal rate of reaction 
LDH = Lactate Dehydrogenase 
LDL receptor = Low density lipoprotein receptor 
LIC = Ligation independent cloning 
LOAD = Late-onset Alzheimer’s disease 
LTD = Long-term depression 
LTP = Long-term potentiation 
mAPP = Mutant amyloid precursor protein (generating elevated Aβ) 
MBP = Maltose-binding protein 
MBP-HSD8 = 17β-HSD8-Maltose-Binding Protein Fusion 
MHBD Deficiency = 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency 
M-MLV Reverse Transcriptase = Moloney murine leukemia virus reverse transcriptase  
MMSE = Mini-Mental State Examination 
MRI = Magnetic resonance imaging 
mRNA = Messenger RNA 
Abbreviations 
17 
 
mtRNase P = Mitochondrial ribonuclease P 
MTT = 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
MWCO = Molecular weight cut-off 
NAD+ = β-Nicotinamide adenine dinucleotide 
NADH = β-Nicotinamide adenine dinucleotide, reduced 
NCI = National Cancer Institute 
NFDM = Non-fat dried milk 
NMDA receptor = N-methyl-D-aspartate receptor   
PCR = Polymerase chain reaction 
PDAPP Mice = V717F mutation of the amyloid precursor protein 
PEI = Polyethylenimine 
PiB-PET = Pittsburgh compound B based positron emission tomography 
PSEN = Presenilin 
RCSB-PDB = Research Collaboratory for Structural Bioinformatics - Protein Data Bank 
ROS = Reactive oxygen species 
SDM = Site directed mutagenesis 
SDR Family = Short-chain dehydrogenase/reductase family  
SDS-PAGE = Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SIB = Severe Impairment Battery 
SOC = Super optimal broth with catabolite repression 
TEV = Tobacco etch virus 
Tg257APP Mice = Swedish mutation of the amyloid precursor protein 
Tm = Protein denaturation temperature 
pcDNA4/TO = Mammalian expression vector with tetracycline operator mediated control of expression 
pcDNA6/TR = Mammalian expression vector harbouring the tetracycline repressor protein 
tRNA = Transfer RNA 
VLDL receptor = Very low density lipoprotein receptor 
Vmax = Maximum rate of reaction 
  
 18 
 
 
  
Chapter 1: Introduction 
19 
 
 
 
Chapter 1: Introduction 
 
 
  
Chapter 1: Introduction 
20 
 
1.1 Neuropathology of Alzheimer’s Disease 
With advancing age there is a well-recognised trend towards decreased cognitive function. In most 
individuals this decline is gradual and mild, however in others it is markedly more pronounced, interfering 
with the ability to perform everyday tasks, a condition termed senile dementia. Whilst numerous 
disorders can underlie the development of senile dementia, Alzheimer’s disease (AD) is by far the most 
common accounting for 50-70% of all cases (Figure 1.01)1,2. 
 
In 2015, there were an estimated 46.8 million people worldwide living with dementia, with an associated 
cost to the global economy of an estimated $818 billion3. With the global trend towards an aging 
population, the number of people with dementia is predicted to increase to 74.7 million by 2030 and 
131.5 million by 20503. When these facts are taken together, it is apparent that dementia and thus 
Alzheimer’s disease, represent a global problem both financially and in terms of patient suffering, which 
is likely to get significantly worse in the near future. Current therapeutic agents against AD are palliative 
in nature; managing symptoms without addressing the underlying cause and thus patient deterioration 
and death remain a certainty. As such, there is a clear and present need for improved therapeutic agents 
to treat Alzheimer’s disease.  
In 1907, Alois Alzheimer undertook the histological examination of the brain of a 51-year-old patient 
presenting with an atypical dementia, leading to the identification of the disease which would 
subsequently bear his name4. Clinically, AD is characterised by a progressive neurodegenerative 
phenotype, with a marked impairment of episodic memory being the characteristic lesion associated with 
the disease5. Following disease progression, additional higher-order cognitive abilities are also perturbed 
Figure 1.01 Prevalence of individual causes of senile dementia. Whilst numerous disorders can generate the clinical 
symptoms of dementia, Alzheimer’s disease is by far the most common accounting for an estimated 62% of cases. 
Data taken from Alzheimer’s Society, 2014 dementia infographic1. 
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leading to executive dysfunction, apraxia and visuospatial dysgnosia5. Patient prognosis is variable, 
showing a strong age dependency, but death typically occurs within 8-10 years of diagnosis6. Following 
post-mortem examination, Alois Alzheimer reported a generalised atrophy of the brain and, using the 
Bielschowsky silver staining methodology, an abnormal accumulation of intracellular fibrillar structures 
alongside similar extracellular deposits, presumed to be the remains of degenerating neuronal cells, 
together termed neurofibrillary tangles (NFTs)4. Concomitantly, it was noted that distributed throughout 
the cortex were additional abnormal foci, later to be termed senile plaques. Subsequently, in 1968, 
Blessed et al. showed for the first time an association between plaque burden and cognitive impairment, 
indicating causation7.  
Senile plaques (Figure 1.02, a8) can be divided into two subtypes, termed diffuse plaques and dense-cored 
plaques. Diffuse plaques are amorphous in nature and are not stained by beta-sheet labelling dyes, 
Thioflavin-S or Congo Red, whereas dense-cored plaques stain positively with the aforementioned 
agents5. Diffuse plaques are not typically associated with dystrophic neurites, synaptic loss or activated 
microglia and are commonly observed in the brains of non-demented individuals indicating that they may 
not in of themselves be a toxic species5,9. Conversely, dense-cored plaques are associated with dystrophic 
neurites, neuronal loss, synaptic loss and an activation of the immune response in the form of activated 
microglia and astrocytes, indicating that this form of amyloid deposit may play a role in the pathogenesis 
of AD5,10-13. 
Similarly, NFT’s (Figure 1.02, b8) can be subdivided into pre-NFT’s, mature NFTs and ghost NFTs based 
upon their appearance following histological analysis5. Pre-NFTs appear as diffuse or punctate staining 
within the cytoplasm of otherwise healthy appearing neurons5. Mature-NFTs are larger and more 
pronounced in nature and are often seen to displace the nucleus of the cell to the outer edge of the 
cytoplasm and extend into abnormal appearing dendrites5. Ghost NFT’s are extracellular deposits of 
hyperphosphorylated tau protein which are thought to represent the remnants of neurons which have 
previously been lost5. 
The temporal and spatial deposition of senile plaques and NFTs within the AD brain shows a characteristic 
pattern of distribution.  
Thal staging describes the deposition of senile plaques within the AD brain and is composed of 5 
phases14,15 (summarised in Figure 1.02, e8) . In phase I, deposits are observed predominantly in the frontal, 
parietal, temporal or occipital neocortex14,15. Phase II is defined by the appearance of senile plaques in 
the allocortex, with deposits observed in the entorhinal cortex, hippocampal CA1 region, the insular 
cortex and, less frequently, the amygdala and cingulate gyrus14,15. Phase III involves additional subcortical 
regions including; the striatum, thalmus, hypothalamus and the basal forebrain14,15. In phase IV, plaque 
pathology is more pronounced in the midbrain and spread to the medulla oblongata becomes 
apparent14,15. Phase V is defined by the appearance of deposits in the pons and the molecular layer of the 
cerebellum14,15. These five distinct phases have subsequently been summarised in three by Serrano-Pozo 
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et al, with stage I showing isocortical involvement, stage II involving the allocortex and limbic systems and 
stage III defined by subcortical involvement5. 
Work conducted by Braak et al. in 1991 showed that the progression of NFT pathology within the AD brain 
also follows a distinct pattern16 (summarised in Figure 1.02, f8). Initially, sparse deposits are observed in 
the transentorhinal cortex of mildly affected individuals (stage I), which increase in density and spread to 
the CA1 region of the hippocampus (stage II)16. Subsequently, NFTs are observed in the entorhinal region 
of the cortex and in the subiculum (Stage III)16. In stage IV, the intensity of NFTs in the transentorhinal and 
entorhinal regions is seen to increase, as does NFT burden in the CA1 region of the hippocampus, sparse 
deposits also begin to become apparent in the amygdala, thalamus and claustrum16. In the final stage, the 
intensity of NFT deposition in the aforementioned regions is seen to increase and pathology is found 
dispersed through the isocortex, first in the associative areas (stage V) followed by the primary sensory 
motor and visual regions (stage VI)16.  
 
 
The isolation and subsequent biochemical characterisation of senile plaques and neurofibrillary tangles 
led to the identification of amyloid-beta peptide (Aβ)17-19 and the microtubule associated protein, tau, as 
their respective major components20-22. 
Amyloid Beta-Peptide: 
Aβ is derived by the proteolytic cleavage of an integral transmembrane protein termed the amyloid 
precursor protein (APP), the gene for which was identified independently by four groups in 198723-26. The 
APP gene is located on chromosome 21 (21q21.3), spans approximately 240 kilobases and contains 18 
exons27. Alternate splicing of the APP gene results in three predominant isoforms, APP770, APP751 and 
APP695, the latter lacking exon 7 and exons 7 and 8 respectively28. APP has been shown to be expressed 
in all tissue types tested, with the highest expression reported in the CNS29,30, particularly in the cerebral 
cortex and the hippocampus31. The tissue based distribution of APP expression is isoform specific, with 
Figure 1.02. Deposition of senile plaques and neurofibrillary tangles in the AD brain. The spatiotemporal deposition 
of senile plaques and neurofibrillary tangles within the Alzheimer’s diseased brain shows a characteristic pattern of 
distribution. a = senile plaques, b = Neurofibrillary tangle, e = Pattern of senile plaque deposition, f f= Pattern of 
neurofibrillary tangle deposition. Figure reproduced from Jucker & Walker8. 
Chapter 1: Introduction 
23 
 
APP695 the predominant form seen in the CNS32,33 whilst APP770 and APP751 are expressed in the 
periphery. Within the CNS, APP expression is also cell-type specific, with APP695 shown to be the 
predominant isoform expressed in neuronal cells29 whilst APP770 and APP751 are preferentially 
expressed by astrocytes29.  
The APP protein consists of two large extracellular domains, E1 and E2, linked via a flexible acidic region, 
a transmembrane domain and an intracellular domain34. The longer APP770 isoform incorporates a 
Kunitz-type protease inhibitor (KPI) domain and an OX-2 antigen domain, the latter of which is absent in 
the APP751 isoform, whilst the APP695 variant lacks both features35. Due to structural flexibility, a 
complete crystal structure of the APP protein has not been generated, however subdomains of the protein 
have been successfully crystallised allowing a putative structure to be assembled (Figure 1.0336).  
 
 
 
 
 
 
 
 
The APP protein can be sequentially processed by an α-secretase and then a γ-secretase or a β-secretase 
and then a γ-secretase, termed the non-amyloidogenic and amyloidogenic pathways, respectively 
(reviewed in37-39). Cleavage by α-secretase occurs within the region encoding Aβ, precluding its 
production37. sAPP-α is released into the extracellular space whilst the membrane bound CTF-83 is 
subsequently cleaved by γ-secretase releasing the amyloid-intracellular domain (AICD) and P3 fragments 
(Figure 1.04, non-amyloidogenic)37. Cleavage by β-secretase produces sAPP-β and the membrane bound 
CTF-99, which is subsequently cleaved by γ-secretase producing the AICD and Aβ (Figure 1.04, 
amyloidogenic)37. Cleavage by γ-secretase, results in Aβ molecules of 38-43 amino acids in length, of which 
Aβ1-40 is the most common, and Aβ1-42 the most aggregation prone40. Aβ1-42 is therefore the predominant 
isoform seen in senile plaques and has classically been considered the main pathogenic isoform. 
Acidic linker region 
E1 domain 
E2 domain 
Transmembrane domain 
APP intracellular domain 
Figure 1.03. Putative Structure of the APP Protein. A complete crystal structure of the APP protein has not been 
generated, however subdomains have been successfully crystallised allowing a hypothetical model to the generated 
(PDB: 1MWP, 1OWT, 3NYL and 1IYT). Figure reproduced from36. 
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The normal physiological roles of APP and the AD associated cleavage product, Aβ, are poorly defined. 
The ectodomain of APP is known to be capable of binding to heparan sulfate proteoglycans41-43, type I 
collagen44 and laminin45, components of the extracellular matrix, and the APP protein colocalises with 
integrins in cultured hippocampal neurons46 indicating a role in cell-ECM adhesion. Such interactions have 
been shown to stimulate neurite outgrowth, suggesting APP acts as a neurotrophic factor44,45,47-50. 
Additionally, APP has also been shown to be involved in intracellular adhesion via the formation of dimers 
at the cell surface, mediated by heparin binding via the E1 and E2 domains of the protein51,52. In 
concordance with these findings, an siRNA mediated knockdown of APP in neuronal cell lines has been 
shown to reduce cell division, cell adhesion and neurite outgrowth53-56, with similar effects observed in 
primary hippocampal neuronal cultures derived from APP knockout mice57. The temporal and spatial 
expression of APP has been shown to peak in areas of the brain associated with synapse formation during 
rat embryonic and post-natal development, suggestive of a role for APP in synaptogenesis58,59. In addition, 
the expression of APP in both the pre and post synaptic termini has been shown to be required for 
neuromuscular synapse formation and the expression of APP in HEK293 cells was found to promote 
synapse formation in contacting co-cultured primary neurons providing further evidence for the role of 
APP in synapse formation60. The E1 domain of the APP protein has been shown to be capable of binding 
metal ions, most notably zinc61 and copper62. The binding of the latter inducing a translocation of the APP 
protein to the cellular surface63 and resulting in the reduction of Cu2+ to Cu+, suggested to result in the 
generation of reactive oxygen species and indicative of a role for APP in the homeostasis of such ions64. 
Figure 1.04. Amyloidogenic and non-amyloidogenic processing of APP. APP can be sequentially cleaved by α-secretase 
and γ-secretase producing the AICD and P3 fragments (non-amyloidogenic) or by β-secretase and γ-secretase 
producing Aβ and AICD (amyloidogenic). Figure adapted from36,39.   
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Using primary neuronal cultures from transgenic mice, a homozygous knockout of APP has been shown 
to protect against copper induced toxicity, thus providing further evidence for the role of APP in copper 
homeostasis65. A homozygous knockout of APP in mice results in viable and fertile animals with reduced 
grip strength66, decreased locomotor activity66, reduced growth, a reduction in brain mass, defects in 
copper homeostasis67 and impaired LTP resulting in learning defects68-71, supporting the aforementioned 
putative functions of the APP protein derived from in vitro studies. The phenotypic abnormalities resulting 
from a homozygous APP knockout in murine models have been shown to be ameliorated or entirely 
reversed by the reintroduction of the sAPP-α domain of the APP protein, suggesting sAPP-α is critical for 
normal APP functionality72.  
The normal function of the AD relevant APP cleavage product, Aβ, is similarly poorly defined. The 
production of Aβ has been shown to be required for the viability of primary neuronal cultures and SH-
SY5Y cells, with the administration of γ-secretase (2-naphthoyl-VF-CHO/γ-secretase inhibitor IX) or β-
secretase (βSI/ βSII) inhibitors seen to induce a decrease in mitochondrial function, as measured using the 
MTT assay73. This effect was found to be neuron specific and was seen to be ameliorated upon treatment 
with exogenous Aβ at concentrations as low as 10 pM, indicating an Aβ specific mechanism73. The 
generation of Aβ has been shown to be dependent on neuronal activity74. In the presence of stimulatory 
or inhibitory compounds (tetrodotoxin, high magnesium, flunitrazepam/picrotoxin) a concomitant 
increase or decrease in the levels of soluble Aβ1-40 and Aβ1-42 generated by organotypic hippocampal 
sections derived from transgenic mice (APP Swedish mutation) was detected, an effect attributed to 
altered β-secretase activity74. The overexpression of APP was seen to induce a significant depression of 
excitatory synaptic responses, an effect which was dependent upon the proteolytic activities of both β-
secretase and γ-secretase, indicating that Aβ is the causative species74. It therefore appears that neuronal 
activity enhances Aβ production, and Aβ inhibits neuronal activity, suggesting Aβ may act in a negative 
feedback loop preventing excessive neuronal stimulation and possibly excitotoxicity74. The in vivo 
sequestration of Aβ using a monoclonal antibody based approach has been shown to inhibit both short-
term and long-term memory formation, an effect which was reduced in magnitude with the concomitant 
administration of purified Aβ1-42 at a physiologically relevant dose (100 pM)75. Similar results were 
reported by Puzzo et al. where the administration of low pM concentrations of Aβ1-42 to mice enhanced 
LTP and memory formation, whilst a scrambled peptide did not76. Both antibody mediated sequestration 
of Aβ1-42 and siRNA mediated knockdown of APP were found to result in defects in LTP and memory 
formation which was rescued by the addition of picomolar concentrations of exogenous Aβ1-4277. Thus it 
seems at low, picomolar concentrations, Aβ exerts positive neurological effects, enhancing neuronal 
viability, LTP and memory formation.  
In the healthy brain, Aβ is rapidly turned over with an estimated rate of production and clearance from 
the CNS of ~7.6% and ~8.3% of total Aβ per hour78. A range of processes are thought to be involved in the 
clearance of Aβ including; draining via the interstitial fluid79, astrocytic or microglial phagocytosis and 
degradation80, transport across the blood-brain barrier into the circulation79,81,82 and enzymatic 
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degradation83. It has been hypothesised that a defect in one or more of the Aβ production or clearance 
pathways induces an abnormal accumulation of Aβ within the brain, giving rise to the characteristic 
neuropathology and clinical symptoms associated with AD84.  
Tau Protein: 
The NFT associated tau protein is encoded by the microtubule-associated protein tau gene (MAPT) which 
consists of 16 exons and maps to chromosome 1785,86. Six predominant isoforms of the tau protein are 
expressed within the adult brain, generated through alternate splicing of exons 2, 3 and 10 and resulting 
in isoforms harbouring either 3 or 4 carboxy-terminal repeat domains (3R/4R)86. The tau protein localises 
to the neuronal axon where it interacts with the microtubule assembly, via the carboxy-terminal repeat 
domains, acting to stabilise its structure and altering the dynamics of assembly and disassembly of the 
cytoskeleton, critical for both neuronal development and maintenance87. The tau protein is also thought 
to influence axonal transport by competing with the molecular motor proteins, dynein and kinesin, for 
the microtubule assembly, retarding both anterograde and retrograde transport along the 
microtubule88,89.  
Whilst the native tau protein harbours an intrinsically disordered structure with low propensity for 
aggregation90, in the AD brain tau forms NFTs, composed of paired helical filaments91. Tau is subject to a 
range of post-translational modifications (reviewed in86), but most notably phosphorylation with around 
45 experimentally verified phosphorylation sites92. The tau protein shows a development associated 
phosphorylation profile, with approximately 7 phosphate groups per molecule during foetal development 
and approximately two per molecule in the adult86. However, in the AD brain, the tau protein is known to 
become hyperphosphorylated, with approximately 8 phosphate groups per tau molecule (although it has 
been suggested that due to post-mortem delay this may be an underestimation)93. Whether 
hyperphosphorylation of tau is sufficient in of itself to promote aggregation is not entirely understood. 
Hyperphosphorylated tau extracted from the brains of human AD patients has been shown to be capable 
of self-assembly into tangles in vitro, an effect which was prevented by dephosphorylation94. However, 
certain phosphorylation sites on the tau protein have been shown to inhibit tangle formation95 and 
reversible AD like hyperphosphorylation  of the tau protein has been shown to occur during hibernation, 
using the European ground squirrel as a model, with no evidence of tangle formation96. In addition, 
transgenic mouse models have shown that neuronal loss does not correlate with tangle formation, with 
cells dying in the absence of observable pathology97 and it has been suggested that cells bearing NFTs can 
remain viable for up to 20 years98. Thus, the mechanism by which tau forms NFTs, and the mechanistic 
link between NFT formation and neuronal loss in vivo remains unknown, and indeed there is now evidence 
that soluble forms of tau may be the true neurotoxic tau species as opposed to NFTs, although there are 
conflicting reports regarding this topic (discussed in86). 
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1.2 The Genetics of Alzheimer’s Disease 
Cases of AD are commonly divided into two classes on the basis of the age of onset. When clinical 
symptoms become apparent prior to the age of 65, the case is classed as early-onset AD (EOAD) and 
conversely, when symptoms become apparent after the age of 65, the case is classed as late-onset AD 
(LOAD). Whilst these brackets are somewhat arbitrary in nature, being based around the typical age of 
retirement, the distinction provided proves useful. For cases of EOAD there is typically an underlying 
causative genetic abnormality, predisposing to disease development and thus giving rise to the 
comparatively early onset of clinical symptoms. Such genetic perturbations are often heritable, leading to 
the term familial AD (FAD), and if inherited in an autosomal dominant fashion, autosomal dominant AD 
(ADAD). No deterministic mutations are known to cause LOAD, rather a number of genetic variations, 
alongside environmental factors, are thought to increase the risk of disease development and thus such 
cases are also referred to as sporadic AD. In terms of prevalence, the vast majority of cases of AD, 94.5%, 
present over the age of 65 and thus fall under the LOAD bracket with the remainder being classified as 
EOAD99. 
Early-Onset Alzheimer’s Disease (EOAD) 
In the majority of EOAD cases, the disease shows an autosomal dominant mechanism of inheritance with 
complete penetrance. The clinical symptoms of such patients mirror those with LOAD but present 
comparatively early100.  
The observation that patients with Trisomy 21 (Down’s Syndrome) often present with AD like symptoms 
at a comparatively young age and, at autopsy, frequently exhibit AD like lesions within the brain, led to 
the hypothesis that a causative mutation may lie on chromosome 2126. The subsequent genetic appraisal 
of four families with FAD via genetic linkage analysis provided support for such a theory with linkage 
observed to chromosome 21101. In 1991, the first EOAD causing mutation was identified as a valine to 
isoleucine missense mutation at position 717 within the gene encoding the amyloid-precursor protein 
(APP), located on chromosome 21102. As a result of subsequent linkage studies, two additional loci were 
identified on chromosome 14 (14q24.3)103-106 and chromosome 1 (1q31.42)107 with causative mutations 
later identified in presenilin 1 (PSEN1)108 and presenilin 2 (PSEN2)109,110 respectively, components of the 
APP processing γ-secretase complex. At the time of writing, 58 causative mutations have been identified 
in the APP gene, 243 in PSEN1 and 48 in PSEN2 (for an up to date list, see Alzforum111). 
EOAD mutations in the APP gene cluster around the cleavage sites for the β-secretase and γ-secretase 
enzymes, components of the amyloidogenic APP processing pathway. The Swedish mutation 
(KM670/671NL) is the only mutation known to increase the efficiency of β-secretase mediated cleavage 
of APP112,113, leading to increased flux through the amyloidogenic pathway and a corresponding increase 
in total Aβ generation114-116. The remaining mutations cluster around the γ-secretase cleavage site and, 
whilst not increasing total Aβ levels, consistently alter the ratio of Aβ1-40 and Aβ1-42, in favour of the latter 
more aggregation prone and thus more pathogenic isoform117,118.  
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The γ-secretase complex is formed by nicastrin (Nct), presenilin (PSEN1, PSEN2), aph-1 and pen-2, with 
presenilin forming the catalytic core of the enzyme (Figure 1.05)119. Whilst a range of EOAD associated 
mutations have been identified in both PSEN1 and PSEN2, a mechanistic appraisal of their affects has 
revealed a consistent alteration in the ratio of Aβ1-40 and Aβ1-42 in favour of the aggregation prone Aβ1-42 
isoform120. Although this increase in Aβ1-42 was initially attributed to a gain of function, thereby increasing 
production of Aβ1-42, subsequent experiments have indicated that the increase in Aβ1-42 was more likely 
due to a defect in the generation of Aβ1-40 resulting in increased production of Aβ1-42 at the expense of Aβ1-
40
121-126. 
 
Also of note is the protective Icelandic mutation of APP (A673T)127. Located adjacent to the β-secretase 
cleavage site, A673T reduces the efficiency of β-secretase cleavage and thus reduces the production of 
Aβ by approximately 40%128. Simultaneously, this mutation also appears to reduce the propensity of Aβ 
to aggregate, protecting against the development of AD129-131.  
Thus, all known EOAD causing mutations affect various facets of Aβ processing, promoting the formation 
of disease causing isoforms of Aβ. Additional autosomal dominant forms of AD have been reported for 
which no causative mutation could be identified in the APP, PSEN1 or PSEN2 genes, suggesting additional, 
as of yet unknown, genes are also involved132. 
Late-Onset Alzheimer’s Disease (LOAD) 
The vast majority of AD cases, 94.5%, are classified as late-onset due to clinical presentation occurring 
after the age of 6599. In contrast to familial forms of EOAD, no deterministic mutations are known to cause 
LOAD, rather a number of risk-associated genetic variants have been identified which, alongside 
environmental factors, are thought to predispose to the diseased state. The most well documented 
genetic risk factor for the development of LOAD is the ε4 allele of apolipoprotein-E (apo-E).  
Figure 1.05. Crystal structure of the γ-secretase complex. γ-secretase complex formed by Nicastrin (green), Presnilin 
1 (blue), PEN-2 (yellow) and Aph-1 (pink) (PDB: 5A63). 
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Apo-E is a 299 amino acid protein expressed in various tissues throughout the body, including the liver, 
brain, kidney and spleen133 (Figure 1.06).  
In the plasma, the apo-E protein is found associated with lipoproteins, such as intermediate density 
lipoproteins, very low density lipoproteins, chylomicrons, chylomicron remnants and some forms of high 
density lipoproteins, together responsible for lipid transport134. Apo-E acts as a ligand, primarily for the 
low-density lipoprotein (LDL) receptor but also LDL receptor related-protein and the VLDL receptor and 
therefore mediates the transport of lipids between the tissues of the body, fulfilling a similar role within 
the brain134.  
In 1991, a linkage based study, performed by Pericak-Vance et al, identified a region of chromosome 19 
as being associated with late-onset cases of AD135. Two years later, apo-E was shown to co-localise with 
neurological lesions characteristic of AD, namely senile plaques, cerebral amyloid angiopathy and 
neurofibrillary tangles136 and, as apo-E is located on chromosome 19 (19q13.2), it was proposed as a 
candidate gene accounting for the previously described genetic linkage136. The ε4 allele of apo-E was 
subsequently found to be over represented in familial forms of LOAD, suggesting a causal link136,137, a 
finding which has since been replicated using genome wide association studies, providing further evidence 
for such an association138,139. The apo-E protein has three alleles, ε2, ε3 and ε4, which differ at two amino 
acids; ε2 (Cys112, Cys158), ε3 (Cys112, Arg158) and ε4 (Arg112, Arg158)140, giving rise to 6 potential 
genotypes (ε2/ε2, ε3/ε3, ε4/ε4, ε2/ε3, ε2/ε4, ε3/ε4)141. The relative frequencies of each allele within the 
normal population are; 8.4%, 77.9% and 13.7% for ε2, ε3 and ε4 respectively142. However, in LOAD cases 
the relative frequency of the ε4 allele has been shown to be increased to 36.7% (Caucasian population)142. 
The ε2 allele is thought to be protective, ε3 neutral, whilst the ε4 allele is thought to increase the risk of 
disease in a dose dependent manner with ε2/ε4 heterozygotes having an odds ratio for disease 
development of 2.6, ε3/ε4 an odds ratio of 3.2 and ε4 homozygotes an odds ratio of 14.9142.   
The molecular mechanism through which the ε4 allele of apo-E exerts its effect is not fully understood 
and likely involves a number of effects. Carriers of the apo-E ε4 allele have been shown to have increased 
deposition of senile plaques within the brain, with no corresponding increase in NFTs, suggestive of an 
amyloid mediated mechanism143-145. The identification of apo-E as a component of neuritic plaques 
prompted the hypothesis that apo-E may bind to and thereby promote the aggregation of Aβ146. Although 
Figure 1.06. Structure of apoE-ε3. The apoE-ε3 structure was solved using NMR in 2010 (PDB: 2L7B). 
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investigations into the relative ability of the three isoforms of apo-E to bind to Aβ in vitro have generated 
conflicting results147-151, it is now generally accepted that apoE-ε2 shows highest affinity, followed by ε3 
and finally ε4152. In vitro apoE-ε4 has been shown to enhance the rate of Aβ1-42 fibril formation 10-20 fold 
whilst the effect of the ε3 variant was found to be less pronounced, followed by that of ε2153. Thus, it 
seems that the apoE protein is capable of interacting with Aβ, and in doing so can speed the formation of 
fibrillary assemblies in an isoform dependent manner154, an effect which correlates with the 
aforementioned allelic disease association (ε4> ε3> ε2).    
In vivo, using the PDAPP (APP V717F mutation) and Tg2576APP (APP Swedish mutation) mouse models, a 
knockout of the murine equivalent of apo-E was found to delay the appearance of Aβ pathology and 
prevent the formation of neuritic plaques, although diffuse plaques were apparent155,156. In the absence 
of APP, the introduction of human apoE-ε4 allele into knockout mice induced cognitive defects, as 
measured using the radial water arm maze, which were not apparent with ε3157. The introduction of 
human apoE-ε4 into transgenic mice overexpressing human APP resulted in markedly higher levels of 
fibrillar Aβ as compared to apoE-ε3156,158,159, consistent with in vitro results and suggesting the ε4 variant 
speeds Aβ fibrillization in vivo.   
A decrease in the level of Aβ1-42 in the CSF has been established as a reliable marker for cerebral amyloid 
accumulation160,161 and, interestingly, in a cohort of cognitively normal individuals, a correlation has been 
shown between apo-E allelic genotype and the abundance of Aβ1-42 in the CSF. Higher levels of Aβ1-42 were 
observed in the CSF of patients with the ε2 allele and lower levels observed with the ε4 allele, indicating 
protection from and exacerbation of cerebral amyloid deposition162, an effect which was subsequently 
confirmed via PiB-PET scanning162. Consistent with the previously described AD association, the ε3 allele 
was found to give rise to an intermediate phenotype (cerebral amyloid deposition: ε4> ε3> ε2). This effect 
was seen to translate to decreased clearance of soluble forms of Aβ from within the brains of aged 
transgenic PDAPP mice (APP-V717F), and a corresponding increase in plaque burden in an apo-E isoform 
dependent manner, suggesting apo-E may play a role in the clearance of Aβ from the brain162.  
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With the advent of genome-wide association studies and next generation sequencing, a number of 
additional risk associated loci have been identified, each with varying levels of molecular characterisation. 
A detailed discussion of these putative disease associated genetic variations is outside the scope of this 
introduction, but is reviewed comprehensively by Karch & Goate (Figure 1.07)163. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.07. Alzheimer’s disease associated genes. A number of genes have been suggested to increase the risk of AD 
development each with a range of potential mechanisms and varying penetrance. Figure reproduced from163.   
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1.3 The Amyloid Cascade Hypothesis and Therapeutic Intervention 
The amyloid cascade hypothesis was proposed by Hardy and Higgins in 1992 and posits that the abnormal 
deposition of Aβ plaques within the brain is the main causative factor for the development of AD, resulting 
in the characteristic neuronal loss associated with the disease164-166. Such a theory is supported by both 
histology, as evidenced by the deposition of abnormal aggregates of Aβ in the brains of AD patients 
(Section 1.1), and genetic association, with mutations in APP, PSEN1 and PSEN2 giving rise to autosomal 
dominant forms of AD (Section 1.2). Whilst there are a number of alternative hypotheses related to the 
underlying cause of AD, predominantly related to the tau protein167 the amyloid cascade hypothesis has 
arguably become the most widely accepted theory within the AD field and will form the basis for the 
subsequent discussion of AD directed therapeutic agents.  
Approved therapeutic agents against AD are at best palliative, treating symptoms but failing to address 
the underlying cause and as such disease progression and patient death remain a certainty. Therapeutic 
agents can be placed into two categories, namely NMDA receptor antagonists, such as memantine (Ebixa), 
and acetylcholinesterase inhibitors, such as donepezil (Aricept), rivastigmine (Exelon) and galantamine 
(Reminyl). Alongside these approved molecules are a number of experimental therapeutic agents at 
varying stages of development, targeting various facets of Aβ production and clearance. 
In order to correctly diagnose AD, to monitor disease progression and crucially to measure the efficacy of 
potential therapeutic agents, a convenient and accurate clinical grading scale is necessary. Several such 
scales have been described, and a brief overview of those relevant to the subsequent discussion of 
therapeutic agents; the Mini Mental State Examination (MMSE)168, the Alzheimer's Disease Assessment 
Scale- Cognitive Subscale (ADAS-cog)169, the Alzheimer's Disease Cooperative Study Activities of Daily 
Living Inventory (ADCS-ADL)170 and the Severe Impairment Battery (SIB)171, is provided herein. 
The MMSE often forms the basis for patient inclusion criteria for clinical trials of novel therapeutics, as 
well as being used to measure efficacy of therapeutic agents. The MMSE is composed of 11 questions 
assessing attention, memory and spatial orientation, the ability to follow commands, both verbal and 
written, to name common objects, creatively write a sentence and to copy a complex image172. Following 
assessment, a numerical score on a range of 0-30 is generated, with lower values indicating a higher 
degree of impairment173. On the basis of the generated score, patients are typically segregated into the 
following groups; cognitively normal (MMSE= 30-24), mildly-cognitively impaired (MMSE= 23-20), 
moderately impaired (MMSE= 19-10) and severely impaired (MMSE= 9-0)173. The MMSE examination has 
been shown to be insensitive to patients with mild cognitive impairment due to “ceiling effects”, ie. some 
subtests are deemed too easy, masking the early signs of dementia, and also insensitive to the 
deterioration of severely demented patients, attributed to “floor effects”173,174. The ADAS-cog consists of 
11 subtests designed to examine memory, language and motor coordination and is commonly used 
alongside the MMSE during clinical trials to examine the efficacy of therapeutic agents169. A score on a 
range of 0-70 is generated, with higher values indicating greater impairment. As with the MMSE, the 
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ADAS-cog is most sensitive to patients with moderate AD, again suffering from floor and ceiling effects175. 
The Alzheimer’s Disease Cooperative Study, conducted in 1997, sought to identify a series of everyday 
activities, such as the ability to dress and feed oneself, which would be of prognostic use in monitoring 
the progression of dementia and would complement cognitive performance directed metrics170. 45 such 
activities were examined, identifying 27 which were deemed to be of use and leading to the generation 
of two scales; the ADCS-ADL19 consisting predominantly of core skills and providing a measure of severe 
AD, and the ADCS-ADL23 used for monitoring mild-moderate AD175. A score out of 78 is generated, with 
lower scores indicating a higher degree of impairment. The SIB was designed with the express intent of 
being able to evaluate patients with advanced dementia, a task to which the MMSE and ADAS-cog metrics 
are poorly suited171,175. The SIB examination tests memory, spatial orientation, language, response to 
name, attentiveness, social interaction, motor coordination and visuospatial abilities175, a score out of 100 
is generated with lower values indicating a higher degree of impairment.  
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1.31 Approved Therapeutic Agents:  
NMDA Receptor Antagonists: 
Memantine was developed by Eli-Lilly in 1963 for the treatment of diabetes but was found to be 
ineffective for this purpose176. In the 1980s, memantine was subsequently found to act as an NMDA 
receptor antagonist, exhibiting a favourable pharmacological profile as compared to similar molecules177. 
Memantine has been shown to act via an uncompetitive mechanism, binding explicitly to the open 
conformation of the NMDA receptor, and consequently blocking the flow of Na+ and Ca2+ ions into the cell 
and K+ out of the cell177-179. 
 
The NMDA receptor is one of three classes of ligand gated ion channel which respond to L-glutamate, the 
others being the AMPA and Kainate classes of receptors180. Glutamate is the major excitatory 
neurotransmitter within the brain, with an estimated 70% of all excitatory synapses responding to this 
molecule181. Stimulation via the NMDA receptor is known to be key for learning and memory, a function 
attributed to NMDA mediated synaptic modulation resulting in long-term potentiation182-186 and long-
term depression187-189. The NMDA receptor forms a heterotetramer composed of four subunits (Figure 
1.09).  To date, a total of seven distinct subunit types have been identified; GluN1, GluN2 (A, B, C, D) and 
GluN3 (A, B), giving rise to a range of NMDA receptor of varying composition and with varying distribution 
and biophysical properties180. 
Figure 1.08. Memantine Molecular Structure. Memantine is an NMDA receptor antagonist used for the treatment 
of moderate to severe AD.  
Figure 1.09. Crystal Structure of the NMDA Receptor. The NMDA receptor is a heterotetramer composed of four 
varying subunits. The structure shown is composed of two dimers of GluN1/GluN2B (PDB: 4PE5). 
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Following stimulation, L-glutamate is released from the pre-synaptic terminal and binds to NMDA 
receptors on the post-synaptic membrane, permitting the channel to open. At normal resting membrane 
potential (-70 mV), Mg2+ ions bind to the NMDA receptor blocking the flow of additional ions through the 
channel190,191. In the presence of a concomitant depolarisation of the postsynaptic membrane, Mg2+ is 
displaced allowing Ca2+ to flow from the extracellular compartment to within the neuronal cell180, 
triggering intracellular calcium dependent signalling cascades, a process critical for both learning and 
memory via long-term potentiation and long-term depression192. However, hyperstimulation can result in 
an excess of intracellular calcium, causing neuronal cell death, a process termed excitotoxicity193,194. The 
mechanism through which NMDA receptor mediated excitotoxicity exerts its affect in the AD brain is not 
fully understood. It has been hypothesised that a generalised metabolic dysfunction within the cell may 
result in a deficit of ATP and a partial depolarisation of the plasma membrane, releasing bound Mg2+ ions 
from the NMDA receptor channel and resulting in chronic, pathological levels of intracellular calcium195. 
However, additional Aβ mediated mechanisms are also likely involved; such as an Aβ-mediated 
augmentation of glutamate release and reuptake (reviewed in196).  
It is thought that the primary mechanism by which memantine exerts its neuroprotective effect is based 
around its higher affinity for the NMDA receptor as compared to Mg2+, helping to prevent chronic, low 
level activation following of the NMDA receptor due to a partial depolarisation of the plasma 
membrane197. However, following a true depolarising event, memantine is released allowing the normal 
function of the NMDA receptor to be maintained, likely explaining its favourable toxicity profile as 
compared to other NMDA receptor antagonists197 (reviewed in197). 
The effects of memantine have been extensively examined in a number of clinical trials, two of which are 
outlined here (see ClinicalTrials.gov for a complete overview). In the first, 252 patients with moderate to 
severe AD were randomly allocated to placebo or memantine treatment and therapy maintained for a 
period of 28 weeks during which cognition was assessed using the Alzheimer's Disease Cooperative Study 
Activities of Daily Living Inventory (ADCS-ADL) and the Severe Impairment Battery (SIB), measuring various 
aspects of cognitive performance including; attention, orientation, language, memory and visuospatial 
ability198. Patients treated with memantine (NAMENDA) were found to have a significantly reduced rate 
of decline as compared to those treated with placebo, as assessed using the ADCS-ADL scale (Figure 1.10), 
and the SIB scale199. 
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A second study investigated the effects of memantine in combination with the acetylcholinesterase 
inhibitor, donepezil. 404 patients with moderate to severe AD were randomly assigned to placebo treated 
and memantine treated groups. Following 24 weeks of treatment, cognitive ability was again assessed 
using the ADCL-ADL and SIB methodologies. Patients treated with a combination of memantine and 
donepezil were again found to exhibit a significantly reduced rate of clinical decline (Figure 1.11)199. 
Figure 1.10. Efficacy of Memantine in Treating Moderate to Severe AD. Patients were treated with memantine 
(NAMENDA) or placebo for a period of 28 weeks during which cognitive performance was assessed using the ADCS-
ADL scale. Patients treated with memantine were found to have a significantly reduced rate of cognitive decline. Figure 
reproduced from199. 
Figure 1.11 Efficacy of Memantine in combination with donepzil in treating moderate to severe AD. Patients were 
treated with either Donepezil alone, or Donepezil in combination with memantine (NAMENDA) for a period of 24 
weeks during which cognitive performance was assessed using the ADCS-ADL scale. Patients treated with donepezil in 
combination with memantine were found to have a significantly reduced rate of cognitive decline. Figure reproduced 
from199. 
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Acetylcholinesterase Inhibitors: 
The second class of approved therapeutic agents for the treatment of AD are collectively known as 
acetylcholinesterase inhibitors. Acetylcholine acts as a neurotransmitter in the peripheral nervous system, 
particularly at the neuromuscular junction and in autonomic ganglia200 and a neuromodulator in the 
central nervous system, altering axonal excitability201-203, the release of neurotransmitters204-208, 
coordinating groups of neurons to fire in unison and influencing synaptic plasticity209-211. Signalling occurs 
through two receptor subtypes; metabotropic muscarinic receptors, located on both the pre and post-
synaptic membranes, and ionotropic nicotinic receptors, dispersed on the neuronal cell surface200. 
Acetylcholine is thought to act in a localised manner at the synapse and also at sites distant from the point 
of release, termed “volume effects”, supported by the disjointed anatomical distribution of sites of 
acetylcholine release and cholinergic receptors200.  Within the synaptic cleft, acetylcholinesterase (AChE) 
degrades released acetylcholine, terminating stimulation and producing acetate and choline, the latter of 
which is taken up by the presynaptic neuron and converted back to acetylcholine via choline acetyl-
transferase (CAT) and acetyl-CoA212 (Figure 1.12 and Figure 1.13). 
 
As a consequence of AD, there is a selective loss of cholinergic neurons in the basal forebrain213 a 
substantial decrease in the activity of choline acetyltransferase214,215, a decrease in the synaptic release 
of acetylcholine216 and also in the subsequent re-uptake of choline, post AChE catabolism217. Thus, on the 
basis of the observed evidence, the cholinergic hypothesis was formulated, postulating that a generalised 
dysfunction of acetylcholine mediated neurotransmission plays a key role in the cognitive impairment 
associated with AD218.   
Figure 1.12. Crystal structure of acetylcholinsterase (AChE). AChE, a homodimer, catabolises the neurotransmitter 
acetylcholine within the synaptic cleft (PDB: 4EY7). 
Figure 1.13. Catabolism and synthesis of acetylcholine. Acetylcholinesterase (AChE) catabolises acetylcholine, 
producing acetate and choline. Choline acetyltransferase (CAT) synthesises acetylcholine using choline and acetyl-
CoA. 
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On the basis of the cholinergic hypothesis, AChE inhibitors were developed with the aim of slowing the 
catabolism of acetylcholine within the synaptic cleft, prolonging its retention time with the aim of 
maximising the activity of the reduced levels of acetylcholine observed in the diseased state212. AChE 
inhibitors can be subdivided into molecules which act via either an irreversible or reversible mechanism, 
the latter being the predominant form employed therapeutically due to their more favourable toxicity 
profiles212. The three most commonly prescribed AChE inhibitors are donepezil, rivastigmine, and 
galantamine (Figure 1.14). 
All three drug molecules have been shown to induce a comparable, modest, improvment in cognition in 
patients with AD219-222. An illustrative example is provided using data derived from a 2002 clinical trial223, 
testing the efficacy of donepezil in treating patients wih mild AD over a period of 24 weeks (5 mg/day for 
6 weeks, 10 mg/day thereafter), indicating an improvement in cognition as measured using the ADAS-cog 
(Figure 1.15) and MMSE metrics (Figure 1.16).  
 
 
 
Figure 1.14. Molecular structure of donepezil, rivastigmine and galantamine. Donepezil, Rrivastigmine and 
galantamine are acetylcholine esterase inhibitors used for the treatment of AD. 
Figure 1.15. Efficacy of donepezil in treating mild-AD. The administration of donepezil was found to elicit an 
improvement in the cognitive performance of patients with mild AD, as measured using the ADAS-cog metric. Figure 
reproduced from223. 
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Whilst inducing an improvement in cognitive performance, the positive impact of both NMDA receptor 
antagonists and acetylcholinesterase inhibitors is modest in nature. In addition, neither class of molecule 
is capable of arresting disease progression, meaning that patient deterioration and eventual death remain 
a certainty and thus prompting the search for true disease modifying treatments, primarily targeting Aβ 
production and clearance, as per the amyloid cascade hypothesis164. Several such agents have been 
trialled, with varying levels of success, whilst others are still in development. Here, a focus is placed on 
therapeutic agents furthest through the development process (for a more complete overview see224). 
 
 
 
 
 
 
 
 
 
 
Figure 1.16. Efficacy of donepezil in treating mild-AD. The administration of donepezil was found to elicit an 
improvement in the cognitive performance of patients with mild AD, as measured using the MMSE metric. Figure 
from223. 
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1.32 Non-approved Therapeutic Agents 
β-secretase and γ-secretase Inhibitors 
On the basis of the amyloid cascade hypothesis164, the direct inhibition of the amyloidogenic processing 
of APP via the therapeutic targeting of either β-secretase or γ-secretase,should serve to ameliorate the 
production of the pathogenic isoforms of Aβ (Aβ1-40 and Aβ1-42), hopefully arresting disease progression. 
A number of such compounds are in development by several large pharmaceutical organisations.  
The compound E2609, a novel β-secretase inhibitor has been jointly developed by Eisai and Biogen 
(structure not published). At the time of writing, 8 phase I clinical trials have been performed using E2609, 
showing the compound to be well tolerated and to induce a dose dependent decrease in Aβ production, 
as measured in blood plasma225. Compound E2609 entered phase II clinical trials in 2014, the results of 
which are anticipated in January 2018226.  MK-8931 (Figure 1.17, right), a second inhibitor of β-secretase 
developed by Merck, successfully passed phase I clinical trials in 2012 showing good tolerability and 
efficacy, measured via a decrease in CSF levels of Aβ. Compound MK-8931 is currently undergoing phase 
II/III trials for the treatment of mild to moderate AD, the results of which are an expected in July 
2019227,228. LY2886721, is a third β-secretase inhibitor, in this instance developed by Eli Lilly (Figure 1.17, 
left). LY2886721 showed early promise, inducing a dose dependent decrease in Aβ1-40 and Aβ1-42, initially 
in cell culture, in mouse and dog models of AD and in human trials229.  However, a phase II trial of 
LY2886721 was terminated prematurely as a result of a subset of patients displaying abnormal liver 
biochemical test results230. 
 
Semagacestat (LY450139) is a γ-secretase inhibitor developed by Eli-Lilly (Figure 1.18, left) which was 
shown to decrease the production of Aβ1-40 and Aβ1-42 in CSF samples in a phase I clinical trial231. However, 
phase II trials raised potential issues. Following Semagacestat treatment, plasma levels of Aβ were found 
to be significantly reduced but with no corresponding decrease within the CSF232,233. In addition, a number 
of patients reported adverse reactions including drug induced rashes and alternations in hair 
pigmentation232. A large scale phase III trial of Semagacestat was halted prematurely when it was 
Figure 1.17. Structure LY2886721 and MK-8931.  Molecular structure of β-secretase inhibitors LY2886721 and MK-
8931 (E2609 not published). 
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recognised that the treatment group were exhibiting comparatively worse cognitive performance as 
compared to controls, measured by the ADAS-cog and ADCS-ADL metrics, and in addition, were exhibiting 
a significantly increased incidence of skin cancer and infection234. Subsequent work has shown 
Semagacestat preferentially inhibits Notch processing (IC50 = 24.62 nM, 95% CI = 15.74-38.51 nM) as 
compared to APP (IC50 = 257.8 nM, 95% CI = 190.2-349.5 nM) possibly explaining the aforementioned 
toxicity235.  
Avagacestat is a γ-secretase inhibitor developed by Bristol-Myers Squib (Figure 1.18, right). Avagacestat 
was initially reported to be 193-fold more specific for APP cleavage as compared to Notch236, although 
this specificity index has subsequently been reported as only 3-fold237. Phase I trials were successful, but 
the compound subsequently failed phase II due to unacceptable side effects, including elevated rates of 
skin cancer, diarrhoea, nausea and rash and, as was seen previously with Semagacestat, a trend towards 
a worsening of cognition following drug treatment238.    
 
 
 
 
 
 
 
Figure 1.18. Structure Semagacestat and Avagacestat. Molecular structure of γ-secretase inhibitors Semagacestat 
and Avagacestat. 
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Aβ Aggregation Inhibitors 
An alternative therapeutic approach relates to the use of small molecules to perturb Aβ aggregation, 
curtailing plaque formation and, in theory, the associated cellular damage and neuronal loss. Alzhemed, 
(3APS, Tramiprosate) is one such aggregation inhibiting compound (Figure 1.19).  
 
In 2007, Alzhemed was shown to be capable of binding Aβ1-40 and Aβ1-42 and to maintain Aβ1-40 in a soluble, 
non-oligomerised form239. This effect was seen to translate into protection against Aβ1-42 induced cell 
death using both rat primary cortical neurons and the neuroblastoma SH-SY5Y cell line239. A reduction in 
the deposition of Aβ plaques in a mouse model of the disease and in plasma and cerebral levels of Aβ1-40 
and Aβ1-42 was also observed post Alzhemed treatment239. During a phase II clinical trial, Alzhemed was 
found to induce a decrease in CSF Aβ1-42, but with no associated improvement in cognition240, results 
mirrored in a subsequent large scale phase III trial241. Development of Alzhemed has subsequently ceased.  
Additional small molecule inhibitors of Aβ aggregation include; Colostrinin242,243, scyllo-inositol 
(ELND005)244, PBT1 (clinoquinol)245 and PBT2246, each at varying levels of development. 
 
 
 
Figure 1.19. Structure Alzhemed. Molecular structure of Aβ aggregation inhibitor Alzhemed (Tramprosate, 3-APS). 
Figure 1.20. Small molecule inhibitors of Aβ aggregation. Scyllo-inositol, PBT1 and PBT2 have been identified as 
compounds capable of perturbing the aggregation of Aβ. 
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Aβ Directed Immunotherapy 
An antibody based approach has also been employed with the aim of clearing amyloid plaques post 
deposition. Monoclonal antibodies directed against the N-terminus of Aβ (residues 1-28) have been 
shown to be capable of disrupting pre-formed fibrillar assemblies of synthetic Aβ247, an effect which was 
subsequently shown to protect neuronal PC12 cells from Aβ induced neurotoxicity in vitro247. 
Following on from this work, a mouse model of AD (PDAPP, harbouring the V717F APP mutation) was 
immunized using Aβ1-42, eliciting an active immune response, both prior to and after the onset of 
neuropathological symptoms. Immunisation prior to the onset of symptoms effectively prevented 
amyloid plaque deposition and hallmarks of plaque induced toxicity, namely the presence of dystrophic 
neurites and astrogliosis248, whilst immunisation later in the disease course was found to dramatically 
reduce the plaque burden as compared to controls248. Such immunisation has subsequently been shown 
to protect against Aβ mediated cognitive deficits using various metrics and a range of mouse models of 
the disease249-252.  
The promising results observed in mouse models led to an initial human trial, conducted by ELAN 
Pharmaceuticals, in which patients with mild to moderate AD were treated with an aggregated form of 
Aβ1-42, termed AN1792, on four occasions (weeks 0, 4, 12 and 24) inducing an active immune response253.  
AN1792 passed phase I clinical trials with no notable adverse effects, but was subsequently halted during 
phase II when 6% of patients developed acute meningoencephalitis254. Despite failing phase II clinical 
trials, the subsequent histological analysis of the brains of patients from within the trial suggested a 
marked clearance of Aβ plaques had indeed occurred whilst NFTs and cerebral amyloid angiopathy were 
still apparent255-258. Although a marked decrease in Aβ plaque abundance was seen in patients treated 
with AN1792, no difference in cognitive performance was observed between treated and control patients 
using a range of assessments including the ADAS-cog and MMSE scales259. A follow-up study has since 
confirmed that patients treated with AN1792, and who exhibited a significantly reduced plaque burden, 
still proceeded to a severe end-stage dementia with no significant difference in survival or time to 
dementia260.   
Also of note are the monoclonal antibody based therapeutic agents; Bapineuzumab, developed jointly by 
Janssen and Pfizer, and Solanezumab, by Eli-Lilly. As opposed to previous trials in which aggregated Aβ1-
42 (AN1792) was used to induce an active immune response, Bapineuzumab, and Solanezumab are instead 
administered as a passive immune therapy. The failure of AN1792 has been attributed to a T-cell mediated 
pro-inflammatory response giving rise to the observed meningoencephalitis261, an effect which should not 
be seen with passive immunisation.  
In phase II trials, Bapineuzumab was administered as 6 infusions over 78 weeks to 124 patients with mild 
to moderate AD (assessed via MMSE score) alongside 110 patients who were given a placebo. The primary 
measure of cognitive performance was the ADAS-cog metric with assessments performed prior to 
treatment, following each infusion and at termination at 78 weeks. No significant differences in cognitive 
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performance, CSF levels of Aβ, total-tau or phospho-tau, or brain volume (via MRI) were observed 
following treatment with Bapineuzumab262. A number of adverse effects were however observed, most 
notably vascular-edema, with a two-fold high prevalence in Bapineuzumab treated patients as compared 
to controls262. Phase III trials were conducted using patients with mild to moderate AD and subdivided 
into apoE-ε4 carriers (673 Bapineuzumab treated, 448 placebo) and non-carriers (807 Bapineuzumab 
treated, 524 placebo)263. Bapineuzumab was administered every 13 weeks for a total of 6 treatments. The 
primary measure of efficacy was the ADAS-cog metric, performed prior to treatment and following each 
infusion (a total of 6 over 78 weeks). PET scanning using the Pittsburgh compound B (PiB), giving a measure 
of cerebral amyloid load, was also employed prior to treatment and at weeks 45 and 71. As was seen 
during phase II trials, no significant differences in cognitive performance were observed between patients 
treated with Bapineuzumab or placebo and similarly, no brain volumetric changes were observed 
between untreated and treated groups, indicating disease progression263. As was seen during phase II 
trials, the most notable adverse effect following Bapineuzumab was an elevated incidence of vascular-
edema263. On the basis of these findings, all subsequent trials of Bapineuzumab were halted. 
Solanezumab is a humanized IgG1 monoclonal antibody targeted against the central domain of the Aβ 
molecule264. In mouse models, peripheral administration of m266, the murine antibody from which 
Solaneuzamab is derived, to PDAPP mice (harbouring the human V171F APP mutation), resulted in almost 
complete sequestration of plasma Aβ and interestingly, the total levels of plasma Aβ were found to be 
increased approximately 1000-fold following treatment, suggesting m266 was acting as an Aβ-sink and 
altering the equilibrium between peripheral and CNS localised Aβ264,265. Following treatment with m266, 
the levels of Aβ within the CSF were found to be rapidly increased, supporting such a theory and 
suggesting mobilisation of Aβ from within the CNS to the CSF and periphery264. This effect was seen to 
translate into a decrease in Aβ derived plaques within the brains of m266 treated mice264.  
Phase I trials mirrored the findings seen previously using PDAPP mice, with a marked increase in CSF and 
plasma levels of Aβ following administration of Solanezumab to patients with mild to moderate AD, with 
no evidence of adverse effects266. At phase II, 52 patients with mild to moderate AD were treated with 
Solanezumab once weekly for a total of 12 weeks267. Plasma and CSF levels of Aβ were assessed using an 
ELISA based assay, and cognitive performance measured using the ADAS-cog test. Treatment with 
Solanezumab was again seen to dramatically increase plasma and CSF levels of Aβ1-40 and Aβ1-42. However, 
no significant difference in cognitive ability was observed267.  
Solanezumab subsequently entered two different phase III clinical trials, termed EXPEDITION1 and 
EXPEDITION2. Patients with mild to moderate AD were allocated to Solanezumab or placebo treatment 
groups and Solanezumab administered once every 4 weeks over an 18-month period268. Cognitive 
performance was primarily assessed using the ADAS-cog and ADCS-ADL metrics. EXPEDITION1 employed 
506 patients in each treatment group, Solanezumab or placebo, whilst EXPEDITION2 designated 521 to 
Solanezumab and 519 to placebo. In both studies, plasma levels of Aβ1-40 and Aβ1-42 were seen to 
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significantly increase following Solanezumab treatment, as were total levels of Aβ1-40 and Aβ1-42 in the 
CSF268. However, no differences in brain amyloid deposition was observed using 18F-florbetapir-PET 
imaging and hippocampal and whole-brain volume was seen to decrease comparably between groups, 
indicative of disease progression268. Critically, no consistent significant difference in cognitive 
performance was observed in either study between patients treated with Solanezumab as compared to 
placebo268. A subsequent analysis of the data, specifically looking at a subset of early stage AD patients 
suggested that Solanezumab treatment may have been beneficial to this patient cohort, slowing cognitive 
decline269.  
Eli-Lilly is now conducting a third clinical trial using Solanezumab, termed EXPEDITION3, expected to end 
in October 2016. The Dominantly Inherited Alzheimer’s Network is also running a phase II/III trial testing 
Solanezumab and Gantenerumab, a monoclonal antibody therapy developed by Roche, targeting familial 
forms of AD. 
Therefore, whilst there is evidence that memantine and AChE inhibitors offer symptomatic improvement 
in patients with AD, the effects are slight and often transient. Bapineuzumab, an antibody based therapy 
targeting Aβ plaques, failed to meet any of its primary endpoints in large scale phase III clinical trials, 
inducing no significant improvement in cognition, and whilst there is evidence that Solanezumab, a second 
antibody mediated therapeutic agent, may induce a modest slowing of the disease process in patients 
with mild forms of AD, this effect has yet to be confirmed and again appears modest in nature.  AN1792 
was found to significantly reduce the plaque burden in patients with AD, with no associated improvement 
in cognition, no delay in the time to dementia, or in time to death, again calling into question the validity 
of targeting insoluble plaques of Aβ for the treatment of AD. Compounds targeting γ-secretase appear to 
have inherent issues of specificity, resulting in marked side effects, an effect most likely attributed to a 
simultaneous inhibition of Notch processing, whilst the efficacy of β-secretase inhibitors remains to be 
seen (results expected in 2018 and 2019). 
Despite the myriad of approaches trialled, no single therapeutic agent has been shown to arrest, or 
markedly slow the progression of AD, nor to induce a marked improvement in cognition. Whether this 
failure is due the therapeutic intervention being made too late in the disease process, or whether the 
amyloid cascade hypothesis as it was originally formulated fails to accurately describe the AD process 
remains to be seen. In recent years, there has been a shift in focus from insoluble extracellular plaques of 
Aβ to soluble intracellular forms, which may be key in driving early disease progression and thus an 
attractive target for therapeutic intervention. 
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1.4 Soluble Aβ and 17β-Hydroxysteroid Dehydrogenase Type 10 
1.41 Soluble Aβ 
Despite being the most influential hypothesis regarding the cause of Alzheimer’s disease, there are a 
number of issues related to the amyloid cascade hypothesis as it was originally formulated164. The 
deposition of Aβ plaques was posited as being the main disease causing lesion associated with the 
development of Alzheimer’s disease164, however plaque burden has been shown to correlate poorly with 
disease progression in both murine models and AD patients. In transgenic mouse models expressing ADAD 
associated mutations of the APP protein, markers of cognitive decline have been reported prior to plaque 
deposition; most notably a decrease in the level of synaptophysin and synaptic electrophysiological 
abnormalities, indicating a loss of functional synapses270-272. A similar lack of correlation between plaque 
burden and disease severity has been reported in AD patients, with the best correlate instead reported 
as synaptic loss273,274, and indeed amyloid deposition has been reported to plateau whilst cognitive decline 
is seen to continue275. In addition, an estimated 20-40% of elderly individuals show sufficient Aβ plaque 
deposition to meet AD diagnostic criteria, despite being cognitively normal276-280. Together these 
observations suggest that plaque formation may not be the key disease driving event in the AD brain. 
Whilst early reports have suggested that Aβ requires assembly into fibrillary structures before toxicity 
becomes apparent281-283 subsequent work has reported that soluble oligomeric forms of Aβ (Figure 1.23, 
right), referred to as Aβ-derived diffusible ligands (ADDLs), are a potent neurotoxic species in their own 
right and exhibit enhanced toxicity as compared to the aforementioned fibrillar assemblies284.  
 
The toxicity of soluble oligomeric forms of Aβ has been shown to be selective in nature, inducing cell death 
in the CA1 region of the hippocampus and the entorhinal cortex of organotypic mouse brain slice cultures 
at low nanomolar concentrations, whilst sparing neurons derived from the cerebellum, a pattern which 
matches that observed in the AD brain and is not observed with fibrillar assemblies of Aβ285. Such species 
also induced a deficit in long-term potentiation in rat hippocampal slices, correlating with observations 
made in mouse models of AD, prior to plaque deposition284. The production of such oligomeric Aβ species 
has been shown to increase in cell lines expressing wild-type APP or ADAD associated APP mutants286,287, 
in transgenic mouse models of AD288,289 and in the brains of AD patients but not in non-diseased 
Figure 1.21. Aβ Oligomerisation. Aβ has been shown to be capable of forming large fibrils (left panel) or small 
diffusible oligomers (ADDLS, right panel) depending on the conditions utilised. Figure reproduced from284. 
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controls290,291. As previously mentioned, a decrease in synaptic density has been shown to be the strongest 
correlate for the neurological decline associated with AD274 and the levels of soluble Aβ have since been 
shown to correlate strongly with both synaptic loss and disease severity in both mouse models and 
patients with AD285,292,293. Thus, it appears that soluble forms of Aβ may be the true toxic species in AD, 
responsible for the neuronal loss and disrupted synaptic function observed in the diseased state and 
independent of plaque formation.   
Soluble forms of Aβ have been identified in various intracellular compartments, including the endoplasmic 
reticulum294-296, the trans-golgi apparatus294,296,297, the cytosol298-300 and lysosomal compartments301. In 
addition, Aβ has also been identified in the mitochondria302-307. Within the mitochondria, Aβ has been 
hypothesised to interact with mitochondrial proteins, disrupting normal function and inducing cell 
death308. The 17β-HSD10 enzyme has been identified as one such mitochondrial Aβ binding protein. 
 
1.42 17β-HSD10 
The 17β-HSD10 enzyme, (also known as amyloid-binding alcohol dehydrogenase (ABAD), endoplasmic 
reticulum-associated amyloid beta-peptide binding protein (ERAB), HADH2, SCHAD, MRRP2, SDR5C1) is a 
member of the short-chain dehydrogenase/reductase (SDR) and 17β-hydroxysteroid dehydrogenase 
families. The monomeric 17β-HSD10 enzyme is 27 kDa in size, consists of 261 amino acids and localises to 
the mitochondrial matrix309-311, the only enzyme within the 17β-hydroxysteroid family known to do so312. 
The enzyme forms a 108 kDa homotetramer (Figure 1.22) and is known to catalyse the conversion of a 
range of substrates, participating in the degradation of isoleucine, the β-oxidation of fatty acids and in the 
metabolism of steroidal hormones313.     
  
The tissue based distribution of the 17β-HSD10 enzyme has been characterised via immunoblotting, with 
highest levels observed in the liver, kidney, heart, brain and gonads309. The gene encoding the 17β-HSD10 
enzyme has been shown to be evolutionarily conserved and its expression necessary for survival314. The 
Drosophila homologue of the 17β-HSD10 enzyme, scully, shows 61% sequence identity with the human 
Figure 1.22. 17β-HSD10 Homotetramer. The 17β-HSD10 enzyme has been shown to form a 108 kDa homotetramer 
in solution. (PDB: 1U7T). 
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protein315 and has been shown to have broadly similar catalytic activities311. Scully is however localised to 
the cytoplasm of the cell, as opposed to the mitochondria, likely due to a truncation of the N-terminus of 
the Drosophila protein resulting in a non-functional or absent mitochondrial targeting sequence311. Four 
mutations within the scully gene have been shown to be lethal during development; scu174 and scu152 
inducing single amino acid substitutions, L33Q and F120I respectively, whilst scu3127 and scu4058 generate 
truncated isoforms of the protein, the former harbouring only 86 N-terminal amino acids out of the full 
255 and thus lacking the majority of functional domains, whilst the latter lacks a C-terminal portion of the 
protein, thought to confer substrate specificity315. In male flies, all four mutants were found to impart a 
dramatic reduction in teste size, a decrease in the abundance of mitochondria and an increase in the 
deposition of intracellular lipid vesicles within testes cells, a phenotypic abnormality attributed to a defect 
in the β-oxidation of fatty acids315.  
In humans, inactivating mutations within the gene encoding the 17β-HSD10 enzyme have been associated 
with an X-linked neurodegenerative disorder termed 2-methyl-3-hydroxybutyryl-CoA dehydrogenase 
(MHBD) deficiency. The first case of MHBD deficiency was reported in 2000 by Zschocke et al.  with the 
patient presenting on the second day of life with Kussmaul respiration associated with metabolic acidosis 
with hypoglycaemia, elevated lactate, hyperammonemia and ketonuria and subsequently recovering 
following glucose administration316. The patient showed normal early development of motor 
coordination, with head control achieved at 4 months of age, the ability to sit supported at 8 months and 
at 13 months the ability to move via rolling, sit unaided and stand with support316. Mental and language 
development were however delayed316. At 14 months of age, the patient began to exhibit regression, 
losing acquired skills, most notably the ability to sit and to stand316. In addition, restlessness and 
involuntary movements developed and by 24 months of age, severe retardation was apparent316. 
Isoleucine challenge was found to result in a marked increase in plasma isoleucine levels within 30 minutes 
of administration (780 μmol/L, normal range, 28–95 μmol/L) which remained outside of the normal range 
over 4 hours (230 μmol/L), suggestive of a defect in isoleucine degradation316. Enzyme assays performed 
using patient fibroblasts revealed an almost complete absence of 17β-HSD10 activity, measured as 0.02 
nmol/min-1mg-1 (controls, 1.48 ± 0.12 nmol/min-1mg-1). During the catabolism of isoleucine, 17β-HSD10 
catalyses the penultimate step, involving the conversion 2-methyl-3-hydroxybutyryl-CoA to 2-
methylacetoacetyl-CoA which is subsequently cleaved by β-ketothiolase, producing propionyl-CoA and 
acetyl-CoA (Figure 1.23)317,318. 
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The administration of an isoleucine restricted diet was seen to arrest neurological decline over the 
following 7 months316. However, the patient has subsequently been reported deceased, although it is not 
known if this was disease related, and the efficacy of isoleucine restriction reported as limited in other 
instances319,320.  It has also been noted that the progression of MHBD deficiency is atypical for a defect in 
the isoleucine degradation pathway, rather mirroring that of a mitochondrial disease319. β-ketothiolase 
deficiency represents a similar defect in isoleucine degradation, with β-ketothiolase responsible for the 
step immediately following that of 17β-HSD10, and presents with an almost identical metabolic profile321. 
β-ketothiolase deficiency results in periods of ketoacidosis with associated severe vomiting which, if not 
appropriately managed, may progress to coma and death. The administration of an isoleucine restricted 
diet treats β-ketothiolase effectively and when combined with the appropriate treatment of periods 
ketoacidosis, normal development is observed in the majority of patients (23 out of 26 sampled)322,323. 
Neurological degeneration is not a characteristic feature of the disease, although psychomotor 
degeneration may occur following severe periods of ketoacidosis suggesting an additional mechanism 
may be at work in the case of MHBD deficiency319,323,324. A number of additional cases of MHBD deficiency 
have since been reported325-329, with symptoms varying depending on the nature of the causative 
mutation. Mutations N247S, R226Q and D86G give rise to a severe “neonatal form” of the disease 
characterised by little neurological development, cardiomyopathy and early death330. R130C, L122V and 
P210S represent the most common mutations associated with MHBD deficiency and generate an 
“infantile form” of the disease, with normal early development followed by a progressive 
Figure 1.23 Isoleucine degradation pathway. The 17β-HSD10 enzyme is known to play a role in the catabolism of 
isoleucine, catalysing the conversion of 2-methy-3-hydroxybutyryl-CoA to 2-methacetoacetyl-CoA (Figure redrawn 
from316).   
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neurodegenerative phenotype330, whilst Q165H is known to generate an “atypical form” of MHBD 
deficiency with normal development330.  
Due to the failure of an isoleucine restricted diet to effectively treat MHBD deficiency, an alternative 
explanation was proposed relating to the role of the 17β-HSD10 enzyme in the metabolism of neuroactive 
steroids, most notably the oxidation and thus inactivation of estrogen and allopregenalone331, positing 
that a loss or indeed a gain of 17β-HSD10 activity would perturb the homeostasis of such molecules 
resulting in the neurological deficits associated with the disease332. However, the subsequent 
characterisation of a number of clinically relevant disease causing mutations demonstrated that the 
severity of MHBD deficiency does not correlate with the residual level of enzymatic activity, suggesting 
another facet of 17β-HSD10 mediated dysfunction is responsible320.  
Using Xenopus as a model organism and morpholino oligonucleotides, the 17β-HSD10 homologue 
(xHSD10) was selectively knocked down, resulting in abnormal mitochondrial morphology, as indicated 
by a marked depletion of cristae (Figure 1.24), and a concomitant increase in the number of apoptotic 
cells, as measured by DNA fragmentation320. Again using Xenopus, the selective knockdown of xHSD10 
was also found to induce defects in both neural and eye development, a phenotype rescued by the 
introduction of human 17β-HSD10320. 
 
Subsequently, two mouse models were produced using the Cre-Lox system, allowing the conditional 
knockout of the 17β-HSD10 enzyme (homozygous knockout reported as lethal)320. When 17β-HSD10 
expression was selectively prevented in endothelial cells and cells of the immune system, the resultant 
mice were found to be viable and fertile but to die at around week 25320. In the second model, the 
expression of the 17β-HSD10 enzyme was selectively eliminated from noradrenergic neurons, causing 
death at occur at around week 26320. The subsequent analysis of mitochondrial integrity, via electron 
Figure 1.24. Xenopus xHSD10 knockdown. A knockdown of the Xenopus 17β-HSD10 homologue (xHSD10) was found 
to induce mitochondrial morphological abnormalities. On the basis of morphological appearance, mitochondria were 
classified as dense, dark (C1), loosely packed (C2) and with depleted cristae (C3) with corresponding quantification of 
each (D). Figure reproduced from320. 
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microscopy, revealed a similar pattern of dysfunction to that seen with Xenopus models (Figure 1.26), 
with an elevation in the number of mitochondria harbouring loose, swollen or depleted cristae in the locus 
coeruleus (17β-HSD10 knockout) as compared to the cerebellum (control region) (Figure 1.25)320.  
  
Using recombinant protein, three clinically relevant mutants of the 17β-HSD10 enzyme; R130C, D86G and 
Q165H, were characterised in terms of residual levels of enzymatic activity, with 64%, 28% and 0% 
observed respectively, as compared to the wild-type enzyme320. Whilst showing the highest levels of 
residual activity, the R130C mutation was found to destabilise the enzyme, indicated by a time-dependent 
decrease in activity following incubation at room temperature, and a decrease in the level of detectable 
protein in lysates taken from patient fibroblasts320. All three mutants were confirmed to localise to the 
mitochondrial matrix, precluding the possibility of improper subcellular localisation influencing results320. 
Despite having no residual enzymatic activity, patients harbouring the Q165H mutation are known to 
display normal neurological development, whilst those with the D86G and R130C mutations present with 
a more severe phenotype320. In cultured fibroblasts the aforementioned mutations of the 17β-HSD10 
enzyme were found to induce abnormalities in mitochondrial morphology as compared to non-diseased 
controls. Those taken from patients harbouring the R130C and D86G mutations showed aberrant 
morphology characterised by swollen or depleted cristae, whilst fibroblasts from patients with the Q165H 
mutation were found to display an intermediate phenotype320.  
Figure 1.25. Murine 17β-HSD10 conditional knockout. A knockout of the 17β-HSD10 protein from noradrenergic 
neurons, present in the locus coeruleus, was found to induce mitochondrial morphological abnormalities. On the 
basis of morphological appearance mitochondria were classified as dense, dark (B1), loosely packed (B2) and with 
depleted cristae (B3) with corresponding quantification of each (C).  Figure reproduced from320. 
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Interestingly, using a Xenopus model, the catalytically inactive Q165H mutant was found to be capable of 
partially rescuing the enhanced levels of apoptosis observed following 17β-HSD10 knockdown, an effect 
not seen with the R130C and D86G mutants (Figure. 1.26)320.  
 
It therefore appears that the 17β-HSD10 enzyme plays a key role in maintaining mitochondrial integrity, 
with a loss of expression resulting in mitochondrial morphological abnormalities. The fact that this effect 
does not correlate with the residual level of enzyme activity indicates that the 17β-HSD10 enzyme 
performs an additional role outside of its catalytic activities, which becomes perturbed in the diseased 
state.  
Subsequent work has shown the 17β-HSD10 enzyme (MRRP2) to be involved in the formation of the 
mitochondrial ribonuclease P complex (mtRNase P), along with tRNA methyltransferase 10C 
(TRMT10C/MRRP1) and proteinaceous RNase P (PRORP/MRRP3)333. Mitochondrial transfer RNA (tRNA) 
molecules are synthesised in an immature form often requiring extensive modification before being 
rendered active334. The mtRNase P complex has been shown to be capable of performing two of these 
steps, namely the endonucleolytic removal of 5’ nucleotide extensions and the N1-methylation of 
adenosine and guanosine, required for the correct folding of tRNA molecules335. The physical presence of 
both TRMT10C and 17β-HSD10 has been shown to be required for mtRNase P activity, however the 
dehydrogenase activity of the 17β-HSD10 enzyme has been shown to be entirely dispensable for both the 
endonucleolytic and methyltransferase activities of the complex335. The selective knockdown of 17β-
HSD10 has been shown to cause a corresponding decrease in the level of TRMT10C protein, with no 
corresponding decrease at the mRNA level, suggesting the primary function of the 17β-HSD10 enzyme in 
the mtRNase P complex may be to bind to and stabilise the TRMT10C subunit (Figure 1.27)330.  
Figure 1.26. Rescue of 17β-HSD10 knockdown induced apoptosis by MHBD causing 17β-HSD10 mutations. The 
knockdown of the Xenopus 17β-HSD10 homologue (xHSD10) was found to induce a marked increase in apoptosis. 
Reintroduction of the 17β-HSD10 enzyme harbouring known MHBD disease causing mutations revealed a partial 
phenotypic rescue using the Q165H mutant but not with R130C or D86G. Figure reproduced from320. 
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When the levels of 17β-HSD10 and TRMT10C were assessed in fibroblasts taken from patients harbouring 
the R130C mutation (high dehydrogenase activity, severe phenotype) or the Q165H mutation (no 
dehydrogenase activity, mild phenotype) markedly lower levels of both proteins were observed with the 
R130C mutation, but less so with Q165H (Figure 1.28)330.  
 
 
 
 
 
 
 
In concordance with these findings, the knockdown of 17β-HSD10 in HeLa cells was found to induce a 
significant increase in unprocessed mitochondrial transcripts, possibly indicating an mtRNaseP defect, an 
effect which was mirrored by the R130C mutation, but not Q165H330. Thus, whilst the residual level of 
17β-HSD10 catalytic activity does not correlate with MHBD disease severity, the absolute level of 17β-
HSD10 protein, and its ability to stabilise the TRMT10C protein, appears to. Therefore, MHBD deficiency 
may primarily be due to a defect in mitochondrial tRNA processing, giving rise to a generalised 
mitochondrial dysfunction, as opposed to a direct loss of 17β-HSD10 enzymatic activity. In support of 
these conclusions, the subsequent assessment of 17β-HSD10 protein levels in an MHBD patient 
harbouring the N247S mutation revealed a decrease in expression, giving rise to a defect in mtRNase P 
activity and resulting in reduced assembly and activity of mitochondrial complexes I, III, IV and V336. 
 
Figure 1.27. Effect of 17β-HSD10 knockdown on TRMT10C (MRPP1) and PRORP (MRRP3) protein levels. The 
knockdown of 17β-HSD10 using siRNA was found to induce a corresponding decrease in the level of expression of the 
TRMT10C protein, with no corresponding decrease at the mRNA level, suggesting 17β-HSD10 may bind to and thereby 
stabilise the TRMT10C subunit of the mtRNase P complex. MRRP3 expression was unaffected. Figure reproduced 
from330. 
Figure 1.28. Expression of mtRNaseP components in MHBD patient fibroblasts. Patients harbouring the R130C 
mutation (high enzymatic activity, severe phenotype) were found to have significantly reduced expression of 17β-HSD10 
and MRPP1 (TRMT10C) as compared to those with the Q165H mutation (no enzymatic activity, mild phenotype). Figure 
reproduced from330. 
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In addition to its role in MHBD deficiency, the 17β-HSD10 enzyme has also been implicated in Alzheimer’s 
disease. Using a yeast-two-hybrid system, the mitochondrial 17β-HSD10 enzyme has been shown to 
interact with Aβ in a highly potent manner337. Intriguingly, in cell culture, the 17β-HSD10/Aβ complex was 
found to be cytotoxic, resulting in enhanced levels of mitochondrial dysfunction and cell death, as 
measured by MTT reduction (Figure 1.29, left) and nuclear DNA fragmentation (Figure 1.29, right), 
compared to either species in isolation337. The disruption of this interaction was found to protect against 
these hallmarks of cellular stress, suggesting that the 17β-HSD10 enzyme may play a role in mediating the 
cytotoxic effects of Aβ and thus may offer a novel therapeutic target for treating AD337. 
 
Subsequent work further characterised the interaction of 17β-HSD10 with Aβ. Using radiolabelled 125I-
17β-HSD10, the interaction was confirmed to be of high affinity, with a KD value of 40-70 nM, measured 
using both Aβ1-40 and Aβ1-42338. Although binding was observed in the low nanomolar range, an inhibition 
of the catalytic activity of the 17β-HSD10 enzyme was only apparent at markedly higher Aβ 
concentrations, with a Ki value of 1.6 ± 0.5 μM, as measured against the 17β-HSD10 conversion of 
acetoacetyl-CoA to L3-hydroxybutyryl-CoA,  possibly indicating that oligomerised forms of Aβ are required 
to inhibit enzymatic activity338. As was shown previously (Figure 1.29), the simultaneous overexpression 
of wild-type 17β-HSD10 alongside Aβ1-42 was again found to be toxic, resulting in oxidative stress and cell 
death, in this instance measured by 4-hydroxynoneal staining, a marker of oxidative damage (Figure 1.30, 
right) and DNA fragmentation (Figure 1.30, left)338. Site directed mutagenesis was used to introduce two 
missense mutations (Y168G/K172G) into the 17β-HSD10 cDNA sequence, altering conserved residues 
within the catalytic triad of the enzyme (S155, Y168, K172) and thereby rendering the enzyme inactive. 
The Y168G/K172G mutant (mutERAB) was confirmed to bind to Aβ1-42 with comparable affinity to the wild-
type enzyme, but when overexpressed alongside Aβ1-42, no marked increase in oxidative damage or cell 
Figure 1.29. Cytotoxic effects induced by co-transfection of 17β-HSD10/Aβ. Transient transfection of COS-7 cells 
with both the 17β-HSD10 enzyme and Aβ was found to induce a marked increase in cellular stress as measured using 
the MTT assay (left) and DNA fragmentation (right) as compared to either species in isolation. Figures reproduced 
from337. 
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death was apparent, suggesting the toxicity of the 17β-HSD10/Aβ interaction is dependent on the catalytic 
activity of enzyme (Figure 1.30)338. 
 
In 2004, Lustbader et al. co-crystallised the 17β-HSD10 enzyme in the presence of molar excess of Aβ1-
40
303. Although SDS-PAGE analysis of the produced crystals showed Aβ1-40 was indeed present, no electron-
density corresponding to Aβ1-40 was observed, suggesting the region to which Aβ1-40 is bound is highly 
disordered. The 17β-HSD10 enzyme harbours a unique insert, termed the loop D region, as compared to 
other members of the 17β-hydroxysteroid dehydrogenase family and as 17β-HSD10 is the only member 
reported to interact with Aβ, it was hypothesised that the loop D region may be the site to which Aβ 
binds303. Using site directed mutagenesis, this was confirmed to be the case, with two key regions found 
to be responsible for Aβ binding, S98-Y101 and T108-T101 (Figure 1.31)303. 
 
 
Figure 1.30. Effect of 17β-HSD10 catalytic activity on 17β-HSD10/Aβ cytotoxicity. Co-transfection of COS-7 cells with 
wild-type 17β-HSD10 (ERAB) and Aβ resulted in a marked increase in DNA fragmentation (left) and 4-hydroxynoneal 
levels (right) whilst a catalytically inactive mutant of the 17β-HSD10 enzyme (Y168G/K172G, mutERAB) with Aβ did 
not. Figures reproduced from338.   
Figure 1.31. Effect of missense mutations on the ability of 17β-HSD10 to bind Aβ. The region of the 17β-HSD10 
enzyme (ABAD) to which Aβ binds was identified as involving amino acids 1-158 and subsequently narrowed to amino 
acids S98A, K99A, T100A and Y101A. Figure reproduced from303. 
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The region of the 17β-HSD10 enzyme encompassing the aforementioned residues (92-120) was cloned 
and fused to the human immunodeficiency virus-1 derived Tat protein, allowing cellular membrane 
penetration and generating a specific inhibitor of the 17β-HSD10/Aβ interaction, termed the ABAD-Decoy 
Peptide (ABAD-DP)303. Through the use of surface-plasmon resonance the ABAD-DP was found to be 
capable of disrupting the 17β-HSD10/Aβ interaction, with a Ki value of 1.72 ± 0.20 μM (Figure 1.32). A 
peptide harbouring the reversed amino acid sequence, termed ABAD-RP (residues 120-92) was found to 
have no effect, suggesting the ABAD-DP induced perturbation of the 17β-HSD10/Aβ interaction is specific 
in nature.  
 
Transgenic mice were subsequently generated, harbouring mutant APP (mAPP), producing elevated levels 
of Aβ, neuronally expressed 17β-HSD10 or the two in combination303. Primary cortical neurons derived 
from 17β-HSD10 transgenic mice were found to display enhanced mobilisation of cytochrome c from the 
membrane fraction to the cytosol following Aβ1-42 challenge, indicative of an induction of apoptosis, whilst 
neurons from dual transgenic animals expressing both 17β-HSD10 and mAPP showed spontaneous 
release of cytochrome c303.  Pre-treatment with the ABAD-DP was found to protect against the observed 
mobilisation of cytochrome c, whilst no such effect was apparent with the ABAD-RP, suggesting disruption 
of this interaction is protective in vitro (Figure 1.33)303. 
Figure 1.32. ABAD-DP mediated disruption of 17β-HSD10/Aβ interaction. Using surface plasmon-resonance, the 
ABAD-DP was found to be capable of disrupting the interaction between 17β-HSD10 (ABAD) and Aβ with a Ki value 
of 1.72 ± 0.20 μM. The reversed peptide sequence (ABAD-RP) had no effect. Figure reproduced from303. 
Figure 1.33. 17β-HSD10/Aβ induced apoptosis. Primary neuronal cultures were derived from transgenic mice 
overexpressing mutant APP, 17β-HSD10 (ABAD) or the two in combination. Aβ1-42 challenge was seen to induce 
apoptosis in 17β-HSD10 expressing neurons, as measured by cytochrome c release, whilst neurons derived from 
dual transgenic animals showed spontaneous cytochrome c mobilisation. The ABAD-DP was found to protect against 
apoptosis, whilst the ABAD-RP did not. Figure reproduced from303.  
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Subsequent work conducted by Yao et al. and Takuma et al. further characterised the protective effects 
of the ABAD-DP. Immunoprecipitation of Aβ from cortical mitochondria was performed using samples 
derived from transgenic mice expressing mutant APP, generating elevated levels of Aβ339. Samples were 
subsequently separated using SDS-PAGE and immunoblotting performed for the 17β-HSD10 enzyme. An 
enrichment of co-immunoprecipitated 17β-HSD10 was observed in mAPP expressing mice, indicative of 
elevated levels of the 17β-HSD10/Aβ complex339. The administration of the ABAD-DP intraperitoneally 
was found to reduce the level of co-immunoprecipitated 17β-HSD10, indicating that the ABAD-DP is 
capable of perturbing the 17β-HSD10/Aβ interaction in vivo, whilst no such effect was apparent with the 
ABAD-RP (Figure 1.34)339. 
  
Mitochondria from mAPP transgenic mice were found to exhibit significantly reduced levels of oxygen 
consumption and reduced activity of complex III and complex IV. In addition, immunocytochemistry 
revealed elevated levels of 4-HNE (a marker of oxidative stress) within the hippocampus in mAPP 
transgenic mice, effects which were reversed by the intraperitoneal administration of the ABAD-DP339. 
Using primary neuronal cultures from dual transgenic mice expressing both mAPP and 17β-HSD10, an 
elevation in reactive oxygen species leakage from the mitochondria was detected (hydrogen peroxide and 
superoxide) and was attributed to a defect in complex IV340. A reduced  level of ATP  was also seen in 
cultures derived from dual transgenic animals, again attributed to a defect in complex IV activity340. 
Following 6 days in culture, an increase in caspase-3 activity, DNA fragmentation and LDH release was 
observed in primary neuronal cultures derived from mAPP/17β-HSD10 dual transgenic mice, as compared 
neurons derived from single transgenic animals, indicating cell death. These effects were seen to be 
diminished in the presence of antioxidants, suggesting elevated reactive oxygen species generation may 
be the underlying cause340. Thus, the 17β-HSD10/Aβ interaction appears to induce mitochondrial 
dysfunction resulting in elevated levels of reactive oxygen species, which promote cell death.  
Figure 1.34. ABAD-DP mediated disruption of the 17β-HSD10/Aβ interaction in vivo. Following Aβ 
immunoprecipitation from purified mitochondria derived from mAPP transgenic mice, an increase in the level of 17β-
HSD10 (ABAD) is apparent in mAPP expressing mice, indicating enhanced levels of 17β-HSD10/Aβ complex. 
Intraperitoneal administration of the ABAD-DP was found to perturb the 17β-HSD10/Aβ complex, whilst the ABAD-
RP did not. Figure reproduced from339. 
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The aforementioned toxic effects of the 17β-HSD10/Aβ interaction were seen to translate into a cognitive 
deficit in mAPP/17β-HSD10 dual transgenic animals as indicated by an increase in the number of errors 
during the radial arm water maze test, characteristic of a defect in spatial learning and memory. Such 
effects were ameliorated upon treatment with the ABAD-DP, but not with the ABAD-RP (Figure 1.35)339.  
 
The histological examination of cholinergic neuronal density in the subiculum of mAPP expressing mice 
revealed a significant reduction in mAPP expressing animals, similar to abnormalities associated with AD, 
a phenotype which was rescued in dual transgenic animals expressing both mAPP and a mitochondrially 
targeted ABAD-DP peptide339. A concomitant decrease in the level of AChE activity was also noted in mAPP 
transgenic animals, which was not apparent in mAPP/mito-ABAD-DP mice339. In terms of behaviour, the 
transgenic expression of mito-ABAD-DP was seen to induce a similar, but less pronounced effect (Figure 
1.36) as compared to the aforementioned intraperitoneal administration of the ABAD-DP (Figure 1.35)339. 
 
 
Figure 1.35. Effect of intraperitoneal administration of the ABAD-DP on radial arm test performance. Transgenic 
mice expressing mAPP were found to have a deficit in spatial learning and memory which was reversed by the 
intraperitoneal administration of the ABAD-DP, but not the ABAD-RP. Figure reproduced from339. 
Figure 1.36. Effect of transgenic expression of the ABAD-DP on radial arm test performance. Transgenic mice 
expressing mAPP were found to have a deficit in spatial learning and memory which was ameliorated, but not 
reversed, in dual transgenic mice expressing mAPP and a mitochondrial targeted ABAD-DP. Figure reproduced 
from339. 
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In the AD diseased state, the level of expression of the 17β-HSD10 enzyme has been shown to be 
increased, 28% in the inferior temporal lobe, 40% in the hippocampus303 and 573% in the CSF341,  with a 
corresponding enrichment in the 17β-HSD10/Aβ complex in AD patients as compared to non-diseased 
controls (Figure 1.37)303. 
 
The proteomic analysis of the brains of dual transgenic mAPP/17β-HSD10 mice has revealed the up-
regulation of peroxiredoxin II, an antioxidant enzyme presumed to represent a compensatory response 
to the elevated levels of oxidative stress associated with the 17β-HSD10/Aβ interaction (Figure 1.38, left) 
with a similar up-regulation apparent in the brains of AD patients (Figure 1.38, right)342.  
 
Figure 1.38. Peroxiredoxin II upregulation. The expression of the antioxidant enzyme peroxiredoxin II has been 
shown to be elevated in the brains of mAPP/17β-HSD10 transgenic mice (left panel) and in the brains of Alzheimer’s 
diseased patients (right panel). Figures reproduced from342. 
Figure 1.37. 17β-HSD10/Aβ complex in AD brain. Aβ was immunoprecipitated from AD brain lysates, samples 
separated by SDS-PAGE and immunoblotting performed for 17β-HSD10. In the brains of AD patients a marked 
enrichment of 17β-HSD10 is observed, indicating elevated levels of the 17β-HSD10/ Aβ complex. Figure reproduced 
from303. 
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Similarly, an upregulation of endophilin I has also been reported in the brains of mAPP/17β-HSD10 
transgenic mice and in the brains of AD patients (Figure 1.39), thought to be involved in cell death 
mediated by an activation of the JNK-1 signalling pathway343. pathways. 
 
The upregulation of peroxiredoxin II and endophilin I in the brains of transgenic mAPP/17β-HSD10 was 
found to be reversed upon treatment with the ABAD-DP, but not the ABAD-RP, suggesting the enhanced 
levels of each are a direct response to the toxic effects of the 17β-HSD10/Aβ interaction (Figure 
1.40)342,343. The fact that such upregulation is also observed in the AD brain suggests the protective effects 
observed by the disruption of the 17β-HSD10/Aβ interaction in mouse models may translate to a cognitive 
improvement in patients with AD. 
 
 
 
 In 2006, Xie et al. showed that Frentizole, an FDA approved antiviral and immunosuppressant compound, 
is capable of disrupting the interaction between the 17β-HSD10 enzyme and Aβ344. Frentizole, the parent 
molecule, was found to be relatively poor at doing so with an IC50 value of approximately 200 μM. 
However, further derivatisation of the Frentizole scaffold generated two molecules with markedly 
improved potency, now with IC50 values of approximately 10 μM344 (Figure 1.42). Frentizole derivatives 
may therefore hold potential for the generation of novel AD directed therapeutic agents, acting to disrupt 
the toxic 17β-HSD10/Aβ interaction. 
Figure 1.39. Endophilin I upregulation. The expression of endophilin I has been shown to be elevated in the brains 
of mAPP/17β-HSD10 transgenic mice (left panel) and in the brains of Alzheimer’s diseased patients (right panel). 
Figures reproduced from343. 
 
Figure 1.40. 17β-HSD10/Aβ dependency of peroxirdoxin II and enophilin I upregulation. Dual transgenic animals 
expressing mAPP/17β-HSD10 show upregulation of peroxiredoxin II (left) and endophilin I (right), an effect which is 
reversed by administration of the ABAD-DP but not the ABAD-RP. Figures reproduced from342, 343. 
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Figure 1.42. Frentizole derived inhibitors of the 17β-HSD10/Aβ interaction. Xie et al.345 identified Frentizole as a 
compound capable of disrupting the 17β-HSD10/Aβ complex and subsequently developed two derivatives exhibiting 
enhanced potency. Figure adapted from344. 
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Summary: 
The amyloid cascade hypothesis was built upon evidence gleaned from the histological analysis of the 
brains of AD patients, revealing a marked increase in the deposition of insoluble extracellular plaques of 
Aβ (Section 1.1), and upon genetic based association studies in which mutations in the amyloid-precursor 
protein, or APP processing enzymes PSEN1 or PSEN2 generate an autosomal dominant form of disease 
(Section 1.2). In its original guise the amyloid cascade hypothesis posited that insoluble extracellular 
plaques of Aβ were the main disease driving lesion in the AD brain. However, the observation that plaque 
load does not correlate with disease severity, and following the failure of several high profile therapies, 
which were found to dramatically reduce the plaque burden with no marked improvement in cognition 
or slowing of the disease process (Section 1.32), led to an alteration of the hypothesis, with soluble forms 
of Aβ now thought to be the main disease driving species (Section 1.41). 
Such soluble species of Aβ have been identified within various subcellular compartments where they are 
hypothesised to interact with cellular proteins, disrupting normal physiological functions and resulting in 
the synaptic dysfunction and cell death characteristic of AD. Mitochondrial Aβ has been shown to interact 
with the 17β-HSD10 enzyme with cytotoxic consequences, and interestingly, these cytotoxic effects 
appear to be dependent on the catalytic activity of the 17β-HSD10 enzyme (Section 1.52). In primary 
neuronal cultures derived from transgenic mice, the 17β-HSD10/Aβ interaction has been shown to result 
in overt mitochondrial dysfunction and cell death, effects which was seen to translate into a cognitive 
deficit in murine models, and were reversed upon disruption of the 17β-HSD10/Aβ interaction. In 
response to the enhanced levels of stress caused by the 17β-HSD10/Aβ, two proteins were found to be 
up-regulated; peroxiredoxin II, an antioxidant enzyme and endophilin I, linked to the induction of 
apoptosis via the JNK pathway. Interestingly, in the brains of AD patients, an enrichment was observed 
for the 17β-HSD10/Aβ complex, as compared with non-diseased controls, with a concomitant increase in 
the levels of peroxiredoxin II and endophilin I, possibly suggesting shared mechanistic pathways. 
Mutations in the 17β-HSD10 gene have been linked to a neurodegenerative disease termed MHBD 
deficiency (Section 1.52). Originally, MHBD deficiency was attributed to a defect in the degradation of 
isoleucine, however the observation that severity of disease did not correlate with the residual level of 
enzymatic activity suggested otherwise. MHBD deficiency is now thought to result from a defect in a 
second non-enzymatic function of the 17β-HSD10 protein, which, alongside TRMT10C and PROPR, forms 
the mtRNase P complex, required for mitochondrial tRNA maturation and protein synthesis. In the context 
of the mtRNase P complex the enzymatic activity of the 17β-HSD10 enzyme has been shown to be entirely 
dispensable, with the enzyme instead thought to perform a structural role, stabilising the TRMT10C 
subunit. Thus, MHBD mutations are thought to perturb the formation of mtRNase P resulting in a 
generalised mitochondrial dysfunction. 
Taken together, these observations suggest that two 17β-HSD10 directed therapeutic approaches may 
hold merit in treating AD, namely the disruption of the 17β-HSD10/Aβ complex or the direct inhibition of 
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17β-HSD10 enzymatic activity (Figure 1.40). The latter being viable provided the enzyme remains 
physically present and capable of performing its function within the mtRNase P complex. 
 
It seems plausible that the ability of the Frentizole scaffold to perturb the interaction between 17β-HSD10 
and Aβ may confer the ability to bind directly to the 17β-HSD10 enzyme, and in doing so may inhibit its 
catalytic activity, potentially allowing both therapeutic avenues to be exploited using a single compound. 
We sought to investigate this further. 
 
 
 
 
 
 
 
 
 
 
Figure 1.41. 17β-HSD10 directed therapeutic intervention. The formation of the 17β-HSD10/Aβ complex has been 
shown to result in mitochondrial dysfunction and cell death, with these effects dependent on the catalytic activity of 
the 17β-HSD10 enzyme. Thus, both the perturbation of the interaction and the direct inhibition of 17β-HSD10 catalytic 
activity may hold merit in treating AD. 
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Project Aims: 
The primary aim of this project was to identify and characterise novel small molecule inhibitors of the 
17β-HSD10 enzyme for the treatment of Alzheimer’s disease.  
To this end, a series of enzyme and cellular-based assays were developed allowing the identification of 
small molecules with inhibitory activity against 17β-HSD10. Two initial, enzyme based screening 
methodologies were employed; a targeted approach using derivatives of the Frentizole scaffold, which 
we suspected may interact directly with the 17β-HSD10 enzyme, and an explorative approach using a 
diverse library of small molecules with the aim of identifying a range of novel inhibitor scaffolds. Assays 
were subsequently developed to assess the drug-like properties of hit compounds; namely potency, 
specificity and mechanism of action.  
Whilst it was unlikely that hit compounds identified herein would in themselves be of use as therapeutic 
agents, such compounds, once validated, could form the basis of new derivative series with more 
favourable drug-like properties. The development of robust screening assays would allow the efficient 
evaluation of compounds of interest and the logical, iterative design of more efficacious compound series.   
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Section 1: Molecular Cloning 
All reagents were purchased from Sigma-Aldrich and all solutions were prepared using MilliQ ultrapure 
water, unless otherwise stated. DNA sequencing was performed using the services offered by MRC PPU, 
DNA Sequencing and Services, Dundee. 
Reagents: 
E. coli BL21(DE3) (NEB: C2527I), E. coli DH5-α (NEB: C2988J), calcium chloride (C3306), glycerol (Thermo 
Fisher: 10021083), agarose (Thermo Fisher: 17850), ethidium bromide (E1510), guanosine (G6752), 
Antarctic Phosphatase (NEB: M0289), T4 DNA ligase (Promega: M1801), Phusion DNA polymerase (NEB: 
M0530), GoTaq-polymerase (Promega: M7122), FastDigest Dpn1 (Thermo Fisher: FD1703), SSPI 
restriction endonuclease (NEB: R0132), T4 DNA polymerase (NEB: M0203S), EDTA (E4884), M-MLV 
reverse transcriptase (Promega: M1701), oligo-dT primers (Promega: C1101), AMV reverse transcriptase 
(Promega: M5101). 
Equipment: 
Agarose gel casting unit (Camlab: H1-set), Qiagen Miniprep Kit (Qiagen: 27104), Qiagen Maxiprep Kit 
(Qiagen: 12163), Wizard SV Gel and PCR Clean-Up kit (Promega: A9281), RNeasy kit (Qiagen: 74106), 
QIAShredder column (Qiagen: 79654). 
1.01 Competent Cell Generation: 
Using aseptic technique, naive E. coli strains, BL21 (DE3) and DH5-α, were streaked from a glycerol stock 
onto agar plates and grown at 37°C overnight. Following incubation, a single colony was picked and 
transferred to a starter culture of 10 mL Luria Broth and grown overnight at 37°C, with agitation at 225 
rpm. 5 mL of overnight culture was added to 500 mL Luria Broth and incubated at 37°C and 225 rpm. 
Optical density was measured periodically until OD600= 0.4. The culture was split equally into two 
centrifuge bottles, placed on ice for 20 minutes and centrifuged at 3000g for 15 minutes at 4°C. The cell 
pellet was resuspended gently (via swirling) in 30 mL ice cold 0.1 M CaCl2 and incubated on ice for 30 
minutes. Cells were centrifuged again at 3000g for 15 minutes at 4°C and resuspended gently (via swirling) 
in 8 mL 0.1 M CaCl2 containing 15% glycerol (v/v). Cells were aliquoted into 1.5 mL microcentrifuge tubes, 
snap frozen using liquid nitrogen and stored long term at -80°C.  
1.02 Heat-Shock Transformation: 
Cells were thawed on ice for approximately 30 minutes. An appropriate amount of DNA (typically 50-100 
ng of purified plasmid) was added, gently mixed and incubated on ice for 20 minutes. Following 
incubation, cells were heat-shocked at 42°C for 45 seconds before being transferred back onto ice for 2 
minutes. 200 μL of SOC media was added and cells incubated at 37°C and 225 rpm for 1 hour. Cells were 
spread onto agar plates containing the appropriate antibiotic and grown overnight at 37°C (if using 
ampicillin, the 1 hour incubation was omitted). 
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1.03 Glycerol Stock Preparation: 
Competent E. coli of the appropriate strain (DH5-α for routine cloning) were transformed with the DNA 
construct of interest via heat-shock, spread onto agar plates containing the appropriate antibiotic and 
incubated overnight at 37°C. A single colony was picked, added to 10 mL of Luria Broth containing the 
appropriate antibiotic and grown overnight at 37°C and 225 rpm. 750 μL of saturated culture was mixed 
with sterile glycerol (20% (v/v) final) in a 1.5 mL microcentrifuge tube. Glycerol stocks were stored long 
term at -80°C. 
1.04 Plasmid DNA Isolation: 
Either a single colony or a sample of glycerol stock was picked and grown in an appropriate volume (varied 
depending upon the desired yield and plasmid copy number) of antibiotic containing Luria Broth. The 
following morning the culture was harvested via centrifugation at 5000g for 15 minutes at 4°C. DNA 
extraction was performed using either the Qiagen Miniprep or Maxiprep kit, depending upon the desired 
yield, as per manufacturer's instructions. 
1.05 Restriction Digest: 
An appropriate quantity of DNA was employed depending upon the desired application. The appropriate 
digest buffer was added to a 1 x concentration (typically NEB CutSmart) and a sufficient quantity of 
restriction endonuclease added (typically a two-fold excess). Total glycerol concentration was maintained 
below 5% (v/v) to avoid star activity. If high-fidelity restriction endonucleases were employed, digests 
were performed overnight at 25°C, otherwise a typical reaction time of 1 hour at 37°C was employed. 
Where possible, dual digests were performed, following appropriate single digest controls, otherwise 
reactions were performed sequentially. 
1.06 Agarose Gel Electrophoresis: 
A suitable concentration of agarose was used depending on the size of fragments to be resolved, for 
routine applications 1% (w/v). Agarose powder was dissolved in 1 x TBE buffer via heating. The gel was 
cooled, ethidium bromide added (0.5 μg/mL) and the gel cast into a Camlab H1-Set agarose gel 
electrophoresis unit. Gels were allowed to set for 1 hour at 4°C after which a sufficient volume of 1 x TBE 
buffer was added to cover both the gel and electrodes. Samples were mixed with 1 x DNA loading dye and 
dispensed into wells. Samples were separated at 80 V for approximately 1 hour (application depending) 
and visualised using either a UV-transilluminator or a BioRad ChemiDoc. 
1.07 DNA Gel Extraction: 
Samples of interest were resolved via agarose gel electrophoresis using 1 x TAE buffer. If using UV 
illumination, guanosine (1 mM) was added to the agarose gel and 1 x TAE running buffer. The band of 
interest was excised using a scalpel blade, and DNA extracted using a Promega SV Gel and PCR Clean-Up 
kit, as per manufacturer's instructions.   
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1.08 Ligation: 
Following gel extraction, cut vector was treated with Antarctic Phosphatase, as per manufacturer's 
instructions. Vector and insert were mixed at varying molar ratios (typically 50 ng vector, 1:3), higher 
quantities of insert were employed for difficult ligations. T4 DNA ligase was added and the mixture 
incubated as per manufacturer's instructions. For difficult ligations, the sample was incubated overnight 
in a BioRad T100 PCR machine cycling between 10°C and 30°C. Following incubation, a sample of the 
ligation mixture was transformed into DH5-α E. coli via heat-shock, spread onto agar plates harbouring 
the appropriate antibiotic and incubated overnight at 37°C. 
1.09 Diagnostic Digest: 
Following ligation, single colonies were picked, cultures grown and DNA extracted via Miniprep. Samples 
were treated using the appropriate restriction endonucleases, depending upon the cloning strategy 
employed. Following digestion, products were separated via agarose gel electrophoresis and imaged using 
a UV-transilluminator, with the presence of a fragment at the expected molecular weight indicating the 
success of the employed cloning strategy.   
1.10 General PCR: 
PCR primers were designed as per standard protocol depending on the desired application. PCR reactions 
for sub-cloning purposes were performed using the high-fidelity Phusion DNA Polymerase, for analytical 
work, the low fidelity GoTaq-polymerase was employed. 
1.11 Site Directed Mutagenesis: 
Agilent QuickChange style primers were designed as per manufacturer's specification (25-45 nucleotides 
in length with 10-15 nucleotides either side of the mismatch, a minimum GC content of 40% and a Tm ≥ 
78°C) and PCR reactions performed using Phusion polymerase (100 ng template), cycling conditions: 
98°C - 5 minutes 
98°C- 30 seconds 
55-72°C - 30 seconds 
72°C - Varied (15-30 seconds/kb) 
72°C - 5 minutes 
4°C - Hold 
 
PCR product was treated with FastDigest Dpn1 as per manufacturer's instructions and the success of each 
reaction assessed via agarose gel electrophoresis. Product was transformed into competent DH5-α E. coli 
via heat-shock, cultures grown, DNA was extracted and samples sent for DNA sequencing. 
For difficult mutations, a modified primer design described by Liu & Naismith was employed, 
incorporating comparatively long 3’ overhangs on both forward and reverse primers345.   
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1.12 Ligation Independent Cloning (LIC): 
PCR primers were designed to amplify the sequence of interest out of the current vector and 
simultaneously add ligation independent cloning tags: 
Forward LIC-tag: 5'-TACTTCCAATCCAATGCA-3' 
Reverse LIC-tag: 5'-TTATCCACTTCCAATGTTATTA-3' 
A standard PCR reaction was performed using Phusion polymerase as per manufacturer’s instructions and 
the product gel purified. The pET-MBP plasmid was a gift from Scott Gradia (Addgene #29656). Vector 
DNA was treated with SSPI restriction endonuclease, as per manufacturer's instructions, and the linear 
product gel purified. Gel extracted vector and PCR product were treated with T4 DNA polymerase in the 
presence of dGTP and dCTP respectively, exploiting the enzyme's intrinsic 3'>5' exonuclease activity to 
generate complementary overhangs. Vector and insert were mixed at varying molar ratios (50 ng vector, 
1:3, 1:5, 1:10) heated to 70°C and allowed to cool to room temperature. EDTA was added to a final 
concentration of 5 mM and the mixture incubated for 5 minutes at room temperature before being 
transformed into competent DH5-α E. coli via heat-shock. Cultures were grown from single colonies, DNA 
extracted, and samples sent for DNA sequencing. 
1.13 cDNA Cloning: 
M-MLV Reverse-Transcriptase: 
mRNA was extracted from 5 x 106 HEK293 cells using a Qiagen RNeasy kit and a QIAShredder column, as 
per manufacturer’s instructionns. A cDNA library was generated using M-MLV reverse transcriptase and 
oligo-dT primers as per manufacturer’s instructions. The cDNA sequence of interest was subsequently 
amplified using Phusion polymerase and gene specific primers (designed using NCBI-Primer Blast) 
harbouring the desired restriction endonuclease sites. The reaction was treated with the corresponding 
restriction enzymes, products separated using agarose gel electrophoresis and the desired band excised 
and purified. Empty vector was similarly digested and the fragment of interest purified and 
dephosphorylated using Antarctic Phosphatase. Fragments were ligated using T4 DNA ligase, transformed 
into competent DH5-α E. coli via heat-shock and spread onto agar plates. Colonies were picked, grown 
and DNA extracted via Miniprep. A diagnostic digest was performed and analysed via agarose gel 
electrophoresis, constructs harbouring an insert of the correct size were subsequently sent for 
sequencing.  
AMV Reverse-Transcriptase: 
mRNA was extracted from 5 x 106 HEK293 cells using a Qiagen RNeasy kit and a QIAShredder column, as 
per manufacturer’s instructions. First strand cDNA synthesis was performed using the reverse gene 
specific primer and AMV reverse transcriptase over a gradient of temperatures (50-70°C). The cDNA of 
interest was subsequently amplified using Phusion polymerase and gene specific primers (designed using 
NCBI-Primer Blast) harbouring the desired restriction endonuclease sites. The reaction was subsequently 
treated with the appropriate restriction enzymes and products separated using agarose gel 
Chapter 2: Materials and Methods 
70 
 
electrophoresis. The desired band was excised and purified via gel extraction. Empty vector was similarly 
digested and the fragment of interest gel purified and dephosphorylated using Antarctic Phosphatase. 
Fragments were ligated using T4 DNA ligase, transformed into competent DH5-α E. coli via heat-shock and 
spread onto agar plates harbouring the appropriate antibiotic. Colonies were picked, cultures grown and 
DNA extracted via Miniprep and sent for sequencing. 
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Section 2: Protein Purification 
All reagents were purchased from Sigma-Aldrich and all solutions were prepared using MilliQ ultrapure 
water, unless otherwise stated. 
Reagents: 
HEPES buffer (H3375), sodium chloride (S9888), Tris-HCl (T3253), glycine (Thermo Fisher: 10061073), 
sodium dodecyl sulfate (L4509), Coomassie Blue R250 (B7920), methanol (Thermo Fisher: 10284580), 
acetic acid (Thermo Fisher: 10394970), kanamycin (K1377), IPTG (Formedium: IPTG025) DTT (Formedium: 
DTT010), glycerol (Thermo Fisher: 10021083), ampicillin (A0166), lysozyme (L6876), E. coli BL21(DE3) 
(C2527I), imidazole (I2399), EDTA (E4884), Roche cOmplete EDTA free Protease Inhibitor Tablets 
(11836170001) 
Equipment:  
Mini-PROTEAN Tetra Handcast system (BioRad: 1658000FC), Mini PROTEAN TetraCell electrophoresis unit 
(BioRad: 552BR), 5mL HisTrap HP column (GE Healthcare: 17-5248-01), SnakeSkin Dialysis Membrane 
10kDa MWCO (Thermo Fisher: 68100), VivaSpin 20 10kDa MWCO (GE HealthCare: 28932360), HiLoad 
16/600 Superdex 75 pg column (GE- Healthcare: 28989333), AKTA-Pure purification rig 
2.1 SDS-PAGE: 
Polyacrylamide gels were cast using the Mini-PROTEAN Tetra kit at the required percentage. A stacking 
gel concentration of 4% polyacrylamide (v/v) was routinely employed, resolving gel percentage varied 
depending upon the resolution required (12% (v/v) for routine work, up to 15% (v/v) for low molecular 
weight proteins). Gels were loaded into a BioRad Mini-Tetra Cell electrophoresis unit and 1 x Tris-Glycine 
running buffer added (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.5). 
An appropriate volume of sample was mixed with 1 x protein loading dye and heated at 95°C for 5-
minutes. Samples were briefly centrifuged and loaded onto a gel of the appropriate percentage. Proteins 
were resolved at 80 V. 
2.2 Coomassie Blue Staining: 
Polyacrylamide gels were treated with Coomassie Blue R-250 staining solution (0.1% (w/v) Coomassie-
R250, 50% (v/v) MeOH, 10% (v/v) glacial acetic acid, 40% (v/v) ddH2O) for 1 hour. Following staining, gels 
were destained by boiling in water. The water was replaced periodically until background sufficiently 
reduced and gels imaged using a BioRad ChemiDoc. 
2.3 Small-Scale Expression Optimisation: 
An aliquot of competent BL21(DE3) E. coli cells were transformed with the appropriate construct 
(peHISTEV-HSD10, peHISTEV-HSD14 or pET-MBP-HSD8) via heat shock, spread onto Kanamycin containing 
agar plates (50 μg/mL) and incubated overnight at 37°C. Following incubation, a single colony was picked 
and transferred to a starter culture of Luria Broth containing the appropriate antibiotic and incubated 
overnight at 37°C and 225 rpm. The saturated culture was diluted 1:50 into antibiotic containing Luria 
Broth and grown at 37°C and 225 rpm until OD600= 0.6-0.8. The culture was split into three flasks, placed 
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at 37°C, 25°C and 15°C, respectively and protein synthesis induced using 1 mM IPTG. 1 mL samples were 
removed prior to induction and at 1, 2, 4, 6, 12 and 24-hour time points. Cells were pelleted by 
centrifugation and resuspended in 500 μL lysis buffer (50 mM HEPES, 0.5 M NaCl, 10% glycerol, pH 8.2) 
and stored at -20°C overnight. The following morning cells were thawed, 25 μL of lysozyme added (0.5 
mg/mL final) and samples incubated at room-temperature for 1.5 hours. Following incubation, cells were 
lysed on ice using sonication (QSonica 500, 2mm probe, 20% amplitude, 10 seconds on, 10 seconds off, 
180 seconds total). Cellular debris was pelleted by centrifugation at 16,000g for 5 minutes, the 
supernatant was transferred to a fresh microcentrifuge tube (soluble fraction). The pelleted debris 
(insoluble fraction) was resuspended in 525 μL of 1 x SDS-PAGE loading dye and boiled for 5-minutes. 7.5 
μL of the soluble fraction was mixed with 7.5 μL 2 x SDS-PAGE loading dye and boiled for 5-minutes. 7.5 
μL of the insoluble fraction and the 15 μL of soluble fraction were separated via SDS-PAGE (12% gel). Gels 
were stained with Coomassie Blue, de-stained and imaged using a BioRad ChemiDoc, allowing the levels 
of soluble and insoluble protein to be assessed under various induction conditions.   
2.4 Tobacco Etch Virus Protease (S219V) Purification: 
The pRK793 construct, encoding the catalytic domain of the TEV protease (S219V mutant) fused with a 
maltose binding domain, was a gift from David Waugh (AddGene Plasmid #8827). An aliquot of competent 
BL21(DE3) E. coli was transformed with the pRK793 construct via heat-shock, spread onto ampicillin 
containing agar plates (100 μg/mL) and incubated overnight at 37°C. A single colony was picked, 
transferred to a 100 mL starter culture of Luria Broth (100 μg/mL ampicillin) and grown to saturation 
overnight at 37°C and 225 rpm. The culture was diluted 1:50 into 3 x 1L flasks of Luria Broth (100 μg/mL 
ampicillin) and grown at 37°C and 225 rpm until OD600= 0.6-0.8. The temperature was lowered to 25°C 
and protein expression induced overnight using 1 mM IPTG. Cells were harvested by centrifugation at 
5000g for 20 minutes at 4°C and the pellet resuspended in 100 mL of lysis buffer (50 mM HEPES, 200 mM 
NaCl, 10% glycerol (v/v), pH 8.0, 1 mg/mL lysozyme) and incubated for 1.5 hours at RT with gentle 
agitation. Cells were lysed using sonication (QSonica 500, 6mm probe, 50% amplitude, 10 seconds on, 20 
seconds off, 5 minutes total) on an ice/water/salt slurry and the lysate cleared via centrifugation at 
35,000g for 1 hour at 4°C followed by filtration (0.45 μm). Cleared lysate was passed over a 5 mL HisTrap 
HP column twice at 4°C. The column was loaded onto an AKTA-Pure purification rig and washed with a 
gradient of imidazole (0-100 mM) until a stable baseline UV absorbance was achieved. Protein was eluted 
using a linear gradient of imidazole (100-500 mM) and the presence of protein in elution fractions 
confirmed by SDS-PAGE and Coomassie Blue staining. Protein containing fraction were pooled and loaded 
into a dialysis membrane (10 kDa MWCO) and incubated in 2 L dialysis buffer (50 mM HEPES, 200 mM 
NaCl, 2.5 mM DTT, 2 mM EDTA, 10% glycerol (v/v), pH 8.0) at 4°C with stirring for 3 hours. The buffer was 
exchanged for 2 L of fresh dialysis buffer and incubated overnight. Protein concentration was measured 
using a NanoDrop 2000 spectrophotometer and adjusted to 1.5 mg/mL. 1 mL aliquots were snap frozen 
in liquid nitrogen and stored long-term at -80°C 
TEV Protease: Abs. 280nm (1% w/v) = 11.26 
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2.5 17β-HSD8, 17β-HSD10 and 17β-HSD14 Purification: 
Competent BL21(DE3) E. coli were transformed with the appropriate construct (peHISTEV-HSD10, 
peHISTEV-HSD14 or pET-MBP-HSD8) via heat-shock. Cells were spread onto agar plates (50 μg/mL 
kanamycin) and grown overnight at 37°C. A single colony was picked and transferred to a 100 mL Luria 
Broth starter culture (50 μg/mL kanamycin) and grown overnight at 37°C and 225 rpm. The culture was 
diluted 1:50 into 3 x 1L flasks of Luria Broth (50 μg/mL kanamycin) and grown at 37°C and 225 rpm, until 
OD600= 0.6-0.8. The incubation temperature was lowered to 25°C and protein expression induced 
overnight using 1 mM IPTG. The following morning, cells were harvested by centrifugation at 5000g for 
20 minutes at 4°C and resuspended in the appropriate lysis buffer: 
 
17β-HSD8 and 17β-HSD10: 
50 mM HEPES, 10% glycerol (v/v), 500 mM NaCl, 10 mM imidazole, 1 x Protease Inhibitor, pH 8.2, 1 mg/mL 
lysozyme 
17β-HSD14: 
50 mM HEPES, 10% glycerol (v/v), 100 mM NaCl, 10 mM imidazole, 1 x Protease Inhibitor, pH 8.2, 1 mg/mL 
lysozyme 
Cells were incubated at room temperature for 1.5 hours with gentle agitation before being lysed via 
sonication (QSonica 500, 6mm probe, 50% amplitude, 10 seconds on, 20 seconds off, 5 minutes total) on 
an ice/water/salt slurry. Lysate was cleared by centrifugation at 35,000g for 1 hour at 4°C followed by 
filtration (0.45 μm). Cleared lysate was passed over a 5 mL His-Trap column twice at 4°C.  
*Note: The MBP-HSD8 fusion protein was found to have low affinity for the HisTrap HP column, thus the 
lysate was passed over the column three times to give adequate binding. 
The column was loaded onto an AKTA-Pure purification rig and washed with a gradient of imidazole (0-
100 mM) until a stable UV absorbance was reached. Protein was eluted using a linear gradient of imidazole 
(100-500 mM) and the presence of protein in elution fractions confirmed using SDS-PAGE and Coomassie 
Blue staining. Protein containing fractions were pooled, loaded into a dialysis membrane (10 kDa MWCO) 
and incubated in 2 L dialysis buffer (50 mM HEPES, 500/150 mM NaCl, 10% glycerol, 20 mM imidazole, 
0.5 mM DTT, pH 8.2) at 4°C with stirring for 3 hours. The buffer was exchanged for 2 L of fresh dialysis 
buffer, TEV protease (S219V) was added at a ratio of 1:25 (w/w) and incubated overnight in a fresh 5 L 
volume of dialysis buffer. 
*Note: The MBP-HSD8 fusion protein is cleaved inefficiently by TEV protease, therefore a ratio of 1:10 
(w/w) was used. 
Following incubation, TEV cleavage was confirmed by SDS-PAGE and Coomassie Blue staining. Uncleaved 
protein, free 6 x His-tags, 6 x His-tagged TEV protease and high affinity contaminants were removed by 
passage through a 5 mL His-Trap column at 4°C. Column flow-through was collected and the presence of 
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the protein of interest confirmed via SDS-PAGE and Coomassie Blue staining. Fractions were pooled and 
concentrated using a Vivaspin 20 column (10 kDa MWCO). 
*Note: The 17β-HSD8 protein has high intrinsic affinity for the HisTrap HP column and so must be eluted 
using 50 mM imidazole. 
Sample was injected into a pre-equilibriated HiLoad 16/600 Superdex 75 pg column and elution fractions 
collected periodically. The presence of the protein of interest in peak fractions was confirmed via SDS-
PAGE and Coomassie Blue staining. Protein containing fractions were pooled and concentrated (17β-
HSD10 and 17β-HSD14: 10 mg/mL, 17β-HSD8: 2 mg/mL) using a VivaSpin 20 spin column (10 kDa MWCO) 
and NanoDrop 2000 spectrophotometer. Samples were snap frozen in liquid nitrogen and stored long 
term at -80°C. Protein identity was confirmed using mass spectrometry. 
17β-HSD10: Abs. 280nm (1%) = 1.66 
17β-HSD14: Abs. 280nm (1%) = 7.04 
17β-HSD8: Abs. 280nm (1%) = 3.14 
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Section 3: Recombinant Enzyme Assays 
All reagents were purchased from Sigma-Aldrich and all solutions were prepared using MilliQ ultrapure 
water, unless otherwise stated. 
Reagents: 
HEPES buffer (H3375), NADH (N8129), acetoacetyl-CoA (A1625), dimethyl sulfoxide (472301), gelatin 
(G2500), 17β-estradiol (E8875), NAD+ (N0632), Tris-HCl (T3253), sodium chloride (S9888) Frentizole 
(R242640). 
Equipment: 
SpectraMax M2e spectrophotometer, clear 96 well plates (Thermo Scientific: 167008), black walled 96 
well plates (Insight Biotechnology: sc-204468). 
3.1 17β-HSD10 
Assay Buffer: 10 mM HEPES, 0.5% gelatin (w/v), pH 7.4. 
  
3.11 Michaelis-Menten Kinetics: 
Acetoacetyl-CoA:  
Solutions containing 500 μM NADH were prepared in assay buffer. Increasing concentrations of 
acetoacetyl-CoA were added (0-200 μM) and samples dispensed (150 μL/well) into a clear 96 well plate, 
in triplicate. The plate was loaded into a SpectraMax M2e spectrophotometer, pre-heated to 37°C, and 
allowed to equilibrate (5 minutes). Following incubation, 17β-HSD10 (0.5 μg/mL, 18.52 nM) was added, 
the plate shaken and absorbance monitored (340 nm, 600 seconds, 30 second intervals). The rate of 
reaction was determined during the initial linear period of the progress curve (R2>0.9). Kinetic parameters 
were calculated using non-linear regression with GraphPad Prism and the Michaelis-Menten equation. 
NADH: 
Solutions containing 120 μM acetoacetyl-CoA were prepared in assay buffer. Increasing concentrations of 
NADH were added (0-600 μM) and samples dispensed (150 μL/well) into a clear 96 well plate, in triplicate. 
The plate was loaded into a SpectraMax M2e spectrophotometer, pre-heated to 37°C, and allowed to 
equilibrate (5 minutes). Following incubation, 17β-HSD10 (0.5 μg/mL, 18.52 nM) was added, the plate 
shaken and absorbance monitored (340 nm, 600 seconds, 30 second intervals). The rate of reaction was 
determined during the initial linear period of the progress curve (R2>0.9). Kinetic parameters were 
calculated using non-linear regression with GraphPad Prism and the Michaelis-Menten equation. 
3.12 DMSO Titration: 
Solutions containing 120 μM acetoacetyl-CoA and 250 μM NADH were prepared in assay buffer. Increasing 
concentrations of DMSO were added (0-5% (v/v)) and samples dispensed (150 μL/well) into a clear 96 well 
plate, in triplicate. The plate was loaded into a SpectraMax M2e spectrophotometer, pre-heated to 37°C, 
and allowed to equilibrate (5 minutes). Following incubation, 17β-HSD10 (0.5 μg/mL, 18.52 nM) was 
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added, the plate shaken and absorbance monitored (340 nm, 600 seconds, 30 second intervals). The rate 
of reaction was taken during the initial linear period of the progress curve (R2>0.9).  
3.13 Small Molecule Screening: 
Solutions containing 120 μM acetoacetyl-CoA and 250 μM NADH were prepared in assay buffer. A fixed 
concentration of each compound of interest, either 100 μM or 25 μM was added. DMSO (1% (v/v)) was 
used as a vehicle control and samples dispensed (150 μL/well) into a clear 96 well plate, in triplicate. The 
plate was loaded into a SpectraMax M2e spectrophotometer, pre-heated to 37°C, and allowed to 
equilibrate (5 minutes). Following incubation, 17β-HSD10 (0.5 μg/mL, 18.52 nM) was added, the plate 
shaken and absorbance monitored (340 nm, 600 seconds, 30 second intervals). The rate of reaction was 
determined during the initial linear period of the progress curve (R2>0.9). 
3.14 Dose Response Experiments: 
Solutions containing 120 μM acetoacetyl-CoA and 250 μM NADH were prepared in assay buffer. 
Compounds of interest were added at a range of concentrations (varied depending on potency). DMSO 
(1% (v/v)) was used as a vehicle control and samples dispensed (150 μL/well) into a clear 96 well plate, in 
triplicate. The plate was loaded into a SpectraMax M2e spectrophotometer, pre-heated to 37°C, and 
allowed to equilibrate (5 minutes). Following incubation, 17β-HSD10 (0.5 μg/mL, 18.52 nM) was added, 
the plate shaken and absorbance monitored (340 nm, 600 seconds, 30 second intervals). The rate of 
reaction was determined during the initial linear period of the progress curve (R2>0.9). IC50 values were 
calculated using GraphPad Prism (variable slope - four parameter model). 
3.15 Mechanism of Inhibition Experiments: 
Acetoacetyl-CoA:  
Solutions containing 500 μM NADH were prepared in assay buffer. Increasing concentrations of 
acetoacetyl-CoA (0-120 μM) and a fixed concentration of inhibitor (1.25 μM or 5 μM) were added. DMSO 
(1% (v/v)) was used as a vehicle control. Samples were dispensed (150 μL/well) into a clear 96 well plate, 
in triplicate. The plate was loaded into a SpectraMax M2e spectrophotometer, pre-heated to 37°C, and 
allowed to equilibrate (5 minutes). Following incubation, 17β-HSD10 (0.5 μg/mL, 18.52 nM) was added, 
the plate shaken and absorbance monitored (340 nm, 600 seconds, 30 second intervals). The rate of 
reaction was determined during the initial linear period of the progress curve (R2>0.9). Hanes-Woolf plots 
were generated for visual representation of the data and absolute kinetic parameters calculated using 
non-linear regression with GraphPad Prism and the Michaelis-Menten equation.  
 
NADH: 
Solutions containing 120 μM acetoaceyl-CoA were prepared in assay buffer. Increasing concentrations of 
NADH (0-600 μM) and a fixed concentration of inhibitor (1.25 μM or 5 μM) were added. DMSO (1% (v/v)) 
was used as a vehicle control. Samples were dispensed (150 μL/well) into a clear 96 well plate, in triplicate. 
The plate was loaded into a SpectraMax M2e spectrophotometer, pre-heated to 37°C, and allowed to 
equilibrate (5 minutes). Following incubation, 17β-HSD10 (0.5 μg/mL, 18.52 nM) was added, the plate 
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shaken and absorbance monitored (340 nm, 600 seconds, 30 second intervals). The rate of reaction was 
determined during the initial linear period of the progress curve (R2>0.9). Hanes-Woolf plots were 
generated for visual representation of the data and absolute kinetic parameters calculated using non-
linear regression with GraphPad Prism and the Michaelis-Menten equation.   
3.16 Small Molecule Aggregation Test: 
Solutions containing 120 μM acetoacetyl-CoA and 250 μM NADH were prepared in assay buffer. 
Compounds of interest were added at a single fixed concentration (2 μM). DMSO (1% (v/v)) was used as 
a vehicle control. Varying concentrations of Triton X-100 were added (0%, 0.01%, 0.1% (v/v)). Samples 
were dispensed (150 μL/well) into a clear 96 well plate, in triplicate. The plate was loaded into a 
SpectraMax M2e spectrophotometer, pre-heated to 37°C, and allowed to equilibrate (5 minutes). 
Following incubation, 17β-HSD10 (0.5 μg/mL, 18.52 nM) was added, the plate shaken and absorbance 
monitored (340 nm, 600 seconds, 30 second intervals). The rate of reaction was determined during the 
initial linear period of the progress curve (R2>0.9).  
3.17 Reversible/Irreversible Inhibition Test: 
Solutions containing 120 μM acetoacetyl-CoA and 250 μM NADH were prepared in assay buffer. 
Compounds of interest were added (K690, K691= 2 μM, AG18051= 200 nM). DMSO (1% (v/v)) was used 
as a vehicle control. 17β-HSD10 was added and the solution incubated at room temperature for 10 
minutes. Following incubation, 17β-HSD10 was diluted to a final concentration of 0.5 μg/mL in 150 μL well 
solution (assay buffer, 120 μM acetoacetyl-CoA, 250 μM NADH) containing either an equivalent 
concentration of inhibitor or DMSO. The plate was loaded into a SpectraMax M2e spectrophotometer, 
pre-heated to 37°C, shaken and absorbance monitored (340 nm, 600 seconds, 30 second intervals). The 
rate of reaction was determined during the initial linear period of the progress curve (R2>0.9).  
3.18 NCI Diversity IV Screening Assay: 
Solutions containing 120 μM acetoacetyl-CoA and 250 μM NADH was prepared in assay buffer. 99 μL of 
assay buffer were added to wells of a clear 96 well plate containing 1 μL of compound of interest (10 mM) 
yielding a final concentration of 100 μM. DMSO (1% (v/v)) was used as a vehicle control. The plate was 
loaded into a SpectraMax M2e spectrophotometer, pre-heated to 37°C, and allowed to equilibrate (5 
minutes). Following incubation, 17β-HSD10 (0.25 μg/mL, 9.26 nM) was added, the plate shaken and 
absorbance monitored (340 nm, 600 seconds, 30 second intervals). The rate of reaction was determined 
during the initial linear period of the progress curve (R2>0.9).  
3.2 17β-HSD8 and 17β-HSD14 
Assay Buffer: 50 mM Tris-HCl, 100 mM NaCl, pH 8.2 
3.21 17β-HSD8 Activity Test: 
Solution containing 50 μM β-estradiol and 500 μM NAD+ were prepared in assay buffer. 100 μL was added 
to wells of a black-walled 96 well plate. 17β-HSD8 was added at varying concentrations to buffer 
containing wells (0, 1, 2.5, 5, 10 μg/mL), in triplicate. The plate was loaded into a SpectraMax M2e 
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spectrophotometer, pre-heated to 37°C, and fluorescence measured (excitation 340 nm, emission 460 
nm, 900 seconds, 30 second intervals). The rate of reaction was determined during the initial linear period 
of the progress curve (R2>0.9).  
3.22 17β-HSD14 Activity Test: 
Solutions containing 50 μM β-estradiol and 500 μM NAD+ were prepared in assay buffer. 100 μL was added 
to wells of a black-walled 96 well plate. 17β-HSD14 was added at varying concentrations to buffer 
containing wells (0, 50, 100, 150, 200, 250 μg/mL), in triplicate. The plate was loaded into a SpectraMax 
M2e spectrophotometer, pre-heated to 37°C, and fluorescence measured (excitation 340 nm, emission 
460 nm, 1 hour, 5 minute intervals). The rate of reaction was determined during the initial linear period 
of the progress curve (R2>0.9). 
3.23 17β-HSD8 Michaelis-Menten Kinetics: 
NAD+:  
Solutions containing 100 μM 17β-estradiol were prepared in assay buffer. Increasing concentrations of 
NAD+ (0-1000 μM) were added and samples dispensed (100 μL/well) into a black-walled 96 well plate, in 
triplicate. The plate was loaded into a SpectraMax M2e spectrophotometer, pre-heated to 37°C, and 
allowed to equilibrate (5 minutes). Following incubation, 17β-HSD8 was added to each well (5 μg/mL, 
185.3 nM), the plate shaken and fluorescence measured (excitation 340 nm, emission 460 nm, 900 
seconds, 30 second intervals). The rate of reaction was determined during the initial linear period of the 
progress curve (R2>0.9). Kinetic parameters were calculated using non-linear regression with GraphPad 
Prism and the Michaelis-Menten equation. 
17β-estradiol:  
Solutions containing 1 mM NAD+ were prepared in assay buffer. Increasing concentrations of 17β-
estradiol (0-100 μM) were added and samples dispensed (100 μL/well) into a black-walled 96 well plate, 
in triplicate. The plate was loaded into a SpectraMax M2e spectrophotometer, pre-heated to 37°C, and 
allowed to equilibrate (5 minutes). Following incubation, 17β-HSD8 was added to each well (5 μg/mL, 
185.3 nM), the plate shaken and fluorescence measured (excitation 340 nm, emission 460 nm, 900 
seconds, 30 second intervals). The rate of reaction was determined during the initial linear period of the 
progress curve (R2>0.9). Kinetic parameters were calculated using non-linear regression with GraphPad 
Prism and the Michaelis-Menten equation. 
3.24 17β-HSD14 Michaelis-Menten Kinetics: 
NAD+:  
Solutions containing 100 μM 17β-estradiol were prepared in assay buffer. Increasing concentrations of 
NAD+ (0-500 μM) and samples dispensed (100 μL/well) into a black-walled 96 well plate, in triplicate. The 
plate was loaded into a SpectraMax M2e spectrophotometer, pre-heated to 37°C, and allowed to 
equilibrate (5 minutes).  Following incubation, 17β-HSD14 was added to each well (150 μg/mL, 5.3 μM), 
the plate shaken and fluorescence measured (excitation 340 nm, emission 460 nm, 1 hour, 5 minute 
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intervals). The rate of reaction was determined during the initial linear period of the progress curve 
(R2>0.9). Kinetic parameters were calculated using non-linear regression with GraphPad Prism and the 
Michaelis-Menten equation. 
17β-estradiol: 
Solutions containing 500 μM NAD+ were prepared in assay buffer. Increasing concentrations of 17β-
estradiol (0-100 μM) were added and samples dispensed (100 μL/well) into a black-walled 96 well plate, 
in triplicate. The plate was loaded into a SpectraMax M2e spectrophotometer, pre-heated to 37°C, and 
allowed to equilibrate (5 minutes). Following incubation, 17β-HSD14 was added to each well (150 μg/mL, 
5.3 μM), the plate shaken and fluorescence measured (excitation 340 nm, emission 460 nm, 1 hour, 5 
minute intervals). The rate of reaction was determined during the initial linear period of the progress 
curve (R2>0.9). Kinetic parameters were calculated using non-linear regression with GraphPad Prism and 
the Michaelis-Menten equation. 
3.25 17β-HSD8 Small Molecule Screening: 
Solutions containing 50 μM 17β-estradiol and 500 μM NAD+ were prepared in assay buffer. A saturating 
dose of inhibitor, as determined against 17β-HSD10 (K690, K691, K1093 = 12.5 μM, AG18051 = 6.25 μM, 
88401 = 50 μM) or an equivalent concentration of DMSO (1% (v/v)) was added. Samples were dispensed 
(100 μL/well) into a black-walled 96 well plate, in triplicate. The plate was loaded into a SpectraMax M2e 
spectrophotometer, pre-heated to 37°C, and allowed to equilibrate (5 minutes). Following incubation, 
17β-HSD8 was added to each well (5 μg/mL, 185.3 nM), the plate shaken and fluorescence measured 
(excitation 340 nm, emission 460 nm, 900 seconds, 30 second intervals). The rate of reaction was 
determined during the initial linear period of the progress curve (R2>0.9). 
3.26 17β-HSD14 Small Molecule Screening: 
Solutions containing 75 μM 17β-estradiol and 150 μM NAD+ were prepared in assay buffer. A saturating 
dose of inhibitor, as determined against 17β-HSD10 (K690, K691, K1093 = 12.5 μM, AG18051 = 6.25 μM, 
88401 = 50 μM) or an equivalent concentration of DMSO (1% (v/v)) was added. Samples were dispensed 
(100 μL/well) into a black-walled 96 well plate, in triplicate. The plate was loaded into a SpectraMax M2e 
spectrophotometer, pre-heated to 37°C, and allowed to equilibrate (5 minutes). Following incubation, 
17β-HSD14 was added to each well (150 μg/mL, 5.3 μM), the plate shaken and fluorescence measured 
(excitation 340 nm, emission 460 nm, 1 hour, 5 minute intervals). The rate of reaction was determined 
during the initial linear period of the progress curve (R2>0.9). 
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Section 4: Differential Scanning Fluorimetry 
All reagents were purchased from Sigma-Aldrich and all solutions were prepared using MilliQ ultrapure 
water, unless otherwise stated. 
Reagents: 
HEPES buffer (H3375), sodium chloride (S9888), SYPRO-Orange (S5692), NADH (N8129), NAD+ (N0632), 
acetoacetyl-CoA (A1625), Aβ1-42 (Abcam: ab120301), Hexafluoroisopropanol (HFIP) (105228), dimethyl 
sulfoxide (472301). 
Equipment: 
Viia7 RT-PCR machine (Thermo Fisher: 4453534) MicroAmp 96 well plates (Thermo Fisher: 4346907), 
MicroAmp Optical Adhesive Film (Thermo Fisher: 4311971), Hamilton Syringe (20703), enhanced 
chemiluminescence solution (Pierce: 32106). 
 
Assay Buffer: 50 mM Hepes, 0.5 M NaCl, pH 8.2 
4.1 Differential Scanning Fluorimetry Assay Optimisation: 
Solutions containing varying concentrations of 17β-HSD10 protein (0, 5, 10, 25, 50 μM) and SYPRO-orange 
(x 0, x 5, x 10, x 20 concentration, absolute values not published) were prepared in assay buffer. Samples 
were dispensed (25 μL/well) into a 96 well MicroAmp Fast Optical plate, in triplicate. The plate was sealed 
with optical grade sealing film, centrifuged briefly at 500g and loaded into a ViiA7 RT-PCR machine (ramp 
speed 0.015°C/second, 25-95°C). Data was exported into GraphPad Prism and Tm values calculated using 
the Boltzmann sigmoidal curve fit equation. 
4.2 NADH Titration: 
Solutions containing increasing concentrations of NADH (0, 0.01, 0.02, 0.039, 0.078, 0.156, 0.313, 0.625, 
1.25, 2.5, 5 mM) were prepared in assay buffer. 17β-HSD10 (10 μM) and SYPRO-orange (x 20) were added 
and samples dispensed (25 μL/well) into a 96 well MicroAmp Fast Optical plate, in triplicate. The plate 
was sealed with optical grade sealing film, centrifuged briefly at 500g and loaded into a ViiA7 RT-PCR 
machine (ramp speed 0.015°C/second, 25-95°C). Data was exported into GraphPad Prism and Tm values 
calculated using the Boltzmann sigmoidal curve fit equation. 
4.3 NAD+ Titration: 
Solutions containing increasing concentrations of NAD+ (0, 0.01, 0.02, 0.039, 0.078, 0.156, 0.313, 0.625, 
1.25, 2.5, 5, 10 mM) were prepared in assay buffer. 17β-HSD10 (10 μM) and SYPRO-orange (x 20) were 
added and samples dispensed (25 μL/well) into a 96 well MicroAmp Fast Optical plate, in triplicate. The 
plate was sealed with optical grade sealing film, centrifuged briefly at 500g and loaded into a ViiA7 RT-
PCR machine (ramp speed 0.015°C/second, 25-95°C). Data was exported into GraphPad Prism and Tm 
values calculated using the Boltzmann sigmoidal curve fit equation. 
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4.4 Acetoacetyl-CoA Titrations: 
Solutions containing increasing concentrations of acetoacetyl-CoA (0, 0.008, 0.016, 0.031, 0.063, 0.125, 
0.25, 0.5, 1, 2 mM) were prepared in assay buffer. 17β-HSD10 (10 μM) and SYPRO-orange (x 20) were 
added and samples dispensed (25 μL/well) into a 96 well MicroAmp Fast Optical plate, in triplicate. The 
plate was sealed with optical grade sealing film, centrifuged briefly at 500g and loaded into a ViiA7 RT-
PCR machine (ramp speed 0.015°C/second, 25-95°C). Data was exported into GraphPad Prism and Tm 
values calculated using the Boltzmann sigmoidal curve fit equation. 
The experiment was subsequently repeated in the presence of 5 mM NAD+. 
4.5 Small Molecule Screening: 
Solutions were prepared containing a serial dilution of compounds of interest (K690, K691, K1093= 100-
0.098 μM). Samples containing an equivalent concentration of vehicle, DMSO (1% (v/v)) were prepared 
and analysed concurrently. 17β-HSD10 (10 μM) and SYPRO-orange (x 20) were added and samples 
dispensed (25 μL/well) into a 96 well MicroAmp Fast Optical plate, in triplicate. The plate was sealed with 
optical grade sealing film, centrifuged briefly at 500g and loaded into a ViiA7 RT-PCR machine (ramp speed 
0.015 °C/sec, 25-95 °C). Data was exported into GraphPad Prism and Tm values calculated using the 
Boltzmann sigmoidal curve fit equation. 
The experiment was subsequently repeated in the presence of 5 mM NAD+ and 2 mM acetoacetyl-CoA. 
4.6 Amyloid-beta Peptide: 
1 mg of recombinant Aβ1-42 was suspended in 221.7 μL of HFIP using a Hamilton syringe and incubated at 
room-temperature for 1 hour. The monomerised Aβ1-42 was dispensed into 10 μL (0.045 μg) aliquots and 
microcentrifuge tubes left open inside a fume hood for 48-hours to allow HFIP evaporation. Following 
incubation, tubes were sealed with parafilm and stored dessicated at -20°C. 
Oligomeric amyloid beta-peptide was prepared by dissolving one aliquot (0.045 μg) of monomerised Aβ1-
42 in 2 μL of DMSO, generating a 5 mM stock. 98 μL of assay buffer was subsequently added generating a 
100 μM stock, vortexed for 15-seconds and incubated overnight at 4°C. 
Solutions were prepared containing 17β-HSD10 (10 μM) and SYPRO-orange (x 20) in assay buffer. An 
increasing concentration of oligomeric Aβ1-42 (0, 1.562, 3.125, 6.25, 12.5, 25, 50 μM) was added and 
samples incubated at 4°C for 1 hour. Samples were dispensed (25 μL/well) into a 96 well MicroAmp Fast 
Optical plate, in triplicate. The plate was sealed with optical grade sealing film, centrifuged briefly at 500g 
and loaded into a ViiA7 RT-PCR machine (ramp speed 0.015°C/sec, 25-95°C). Data was exported into 
GraphPad Prism and Tm values calculated using the Boltzmann sigmoidal curve fit equation.  
4.7 17β-HSD10/Aβ Interaction Western Blot 
Oligomeric Aβ1-42 was prepared as described previously (Materials and Methods: Section 4.6). Solutions 
containing 10 μM 17β-HSD10 and 50 μM oligomeric Aβ1-42 were prepared in assay buffer (50 mM Hepes, 
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0.5 M NaCl, pH 8.2). Compounds of interest were added at varying concentrations (6.25 μM–0.156 μM) 
and samples incubated at 4°C for 1 hour. DMSO (2% (v/v)) was used as a vehicle control. Following 
incubation, proteins were separated using SDS-PAGE electrophoresis (15% resolving gel) and transferred 
to a methanol activated PVDF membrane (25 V, 1-hour). Membranes were blocked for 1-hour at room-
temperature (5% BSA), and probed using an anti-amyloid antibody (D54D2) overnight at 4°C. Membranes 
were washed (3 x 10 minutes TBS-T) incubated with the appropriate secondary antibody, washed (3 x 10 
minutes TBS-T) and imaged using an LAS-3000 unit and an enhanced chemiluminescent solution. 
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Section 5: Cell Culture 
All reagents were purchased from Sigma-Aldrich and all solutions were prepared using MilliQ ultrapure 
water, unless otherwise stated 
Reagents: 
DMEM-Glutamax (Thermo Fisher: 31966), foetal bovine serum (Gibco: 10270098), 
Penicillin/Streptomycin (Thermo Fisher: 15140122), TrypLe-Express (Thermo Fisher: 12604013), dimethyl 
sulfoxide (D2650), Lactate Dehydrogenase Kit (MAK066), polyethylenamine (408727), Opti-MEM (Thermo 
Fisher: 31985062), magnesium chloride (M8266), potassium chloride (P9541), DTT (Formedium: DTT010), 
Triton X-100 (T8787), Roche cOmplete EDTA free protease inhibitor tablets (11836170001), sodium 
dodecyl sulfate (L3771), sodium deoxycholate (D6750), methanol (Thermo Fisher: 10284580), Tris-HCl 
(T3253), glycine (Thermo Fisher: 10061073), bovine serum albumin (A9647), enhanced 
chemiluminescence solution (Pierce: 32106), Aβ1-42 (Abcam: ab120301) 
Equipment: 
Hemacytometer (Z359629), Mr. Frosty freezing unit (Thermo Fisher: 5100-0001), T75 cell culture flasks 
(Thermo Fisher: 156499), T25 cell culture flasks (Thermo Fisher: 156340), SH-SY5Y nucleofection kit 
(Lonza: VACA-1003), 1 mL dounce homogeniser (Thermo Fisher: 357538), BCA Kit (Pierce: 23223), PVDF 
membrane (MilliPore: IPVH00010), XCell SureLock electrophoresis unit (Thermo Fisher: EI0001) 
5.01 Culture Media: 
HEK293 cells were maintained in DMEM-Glutamax supplemented with 10% foetal bovine serum, 50 
units/mL penicillin and 50 μg/mL streptomycin.  
SH-SY5Y cells were maintained in DMEM-F12 supplemented with 10% foetal bovine serum, 50 units/mL 
penicillin and 50 μg/mL streptomycin. 
5.02 Foetal Bovine Serum (FBS) Heat Inactivation: 
FBS was heated to 56°C for 30 minutes with periodic agitation. Heat inactivated FBS was dispensed into 
50 mL aliquots and stored long term at -20°C. 
5.03 Cryogenic Storage of Cell Lines: 
The cell line of interest was grown to 70-80% confluency in a T75 cell culture flask. Culture media was 
removed, cells washed with pre-warmed 1 x PBS, 1 mL of TrypLe added and the flask incubated at 37°C 
and 5% CO2 for 15 minutes to allow cell detachment. Cells were taken up in 9 mL of culture media and 
gently resuspended. Cells were counted using a haemocytometer, pelleted (500g, 5 minutes) and 
resuspended in a suitable volume of freezing media (90% FBS, 10% DMSO (v/v)) to give the desired 
concentration (typically 2-4 x 106 cells/mL). Cells were dispensed into 1 mL aliquots in cryovials, placed in 
a Mr. Frosty freezing unit and placed at -80°C overnight. The following morning, vials were moved to liquid 
nitrogen for long term storage. 
5.04 Thawing of Cryogenically Stored Cell Lines: 
A cryovial containing the cells of interest was removed from long-term storage in liquid nitrogen. The 
cryovial was placed in a waterbath pre-warmed to 37°C until thawed and the cells transferred to a T25 
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cell culture flask containing 8 mL of pre-warmed cell culture media and incubated overnight at 37°C and 
5% CO2. The following morning, the culture media was replaced and cells again incubated at 37°C and 5% 
CO2. Culture media was replaced periodically and cells allowed to grow until 70-80% confluent before 
being transferred to a T75 flask and used experimentally.    
5.05 Lactate Dehydrogenase (LDH) Assay: 
HEK293 and SH-SHY5Y cells were dispensed into clear 96 well plates at a density of 15,000 cells per well 
and incubated overnight at 37°C and 5% CO2. Following incubation, compounds of interest were added at 
varying concentrations, in triplicate. Control wells containing an equivalent concentration of DMSO (0.5% 
(v/v)) were prepared and analysed concurrently. Cells were incubated with compounds of interest for 24 
at 37°C and 5% CO2. Following incubation 0.1% Triton X-100 was added to additional control wells, giving 
a measure of maximum cell death. The LDH assay was then performed as per manufacturer's instructions 
(MAK066). 
 
To check for compound induced assay interference, the LDH reaction was performed using purified LDH 
enzyme both in the presence and absence of compounds K690 and K691 (50 μM) as per manufacturer’s 
instructions. 
5.06 HEK293 Polyethylenimine (PEI) Transfection: 
A stock solution of PEI was prepared at 1 mg/mL in MilliQ water, the pH adjusted to 7.0 and filter sterilised 
(0.22 μm). Aliquots were stored long term at -80°C. 
HEK293 cells were dispensed into a 24 well plate at an appropriate density (60-70% confluency) and 
incubated overnight at 37°C and 5% CO2. Transfection mixtures were prepared in serum free Opti-MEM. 
25 μL of Opti-MEM was mixed with 750 ng of DNA (ethanol precipitated) and mixed gently via pipetting. 
3 μL of PEI (1 mg/mL stock) was added, the microcentrifuge tube vortexed (15 x 1 second pulses) and 
incubated at room-temperature for 45 minutes. 500 μL of complete media was transferred from the cell 
containing well, mixed with the transfection solution and transferred back to the well. Cells were 
incubated for 24 hours at 37°C and 5% CO2 after which the culture media was replaced. Analysis was 
performed 24-48 hours post transfection. 
The given conditions were optimised using the pmaxGFP plasmid for transfection in a 24 well plate. For 
alternative cell culture vessels, the PEI:DNA ratio was maintained and the reaction scaled according to 
total surface area of the culture vessel. 
5.07 SH-SY5Y Nucelofection: 
Culture media was aspirated from a T75 flask of SH-SY5Y cells (70-80% confluent), cells washed with pre-
warmed 1 x PBS, 1 mL of TrypLe added and the flask incubated at 37°C and 5% CO2 for 15 minutes to allow 
cell detachment. Cells were taken up in 9 mL of culture media and gently resuspended. Cells were counted 
using a haemocytometer and 1-2 x 106 SH-SY5Y cells pelleted and resuspended in the appropriate 
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nucleofection solution (Lonza, VACA-1003) containing 2 μg of DNA. Cells were nucleofected using an 
Amaxa 2b Nucleofector (protocol #A-023). Analysis was performed 24-48 hours post transfection.  
5.08 Enzyme Activity in Cell Lysates: 
HEK293 cells were seeded at an appropriate density into 60mm dishes and incubated overnight at 37°C 
and 5% CO2. Cells were transiently transfected with the desired constructs or empty vector using PEI. Cells 
were incubated for 24 hours at 37°C and 5% CO2. Following incubation cells were detached using TrypLe 
and transferred to 1.5 mL microcentrifuge tubes, pelleted at 2000g and resuspended in 1 mL of hypotonic 
buffer (10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, pH 7.9) and lysed using a dounce 
homogeniser (25 strokes). The cell lysate was transferred to fresh microcentrifuge tubes, centrifuged at 
16,000g for 3 minutes and the supernatant transferred to new microcentrifuge tubes. Acetoacetyl-CoA 
and NADH were added to the supernatant (120 μM and 250 μM respectively) the lysate divided 150 
μL/well into a clear 96 well plate, in triplicate and absorbance measured at 340 nm (900 seconds, 30 
second intervals, 37°C). The rate of reaction was determined during the initial linear period (R2>0.9) and 
normalised to total protein content using the BCA assay, as per manufacturer’s instructions.  
 
Inhibitors were spiked into lysates from cells transiently transfected with 17β-HSD10 at 50 μM and 
enzyme activity measured as detailed previously. DMSO (1% (v/v)) was used as a vehicle control. 
5.09 Stable Cell Line Generation: 
Cells were transiently transfected with the construct of interest using the appropriate methodology 
(HEK293-PEI, SH-SH5Y-nuclofection) and incubated at 37°C and 5% CO2. Control cells, harbouring no 
construct were similarly treated. 48 hours post transfection the culture media was removed and replaced 
with media containing an appropriate concentration of selection agent (500 μg/mL Geneticin, 250 μg/mL 
Zeocin). Media was replaced every 2 days and cells maintained in selection until control cells were no-
longer viable and foci of resistant cells apparent (typically 1-2 weeks). Selection media was removed and 
replaced with maintenance media (200 μg/mL Geneticin, 100 μg/mL Zeocin) and cells allowed to grow to 
confluency before being cryogenically frozen or used experimentally. Protein overexpression was 
confirmed via western blot. 
5.10 Cell Lysate Generation: 
Following experimental manipulation, cells were washed with ice-cold PBS and an appropriate volume of 
ice-cold RIPA lysis buffer added (50 mM Tris, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 
0.1% SDS, 1 mM EDTA, pH 7.4, 1 x protease inhibitor). Cells were detached via scraping and transferred 
to pre-cooled microcentrifuge tubes. Tubes were incubated on ice for 30-minutes, centrifuged at 16,000g 
for 20-minutes at 4°C and the supernatant transferred to fresh microcentrifuge tubes. Protein 
concentration was determined using the BCA assay as per manufacturer's instructions. Lysates were 
stored long term at -80 °C. 
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5.11 Generalised Western Blot: 
An appropriate volume of lysate (depending on protein abundance) was resolved via SDS-PAGE (Materials 
and Methods: Section 2.1). Proteins were transferred to a methanol activated PVDF membrane using a 
XCell SureLock transfer unit. The transfer of proteins was performed at 25 V for approximately 1.5 hours 
using 1 x Transfer Buffer (25 mM Tris, 192 mM glycine, 20% (v/v) MeOH) as per manufacturer's 
instructions.  Membranes were blocked using the appropriate blocking agent (typically 5% w/v BSA or 
NFDM prepared in 1 x TBS-T) for 1 hour at RT and incubated in the appropriate dilution of primary 
antibody overnight at 4°C. Membranes were washed using TBS-T (3 x 10 minutes) and incubated at room-
temperature for 1 hour in the appropriate dilution of secondary antibody (HRP-conjugated). Membranes 
were washed using TBS-T (3 x 10 minutes) and treated with enhanced chemiluminesence solution before 
being imaged using an LAS-3000 imaging unit.    
If required, membranes were stripped using Abcam mild-stripping buffer, as per manufacturer’s 
instructions, blocked for 1 hour at room-temperature and re-probed using the desired antibody overnight 
at 4°C. Membranes were washed (3 x 10 minutes TBS-T) incubated with the appropriate secondary 
antibody, washed (3 x 10minutes TBS-T) and imaged using a LAS-3000 unit and enhanced 
chemiluminescence solution. 
 
Target Primary Antibody Dilution Secondary Antibody Dilution 
17β-HSD10 ab10260 (5F3) 1:1000 (5% NFDM) Anti-Mouse- ab6709 1:20,000 (5% NFDM) 
β-Actin A1978 1:10,000 (5% NFDM) Anti-Mouse- ab6709 1:20,000 (5% NFDM) 
Amyloid-Beta D54D2 (8243) 1:500-1:1000 (5% BSA) Anti-Rabbit- ab97200 1:75,000 (5% BSA) 
Amyloid Precursor 
Protein 
ab32136 1:20,000 (5% NFDM) Anti-Rabbit- ab97200  1:50,000 (5% NFDM) 
4-hydroxynoneal ab46545 1:500 (5% NFDM) Anti-Rabbit- ab97200  1:50,000 (5% NFDM) 
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Chapter 3 - Introduction and Aims: 
Whilst there are numerous theories related to the underlying cause for the development of Alzheimer’s 
disease (AD), arguably the most widely accepted is the amyloid cascade hypothesis. First described by 
Hardy and Higgins in 1992164, the amyloid cascade hypothesis proposes that an abnormal accumulation 
of amyloid beta-peptide (Aβ) is the main causative factor for the development of AD, disrupting normal 
cellular processes and giving rise to the characteristic neuronal loss associated with the disease. Although 
originally attributed to plaque deposition, in recent years there has been a shift in focus from extracellular 
insoluble plaques of Aβ, to soluble intracellular forms and their binding partners284,285.  
The mitochondrial 17β-HSD10 enzyme is one such binding partner337,338. The interaction between the 17β-
HSD10 enzyme and Aβ has been shown to be cytotoxic, resulting in oxidative stress and cell death303,338-
340. Interestingly, hallmarks of this toxicity have been shown to be dependent on the catalytic activity of 
the 17β-HSD10 enzyme338 and thus, small molecule inhibitors of the 17β-HSD10 enzyme may be of 
therapeutic merit in treating AD.  
The primary aim of this chapter was to purify the 17β-HSD10 protein to homogeneity and to develop a 
robust screening assay for measuring catalytic activity. Subsequently, to use this assay to screen several 
libraries of compounds, with the aim of identifying a range of molecules capable of enzyme inhibition. To 
confirm such hits through the use of de-selection assays and characterise the most promising molecules 
in terms of mechanism of action and potency. Once validated, these compounds would form the basis for 
the development of subsequent series of derivative compounds, with more favourable drug-like 
properties, which may form the basis for the development of novel therapeutic agents against Alzheimer’s 
disease.   
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3.01 Protein Purification: 
In order to evaluate the potential of compounds of interest to modulate the catalytic activity of the 17β-
HSD10 enzyme, first highly pure recombinant protein was required. A previous PhD student within the 
group, Dr. Kirsty Muirhead, developed and optimised the expression and purification of the 17β-HSD10 
enzyme using the peHISTEV vector346 (Figure 3.01, construct herein referred to as peHISTEV-HSD10) and 
the BL21(DE3) E. coli variant. Expression using this system yields recombinant protein with a TEV 
cleavable, N-terminal, 6 x His-Tag and was used for large scale protein purification. 
 
In brief, the peHISTEV-HSD10 construct was transformed into competent E. coli BL21(DE3) cells, grown to 
OD600= 0.6-0.8 and protein expression induced overnight at 25°C. Cells were lysed via sonication and 
protein purified using a combination of Ni-NTA affinity chromatography and size exclusion 
chromatography. Samples were analysed throughout the purification procedure to ensure the success of 
the preceding step, to give a measure of purity and also a rough gauge of yield.  
Ni-NTA affinity chromatography exploits the ability of histidine residues to form coordinate bonds to 
immobilised metal ions, in this case Ni2+. As cell lysate is passed over the purification column, histidine 
residues within the 6 x HisTag form coordinate bonds to immobilised Ni2+ ions held within the Ni-NTA 
resin and thus remain bound (Figure 3.02). Non-tagged proteins exhibit comparatively low affinity and 
pass through without binding. 
 
 
 
 
Figure 3.01. peHISTEV-HSD10 expression vector. The 17β-HSD10 cDNA sequence was cloned into the peHISTEV345 
vector by using the NcoI and SalI restriction enzyme sites. 
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An initial check for both 17β-HSD10 expression and column binding was made by analysing a sample of 
cleared lysate and column flow-through via SDS-PAGE and Coomassie Blue staining. A prominent band is 
apparent in the cleared lysate at approximately 27 kDa, corresponding to the 17β-HSD10 protein. 
Following passage through a HisTrap HP column, this band is no longer seen, indicating the 17β-HSD10 
protein is now bound to the purification column (Figure 3.03). 
Figure 3.03. Expression and column binding of recombinant 17β-HSD10 protein. A sample of cleared lysate and 
column flow-through were analysed using SDS-PAGE and Coomassie staining. A prominent band is apparent in the 
cleared lysate at approximately 27 kDa, but not in the column flow-through, corresponding to the recombinant 17β-
HSD10 protein pre and post column binding. Lane 1 = Ladder, Lane 2 = Cleared Lysate, Lane 3 = Column Flow Through. 
 
Figure 3.02. Ni-NTA Resin. Histidine residues are able to form coordinate bonds to immobilised Ni2+ ions held in the 
Ni-NTA support, allowing the isolation of tagged proteins of interest. 
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A number of proteins native to the E. coli cell are known to have an intrinsic affinity for the Ni-NTA resin, 
usually by virtue of a natural abundance of histidine residues, and so bind to the Ni-NTA resin in a non-
specific manner347. Imidazole will compete with bound proteins for the Ni-NTA resin and at a sufficient 
concentration cause them to elute from the column. Contaminating proteins typically exhibit low affinity 
as compared to a 6 x His-tagged protein and therefore by washing the column with a gradient of imidazole 
low affinity contaminants can be removed leaving the protein of interest bound.  
 
Although a multitude of workflows are possible for column loading, wash and elution steps (syringe based, 
batch based, gravity flow etc.), the use of an automated purification system makes the procedure 
significantly less time and labour intensive. Thus, to facilitate wash and elution steps, the HisTrap HP 
column was loaded onto an AKTA-Pure purification rig and the column washed with a stepwise increase 
in imidazole concentration (0-100 mM). Once a stable UV baseline was reached, indicating that no further 
protein was being eluted and low affinity contaminants were removed, the 17β-HSD10 protein was eluted 
using a linear gradient of imidazole (100-500 mM) and fractions taken periodically. The presence of 17β-
HSD10 protein in elution fractions was confirmed using SDS-PAGE and Coomassie Blue staining, with clean 
17β-HSD10 protein being observed in fractions 7-10 (Figure 3.05). 
Figure 3.05. 17β-HSD10 wash and elution fractions. The HisTrap HP column, loaded with 17β-HSD10 protein was 
washed with a stepwise increase in imidazole (0-100 mM) removing low affinity contaminants. 17β-HSD10 protein 
was subsequently eluted using a linear gradient of imidazole (100-500 mM). Lane 1 = Ladder, Lane 2 = Cleared Lysate, 
Lane 3 = Column Flow Through, Lanes 4-6 = Wash Fractions, Lanes 7-10 = Elution Fractions 
Figure 3.04. Structure of Imidazole and Histidine. Imidazole is able to compete with histidine residues for the Ni-NTA 
matrix and, at sufficient concentration, causes proteins to elute from the column. 
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As the 6 x HisTag is relatively small, in many cases it can be left attached to a protein of interest without 
altering its function. However, previous work has shown that the presence of an N-terminal 6 x HisTag 
significantly reduces the enzymatic activity of the 17β-HSD10 protein (Dr. Kirsty Muirhead, unpublished 
observation) and thus it must be removed prior to further analysis, a task accomplished through the use 
of 6 x His-tagged TEV-protease (S219V variant). TEV protease cuts at the recognition sequence ENLYFQ-
G, previously engineered into the peHISTEV vector between the 6 x HisTag and multiple cloning site. As 
imidazole is known to inhibit TEV protease activity it must be removed prior to cleavage, accomplished 
here through the use of dialysis. Fractions 7-10 were pooled, loaded into a dialysis membrane and allowed 
to equilibrate with imidazole free buffer. The dialysis membrane was placed into a second container of 
fresh buffer, TEV protease added and the mixture incubated at 4°C overnight. TEV cleavage was confirmed 
via SDS-PAGE and Coomassie Blue staining the following morning. 
Following treatment with TEV protease, the band corresponding to the 17β-HSD10 protein was found to 
be shifted down, corresponding to a loss of mass and charge, indicative of successful cleavage (Figure 
3.06, Lane 3). A faint band of un-cleaved protein and TEV protease itself can be seen above.  
 
The TEV protease treated sample was again passed over a HisTrap HP column, this time allowing the 
binding of free 6 x His-tags, 6 x His-tagged-TEV protease, uncleaved 17β-HSD10 protein and any remaining 
high affinity contaminants. Column flow-through, now containing the protein of interest, was collected 
and concentrated for gel filtration using a VivaSpin 20 spin-column (10 kDa MWCO). Sample was injected 
into a pre-equilibrated HiLoad Sephadex 75 prep-grade column and fractions taken periodically. Those 
corresponding to the start, middle and end of the peak were run on a polyacrylamide gel and stained 
using Coomassie Blue, confirming the presence of pure 17β-HSD10 protein (Figure 3.07).  
 
Figure 3.06. 17β-HSD10 TEV cleavage confirmation. TEV protease was employed to remove the 6 x His-tag from the 
17β-HSD10 enzyme.  A sample of 17β-HSD10 protein was taken pre and post TEV treatment and analysed using SDS-
PAGE and Coomassie staining. Following TEV treatment the band corresponding to the 17β-HSD10 protein is shifted 
down, indicative of successful cleavage. Lane 1 = Ladder, Lane 2 = Pre-TEV, Lane 3 = Post-TEV. 
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Gel filtration fractions, harbouring pure 17β-HSD10 protein, were pooled and concentrated to 10 mg/mL 
before being flash frozen in liquid nitrogen and stored long-term at -80°C. Protein identity was confirmed 
using mass spectrometry (see Appendix: A).   
  
Figure 3.07. 17β-HSD10 post gel filtration. Ni-NTA purified 17β-HSD10 protein was concentrated and loaded onto a 
pre-equilibrated HiLoad Sephadex 75 prep-grade column. Fractions were taken periodically and those corresponding 
to the start, middle and end of the peak were analysed using SDS-PAGE and Coomassie staining confirming the 
presence of pure 17β-HSD10 protein.  Lane 1 = Ladder, Lanes 2-4 = Start, middle and end of elution peak. 
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3.02 Activity Assay Development: 
Now that highly pure 17β-HSD10 protein was available, a robust screening assay for measuring enzymatic 
activity was required. Such an assay has been worked on previously, but with limited success. The 
conditions utilised were found to have issues associated with reproducibility, throughput, compound 
solubility and enzyme stability. The screening assay employed measures the 17β-HSD10 catalysed 
conversion of acetoacetyl-CoA to L-3-hydroxybutyryl-CoA (Scheme 3.01). 
 
In the forward direction, NADH is utilised as a cofactor and becomes oxidised, producing NAD+. NADH 
shows marked absorbance at 340 nm, whilst NAD+ does not, and thus enzymatic activity can be measured 
by a decrease in absorbance over time as substrate is converted to product and NADH is converted to 
NAD+ in a stoichiometric manner. NADH also shows a peak in fluorescence at 460 nm when excited at 340 
nm, a property not shared by NAD+, and thus a fluorescence-based readout could also be employed. Both 
approaches have merit, with the absorbance assay showing linearity over a wider range of NADH 
concentrations (Figure 3.08, left) and the fluorescence assay being more sensitive to low concentrations 
of NADH (Figure 3.08, right).  
 
As we are measuring the forward reaction, the initial concentration of NADH will be high causing the 
associated signal to fall outside of the linear range of the fluorescence-based assay. Therefore, to simplify 
data analysis, an absorbance based read-out was adopted. 
Scheme 3.01. 17β-HSD10 catalysed conversion of acetoacetyl-CoA (forward reaction). The 17β-HSD10 enzyme is 
known to catalyse the NADH dependent conversion of acetoacetyl-CoA to L-3-hydroxybutyryl-CoA, a reaction which 
forms the basis for the in-house enzyme activity assay. 
Figure 3.08. Absorbance and fluorescence as a function of NADH concentration. NADH shows marked absorbance 
(340 nm) and fluorescence (ex. 340 nm, em. 460 nm). An absorbance-based readout shows linearity over a larger 
range of NADH concentrations (left), whilst the fluorescence-based assay is more sensitive to low concentrations of 
NADH (right).  Values shown are an average from one experiment with three technical repeats ± SEM. 
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The previous assay buffer consisted of 10 mM HEPES buffer, 100 mM NaCl, 120 μM acetoacetyl-CoA, 250 
μM NADH, pH 7.0, 30°C. 17β-HSD10 enzyme was added at a final concentration of 0.5 μg/mL and the rate 
of reaction determined during the linear period of the progress curve (R2 > 0.9). Under these conditions it 
was possible to reproducibly measure 17β-HSD10 activity; however, compounds of interest consistently 
precipitated from the solution giving highly variable results and making useful inference impossible. An 
illustrative example is provided in Figure 3.09, using a series of Frentizole derivative compounds.  
 
As such, a number of buffer parameters were altered in an attempt to improve the quality of the assay. 
Various salt concentrations and temperatures were trialled, with the net effect of NaCl being removed 
and the temperature of the assay increased to 37°C. The addition of a low concentration of gelatin has 
previously been shown to improve the solubility of small molecules in aqueous solution348, and thus 0.5% 
gelatin was added to the buffer system, simultaneously improving compound solubility and also enzyme 
stability.  
At this point it was deemed necessary to prepare fresh compound solutions from anhydrous stocks. The 
preparation of fresh 10 mM stocks revealed a marked difference in colouration between the inherited 
solutions and those freshly prepared, suggesting an error in calculation had been made previously. 
Examination of the calculations performed confirmed such an error, with the result of the previous 
compound stocks being 100 mM rather than 10 mM and explaining the associated solubility issues. Once 
this was known, compound solubility was no longer an issue and the assay became markedly more 
reproducible.  
Figure 3.09. Inherited 17β-HSD10 activity assay. Enzyme activity was assessed in the presence of compounds K684-
K711 at 100 μM using the inherited assay conditions. The inherited assay was found to produce highly variable results, 
making meaningful inference impossible. Values shown are an average taken from two independent experiments 
each with three technical repeats ± SEM. 
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Initial experiments made use of a BMG FluoStar Optima plate reader. This spectrophotometer was only 
capable of performing kinetic reads of the required interval on a single well at a time, severely limiting 
throughput and introducing a large amount of variability into the assay. To rectify this, a different 
spectrophotometer was used, initially a SpectraMax 250 and later a SpectraMax M2e, both of which are 
capable of taking readings from an entire 96 well plate at once, ameliorating the aforementioned issues 
and dramatically improving the reliability of results.   
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3.03 Michaelis-Menten Kinetics: 
When performing screening experiments with the aim of identifying enzyme inhibitors, it is important to 
select appropriate concentrations of substrate and cofactor for use in the reaction. Michaelis-Menten 
kinetic parameters, Vmax and Km, are typically used to guide this selection. The kinetic parameters of the 
17β-HSD10 enzyme were assessed with respect to cofactor, NADH, and substrate, acetoacetyl-CoA, using 
non-linear regression and the Michaelis-Menten equation. Thus, 17β-HSD10 activity was measured in the 
presence of a saturating concentration of NADH and increasing concentrations of acetoacetyl-CoA and 
subsequently, in the presence of a saturating concentration of acetoacetyl-CoA and increasing 
concentrations of NADH. A Vmax value of 10.64 ± 0.42 μmol mg-1 min-1 and Km of 11.79 ± 1.87 μM were 
calculated with respect to acetoacetyl-CoA (Figure 3.10, top). A Vmax value of 15.54 ± 0.96 μmol mg-1 min-
1 and a Km value of 99.84 ± 21.34 μM were calculated with respect to NADH (Figure 3.10, bottom).  
 
 
Figure 3.10. 17β-HSD10 enzymatic activity as a function of acetoacetyl-CoA concentration (Top) and NADH 
concentration (Bottom). The rate of reaction was measured in the presence of increasing concentrations of 
acetoaceyl-CoA or NADH, allowing the calculation of kinetic parameters Vmax and Km. A Vmax value of 10.64 ± 0.42 μmol 
mg-1 min-1 and a Km value of 11.79 ± 1.87 μM were calculated with respect to acetoacetyl-CoA. A Vmax value of 15.54 
± 0.96 μmol mg-1 min-1 and a Km value of 99.84 ± 21.34 μM were calculated with respect to NADH. Values shown are 
an average taken from two independent experiments each with three technical repeats ± SEM. 
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Typically, screening assays with the aim of identifying enzyme inhibitors will utilise substrate and co-factor 
concentrations at or around the value of Km, ensuring that the assay is capable of identifying inhibitors 
acting via a competitive mechanism, as they will not be out-competed by either substrate or co-factor. 
The concentrations of acetoacetyl-CoA and NADH utilised in the inherited assay were both markedly 
above the Km value at 120 μM and 250 μM respectively, effectively masking the influence of inhibitors 
acting via a competitive mechanism; however, compounds acting via a non-competitive mechanism 
would still be apparent. The active site of the 17β-HSD10 enzyme is known to undergo a marked 
conformational change once bound to Aβ303,349 and as such, competitive inhibitors are unlikely to remain 
active against the disease relevant 17β-HSD10/Aβ complex. Therefore, a decision was made to continue 
with the previous concentrations of 120 μM acetoacetyl-CoA and 250 μM NADH and to focus on the 
identification of non-competitive inhibitors of the 17β-HSD10 enzyme. 
3.04 DMSO Titration: 
To facilitate ease of screening, all in-house compounds were prepared using dimethyl sulfoxide (DMSO), 
a polar, aprotic solvent capable of dissolving both polar and non-polar compounds. Prior to the 
commencement of small molecule screening, an initial experiment was performed to assess the effect of 
increasing concentrations of solvent on 17β-HSD10 enzymatic activity. Any changes in enzyme activity 
observed in the presence of compounds of interest could then reliably be attributed to the said compound 
and not simply solvent effects. As such, the activity of the 17β-HSD10 enzyme was assessed in the 
presence of increasing concentrations of DMSO (0-5% (v/v)).  A measurable decrease in activity was seen 
even at the lowest concentration tested (0.5% (v/v)), suggesting the 17β-HSD10 enzyme is reasonably 
sensitive to this solvent. A concentration of 1% DMSO (v/v) was deemed to induce an acceptable decrease 
in activity (4.8%) whilst allowing a reasonable range of compound concentrations to be tested and thus 
was employed for subsequent compound screening experiments. 
 
Figure 3.11. Effect of increasing DMSO concentration on 17β-HSD10 enzymatic activity. The catalytic activity of the 
17β-HSD10 enzyme was measured in the presence of increasing concentrations of DMSO (0-5 % (v/v)) . A concentration 
of 1% (v/v) was selected for subsequent compound screening experiments. Values shown are an average taken from 
one experiment with three technical repeats ± SEM. 
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3.05 Assay Validation: AG18051 Dose-Response and Z-Factor calculation  
As validation of the aforementioned 17β-HSD10 activity assay, an IC50 value was calculated using 
compound AG18051. Identified in 2004 by Kissinger et al., AG18051 is a known potent inhibitor of the 
17β-HSD10 enzyme with a reported IC50 value of 92 nM350 (Figure 3.12). 
 
Using the previously defined in-house enzyme based assay, an IC50 value of 68.61 nM (95% CI = 64.5-72.99) 
was calculated for compound AG18051 (Figure 3.13).  
The IC50 values reported herein and previously by Kissinger et al. were found to correlate well, showing 
the in-house enzyme assay is functioning as expected and is suitable for further explorative screening 
experiments. 
Repeat experiments using a saturating concentration of compound AG18051 were performed on three 
sequential days, indicating an extremely high degree of reproducibility (data not shown). As the 
experiments are performed using purified 17β-HSD10 enzyme there should, with the exception of human 
and equipment error, be no biological variation between repeat experiments, as was indicated by the 
observed high degree of reproducibility. Thus, for small molecule characterisation based assays, two 
Figure 3.12. Structure AG18051.  Compound AG18051 was identified as a potent inhibitor of the 17β-HSD10 enzyme 
by Kissinger et al. in 2004350. 
Figure 3.13. Compound AG18051 dose response. 17β-HSD10 enzyme activity was measured in the presence of 
increasing concentrations of compound AG18051, a known potent inhibitor of the 17β-HSD10 enzyme. An IC50 value 
of 68.61 nM (95% CI = 64.5-72.99) was calculated using GraphPad Prism. Values shown are an average taken from 
two independent experiments each with three technical repeats ± SEM. 
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independent experiments would be performed on sequential days, each harbouring three technical 
repeats and an average taken. The inclusion of technical repeats would allow equipment error to be 
controlled for, whilst performing two entirely independent experiments would account for any biological 
variation between enzyme aliquots, and allow any gross human error to be readily identified, whilst also 
acting to conserve limited compound and protein stocks. 
To test the robustness of such an experimental design, a Z-factor value was calculated for the assay. The 
Z-Factor, described by Zhang et al., is commonly used to assess the robustness of a screening assay, 
providing a measure of both dynamic range and reproducibility351. A Z-Factor value was calculated for the 
17β-HSD10 activity assay using data taken from two independent experiments, each with three technical 
repeats (comparable to conditions used for subsequent screening experiments), using the formula: 
𝑍 = 1 −
(3𝑆𝐷 𝑜𝑓 𝑆𝑎𝑚𝑝𝑙𝑒 +  3𝑆𝐷 𝑜𝑓 𝐶𝑜𝑛𝑡𝑟𝑜𝑙) 
(𝑀𝑒𝑎𝑛 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 − 𝑀𝑒𝑎𝑛 𝑜𝑓 𝐶𝑜𝑛𝑡𝑟𝑜𝑙)
 
Z = 1, An ideal assay 
1>Z> 0.5, An excellent assay 
0.5>Z>0, A marginal assay 
Z= 0, An assay unsuitable for screening purposes 
DMSO (1% (v/v)) was employed as a vehicle control and a saturating concentration of compound AG18051 
used as a positive control for inhibition. A Z-Factor value of 0.895 was obtained, falling well within the 
"excellent assay" bracket and indicating that the described screening assay is robust in nature and suitable 
for further explorative screening experiments. 
Whilst potent, the mechanism of action utilised by compound AG18051 involves the formation of a 
covalent bond to cofactor, NAD+, altering the conformation of the Rossmann fold motif and thereby 
inhibiting enzyme activity350. As both NAD+ and the Rossmann fold are features common to many families 
of enzyme352, it was hypothesised that compound AG18051 would be promiscuous in nature and hence a 
poor drug candidate, prompting the search for alternatives. 
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3.06 Frentizole Derivatives - Initial Screens: 
In 2006, Xie et al. showed that Frentizole, an FDA approved antiviral and immunosuppressant compound, 
is capable of perturbing the interaction between the 17β-HSD10 enzyme and Aβ, albeit poorly with an 
IC50 value of approximately 200 μM344. Two derivatives of the parent Frentizole scaffold were generated 
with markedly improved potency against the 17β-HSD10/Aβ interaction, with IC50 values <10 μM (Figure 
3.14)344.  
 
We hypothesised that the ability of the compounds described by Xie et al. to perturb the interaction 
between the 17β-HSD10 enzyme and Aβ, may confer the ability to bind directly to 17β-HSD10 and in doing 
so may inhibit the catalytic activity of the enzyme. Thus, Frentizole derivatives may hold the potential for 
the generation of dual purpose therapeutics, simultaneously disrupting the 17β-HSD10/Aβ interaction, 
whilst also inhibiting the catalytic activity of the enzyme.  
To investigate this further, our collaborators in the Czech Republic synthesised derivative compounds 1 
and 2 (Figure 3.14, Table 3.01: K710-K711) and an additional 25 compounds harbouring various 
substitutions on the phenylurea moiety, with the aim of generating novel inhibitors of the 17β-HSD10 
enzyme (Table 3.01: K684-K709). Frentizole, the parent molecule, was available commercially and thus 
was purchased, allowing comparative biological evaluation (see Appendix: C for compound NMR). 
 
  
Figure 3.14. 17β-HSD10/Aβ interaction perturbing compounds. Frentizole, the parent compound was found to be 
capable of disrupting the interaction between the 17β-HSD10 enzyme and Aβ (IC50>200 μM) derivatives 1 and 2 were 
found to be markedly more potent (IC50<10 μM). Redrawn from344.  
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Table 3.01. Series 1: Frentizole derivative compounds (K684-K711). A series of 25 Frentizole derivatives were 
synthesised with the aim of generating novel inhibitors of the 17β-HSD10 enzyme (K684-K709). Two known 17β-
HSD10/Aβ interaction disrupting compounds were also synthesised (K710-K711)344. 
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Using the aforementioned 17β-HSD10 activity assay (Chapter 3: Section 3.02), an initial screen of the 
synthesised Frentizole derivatives was performed at 100 μM. At this concentration five compounds 
capable of inhibiting the 17β-HSD10 enzyme were identified; compounds K688, K689, K690, K691 and 
K693 (Figure 3.15). Interestingly, compounds known to perturb the 17β-HSD10/Aβ interaction (Frentizole, 
K710-K711) were found to be incapable of directly inhibiting the catalytic activity of the enzyme. 
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In an attempt to identify the most potent inhibitors, a second compound screen was subsequently 
performed at 25 μM. At this concentration compounds K690 and K691 were found to retain a similar level 
of inhibition to that seen at 100 μM whilst compounds K688, K689 and K693 showed less marked 
inhibition, suggesting compounds K690 and K691, harbouring a hydroxyl group in the para position and 
chloro group in the meta position of the phenylurea moiety, are the most potent inhibitors within this 
series (Figure 3.16). 
 
 
 
 
Figure 3.15. 17β-HSD10 activity in the presence of compounds K684-K711 at 100 μM. An initial screen of the 
synthesised frentizole derivatives was performed at 100 μM. At this concentration 5 compounds, K688, K689, K690, 
K691 and K693, were found to be capable of significantly inhibiting the catalytic activity of the 17β-HSD10 enzyme. 
Values shown are an average taken from two independent experiments each with three technical repeats ± SEM. 
Statistical analysis was performed using GraphPad Prism and a one-way ANOVA with Bonferonni multiple 
comparisons. * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, **** = P ≤ 0.0001. 
 
Figure 3.16. 17β-HSD10 activity in the presence of compounds K684-K711 at 25 μM. A second screen of the 
synthesised frentizole derivatives was performed at 25 μM. At this concentration 3 compounds, K689, K690 and K691 
were found to be capable of significantly inhibiting the 17β-HSD10 enzyme. Values shown are an average from two 
independent experiments each with three technical repeats ± SEM. Statistical analysis was performed using GraphPad 
Prism and a one-way ANOVA with Bonferonni multiple comparisons. * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, **** 
= P ≤ 0.0001. 
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A second compound series was designed on the basis of information obtained from the first (Table 3.02: 
K795-K805). Substitution of the benzothiazole moiety with a chloro group at position 5 was retained and 
the phenylurea moiety substituted with chloro and hydroxyl groups, in various combinations and 
positions, in the hope of generating structure activity relationships, and more potent inhibitors of the 17β-
HSD10 enzyme (see Appendix: C for compound NMR).  
Table 3.02. Series 2: Frentizole derivative compounds (K795-K805). A second series of 11 Frentizole derivatives 
were synthesised with the aim of further characterising the structural motifs required for inhibition of the 17β-
HSD10 enzyme. 
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As before, compounds K795-K805 were first screened at 100 μM and subsequently at 25 μM. At the 100 
μM concentration compounds K798, K801, K803 and K805 were found to be capable of significantly 
reducing enzyme activity (Figure 3.17).  
 
A second screen, performed at a lower 25 μM concentration, identified compound K801 as the most 
potent inhibitor within this series (Figure 3.18).  
 
 
Figure 3.17. 17β-HSD10 activity in the presence of compounds K795-K805 at 100 μM. An initial screen of the 
synthesised frentizole derivatives was performed at 100 μM. At this concentration 4 compounds, K798, K801, K803 
and K805, were found to be capable of significantly inhibiting the catalytic activity of the 17β-HSD10 enzyme. Values 
shown are an average taken from two independent experiments each with three technical repeats ± SEM. Statistical 
analysis was performed using GraphPad Prism and a one-way ANOVA with Bonferonni multiple comparisons. * = P ≤ 
0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, **** = P ≤ 0.0001. 
 
  
Figure 3.18. 17β-HSD10 activity in the presence of compounds K795-K805 at 25 μM. A subsequent screen of the 
synthesised frentizole derivatives was performed at 25 μM. At this concentration 4 compounds, K798, K801, K803 
and K805, were found to be capable of significantly inhibiting the catalytic activity of the 17β-HSD10 enzyme. Values 
shown are an average taken from two independent experiments each with three technical repeats ± SEM. Statistical 
analysis was performed using GraphPad Prism and a one-way ANOVA with Bonferonni multiple comparisons. * = P ≤ 
0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, **** = P ≤ 0.0001. 
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As was seen previously with compounds K690 and K691 (Figures 3.15 and 3.16), substitution of the 
phenylurea moiety with a hydoxyl group in the para position and chloro group in the meta position was 
found to give rise to the highest level of enzyme inhibition, seen here with compound K801.  
3.07 K690, K691 and K801 Dose-Response Curves:  
Whilst an initial compound screen using a single fixed concentration is useful for identifying compounds 
capable of inhibition, it does little to describe their relative potencies, making meaningful comparisons 
between inhibitors difficult. The generation of dose response curves and the calculation of IC50 values 
provides a much more descriptive assessment of potency and allows robust comparisons between 
compounds of interest, critical for the assessment of subsequent generations of, hopefully, more potent 
series of compounds. 
Dose response curves were generated for compounds K690, K691 and K801 (Figure 3.19, A, B and C). As 
would be expected given their close structural similarity all three compounds were found to be similarly 
potent, with IC50 values of 1.89 μM (95% CI = 1.52-2.35), 1.67 μM (95% CI = 1.30-2.13) and 1.94 μM (95% 
CI = 1.75-2.10) calculated for compounds K690, K691 and K801, respectively. At saturation, all three 
inhibitors were found to result in incomplete inhibition of the 17β-HSD10 enzyme with approximately 30-
40% residual activity observed. 
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Figure 3.19. Dose response K690, K691, K801. 17β-HSD10 activity was measured in the presence of increasing 
concentrations of compound K690, K691 and K801. IC50 values of 1.89 μM (95% CI= 1.52-2.35), 1.67 μM (95% CI= 1.30-
2.13) and 1.94 μM (95% CI= 1.78-2.10) were calculated for compounds K690, K691 and K801 respectively. Values 
shown are an average of two independent experiments each with three technical repeats ± SEM 
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Compound K801 is substituted with an additional chloro group on the phenylurea moiety, as compared 
to compounds K690 and K691, resulting in a compound with less favourable physiochemical properties 
and no corresponding increase in potency. As such, it was deemed a less promising candidate and was 
not further pursued. 
Subsequent generations of compounds with alternative substitutions of the benzothiazole moiety were 
designed on the basis of inhibitors K690, K691 and K801.  The screening of these compounds, performed 
by Becka Hughes, a Masters student in the lab, identified compound K1093 (Figure 3.20) as being both 
more potent and more soluble than the parent molecules, as indicated by the lower IC50 value and the 
lower residual activity observed at saturation (Figure 3.21). Compound K1093 was thus passed forward 
into further testing. 
 
Figure 3.20. Structure K1093. Additional series of compounds were designed on the basis of inhibitors K690 and 
K691. Various substitutions of the benzothiazole moiety were trialled with the aim of improving potency and 
solubility. Compound K1093 was found to be both more potent and more soluble than K690 and K691. 
Figure 3.21. Dose Response K1093. 17β-HSD10 activity was measured in the presence of increasing concentrations 
of compound K1093. An IC50 value of 1.03 μM (95% CI = 0.79-1.35) was calculated for compound K1093. Values shown 
are an average of two independent experiments each with three technical repeats ± SEM 
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3.08 K690 and K691 Mechanism of Inhibition: 
Arguably, the gold standard for understanding the mechanism by which an enzyme inhibitor exerts its 
effect is through the generation of a crystal structure of the enzyme-inhibitor complex, allowing a detailed 
understanding of the interactions formed and the subsequent rational design of molecules with enhanced 
potency and specificity. Whilst a number of crystal structures of the 17β-HSD10 enzyme have been 
published previously (PDB identifiers: 2O23, 1U7T, 1SO8), our group has been unable to replicate these 
results. As such, in an attempt to characterise the mechanism of inhibition utilised by compounds K690 
and K691, a kinetics based appraisal was instead undertaken. 
By assessing their effect on the Michaelis-Menten parameters, Vmax and Km, enzyme inhibitors can be 
placed into three main classes; competitive, non-competitive and uncompetitive. Competitive inhibitors 
are typically structural analogues of either substrate or cofactor and occupy the substrate or cofactor 
binding site. In doing so, competitive inhibitors prevent reactant binding via steric-occlusion and thereby 
halt catalysis. In the presence of increasing concentrations of substrate/cofactor the inhibitor molecule 
will eventually be outcompeted, giving a restoration in enzymatic activity. Thus, in the presence of a 
competitive inhibitor, Vmax will remain constant but a higher concentration of substrate will be required 
to reach it, indicated by an elevation in the value of Km. Non-competitive inhibitors bind outside of the 
active site and therefore increasing concentrations of substrate/cofactor will be unable to relieve 
inhibition. As such, Vmax will be reduced but as the binding of the inhibitor does not alter the binding of 
cofactor or substrate, Km will remain constant. Uncompetitive inhibitors bind solely to the enzyme-
substrate complex resulting in a decrease in Vmax and a corresponding decrease in Km.  
Traditionally, Lineweaver-Burk plots have been used to determine the values of Vmax and Km from 
Michaelis-Menten curves, providing a linear transformation of such data. However, the transformation 
used (1/V vs 1/[S]) results in unequal error distribution across the dataset potentially influencing 
results353. The Hanes-Woolf transformation ([S]/V vs [S]) gives a more uniform distribution of error and 
likely more accurate estimations of kinetic parameters353. With the invention of computers and the 
comparative ease with which non-linear regression analysis can now be performed, both have been 
superseded but remain useful for providing a visual representation of the data. As such, Hanes-Woolf 
plots were used to visually display the produced kinetic data, whilst absolute values for Vmax and Km were 
determined via non-linear regression using GraphPad Prism and the Michaelis-Menten equation.  
With respect to NADH, both K690 and K691 were found to act via a non-competitive mechanism of 
inhibition. Both inhibitors were found to induce a reduction in Vmax, indicated by an increase in the slope 
of the line, with no apparent change in Km, as shown by the convergence on the x-axis (Figure 3.22). These 
results indicate that the binding of NADH and the binding of inhibitor are not mutually exclusive and that 
increasing concentrations of NADH are not able to prevent inhibition. As such, it can be reasoned that 
compounds K690 and K691 are not binding to the cofactor binding site.  
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Such conclusions are supported by the values of Vmax and Km as determined by non-linear regression using 
the Michaelis-Menten equation. In the presence of either inhibitor, Vmax was found to be significantly 
decreased whilst Km was unchanged (Table 3.03).  
 
 
Figure 3.22. Hanes-Woolf plot: K690 and K691 vs NADH. Initial velocities of the 17β-HSD10 enzyme were measured 
with the indicated concentrations of NADH, both in the absence and presence of compounds K690 (A) and K691 (B) 
(1.25 μM and 5 μM). Values shown are an average of two independent experiments, each with two technical repeats. 
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With respect to substrate, acetoaceyl-CoA, both K690 and K691 were found to act via a mixed non-
competitive mechanism of inhibition, as shown by both the slope of the line and the x-intercept being 
altered in the presence of either compound, indicative of a reduction in both Vmax and Km and suggesting 
compounds K690 and K691 are able to bind to both the free enzyme and to the enzyme-substrate complex 
with differing affinities for each (Figure 3.23). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.03.  Effect of compounds K690 and K691 on Vmax and Km. with respect to NADH.  Compounds K690 and K691 
were found to induce a significant decrease in Vmax with no significant alteration in Km. Values shown are an average 
of two independent experiments each with two technical repeats. Statistical analysis was performed with GraphPad 
Prism using a sum of squares F-test. NS = P > 0.05, * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, **** = P ≤ 0.0001. 
  
 
P > 0.05 
 
* 
  
 
P ≤ 0.05 
 
** 
  
 
P ≤ 0.01 
 
*** 
  
 
P ≤ 0.001 
 
**** 
  
 
 P ≤ 0.0001  
Vmax (μmol min
-1 mg-1) Significance Km Significance
DMSO 18.28 ± 0.99 115.2 ± 20.27
1.25 μM K690 14.21 ± 0.75 * 145.3 ± 22.09 NS
5 μM K690 10.56 ± 0.57 *** 146.2 ± 22.74 NS
DMSO 21.51 ± 0.58 157.3 ± 11.92
1.25 μM K691 15.04 ± 1.02 *** 176.2 ± 31.78 NS
5 μM K691 10.24 ± 1.05 **** 162.6 ± 45.70 NS
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Such conclusions are supported by the results of non-linear regression analysis using GraphPad Prism and 
the Michaelis-Menten equation. With respect to acetoacetyl-CoA, compounds K690 and K691 were found 
to induce a significant decrease in both Vmax and Km (Table 3.04). 
 
 
 
 
Figure 3.23. Hanes-Woolf plot: K690 and K691 vs acetoacetyl-CoA. Initial velocities of the 17β-HSD10 enzyme were 
measured with the indicated concentrations of acetoacetyl-CoA, both in the absence and presence of compounds 
K690 (A) and K691 (B) (1.25 μM and 5 μM). Values shown are an average of two independent experiments, each with 
two technical repeats. 
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Table 3.04. Effect of compounds K690 and K691 on Vmax and Km with respect to acetoacetyl-CoA.  Compounds K690 
and K691 were found to induce a significant decrease in both Vmax and Km. Values shown are an average of two 
independent experiments each with two technical repeats. Statistical analysis was performed with GraphPad Prism 
using a sum of squares F-test. NS = P > 0.05, * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, **** = P ≤ 0.0001. 
 
Vmax (μmol min
-1 mg-1) Significance Km Significance
DMSO 13.23 ± 0.39 14.52 ± 1.51
1.25 μM K690 8.63 ± 0.28 **** 14.32 ± 1.64 NS
5 μM K690 6.01 ± 0.29 **** 4.73 ± 1.25 ***
DMSO 11.53 ± 0.14 11.49 ± 0.54
1.25 μM K691 6.01 ± 0.15 **** 8.36 ± 0.91 **
5 μM K691 3.42 ± 0.17 **** 5.12 ± 1.34 **
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3.09 K690 and K691 Small Molecule Aggregation Test: 
A frequent problem encountered during small molecule screening is the identification of false positives. 
Often, small molecules form aggregates which sequester and inactive enzyme molecules in a non-specific 
fashion, yielding what appear promising hits354. To test this, enzyme activity can be measured with a 
suspected inhibitor both in the presence and absence of a detergent, such as Triton X-100354. The addition 
of detergent will disrupt aggregate formation and thus if enzyme activity were to be restored in the 
presence of Triton X-100, it would imply that the inhibitor is indeed acting via a non-specific aggregation 
based mechanism. The effect of compounds K690 and K691 on enzyme activity was assessed in the 
presence and absence of two concentrations of Triton X-100. In both cases no reversal of inhibition was 
observed suggesting a non-specific aggregation based mechanism is not at work (Figure 3.24). 
 
In addition, a check was made for known troublesome chemical motifs using the Pan Assay Interference 
Compounds (PAINS) database, a web-based tool aimed at the identification of compounds likely to exert 
a biological effect in a non-specific manner355. A database search was performed using the structures of 
compounds K690 and K691, with no reported issues. 
 
 
 
 
Figure 3.24. Small molecule aggregation test. 17β-HSD10 activity was assessed with 2μM K690, K691 or DMSO both 
in the presence and absence of Triton X-100 (0.1%, 0.01%).  In both cases, no reversal of inhibition was observed in 
the presence of Triton X-100. Values shown are an average of one experiment with three technical repeats ± SEM. 
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3.10 K690, K691 and AG18051 - Reversible/Irreversible Inhibition 
Depending upon the nature of the interaction formed between protein and ligand, enzyme inhibition can 
be either reversible or irreversible in nature. To test whether the mechanism of action used by compounds 
K690, K691 and AG18051 was reversible or irreversible, the 17β-HSD10 enzyme was treated with a 
saturating dose of inhibitor molecule (12.5 μM for K690/K691 and 0.39 μM for AG18051) and 
subsequently diluted into well solution containing an equivalent concentration of inhibitor molecule, 
yielding no net dilution, or no inhibitor molecule, yielding a dilution to a non-saturating dose. If reversible, 
activity should be restored upon dilution. In all cases, enzyme activity was found to be restored upon 
dilution, indicating all three inhibitors act via a reversible mechanism (Figure 3.25). 
 
 
  
Figure 3.25. K690, K691, AG18051 reversible/irreversible inhibition.  17β-HSD10 was treated with a saturating dose 
of compounds K690, K691 or AG18051 and subsequently diluted into well solution containing an equal concentration 
of inhibitor (no dilution) or no-inhibitor (diluted). Following dilution, 17β-HSD10 activity was seen to be restored, 
indicating all three inhibitors act via a reversible mechanism of inhibition. Values shown are an average of one 
experiment with three technical repeats ± SEM. 
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3.11 Frentizole Derivatives - Differential Scanning Fluorimetry 
Through the use of an enzyme activity assay, we have identified three novel, reasonably potent inhibitors 
of the 17β-HSD10 enzyme, termed K690, K691 and K1093. To confirm suspected hit compounds a second 
independent technique is often employed, reducing the chance of such hits being an artefact of the 
primary screening methodology. As confirmation of a direct interaction between the 17β-HSD10 enzyme 
and compounds K690, K691 and K1093, differential scanning fluorimetry (DSF/thermal shift/thermofluor) 
was utilised.  
When correctly folded, hydrophobic residues in the primary structure of a protein are held within the core 
of the tertiary structure, sequestered away from water in the external environment. Depending upon the 
nature of the protein, this tertiary structure has an intrinsic stability, which can be measured using DSF as 
the temperature at which the protein becomes denatured. SYPRO orange, a fluorophore which shows low 
fluorescence in an aqueous environment, but marked fluorescence in a hydrophobic environment, is 
employed for this purpose. As the temperature of the reaction is increased, the protein of interest will at 
a certain point become denatured, exposing the hydrophobic core and allowing SYPRO orange to bind 
and resulting in a peak in fluorescence. Therefore, the melting temperature (Tm) of a protein can be 
determined as a function of SYPRO orange fluorescence. The binding of ligand to protein will often result 
in a stabilisation or destabilisation of the tertiary structure, measured here as an increase or decrease in 
Tm, providing direct biophysical evidence of an interaction being formed356. 
An initial range-finding experiment was performed to identify optimal concentrations of SYPRO orange 
and 17β-HSD10 protein, giving a high signal to noise ratio and a sharp transition from the native to 
denatured state. A combination of x 20 SYPRO Orange (absolute concentration not published) and 10 μM 
17β-HSD10 was found to give the highest signal to noise ratio (approximately 5-fold) and a sharp 
transition, whilst also using a reasonable amount of protein. Using an initial buffer system of 50 mM HEPES 
(pH 8.2) and 0.5 M NaCl, a Tm of 55.32 ± 0.01°C was calculated for 17β-HSD10.  
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To validate that the DSF experiment was functioning correctly and was capable of detecting a known 
protein-ligand interaction, GraphPad Prism and the Boltzmann sigmoidal curve fit equation were used to 
calculate Tm values for both the free enzyme, and the enzyme in the presence of increasing concentrations 
of NADH, a known binding partner of 17β-HSD10. The addition of NADH to the buffer system induced a 
dose dependent increase in Tm from 56.28 ± 0.10°C for the free enzyme to 63.16 ± 0.02°C with 5 mM 
NADH (Figure 3.26, Table 3.05), validating that the DSF experiment was functioning correctly.  
 
 
 
Figure 3.26. Melt-profile of 17β-HSD10 in the presence of increasing concentrations of NADH. The melting 
temperature of the 17β-HSD10 enzyme was measured in the presence of increasing concentrations of NADH. Binding 
of NADH was found to result in a dose dependent increase in Tm. Values shown are an average of raw fluoresence 
taken from two experiments each with three technical repeats. For clarity, error bars have been omitted. 
 
Table 3.05. Effect of increasing NADH concentration on 17β-HSD10 Tm. Binding of NADH was found to result in a 
dose dependent increase in the  Tm value of the 17β-HSD10 enzyme. Values shown are an average of best-fit Tm values 
taken from two independent experiments each with three technical repeats, relative to the free enzyme. 
[NADH] mM  ΔTm (°C) SEM
0.00 0.00 0.12
0.02 0.25 0.14
0.04 0.88 0.02
0.08 1.62 0.11
0.16 2.74 0.02
0.31 3.58 0.09
0.63 4.85 0.06
1.25 5.62 0.08
2.50 6.32 0.03
5.00 6.88 0.07
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With the assay validated, compounds K690 and K691 were screened against the free 17β-HSD10 enzyme 
at 25 μM. However, no change in Tm was observed in the presence of either compound. 
Based upon previous kinetic based experiments (Section 3.08), inhibitors K690 and K691 act via a non-
competitive mechanism of inhibition with respect to cofactor, NADH, and thus the binding of NADH does 
not impact upon the binding of either inhibitor molecule. However, a mixed mechanism of inhibition was 
observed with respect to substrate, acetoacetyl-CoA suggesting K690 and K691 are capable of binding to 
both the free enzyme and the enzyme substrate complex, with differing affinities for each. As such, 
compounds K690 and K691 may preferentially bind to the enzyme-substrate complex, explaining the lack 
of a shift in Tm with the free enzyme. A dose-response experiment was performed using acetoacetyl-CoA 
in an attempt to identify a saturating concentration against which compounds K690 and K691 could be 
screened. 
At the lower concentrations of acetoacetyl-CoA tested, no alternation in Tm was apparent. A modest 
decrease in Tm was observed at higher concentrations (Figure 3.27, Table 3.06). 
 
Figure 3.27. Melt-profile of 17β-HSD10 in the presence of increasing concentrations of acetoacetyl-CoA. The melting 
temperature of the 17β-HSD10 enzyme was measured in the presence of increasing concentrations of acetoacetyl-
CoA. At the higher concentrations tested, a dose dependent decrease in Tm was seen. Values shown are an average 
of raw fluoresence taken from two experiments each with three technical repeats. For clarity, error bars have been 
omitted 
 
Chapter 3: 17β-HSD10 Small Molecule Screening 
121 
 
 
Based on previously derived Km values, acetoacetyl-CoA should have a higher affinity for the 17β-HSD10 
enzyme as compared to NADH (Chapter 3: Section 3.03). Using DSF, a measurable shift in Tm was observed 
at NADH concentrations as low as 0.04 mM and as such, a shift in Tm due to the binding of acetoacetyl-
CoA would be expected at or below 0.04 mM, however, this was not observed (Figure 3.27, Table 3.06). 
Two possibilities may underlie the lack of a shift in Tm observed with acetoacetyl-CoA, either the binding 
of this molecule gives rise to no marked alteration in the stability of the 17β-HSD10 enzyme, or, the 
reaction may progress via an order sequential mechanism with the binding of acetoacetyl-CoA being 
dependent on the 17β-HSD10 enzyme having already bound cofactor. The addition of NADH to the 
reaction system would provide all necessary components for catalysis, and thus there would be 
continually changing levels of reactants in the reaction mixture until an equilibrium was reached, 
potentially influencing results. 
NAD+ is identical to NADH, with the exception of a single hydrogen atom and so any conformational 
changes in the 17β-HSD10 enzyme observed with NADH are likely to also be seen with NAD+, however 
catalysis of acetoacetyl-CoA would not occur. Thus, a dose response experiment was performed using 
NAD+ in place of NADH. As before, with increasing cofactor concentration, a dose dependent increase in 
Tm was observed (Figure 3.28, Table 3.07). However, the maximum increase in Tm was found to be lower 
with NAD+ as compared to NADH, 3.38°C and 6.88°C respectfully, suggesting the conformational changes 
associated with the binding of each molecule may not be identical. 
Table 3.06. Effect of increasing acetoacetyl-CoA concentration on 17β-HSD10 Tm. Binding of acetoacetyl-CoA was 
found to result in a dose dependent decrease in the  Tm value of the 17β-HSD10 enzyme. Values shown are an average 
of best-fit Tm values taken from two independent experiments each with three technical repeats, relative to the free 
enzyme. 
 
[Acetoacetyl-CoA] mM  ΔTm (°C) SEM
0.00 0.00 0.20
0.13 -0.28 0.07
0.25 -0.43 0.08
0.50 -1.17 0.16
1.00 -1.32 0.12
2.00 -1.59 0.07
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Irrespective, a saturating concentration of 5 mM NAD+ was passed forward and a titration of acetoacetyl-
CoA concentrations again tested. In contrast to the free enzyme, in the presence of 5 mM NAD+ a dose 
dependent elevation in Tm was observed with increasing acetoacetyl-CoA concentration, indicating that 
high affinity binding of acetoacetyl-CoA is dependent on the enzyme having previously bound cofactor, 
and thus suggesting that the reaction does indeed proceed via an order sequential mechanism (Figure 
3.29, Table 3.08). As was seen previously in the absence of cofactor, at the highest concentrations of 
acetoacetyl-CoA tested this elevation in melting temperature was reversed, with a decrease in Tm 
observed.  
Figure 3.28. Melt-profile of 17β-HSD10 in the presence of increasing concentrations of NAD+. The melting 
temperature of the 17β-HSD10 enzyme was measured in the presence of increasing concentrations of NAD+. Binding 
of NAD+ was found to induce a dose dependent increase in Tm. Values shown are an average of raw fluoresence taken 
from two experiments each with three technical repeats. For clarity, error bars have been omitted. 
 
Table 3.07. Effect of increasing NAD+ concentration on 17β-HSD10 Tm. Binding of NAD+ was found to result in a dose 
dependent increase in the Tm value of the 17β-HSD10 enzyme. Values shown are an average of best-fit Tm values 
taken from two independent experiments each with three technical repeats, relative to the free enzyme. 
 
[NAD
+
] mM  ΔTm (°C) SEM
0.00 0.00 0.09
0.31 0.29 0.08
0.63 1.13 0.09
1.25 2.03 0.12
2.50 2.97 0.09
5.00 3.34 0.03
10.00 3.40 0.13
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A saturating concentration of both NAD+ (5 mM) and acetoacetyl-CoA (0.5 mM) were utilised for the 
screening of compounds K690 and K691, but again no consistent alteration in Tm was observed.  
Figure 3.29. Effect of increasing acetoacetyl-CoA concentration on the melting temperature of the 17β-HSD10 
enzyme in the presence of 5 mM NAD+. In the presence of a saturating concentration of NAD+, a dose dependent 
increase in Tm was observed with increasing acetoacetyl-CoA concentration. At the highest concentrations of 
acetoacetyl-CoA tested this stabilisation was seen to be reversed, indicated via a decrease in Tm. Values shown are an 
average of raw fluoresence taken from two experiments each with three technical repeats. For clarity, error bars have 
been omitted 
Table 3.08. Effect of increasing acetoacetyl-CoA concentration on the melting temperature of the 17β-HSD10 
enzyme in the presence of 5 mM NAD+. In the presence of a saturating concentration of NAD+, a dose dependent 
increase in Tm was observed with increasing acetoacetyl-CoA concentration. At the highest concentrations of 
acetoacetyl-CoA tested this stabilisation was seen to be reversed. Values shown are an average of best-fit Tm values 
taken from two independent experiments each with three technical repeats, relative to the free enzyme. 
5 mM NAD
+ 
+ [Acetoacetyl-CoA] mM  ΔTm (°C) SEM
0.000 0.00 0.08
0.002 0.07 0.03
0.004 0.20 0.08
0.008 0.56 0.04
0.016 1.09 0.10
0.031 1.74 0.03
0.063 2.20 0.05
0.125 2.66 0.13
0.250 2.81 0.10
0.500 3.06 0.04
1.000 2.65 0.16
2.000 2.54 0.04
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Compound K1093, a derivative of K690 and K691, shows both improved aqueous solubility and enhanced 
potency against the free 17β-HSD10 enzyme (Section 3.07). As such, this compound was similarly 
screened using DSF. In this instance, a dose dependent increase in Tm was observed, indicative of a direct 
interaction between inhibitor and the 17β-HSD10 enzyme (Figure 3.30, Table 3.09). This increase was only 
apparent at 25 μM and above, beyond the limit of solubility profile of compounds K690 and K691. 
 
 
 
 
  
Table 3.09. Effect of increasing concentrations of K1093 on the melting temperature of the 17β-HSD10 enzyme. A 
dose dependent increase in Tm was observed in the presence of increasing concentrations of compound K1093. Values 
shown are an average of best-fit Tm values taken from two independent experiments each with three technical 
repeats, relative to the free enzyme. 
Figure 3.30. Effect of increasing concentrations of K1093 on the melting temperature of the 17β-HSD10 enzyme. A 
dose dependent increase in Tm was observed in the presence of increasing concentrations of compound K1093 Values 
shown are an average of raw fluoresence taken from two experiments each with three technical repeats. For clarity, 
error bars have been omitted. 
 
[K1093] μM  ΔTm (°C) SEM
0 0.00 0.07
12.5 0.20 0.09
25 2.49 0.14
50 4.32 0.09
100 5.04 0.06
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3.12 Quantifying The 17β-HSD10-Aβ Interaction 
In 2006, Xie et al. identified Frentizole as a compound capable of disrupting the interaction between the 
17β-HSD10 enzyme and Aβ, albeit relatively poorly with an IC50 value of approximately 200 μM344. 
Subsequent derivatization of the parent scaffold generated two analogues (here referred to as K710 and 
K711, Table 3.01) with markedly improved potency against this interaction344. Through the use of a 17β-
HSD10 based enzyme assay, we have shown that both Frentizole and its derivatives K710 and K711 are 
unable to directly inhibit the catalytic activity of the 17β-HSD10 (Chapter 3: Section 3.06). However, 
further modification of the Frentizole scaffold was found to generate three reasonably potent 17β-HSD10 
inhibitors, termed K690, K691 and K1093 (Section 3.07). As both the direct inhibition of 17β-HSD10 
activity338, and the disruption of the 17β-HSD10/Aβ interaction303 have been shown to be of therapeutic 
merit in treating Alzheimer's disease, we were curious as to whether compounds K690 and K691 would 
retain the ability to perturb the 17β-HSD10-Aβ complex, potentially allowing both therapeutic avenues to 
be pursued with a single compound. 
Previously, an ELISA based technique was used to investigate the interaction between the 17β-HSD10 
enzyme and Aβ344. Here, a combination of differential scanning fluorimetry and western blotting was 
instead used.  
Initial experiments employed differential scanning fluorimetry with the aim of identifying a concentration 
of oligomeric Aβ1-42 capable of saturating a given concentration of 17β-HSD10 (10 μM). With increasing 
Aβ1-42 concentration, a dose dependent decrease in Tm was observed, suggesting that the binding of Aβ1-
42 to 17β-HSD10 results in destabilisation of the tertiary structure of the enzyme. At the higher 
concentrations of Aβ1-42 tested, this reduction in Tm was seen to plateau, indicating saturation of the 17β-
HSD10 enzyme (Figure 3.31). In the absence of the 17β-HSD10 enzyme, no marked melt transition was 
observed, suggesting that either the Aβ1-42 protein harbours no hydrophobic core or that the tertiary 
structure of the protein is too stable to unfold in the temperature range tested. An increase in background 
fluorescence was however observed, suggesting the surface of the Aβ1-42 protein may harbour 
hydrophobic residues capable of binding to SYPRO-orange. A saturating concentration of 50 μM Aβ1-42 
was passed forward into western blotting based experiments. 
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As an initial trial experiment, solutions containing 10 μM 17β-HSD10, 50μM Aβ1-42, or the two combined 
were prepared in assay buffer. Additional samples containing both 17β-HSD10 and Aβ1-42 were prepared 
in the presence of increasing concentrations of compound K711, known to disrupt the interaction 
between 17β-HSD10 and Aβ1-42344. Samples were incubated for 1 hr at 4°C after which proteins were 
resolved using SDS-PAGE and the localisation of the Aβ1-42 protein assessed via western blot. A faint band 
was observed with the 17β-HSD10 enzyme in isolation, subsequently found to be due to non-specific 
binding of the secondary antibody (Figure 3.32, Lane 1). Aβ1-42 was found to give rise to a number of bands, 
indicating a mixture of oligomeric forms, but none at 27 kDa, the molecular weight of the 17β-HSD10 
enzyme (Figure 3.32, Lane 2). Following incubation together, a prominent band was observed at 27 kDa, 
indicative of an interaction between 17β-HSD10 and Aβ1-42 (Figure 3.32, Lane 3). In the presence of 
increasing concentrations of compound K711, this interaction was found to be disrupted in a dose 
dependent manner, confirming the work of Xie et al., and validating the assay is capable of identifying 
compounds which disrupt this interaction (Figures 3.32, Lanes 3-6). 
 
 
Figure 3.32. Western blot for the 17β-HSD10/Aβ1-42 interaction. Samples were prepared containing 17β-HSD10 and 
Aβ both in isolation and together. Additional samples were prepared containing both 17β-HSD10 and Aβ with varying 
concentrations of compound K711, known to prevent the 17β-HSD10/Aβ interaction. Samples were subjected to 
western blot analysis using an anti-amyloid antibody, indicating the presence of an interaction between 17β-HSD10 
and Aβ, and the disruption of this interaction by compound K711. Lane 1 = 17β-HSD10, Lane 2 = Aβ, Lane 3 = 17β-
HSD10 + Aβ + DMSO, Lane 4 = 17β-HSD10 + Aβ +1.56 μM K711, Lane 5 = 17β-HSD10 + Aβ + 3.125 μM K711, Lane 6 = 
17β-HSD10 + Aβ + 6.25 μM K711. 
 
 
Figure 3.31. Best fit Tm values for the 17β-HSD10 enzyme in the presence of the indicated concentrations of Aβ1-42. 
Oligomeric Aβ1-42 was found to induce a dose-dependent decrease in the melting temperature of the 17β-HSD10 
enzyme. Values shown are an average taken from two independent experiments, each with three technical repeats 
± SEM. 
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Densitometry based analysis was found to confirm the visual assessment, again showing compound K711 
induces a dose dependent decrease in Aβ1-42 binding to the 17β-HSD10 enzyme (Figure 3.33). 
 
The experiment was repeated to confirm the observed results but was not found to be consistently 
reproducable, possibly due to the procedure used to generate monomeric Aβ1-42. Due to time constraints, 
this experiment was not further persued.  
  
Figure 3.33. Densitometry 17β-HSD10/Aβ1-42 interaction. Denistometry based analysis of Figure 3.32 was performed 
using ImageJ.  A dose-dependent decrease in bound Aβ1-42 was observed in the presence of increasing concentrations 
of compound K711.  
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3.13 NCI Diversity IV Initial Screen: 
Whilst a number of Frentizole derived 17β-HSD10 inhibitors have thus far been identified (Section 3.07) 
it is unlikely that any one hit scaffold will fulfil all requirements (ie. specific, non-toxic, membrane 
permeable, potent etc). As such, a decision was made to try and identify additional compound scaffolds 
capable of 17β-HSD10 inhibition, thereby diversifying the portfolio of compounds available and increasing 
the chance of success. The National Cancer Institute (NCI) houses an extensive compound library, 
comprising around 150,000 drug-like molecules, samples of which are available to academic researchers 
for the cost of shipping and handling. In addition, a diversity set of 1596 pre-plated compounds is also 
available. This comparatively small library holds compounds representative of the majority of the core 
scaffolds found within the complete library, allowing smaller screening institutions to sample a much 
larger chemical space than would otherwise be possible. Each compound within the diversity library 
typically has a number of structural analogues, which are similarly available and thus the procurement of 
follow-up samples and the generation of structure-activity relationships are both possible. 
In an attempt to identify additional core scaffolds, which could form the basis for subsequent series of 
17β-HSD10 inhibitors, an application was made to the NCI for the plated NCI Diversity Library (at the time 
of application, the fourth iteration) which was subsequently granted. Compounds were supplied as 10 
mM stocks in DMSO and were screened using a modification of the aforementioned recombinant 17β-
HSD10 screening assay (Materials and Methods: 3.18). Due to the high cost in terms of both labour and 
consumables, an initial screen of the entire library was run once with promising hit compounds further 
characterised thereafter. 
An initial 100 μM screen of the entire compound library identified a number of potential enzyme 
inhibitors. Suspected hit compounds were ranked on the basis of residual 17β-HSD10 activity (Table 3.10, 
see Appendix: D for a more comprehensive list of hit compounds). An effort was made to focus on 
compounds for which a relatively large number of analogues were available in the hope of generating 
structure-activity relationships. Compound 17796 was deemed to be of interest due to its small size and 
relatively high potency, whilst compound 88402 was found to have a large range of analogues available 
and so was also selected for further evaluation. 
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Table 3.10. NCI Diversity IV derived 17β-HSD10 inhibitors. An initial screen of the NCI Diversity IV compound library 
was performed at 100 μM. Compounds were ranked on the basis of residual enzyme activity relative to control (1% 
DMSO (v/v)). 
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17796 Analogues 
To confirm 17796 as a true hit and in an attempt to generate structure activity relationships, a request 
was sent for a follow up sample of compound 17796 and also 31 analogues of this molecule. Upon receipt, 
an initial screen was performed at 100 μM confirming compound 17796 as an active 17β-HSD10 inhibitor 
and also identifying four related compounds capable of high level enzyme inhibition, NSC numbers: 
114063, 350076, 66128 and 77847 (Figure 3.34, Table 3.11).  
  
Figure 3.34. Compound 17796 analogues. 31 analogues of compound 17796 were screened at 100 μM, confirming 
17796 as a 17β-HSD10 inhibitor and identifying additional inhibitors; compounds 114063, 350076, 66128 and 77847. 
Values are an average of one experiment with three technical repeats ± SEM 
Table 3.11. Molecular structures of 17796 derived 17β-HSD10 inhibitors . The screening of 31 analogues of inhibitor 
17796 identified three additional compounds of interest; 114063, 350076 and 77847. 
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Compounds 114063, 17796, 350076 and 77847 were re-screened at 100 μM and 25 μM, highlighting 
compounds 114063 and 350076 as the most potent inhibitors identified within this series thus far (Figure 
3.35). Compound 66128 was found to interfere with the assay and so was not further pursued. 
 
 
To give a more robust measure of potency, IC50 curves were generated for compounds 114063, 350076 
and 17796. IC50 values of 10.44 μM (95% CI = 9.62-11.33), 7.87 μM (95% CI = 7.36-8.40) and 20.33 μM 
(95% CI= 16.45-25.12) were calculated for compounds 114063, 350076 and 17796 respectively, again 
highlighting compounds 114063 and 350076 as the most potent inhibitors identified within this series.  
 
 
 
 
 
 
 
 
 
Figure 3.35. 17796 derived 17β-HSD10 inhibitors. Inhibiting compounds derived from compound 17796 were re-
screened at 100 μM and 25 μM, identifying compounds 114063 and 350076 as the most potent inhibitors within this 
series. Values shown are an average taken from two independent experiments, each with three technical repeats ± 
SEM. 
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At this point it was noted that all inhibiting compounds of this series harbour a thiol group, whilst non-
inhibiting compounds do not, suggesting that this group may be key for inhibition. To test this hypothesis 
further, our collaborators in the Czech Republic synthesised a custom series of compounds (Table 3.12: 
K945-K950). Should the thiol group seen in compounds 11796, 114063 and 350076 be acting as a 
hydrogen bond donor, compound K947 harbouring a primary amine group should be similarly active. 
Should the thiol group be acting as a hydrogen bond acceptor compounds K945 and K947, harbouring a 
keto and primary amine group respectively, should also be active. However, if compounds 11796, 114063 
and 350076 are utilising the thiol as a potential nucleophile for disulphide bond formation, only 
compounds K946, K948 and K950 should be active, each harbouring a thione group, predicted to be in 
resonance with a thiol.  
Figure 3.36. Dose-response curves for compound 114063 (Top), 350076 (Middle) and 17796 (Bottom). 17β-HSD10 
activity was measured in the presence of increasing concentrations of compounds 114063, 350076 and 17796 with 
IC50 values of 10.44 μM (95% CI = 9.62-11.33), 7.87 μM (95% CI = 7.36-8.40) and 20.033 μM (95% CI = 16.45-25.12) 
calculated for each compound respectfully. Values shown are an average of two independent experiments each with 
three technical repeats ± SEM 
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When screened at 100 μM using the in-house 17β-HSD10 assay, only compounds K946, K948 and K950, 
harbouring a thione group, showed marked inhibitory activity, suggesting that the thiol group is indeed 
required for inhibition and possibly that a disulphide bridge may be being formed to an active site cysteine 
residue, although the mechanism by which this may occur is not clear. This inhibition was seen to be 
reversible upon the addition of DTT, again providing further evidence for such an effect (Figure 3.37).  
 
 
 
Table 3.12 Compounds K945-K950. A series of compounds were synthesised with the indicated substiutions with the 
aim of investigating the mechanism of action utilised by compound 17796 and its analogues 114063 and 350076.  
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Upon examination of the crystal structure of the 17β-HSD10 enzyme, an active site cysteine is indeed 
present, located in the cofactor binding site (Figure 3.38). Whilst this cysteine residue is not predicted to 
form part of catalytic triad, or shown to form bonds to cofactor, the binding of compound 17796 or its 
derivatives may prevent cofactor binding through steric-occlusion thereby halting catalysis.  
 
  
  
Figure 3.37. Crystal structure of 17β-HSD10 (PDB:1U7T). The 17β-HSD10 enzyme was found to harbour an active site 
cysteine residue (Residue C91: Red), potentially explaining the mechanism of action utilised by thiol containing 
inhibitors  17796, 350076 and 114063.     
Figure 3.37. 17β-HSD10 inhibition induced by compounds K945-K950. Compounds K945-K950 were assessed for the 
ability to inhibit the 17β-HSD10 enzyme at 100 μM. Only compounds harbouring a thione group, K946, K948 and K950 
were found to induce marked inhibition and this was shown to be reversed by the addition of DTT, suggesting the 
formation of a disulphide bridge is responsible for the observed inhibition. Values shown are an average of two 
experiments each with three technical repeats ± SEM. 
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88402 Analogues 
Subsequently, to confirm compound 88402 as a true hit and in an attempt to generate structure activity 
relationship which could inform the design of subsequent compound series, an additional sample of 
compound 88402 was requested, as well as samples of eighteen structural analogues.  When screened at 
100 μM compound 88402 was confirmed as a true inhibitor, and a range of additional molecules of 
interest were identified (Figure 3.39). 
 
A dose response experiment was performed for the most potent inhibitor identified in this series, 
compound 88401, and an IC50 value of 10.30 μM (95% CI = 9.51-11.16) calculated (Figure 3.40).   
 
 
Figure 3.40. Dose response curve compound 88401. 17β-HSD10 enzyme activity was measured in the presence of 
increasing concentrations of compounds 88401. An IC50 value of 10.30 μM (95% CI = 9.51-11.16) was calculated using 
GraphPad Prism. Values shown are an average of two independent experiments each with three technical repeats ± 
SEM. 
 
Figure 3.39. 88402 Analogues. 18 analogues of compound 88402 were procured from the NCI and screened 
against the 17β-HSD10 enzyme at 100 μM. Values shown are an average of two independent experiments each 
will three technical repeats ± SEM.  
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Chapter 3 - Discussion 
Previous work has shown that the 17β-HSD10 enzyme forms a toxic complex with Aβ, resulting in oxidative 
stress and cell death303,337,338. Interestingly, hallmarks of this toxicity appear to be dependent on the 
catalytic activity of the 17β-HSD10 enzyme and as such two 17β-HSD10 directed therapeutic approaches 
may hold merit in treating Alzheimer's disease, namely the disruption of the 17β-HSD10/Aβ interaction 
or the direct inhibition of 17β-HSD10 catalytic activity.  
Here, I have developed a highly robust screening assay for measuring the activity of the 17β-HSD10 
enzyme and have subsequently shown for the first time that derivatives of Frentizole, a compound known 
to be capable of perturbing the interaction between 17β-HSD10 and Aβ, can be turned into reasonably 
potent inhibitors of 17β-HSD10 enzymatic activity, potentially allowing both therapeutic approaches to 
be pursued with a single compound. From two initial series of Frentizole derivatives, three novel inhibitors 
of the 17β-HSD10 enzyme were identified, termed K690, K691 and K801 (Figure 3.41).  
 
One additional inhibitor, K1093, with improved potency and solubility was identified thereafter as a result 
of a subsequent series of derivative compounds (Figure 3.42).  
 
 
 
 
Based upon the results of the initial screens of compounds K684-K711, it would appear that for the direct 
inhibition of 17β-HSD10 activity substitution of the benzothiazole moiety with a chlorine atom is 
preferable to fluorine, as evidenced by the enhanced levels of inhibition seen with chloro-substituted 
compounds K689 and K693 versus fluoro-substituted compounds K688 and K692 (Figure 3.15) and 
between compounds K689 and K688 (Figure 3.16). The presence of a hydroxyl group on the phenylurea 
moiety appears to be required for inhibition, likely involved in the formation of a hydrogen bond to the 
Figure 3.41. Frentizole derived 17β-HSD10 inhibitors. From two initial series of Frentizole derivatives, three 17β-
HSD10 inhibiting compounds were identified, termed compounds K690, K691 and K801. 
Figure 3.42 Frentizole derived 17β-HSD10 inhibitors (2). Screening of a number of follow-up series of Frentizole 
derivatives, identified inhibitor K1093 with improved potency and solubility. 
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17β-HSD10 enzyme. The position of this substitution on the phenylurea moiety also appears vital. A single 
hydroxyl group in the ortho position (Figures 3.15 and 3.16, K688 and K689) was found to be sufficient for 
inhibition, whilst substitution in the para position gave rise to no marked decrease in enzymatic activity 
(Figures 3.15 and 3.16, K684 and K685).  
 
Interestingly, substitution with a hydroxyl group in the para position in combination with a chloro group 
in the meta position gave rise to the most potent inhibitors (Figure 3.16 and Figure 3.18, K690, K691, 
K801) with movement of either group or alternative substitution found to result in a decreased level of 
inhibition (Tables 3.01 and 3.02, Figures 3.16 and 3.18). As substitution with a hydroxyl group in the ortho 
position was found to be sufficient in itself for inhibition (Figure 3.15 and 3.16, K688 and K689), it may be 
advantageous to add this substitution to the scaffold of compound K691, potentially improving potency 
(Figure 3.44). Similarly, on the basis of the enhanced solubility and potency of inhibitor K1093, (Figure 
3.42) further substitution of the benzothiazole moiety at position 5 should be investigated. Such 
compound series are currently in the process of being designed, synthesised and evaluated by Dr. Laura 
Aitken, in collaboration with Professor Kamil Musilek, Ondrej Benek and Lukas Hroch. 
 
At saturation, all compounds were found to result in incomplete inhibition of the 17β-HSD10 (Figures 3.19 
and 3.21). Originally, this was attributed to a partial mechanism of inhibition, in which the enzyme-
Figure 3.43. Frentizole derived enzyme inhibitors. Compounds K684 and K685 harbouring a hydroxyl group in the 
para position of the phenylurea moiety were found to be incapable of direct inhibition of the 17β-HSD10. Whilst 
compounds K688 and K689, with substitution in the ortho position gave rise to significant levels of inhibition. 
Figure 3.44. Proposed Frentizole derived inhibitor. On the basis of previously identified inhibitors, the addition of 
a hydroxyl group in the ortho position of the phenylurea moiety of inhibitor K691 may generate a more potent 
inhibitor. Additional substation at position X should also be investigated. 
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substrate-inhibitor complex would continue to generate product at a diminished rate. However, it now 
seems such a phenomenon is instead due to the limited solubility profiles of these initial hit compounds, 
forming a point of focus for subsequent series. 
In the absence of an X-ray crystallography derived model, the exact stereochemistry of binding is difficult 
to ascertain. As such, in an attempt to gain more insight into the mechanism of action utilised by 
compounds K690 and K691, a kinetics based appraisal was undertaken. Both compounds were found to 
act via a non-competitive mechanism with respect to cofactor, NADH, and a mixed non-competitive 
mechanism with respect to substrate, acetoacetyl-CoA (Section 3.08), somewhat unsurprising given that 
the assay conditions were designed to predispose to the identification of inhibitors of this type (Section 
3.03). In terms of drug like properties, non-competitive inhibitors are generally viewed favourably. In the 
presence of a competitive inhibitor, enzyme activity will be reduced resulting in a build-up of substrate 
and cofactor until a level is reached at which the inhibitor is outcompeted and activity restored. Inhibitors 
acting via a non-competitive mechanism do not suffer from this limitation, and thus typically require lower 
doses to maintain the desired effect, decreasing off-target effects and toxicity357. The generated data 
suggests that the binding of substrate, cofactor and inhibitor are not mutually exclusive events and thus 
both NADH and acetoacetyl-CoA may be of use as stabilising agents to facilitate the generation 17β-
HSD10-inhibitor crystals, an approach not previously attempted within the group. The generation of such 
a crystal would be highly advantageous allowing a detailed understanding of the interactions formed 
between inhibitor and protein and thus, the rational design of improved derivatives.  
As a confirmation assay, differential scanning fluorimetry was employed, providing direct biophysical 
evidence of an interaction between inhibitor, K1093, and the 17β-HSD10 enzyme and reducing the chance 
of such hits simply being the result of screening artefacts. Compounds K690 and K691 were not found to 
elicit a marked shift in the melting temperature of either the free 17β-HSD10 enzyme, or the enzyme in 
complex with cofactor and substrate. The lack of an observed shift in Tm may be due to the fact that the 
binding of compounds K690 and K691 induces no significant alteration in the stability of the 17β-HSD10 
enzyme, or more likely, due to an inherent limitation of the assay. DSF based experiments require ligand 
to remain bound at significantly elevated temperatures, 40-70°C, as compared to the initial enzymatic 
screening assay, performed at 37°C (Section 3.07), possibly effecting binding affinity. Given the reversible 
nature of inhibition exerted by compounds K690 and K691 (Figure 3.25) and the limited aqueous solubility 
of both molecules, the concentration of inhibitor required for significant binding to occur under the 
conditions necessary for DSF may simply be unattainable.  Compound K1093, with enhanced potency and 
solubility, was found to induce a dose dependent stabilisation of the enzyme structure but only at 
concentrations above 25 μM, beyond the limited solubility profile of compounds K690 and K691, providing 
further evidence that the lack of an observed shift with these molecules was due to inherent limitations 
of the DSF experiment and confirming Frentizole derived inhibitors as true hits. 
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One of the main advantages of compounds derived from the Frentizole scaffold is the potential for such 
compounds to simultaneously inhibit the catalytic activity of the 17β-HSD10 enzyme whilst also 
preventing binding to Aβ. The parent Frentizole scaffold has previously been shown to be capable of 
disrupting the 17β-HSD10/Aβ complex344 and thus we sought to ascertain whether inhibitors K690, K691 
and K1093 would retain this ability. Through the use of differential scanning fluorimetry and western 
blotting an attempt was made to generate a means of quantifying the amount of Aβ bound to the 17β-
HSD10 enzyme (Section 3.12). Although a lack of reproducibility meant that these experiments were 
deemed unsuitable for compound screening, it seems likely that with further optimisation a western blot 
based approach may be viable as a means of quantifying the ability of compounds of interest to perturb 
the 17β-HSD10/Aβ interaction. Whilst the exact cause for the observed lack of reproducbility is difficult 
to decipher, the most likely reason seems to be inconsistencies in the preparation of oligomeric Aβ. 
Commercially available recombinant Aβ must first be treated with a monomerising agent prior to an aging 
step to generate the desired oligomeric state. Traditionally, hexafluoroisopropanol (HFIP) has been used 
for this purpose, however the efficiency of such treatment has since been called into question. HFIP-
treated Aβ has been shown to harbour a mixture of species, indicated by the presence of a range of elution 
products following size exclusion chromatography (Figure 3.45)358 with the presence of such oligomeric 
species subsequently shown to speed the rate of fibril formation using a thioflavin-T assay, presumably 
through a seeding based mechanism (Figure 3.45)358.  
 
The 17β-HSD10 enzyme has been proposed to interact with oligomeric forms of Aβ349. Thus, if the starting 
material were to contain a mixture of monomeric and oligomeric species, as a result of incomplete 
monomerisation via HFIP, varying levels of oligomers and fibrils would be present following an amyoid 
aging step, resulting in varying levels of 17β-HSD10 bound Aβ and explaining the observed experimental 
variance. The use of NaOH has been proposed as an alternative method of amyloid monomerisation and 
has been shown to produce a more homogenious monomeric starting solution (Figure 3.45)358. Therefore, 
Figure 3.45. HFIP treatment results in a range of oligomeric species of Aβ. HFIP was found to result in incomplete 
monomerisation of Aβ, indicated here using size exclusion chromatography. NH4OH was shown to result in a more 
homogeneous monomeric preparation. Figure from358. 
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the use of NaOH in place of HFIP may serve to ameloriate the observed variance between replicate 
experiments and make the assay viable for small molecule screening. 
Whilst Frentizole derived inhibitors offer a promising starting point for the generation of disease 
modifying compounds, it is unlikely that any one series of compounds will fulfil all requirements and as 
such, a search for addition inhibitor scaffolds was made allowing a diversification of the portfolio of 
compounds available for evaluation and thereby increasing the chance of success. Additionally, in the 
absence of a crystal structure, pharmacophore mapping may be used to compare validated inhibitors and 
identify common structural features, providing insight into the key moieties necessary for inhibition, on 
the proviso that such inhibitors are confirmed to be operating at the same site. A large explorative 
screening experiment, using the NCI diversity IV compound library, identified a range of 17β-HSD10 
inhibitors, which, following further evaluation, may prove useful for such purposes (Section 3.13). 
Two inhibitors identified as a result of the NCI Diversity IV screen, compounds 17796 and 88402, were 
further investigated (Section 3.13). Compound 17796 and its associated derivatives with inhibitory activity 
were found to all harbour a thiol group, suggesting inhibition may be due to the formation of a disulphide 
bridge to an active site cysteine residue. Inhibition was found to be reversible in the presence of DTT, a 
reducing agent, providing further support for this hypothesis. As further validation of such a mechanism, 
17β-HSD10 activity could be assessed in the presence of increasing concentrations of N-ethylmaleimide, 
a compound which will irreversibly react with exposed thiol groups on cysteine residues. 
The screening of derivatives of compound 88402, identified compound 88401, harbouring substitution of 
the heterocyclic ring with two chloro groups at positions 5 and 6, which was more potent than the original 
hit compound, 88402, substituted at the 5 position with a methoxy group (Figure 3.39). A lack of 
substitution at this position, compounds 175834, 88398, 88400, 90501, was seen to result in 
comparatively poor inhibition, as did substitution with a methyl group, compound 88399. Thus suggesting 
the addition of small electronegative groups, particularly at position 5 of the heterocyclic moiety enhances 
inhibition (Table 3.13). 
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The presence of a methoxybenzene extension was also found to be important for inhibition, with 
substitution with a methylbenzene group resulting in less marked inhibition, as seen with compounds 
88402 and 88382 (Table 3.14).  
Table 3.13. 17β-HSD10 inhibition by analogues of compound 88402 analogues (subset 1). 17β-HSD10 enzyme 
activity was assessed in the presence of the indicated compound at 100 μM. Compound are ranked on the basis of 
residual enzyme activity. Values shown are an average of two independent experiments each with three technical 
repeats ± SEM. 
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The presence of a secondary amine on the heterocyclic ring was also found to be crucial for inhibition. 
Replacement with a tertiary amine, as with compound 88386, resulted in dramatically reduced inhibition 
as compared with compound 88382, suggesting the secondary amine is acting as a hydrogen bond donor 
and that the formation of this bond is critical for the inhibition of the 17β-HSD10 enzyme. The position of 
this secondary amine appears to become more important when substitution at position 5 of the 
heterocyclic ring is also present. The replacement of one of the two secondary amine groups with a 
tertiary amine, in the absence of an electron withdrawing group at position 5 of the heterocyclic moiety, 
had comparatively little effect on inhibition, as seen with compounds 88398 and 88400 (Table 3.13). In 
the absence of substitution on the heterocyclic ring, the inhibitor molecule may be more flexible, which 
may allow the second secondary amine to form this key hydrogen bond. Once an electron withdrawing 
group is added, the bound inhibitor molecule may become sterically restricted, preventing this hydrogen 
bond from being formed and explaining the comparatively large reduction in inhibition seen between 
compounds 88382 and 88386 (Table 3.14). 
 
In summary, we now have a highly robust method for measuring the catalytic activity of the 17β-HSD10 
enzyme, forming the basis of our primary small molecule screening assay. Alongside this, we have a 
second robust de-selection assay in the form of differential scanning fluorimetry, allowing the validation 
of suspected small molecule inhibitors. Through the use of these experiments we have identified 3 
derivatives of the Frentizole scaffold which are capable of enzyme inhibition, termed K690, K691 and 
K1093. As a result of a comparatively large NCI Diversity IV screen, a range of additional inhibitor scaffolds 
were identified., with two, compounds 17796 and 88402, being further investigated and possibly forming 
the basis for new inhibitor series. Subsequent experiments were conducted to assess inhibitor specificity 
Table 3.14. 17β-HSD10 inhibition by analogues of compound 88402 analogues (subset 2). 17β-HSD10 activity was 
assessed in the presence of the indicated compound at 100 μM. Compound are ranked on the basis of residual 
enzyme activity. Values shown are an average of two independent experiments each with three technical repeats ± 
SEM. 
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(Chapter 4) and to generate a cellular disease model against which compounds of interest could be tested 
(Chapter 5).
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Chapter 4: Inhibitor Specificity - Molecular Cloning and 
Purification of 17β-HSD8 and 17β-HSD14 
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Chapter 4 - Introduction and Aims: 
A frequent issue associated with the development of small molecule enzyme inhibitors is specificity of 
action. Enzymes are clustered into families, based on substrate utilisation and primary sequence 
similarities and into super-families on the basis of shared mechanistic and structural features. Whilst a 
decrease in the level of activity of one enzyme within a family may be therapeutically beneficial, the 
simultaneous inhibition of closely related homologues can often give rise to toxicity. Thus, an 
understanding of the specificity of a compound of interest for a given target is highly valuable during the 
drug development process. The 17β-HSD10 enzyme represents but one of fourteen enzymes within the 
17β-hydroxysteroid dehydrogenase family and therefore the possibility of off target affects appears high 
and worthy of investigation. 
In terms of primary sequence similarity, members of the 17β-HSD family are diverse in nature, typically 
sharing less than 30% identity, and thus enzymes of this class are primarily grouped on the basis of shared 
mechanistic and structural features359. A structural similarity search was performed using the previously 
published 17β-HSD10 crystal structure (PDB ID: 2O23) and the RCSB Protein Data Bank web-interface, 
identifying two closely related enzymes within the same family, 17β-HSD8 (PDB: 2PD6) and 17β-HSD14 
(PDB: 1YDE). As expected, an alignment of the primary sequences of 17β-HSD8 and 17β-HSD14 to that of 
17β-HSD10 revealed a low degree of identity between the proteins, 32% and 31% respectively. However, 
a structural alignment, performed using Pymol, revealed a high degree of structural homology (Figure 
4.01), with RMSD scores of 0.919 and 0.997 calculated for 17β-HSD8 and 17β-HSD10, and 17β-HSD14 and 
17β-HSD10, respectively. The aim of this chapter was to clone the cDNA sequences encoding the 17β-
HSD8 and 17β-HSD14 enzymes, purify both proteins to homogeneity and develop enzyme activity assays 
for each, allowing a measure of the specificity of known 17β-HSD10 enzyme inhibitors to be made. 
 
 
Figure 4.01. Structural alignment of 17β-HSD8 and 17β-HSD14 to 17β-HSD10. Using PyMOL, a structural alignment 
was made between the 17β-HSD8, 17β-HSD14 and 17β-HSD10 enzymes. In both instances, a high degree of structural 
similarity was seen, as indicated by RMSD values of 0.919 and 0.997. Left Image= Alignment 17β-HSD8 and 17β-
HSD10. Right Image= Alignment 17β-HSD14 and 17β-HSD10. Green cartoon = 17β-HSD10. 
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4.1: 17β-HSD8 and 17β-HSD14 cDNA Cloning 
4.11 peHISTEV-HSD8 
In recent years, the ability to artificially synthesise entire genes has become both feasible and 
economically viable. In brief, short oligonucleotide fragments encompassing the sequence of interest are 
synthesised de novo and subsequently ligated using a DNA polymerase reaction, producing the full length 
coding sequence. The product is sequence verified and typically provided to the end user in a maintenance 
vector. The GeneArt service offered by ThermoFisher was used for this project. 
As the sole purpose of this project was the production of recombinant protein, the human 17β-HSD8 
coding sequence, as provided by Ensembl website360, was codon optimised for expression using E. coli. 
NcoI and SalI sites were added 5’ and 3’ respectively, allowing downstream cloning into the desired 
expression vector. The generated construct was delivered in a pMAT vector backbone harbouring an 
ampicillin resistance marker (Figure 4.02).  
 
 
Our in-house expression system for 17β-HSD10 utilises the peHISTEV expression vector which produces a 
TEV-cleavable, N-terminal 6 x His-tagged protein for subsequent purification using Ni-NTA affinity 
chromatography (Chapter 3 - Section 3.01). The 17β-HSD10 cDNA sequence had previously been ligated 
into the multiple cloning site of the peHISTEV-vector using the NcoI and SalI restriction enzymes (Figure 
4.03). 
  
 
 
Figure 4.02. pMAT-HSD8 Vector Map. The 17β-HSD8 cDNA sequence was synthesised using the GeneArt service 
offered by ThermoFisher and was delivered in a pMAT maintenance vector. 
Chapter 4: Inhibitor Specificity 
148 
 
 
Thus, the initial cloning strategy entailed the digestion of the peHISTEV-HSD10 expression vector using 
the NcoI and SalI restriction endonucleases, liberating the 17β-HSD10 cDNA sequence. Following 
digestion, the 17β-HSD8 cDNA sequence would subsequently be ligated within the vector, producing a 
peHISTEV-HSD8 expression construct (Figure 4.04).  
 
However, a cursory check that the NcoI and SalI restriction enzymes were behaving as expected identified 
an issue. Diagnostic digests were performed with the pMAT-HSD8 and peHISTEV-HSD10 constructs using 
the NcoI and SalI enzymes, both individually and in a dual digest. Each enzyme in isolation would be 
expected to cut the supercoiled pMAT-HSD8 construct once, producing a single linear fragment of 
approximately 3.2 kb. Dual digestion with both enzymes would liberate the 17β-HSD8 coding sequence, 
producing two linear fragments, one corresponding to the empty pMAT vector, approximately 2.4 kb in 
Figure 4.03. peHISTEV-HSD10 Vector Map. The cDNA sequence encoding the 17β-HSD10 enzyme had previously been 
cloned into the peHISTEV expression vector using the NcoI and SalI restriction enzyme sites. The peHISTEV vector 
produces a TEV cleavable, 6 x His-tagged protein for subsequent purification using Ni-NTA affinity chromatography. 
Figure 4.04 peHISTEV-HSD8 initial cloning strategy. The peHISTEV-HSD10 construct was to be cut using the NcoI and 
SalI restriction endonuceleases, liberating the 17β-HSD10 cDNA sequence and allowing the 17β-HSD8 cDNA sequence 
to be ligated in its place, producing a peHISTEV-HSD8 expression vector. 
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size, the second corresponding to the 17β-HSD8 coding sequence, approximately 0.8 kb in size. Similarly, 
with the peHISTEV-HSD10 construct, cleavage with each enzyme individually should yield a single linear 
fragment, approximately 6.1 kb in length. Digestion with both the NcoI and SalI enzymes should yield two 
linear fragments, of approximately 5.3 kb and 0.8 kb, corresponding to the empty peHISTEV vector and 
the 17β-HSD10 insert respectively. 
Cleavage with NcoI was found to produce a single linear fragment, as expected. However, with both 
constructs, cleavage with SalI was found to produce a mixture of linear fragments as opposed to the 
expected one (Figures 4.05 and 4.06, Lane 4). In the case of the pMAT-HSD8 construct, three distinct 
species are apparent, the largest being equal in size to the NcoI digested DNA (Figure 4.05, Lane 3) and 
thus likely representing the expected linear digestion product (Figure 4.05, Lane 4). Two additional smaller 
species are however also apparent (Figure 4.05, Lane 4). 
 
The most likely explanations for the observed dual cleavage by SalI were checked, namely cross 
contamination of enzyme stocks and the inadvertent introduction of a second SalI site during cloning, 
neither of which offered an explanation for the observed digestion pattern. The SalI enzyme used was a 
high-fidelity variant and thus star activity was unlikely. The exact cause for this dual cleavage remains 
unknown. 
To circumvent this issue, the peHISTEV-HSD10 construct was replaced with a naive peHISTEV vector, 
precluding the possibility of issues introduced during the previous cloning strategy. In addition, the next 
3' restriction enzyme site within the MCS, HindIII, was used in place of SalI. A diagnostic digest was 
Figure 4.05. pMAT-HSD8 digestion with NcoI and SalI. Cleavage of the pMAT-HSD8 construct with NcoI was found 
to generate a single linear fragment, as expected. However, cleavage using SalI was found to produce three linear 
fragments. Lane 1 = Ladder, Lane 2 = Uncut pMAT-HSD8, Lane 3 = NcoI, Lane 4 = SalI, Lane 5 = NcoI + SalI.  
 
Figure 4.06. peHISTEV-HSD10 digestion with NcoI and SalI. Cleavage of the peHISTEV-HSD10 construct with NcoI 
was found to generate a single linear fragment, as expected. However, cleavage using SalI was found to produce two 
linear fragments. Lane 1 = Ladder, Lane 2 = Uncut peHISTEV-HSD10, Lane 3 = NcoI, Lane 4 = SalI, Lane 5 = NcoI + SalI.  
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performed using the NcoI and HindIII restriction endonucleases and the empty peHISTEV construct, 
yielding the expected digestion products. 
With the NcoI and HindIII restriction enzymes validated as cutting correctly, a pair of PCR primers were 
designed to amplify the 17β-HSD8 coding sequence out of the pMAT backbone and simultaneously change 
the 3’-SalI restriction enzyme site to a HindIII recognition sequence: 
Forward: 5'-atctgCCATGGCGAGCCAGCTGC-3' 
Reverse: 5'-tcgaAAGCTTACATAAACAGACCACCGGTCACTTCAACG-3' 
(Lowercase = Spacer Sequence, Bold = Restriction enzyme site) 
 
To optimise primer annealing temperatures, three small scale PCR reactions were performed with primer 
annealing at 72°C, 65°C and 55°C. A prominent band was seen in each reaction at the correct size, 0.8 kb, 
and thus an annealing temperature of 72°C was selected for further use (Figure 4.07).  
 
The amplified 17β-HSD8 insert and the empty peHISTEV backbone were cleaved using the NcoI and HindIII 
restriction endonucleases, the products separated using agarose gel electrophoresis and the fragments 
of interest gel extracted. The purified vector and insert were ligated using T4 DNA ligase, yielding the 
desired construct (Figure 4.08), herein referred to as peHISTEV-HSD8. 
Figure 4.07. 17β-HSD8 PCR primer check. PCR primers were designed to amplify the 17β-HSD8 cDNA sequence out 
of the pMAT backbone and simultaneously exchange the 3'SalI restriction site to a HindIII recognition sequence. To 
optimise primer annealing, three temperatures were trialled. Lane 1= Ladder, Lane 2= 72°C annealing, Lane 3= 65°C 
annealing, Lane 4= 55°C annealing. 
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Figure 4.08. peHISTEV-HSD8 expression vector. The 17β-HSD8 cDNA sequence was ligated into the empty peHISTEV 
vector using the NcoI and HindIII restriction endonucelease sites producing a peHISTEV-HSD8 expression vector. 
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4.12 peHISTEV-HSD14 
An alternative cloning strategy was employed for 17β-HSD14. Rather than having the gene synthesised, 
reverse-transcription of an mRNA template was instead used. At the mRNA level, the 17β-HSD14 gene is 
known to be highly expressed in kidney tissue, as shown by the Protein Atlas361 and so mRNA was 
extracted from a human embryonic kidney cell line (HEK293) for use as a template. Initially, a cDNA library 
corresponding to the poly-A tailed mRNA transcripts was generated using M-MLV reverse transcriptase 
and oligo(dT) primers. Gene specific primers were subsequently used to amplify the cDNA of interest, 
here the 17β-HSD14 coding sequence, from the cDNA library and simultaneously add appropriate 
restriction enzyme sites, 5’-NcoI and 3’-XhoI, for downstream cloning: 
Forward: 5'-gatcgaCCATGGCTACGGGAACGCGCTATGC-3' 
Reverse: 5'-catgtaCTCGAGTCAGGAAGGGATATCGGGGGCGTCC-3' 
(Lowercase = Spacer sequence, Bold = Restriction enzyme site) 
 
To verify that first strand cDNA synthesis had been successful, and in an attempt to generate the cleanest 
PCR product possible, three small scale PCR reactions were performed with varying primer annealing 
temperatures (72°C, 65°C and 55°C). Amplification of the 17β-HSD14 cDNA sequence was observed at 
each temperature tested, as indicated by the presence of a band at approximately 0.8 kb, suggesting first 
strand cDNA synthesis had been successful (Figure 4.09). A primer annealing temperature of 72°C was 
selected for further use, giving the most stringent binding and likely most specific product. 
 
 
As issues had been related to non-specific cleavage had been encountered previously during restriction 
digests (Section 4.11), a check was made to ensure the naive peHISTEV vector was cleaved correctly using 
the NcoI and XhoI restriction endonucleases. In both cases, the expected digestion pattern was observed 
and thus the amplified 17β-HSD14 cDNA sequence and the empty peHISTEV vector were cleaved using 
Figure 4.09. 17β-HSD14 cDNA amplification. The 17β-HSD14 cDNA sequence was PCR amplified using gene specific 
primers and a cDNA template generated using M-MLV reverse transcriptase and oligo(dT) primers. Three annealing 
temperatures were trialled, with 72°C being selected for further use. Lane 1= Ladder, Lane 2= 72°C annealing, Lane 3 
= 65°C annealing, Lane 4= 55°C annealing. 
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the NcoI and XhoI restriction endonucleases, the products separated via agarose gel electrophoresis, the 
fragments of interested gel extracted and ligated using T4 DNA ligase. Product was transformed into 
competent DH5-α E. coli, cells plated, cultures grown and DNA extracted. 
Sequencing of the resultant peHISTEV-HSD14 constructs showed perfect alignment with the expected 
coding sequence at both the 5' and 3' ends of the cDNA sequence. However, short regions within the 
coding sequence were consistently absent (Figure 4.10). Initially, it was presumed that these missing 
sections may be a consequence of alternate splicing and thus represent different isoforms of the protein, 
of which there are four.  However, using the Ensembl website360, the produced sequencing results were 
not found to correspond to any known splice variant of the 17β-HSD14 enzyme and were therefore 
assumed to be a consequence of mRNA secondary structure during first strand cDNA synthesis. 
 
To rectify this, AMV reverse transcriptase, which has been shown to be able to tolerate higher reaction 
temperatures362, was used in place of M-MLV for first strand cDNA synthesis and the cDNA synthesis step 
performed over a gradient of temperatures (50-72°C). Oligo(dT) primers will not anneal efficiently at these 
elevated temperatures and so were replaced with the reverse gene specific primer for 17β-HSD14. Thus, 
rather than a library of cDNA molecules, only one corresponding to the 17β-HSD14 mRNA transcript would 
be produced. This would have the added benefit of likely decreasing non-specific priming during the 
second round of cDNA amplification via PCR, giving a cleaner product.  
Figure 4.10. peHISTEV-HSD14 example sequencing result. Sequencing of the resultant peHISTEV-HSD14 constructs 
revealed perfect alignment with the expected coding sequence at the 5' and 3' ends of the cDNA sequence. However, 
short stretches within the sequence were found to be absent, assumed to be a consequence of secondary structure 
within the mRNA template. 
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To check for successful cDNA generation, a test PCR reaction was performed using a sample of cDNA from 
each reaction temperature and the products visualised by agarose gel electrophoresis. In all reactions, a 
fragment was observed at the expected size, approximately 0.8 kb, suggesting cDNA synthesis was 
successful at all temperatures trialled. An additional smaller fragment was also observed at every 
temperature, which may still be a consequence of off target amplification (Figure 4.11). 
 
Concerns that the AMV-RT enzyme may exhibit reduced fidelity at elevated incubation temperatures led 
to the cDNA generated at 55°C being selected for use as a template for the PCR amplification of the 17β-
HSD14 cDNA sequence. The resultant PCR product and the empty peHISTEV vector were cut using the 
NcoI and XhoI restriction enzymes and the products separated using agarose gel electrophoresis. The 
fragments of interest were gel extracted and ligated using T4 DNA ligase. Sequencing was found to confirm 
that the elevated cDNA synthesis temperature had indeed resulted in the production of a full length 
transcript, but also that concerns regarding enzyme fidelity were correct. Two missense mutations were 
found to be present within the coding sequence of the 17β-HSD14 gene (A91>G and G303>A).  
Thus, to restore the native coding sequence, two rounds of site directed mutagenesis were performed 
sequentially as per the Liu & Naismith protocol345 with prominent product observed at each reaction 
temperature trialled (Figures 4.12 and 4.13). 
A91>G Forward: 5'-CCTTCGTGaACAGCGGGGCCCGAGTGGTTATCTGC-3' 
A91>G Reverse: 5'- GCTGTtCACGAAGGCGCGCACGATCCC-3' 
 
 
Figure 4.11. 17β-HSD14 AMV cDNA synthesis. In an attempt to overcome issues related to secondary structure in 
the mRNA template, 17β-HSD14 cDNA was synthesised over a range of reaction temperatures. A trial PCR reaction 
was performed a sample of cDNA generated at each reaction temperature. A band of the correct size was observed 
in each case (0.8 kb), verifying the success of cDNA synthesis. Lane 1 = Ladder, Lanes 2-7 = 72°C-50°C reaction 
temperature. 
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G303>A Forward: 5'-CCTGAGGAgACCTCTGCCCAGGGATTCC-3' 
G303>A Reverse: 5'- CAGAGGTcTCCTCAGGCCTCTGTGG-3' 
 
Sequencing of the resultant constructs confirmed the restoration of the native coding sequence (see 
Appendix: B for sequencing results), construct herein referred to as peHISTEV-HSD14 (Figure 4.17) 
Figure 4.12. 17β-HSD14 SDM #1. Using Liu & Naismith style SDM primers the A>91G missense mutation was 
corrected. Lane 1 = Ladder, Lane 2 = Dpn1 Control, Lanes 3-10 = Annealing Thermal Gradient 72°C-50°C. 
Figure 4.14. peHISTEV-HSD14 Vector Map. The 17β-HSD14 cDNA sequence was cloned into the empty peHISTEV 
vector using the NcoI and XhoI restriction endonuclease sites producing a peHISTEV-HSD14 protein expression 
construct. 
Figure 4.13. 17β-HSD14 SDM #2. Using  Liu & Naismith style SDM primers the A440G missense mutation was 
corrected. Lane 1 = Ladder, Lane 2 = Dpn1 Control, Lanes 3-8 = Annealing Thermal Gradient 72°C-50°C. 
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4.2: 17β-HSD8 and 17β-HSD14 Protein Expression 
4.21 Whole Cell Lysates: 
The expression of eukaryotic protein in a prokaryotic system allows for the quick and cheap purification 
of large quantities of a protein of interest. However, in some instances such expression can prove toxic to 
the host cell, resulting in little to no protein production. Thus, an initial check for expression was made by 
examining whole cell lysates. 
The expression constructs generated for 17β-HSD8 and 17β-HSD14 (Section 4.11 and 4.12) were 
transformed into BL21(DE3) E. coli. A single colony was picked, grown and protein expression induced 
overnight. Whilst the optimal temperature for E. coli growth is 37°C, the induction of protein synthesis at 
a lower temperature often improves both protein solubility and yield, presumably by slowing the rate of 
synthesis and thereby giving the cell more time to fold the protein into the correct conformation363. As 
such, protein expression was induced overnight at three temperatures, 15°C, 25°C and 37°C. The following 
morning whole cell lysates were taken from both induced and non-induced cultures, proteins separated 
by SDS-PAGE and gels stained using Coomassie Blue. In both instances a prominent band was observed 
post induction at approximately the expected molecular weight (Figures 4.18 and 4.19). The bands of 
interest were excised and sent for mass-spectrometry, confirming the identity of both proteins. 
 
 
 
 
 
Figure 4.18. peHISTEV-HSD8 expression trial. Protein expression was induced overnight at 15°C, 25°C and 37°. The 
following morning samples were taken and whole cell lysates generated. Protein expression was assessed via SDS-
PAGE and Coomassie Blue staining. Lane 1 = Ladder, Lanes 2/3 = 15°C Non-Induced/Induced, Lanes 4/5 = 25°C Non-
Induced/Induced, Lanes 6/7 = 37°C Non-Induced/Induced.  
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4.22 Optimisation of E. coli Cell Lysis: 
Whilst the assessment of protein levels using whole-cell lysates is useful for confirming protein expression, 
it gives no information regarding whether the protein of interest is soluble or insoluble under the 
induction conditions used. Although it is possible to purify proteins from the insoluble fraction, this 
typically involves the denaturation and subsequent refolding of the protein of interest, introducing the 
possibility that the protein may refold into a non-native conformation with downstream implications. 
Thus, it is generally preferable to induce expression in such a way that the produced protein is synthesised 
in a soluble form. Before the partitioning of the 17β-HSD8 and 17β-HSD14 proteins between the insoluble 
and soluble fractions could be assessed, thorough cell lysis conditions were first required. 
To this end, E. coli BL21 (DE3) cells were transformed with the peHISTEV-HSD10 construct, an expression 
construct known to produce reasonable levels of soluble protein. The following morning a single colony 
was picked, grown and protein expression induced overnight at 25°C. Samples were taken, treated with 
lysozyme and subsequently lysed via sonication for varying lengths of time (0-600 seconds). Cellular debris 
was pelleted via centrifugation and the total protein content in the soluble fraction assessed using the 
Bradford assay. Sonication for 180 seconds was found to be sufficient for thorough cell lysis following pre-
treatment with lysozyme, as indicated by the plateau in soluble protein levels after this time-point (Figure 
4.20). Thus, lysozyme pre-treatment followed by 180 seconds of sonication was used for the subsequent 
optimisation of induction parameters for the 17β-HSD8 and 17β-HSD14 proteins. 
 
 
Figure 4.19. peHISTEV-HSD14 expression trial. Protein expression was induced overnight at 15°C, 25°C and 37°. The 
following morning samples were taken and whole cell lysates taken and assessed via SDS-PAGE and Coomassie Blue 
staining. Lane 1 = Ladder, Lanes 2/3 = 15°C Non-Induced/Induced, Lanes 4/5 = 25°C Non-Induced/Induced, Lanes 6/7 
= 37°C Non-Induced/Induced. 
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Figure 4.20. E. coli sonication optimisation. BL21(DE3) E. coli harbouring the peHISTEV-HSD10 construct were grown 
and protein synthesis induced overnight at 25°C. Following lysozyme treatment, cells were lysed using sonication and 
total protein level in the soluble fraction assessed using the Bradford assay. Lysozyme treatment followed by 180 
seconds of sonication was used for subsequent experiments. Values shown are an average taken from one experiment 
with three technical repeats ± SEM. 
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4.23 Recombinant 17β-HSD8 and 17β-HSD14 Solubility Assessment 
Samples of peHISTEV-HSD8 and peHISTEV-HSD14 expressing BL21(DE3) E. coli were taken following 
overnight induction at 15°C, 25°C and 37°C and lysed using the aforementioned conditions (Section 4.22), 
allowing the partitioning of each protein into the soluble and insoluble fractions to be assessed. Following 
SDS-PAGE analysis and Coomassie Blue staining, no soluble 17β-HSD8 protein was observed at any 
induction temperature (Figure 4.21). 
 
In contrast, the peHISTEV-HSD14 construct was found to yield soluble protein at all temperatures tested 
(Figure 4.22). The highest level of soluble 17β-HSD14 protein was observed with induction at 25°C and 
therefore, overnight induction at 25°C was used for the subsequent large-scale purification of the 17β-
HSD14 protein.  
Figure 4.21. peHISTEV-HSD8 insoluble/soluble partitioning. Protein expression was induced overnight at 15°C, 25°C 
and 37°. The following morning samples were taken and lysed via lysozyme treatment and sonication. Levels of 
soluble and insoluble protein were assessed via SDS-PAGE and Coomassie Blue staining. Lane 1 = Ladder, Lanes 2/3 = 
15°C Insoluble/Soluble, Lanes 4/5 = 25°C Insoluble/Soluble, Lanes 6/7 = 37°C Insoluble/Soluble. 
Figure 4.22. peHISTEV-HSD14 insoluble/soluble partitioning. Protein expression was induced overnight at 15°C, 
25°C and 37°. The following morning samples were taken and lysed via lysozyme treatment and sonication. Levels of 
soluble and insoluble protein were assessed via SDS-PAGE and Coomassie Blue staining. Lane 1 = Ladder, Lanes 2/3 
= 15°C Insoluble/Soluble, Lanes 4/5 = 25°C Insoluble/Soluble, Lanes 6/7 = 37°C Insoluble/Soluble. 
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A more thorough time-course of induction was undertaken using the peHISTEV-HSD8 construct and 
BL21(DE3) E. coli to ascertain if the solubility of the 17β-HSD8 protein shows a time dependency. Three 
cultures were prepared and protein expression induced at 15°C, 25°C and 37°C. Samples were taken pre-
induction and at 1, 2, 4, 6, 12 and 24-hours post-induction. The relative levels of soluble and insoluble 
17β-HSD8 protein was assessed using the aforementioned methodology (Section 4.22). In all instances, a 
time-dependent increase in 17β-HSD8 expression was observed, with the rate of expression slower at 
lower temperatures, as would be expected. However, the 17β-HSD8 protein was found to be insoluble 
irrespective of the temperature or time of induction (Figure 4.23). 
  
Figure 4.23. peHISTEV-HSD8 temperature and time-course of induction. Protein expression was induced at 15°C 
(top), 25°C (middle) and 37°C (bottom),. Samples were taken pre-induction and at 1, 2, 4, 6, 12 and 24hr timepoints. 
Levels of soluble and insoluble protein  were assessed via SDS-PAGE and Coomassie Blue staining. Lane 1 = Ladder, 
Lanes 2/3 = Pre-induction insoluble/soluble, Lanes 4/5 = 1hr insoluble/soluble, Lanes 6/7= 2hr insoluble/soluble, Lanes 
8/9= 4hr insoluble/soluble, Lanes 10/11= 6hr insoluble/soluble, Lanes 12/13= 12hr insoluble/soluble, Lanes 14/15= 
24hr insoluble/soluble. 
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4.24 17β-HSD8-Maltose Binding Protein Fusion 
A common approach used to improve the solubility of a protein of interest is to generate a fusion protein 
with a solubility enhancing tag, such as the Maltose-Binding-Protein (MBP). A pET derived expression 
construct was obtained from AddGene (#29656), herein referred to as pET-MBP, allowing the generation 
of an N-terminal, 6 x His-tagged, TEV cleavable MBP fusion protein through the use of ligation 
independent cloning (LIC) (Figure 4.24).  
 
LIC exploits the 3' to 5' exonuclease activity of T4 DNA polymerase. Under normal reaction conditions, in 
which saturating concentrations of dNTPs are present, the 5’ to 3’ DNA synthesis activity of T4 DNA 
polymerase counter-acts its 3’ to 5’ exonuclease activity, meaning as soon as a base is removed from the 
3' end of a DNA strand, a new base is added. However, the reaction conditions for LIC are designed such 
that only a single dNTP is present in the reaction mixture and therefore bases will be removed from the 
3' end of a DNA strand until this base is encountered, at which point the polymerase activity will cause 
the exonuclease activity to stall. Through the design of appropriate primers, this property can be used to 
rapidly generate long complementary overhangs on both vector and insert. Such overhangs are stable 
enough to survive transformation without being covalent linked via ligation and thus this time consuming 
and inefficient step is omitted.  
Primers were designed to amplify the 17β-HSD8 cDNA sequence out of the peHISTEV backbone and add 
5' and 3' ligation independent cloning tags. 
 
Forward: 5'-TACTTCCAATCCAATGCAATGGCGAGCCAGCTGC-3' 
Reverse: 5'-TTATCCACTTCCAATGTTATTATTACATAAACAGACCACCGGTCACTTCA-3' 
(Bold = LIC tag) 
Figure 4.24. pET-MBP Vector Map. The pET-MBP plasmid (AddGene #29656) allows the generation of an N-terminal, 
6 x His-tagged, TEV cleavable MBP fusion protein. 
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In order to identify an optimal primer annealing temperature, three trial PCR reactions were performed 
with annealing at 72°C, 65°C and 55°C. In all reactions, product was observed at the expected size, 
approximately 0.8 kb, and thus a 72°C annealing temperature was selected (Figure 4.25).  
 
The PCR product was purified by agarose gel electrophoresis followed by gel extraction (required to 
ensure the removal of dNTP molecules present in the PCR reaction prior to T4 DNA polymerase 
treatment). The insert was subsequently treated with T4 DNA polymerase in the presence of dCTP, 
exploiting the enzymes intrinsic 3' to 5' exonuclease activity to generate long 15 bp overhangs. 
pET-MBP vector DNA was treated with SSPI restriction endonuclease to generate a linear fragment which 
was subsequently gel extracted and treated with T4 DNA polymerase in the presence of dGTP generating 
15 bp overhangs, complementary to the insert. Vector and insert were mixed at varying molar ratios and 
transformed into competent DH5-α E. coli. The following morning colonies were picked, grown, DNA 
purified and analysed by agarose gel electrophoresis. All colonies were found to harbour an insert of the 
correct size, and the generation of the desired expression construct confirmed via DNA sequencing (see 
Appendix: B for sequencing results). Construct herein referred to as pET-MBP-HSD8 (Figure 4.26). 
Figure 4.25. 17β-HSD8 PCR primer check. PCR primers were designed to amplify the 17β-HSD8 coding sequence out of 
the pMAT backbone and simultaneously add LIC cloning tags. To allow for the selection of an optimal annealing 
temperature, a trial PCR reaction was performed at three temperatures. Lane 1=72°C annealing, Lane 2= 65°C 
annealing, Lane 3 = 55°C annealing.   
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The pET-MBP-HSD8 construct was transformed into BL21(DE3) E. coli and protein expression induced at 
15°C, 25°C and 37°C overnight. The following morning, expression of the MBP-HSD8 fusion protein was 
assessed using whole cell lysates. Following induction, a band was observed at approximately 67 kDa, the 
expected size of the MBP-HSD8 fusion protein (Figure 4.27). 
 
An assessment of the solubility of the MBP-HSD8 fusion protein was made using the previously described 
methodology (Section 4.22). Soluble protein was observed with induction at 15°C and 25°C, whilst 
induction at 37°C gave rise to high levels of insoluble protein (Figure 4.28). Overnight induction at 25°C 
was found to give rise to the highest level of soluble protein and therefore was used for the large scale 
Figure 4.27. MBP-HSD8 expression trial. Protein expression was induced overnight at 15°C, 25°C and 37°. The 
following morning samples were taken and whole cell lysates generated. Protein expression was assessed via SDS-
PAGE and Coomassie Blue staining. Lane 1 = Ladder, Lanes 2/3 = 15°C Non-Induced/Induced, Lanes 4/5 = 25°C Non-
Induced/Induced, Lanes 6/7 = 37°C Non-Induced/Induced. 
Figure 4.26. pET-MBP-HSD8 Vector Map. The 17β-HSD8 cDNA sequence was cloned into the pET-MBP vector using 
ligation independent cloning, generating a pET-MBP-HSD8 protein expression vector. 
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purification of the MBP-HSD8 fusion protein. The band corresponding to the MBP-HSD8 protein was 
excised and sent for mass-spectrometry, confirming protein identity. 
  
Figure 4.28. MBP-HSD8 insoluble/soluble partitioning. Protein expression was induced overnight at 15°C, 25°C and 
37°. The following morning samples were taken and lysed via lysozyme treatment and sonication. Levels of soluble 
and insoluble protein were assessed via SDS-PAGE and Coomassie Blue staining. Lane 1 = Ladder, Lanes 2/3 = 15°C 
Insoluble/Soluble, Lanes 4/5 = 25°C Insoluble/Soluble, Lanes 6/7 = 37°C Insoluble/Soluble. 
 
Chapter 4: Inhibitor Specificity 
165 
 
4.25 17β-HSD14: Large-Scale Purification 
Initial attempts at the large scale purification of the 17β-HSD14 protein employed the lysis buffer used 
previously for 17β-HSD10, resulting in significant protein precipitation during loading of the HisTrap Ni-
NTA column, clogging the column and resulting in extremely low yields. Optimisation of pH, temperature 
and NaCl concentration resulted in a reduction of the NaCl concentration used in the cell lysis buffer, from 
500 mM to 100 mM, maintaining protein solubility and dramatically improving yield.  
Using the newly optimised lysis buffer, a large scale purification of the 17β-HSD14 enzyme was 
undertaken. In brief, BL21(DE3) E. coli cells harbouring the peHISTEV-HSD14 construct were grown to 
OD600= 0.6-0.8 and protein expression induced overnight at 25°C. Cells were harvested, lysed and the 
crude lysate applied to a 5 mL HisTrap column. An initial check for protein expression and column loading 
was made by analysing a sample of cleared lysate and column flow through using SDS-PAGE and 
Coomassie Blue staining. A prominent band can be seen in the cleared lysate, at approximately 28 kDa, 
which is no-longer apparent in the column flow-through indicating both 17β-HSD14 expression and 
column binding (Figure 4.29). 
  
The column was loaded onto an AKTA-Pure purification rig and washed with a stepwise increase in 
imidazole concentration until a stable UV baseline was reached. Protein was eluted using a linear gradient 
of imidazole (100-500 mM) and elution fractions collected periodically. The presence of the 17β-HSD14 
enzyme in elution fractions was confirmed by SDS-PAGE and Coomassie Blue staining. A band was 
observed in all elution fractions, at approximately 28 kDa, corresponding to the 17β-HSD14 enzyme 
(Figure 4.30). In all cases, a second band was also observed at a lower molecular weight. Using mass-
spectrometry, this band was also identified as being 17β-HSD14 and thus may represent a truncated 
Figure 4.29. 17β-HSD14 expression and column binding. A sample of cleared lysate and column flow-through were 
analysed using SDS-PAGE and Coomassie Blue staining. A prominent band is apparent in the cleared lysate at 
approximately 28 kDa, but not in the column flow-through, corresponding to the recombinant 17β-HSD10 protein pre 
and post column binding Lane 1 = Ladder, Lane 2 = Cleared Lysate, Lane 3 = Column Flow Through. 
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isoform of the protein. As elution fraction 5 (Figure 4.30, lane 8) was found to harbour comparatively little 
of this contaminant, it was carried forward for further processing.  
 
The protein containing sample was dialysed to remove imidazole, TEV-protease added and the solution 
incubated overnight at 4°C. The following morning TEV cleavage was confirmed via SDS-PAGE and 
Coomassie Blue staining. Following TEV treatment the band of interest was found to be shifted down, 
indicative of successful cleavage (Figure 4.31, lane 3).  
 
 
Figure 4.30. 17β-HSD14 Elution Fractions. The HisTrap HP column, loaded with 17β-HSD10 protein was washed with 
a stepwise increase in imidazole (0-100 mM) removing low affinity contaminants. 17β-HSD10 protein was 
subsequently eluted using a linear gradient of imidazole (100-500 mM). Lane 1 = Ladder, Lane 2 = Cleared Lysate, Lane 
3 = Column Flow Through, Lanes 4-10 = Elution Fractions. 
 
Figure 4.31. 17β-HSD14 TEV cleavage confirmation. TEV protease was employed to remove the 6 x His-tag from the 
17β-HSD14 enzyme.  A sample was taken pre and post-TEV treatment and analysed using SDS-PAGE and Coomassie 
Blue staining. Following TEV treatment the band corresponding to the 17β-HSD14 protein is shifted down, indicative 
of successful cleavage. Lane 1 = Ladder, Lane 2 = Pre-TEV, Lane 3 = Post-TEV. 
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The TEV cleaved protein was again passed over a HisTrap column, this time allowing the binding of 
uncleaved protein, 6 x His-tagged TEV protease, free 6 x His-tags and any residual high affinity 
contaminants. Column flow-through, now containing the protein of interest, was collected.  
As a final step, gel filtration was employed. The sample was concentrated using a VivaSpin column (10 kDa 
MWCO), loaded onto a pre-equilibrated HiLoad Sephadex 75 prep-grade column and elution fractions 
collected periodically. Samples corresponding to the start, middle and end of the peak were analysed 
using SDS-PAGE and Coomassie Blue staining, showing high levels of pure 17β-HSD14. The enzyme is 
known to form a dimer, observed as a faint band present at approximately 56 kDa (Figure 4.32).  
 
Peak fractions were pooled and concentrated to 10 mg/ml before being snap frozen in liquid nitrogen and 
stored long term at -80°C. Protein identity confirmed via mass spectrometry. 
 
  
  
Figure 4.32. 17β-HSD14 Gel Filtration. 17β-HSD14 protein was further purified using gel filtration. Fractions were 
taken periodically and those corresponding to the start, middle and end of the peak were analysed using SDS-PAGE 
and Coomassie Blue staining confirming the presence of pure 17β-HSD14 protein.  Lane 1 = Ladder, Lanes 2-4 = Start, 
middle and end of elution peak. 
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4.26 17β-HSD8: Large-Scale Purification: 
The pET-MBP-HSD8 construct was transformed into BL21(DE3) E. coli., grown to OD600= 0.6-0.8 and 
protein expression induced overnight at 25°C. The following morning cells were harvested, lysed and the 
lysate passed over a 5 mL HisTrap Ni-NTA column. To confirm protein expression and column loading, a 
sample of cleared lysate and column flow through were analysed using SDS-PAGE and Coomassie Blue 
staining. A prominent band is apparent in the cleared lysate at approximately 67 kDa, corresponding to 
the MBP-HSD8 fusion protein. This band decreases in intensity in the flow-through but, unlike 17β-HSD10 
and 17β-HSD14, does not disappear entirely, indicating that the MBP-HSD8 protein exhibits a lower 
affinity for the Ni-NTA resin, or that the 5 mL HisTrap column has become saturated with the 
comparatively large fusion protein (Figure 4.33).  
 
The column was loaded onto an AKTA-Pure purification rig and washed with a stepwise increase in 
imidazole concentration (0-100 mM) until a stable UV baseline was reached, indicating low affinity 
contaminants had been removed. The MBP-HSD8 protein was eluted using a linear gradient of imidazole 
(100-500 mM) and fractions taken periodically. The presence of MBP-HSD8 protein in elution fractions 
was confirmed by SDS-PAGE and Coomassie Blue staining (Figure 4.34), with clean protein observed in 
elution fractions 2 and 3 (lanes 8 and 9). 
Figure 4.33. MBP-HSD8 expression and column binding. A sample of cleared lysate and column flow-through were 
analysed using SDS-PAGE and Coomassie Blue staining. A prominent band is apparent in the cleared lysate at 
approximately 67 kDa, and decrease in intensity in the column flow-through, corresponding to the MBP-HSD8 fusion 
protein pre and post column binding. Lane 1 = Ladder, Lane 2 = Cleared Lysate, Lane 3 = Column Flow Through. 
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Elution fractions 2 and 3 were pooled, loaded into a dialysis membrane (10 kDa MWCO) and incubated in 
fresh buffer, removing imidazole. TEV protease was added and the sample incubated overnight at 4°C. 
The following morning cleavage was assessed using SDS-PAGE and Coomassie Blue staining. Following TEV 
treatment, the bands corresponding to the free MBP-tag and free 17β-HSD8 proteins are markedly more 
prominent, indicating TEV cleavage was successful (Figure 4.25, lane 3). TEV protease itself can be seen 
below 17β-HSD8 and a faint band of uncleaved fusion protein remains. 
Figure 4.34. MBP-HSD8 wash and elution fractions. The HisTrap HP column, loaded with MBP-HSD8 fusion protein 
was washed with a stepwise increase in imidazole (0-100 mM) removing low affinity contaminants. MBP-HSD8 protein 
was subsequently eluted using a linear gradient of imidazole (100-500 mM). Lane 1 = Ladder, Lane 2 = Cleared Lysate, 
Lane 3 = Column Flow Through, Lanes 4-6 = Wash Fractions, Lanes 7-10 = Elution Fractions. 
 
Figure 4.35. MBP-HSD8 TEV cleavage confirmation. TEV protease was employed to remove the MBP-tag from the 
17β-HSD8 enzyme.  A sample of MBP-HSD8 fusion protein was taken pre and post TEV treatment and analysed using 
SDS-PAGE and Coomassie Blue staining. Following TEV treatment two bands were apparent, corresponding to the free 
MBP protein and the 17β-HSD8 enzyme, indicative of successful cleavage. Lane 1 = Ladder, Lane 2 = Pre-TEV, Lane 3 = 
Post-TEV. 
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The TEV treated sample was again passed over a HisTrap column, this time allowing the binding of 
uncleaved protein, 6 x His-tagged TEV protease, 6 x His-tagged MBP protein and any residual high affinity 
contaminants. A sample pre and post-column loading was assessed via SDS-PAGE and Coomassie Blue 
staining, showing removal of uncleaved fusion protein, the 6 x His-tagged-MBP protein and 6 x His-tagged-
TEV protease (Figure 4.36). 
 
The quantity of 17β-HSD8 in the column flow-through was found to be comparatively low, suggesting the 
protein has an intrinsic affinity for the Ni-NTA resin. Thus, a stepwise increase in imidazole was used to 
elute protein bound to the column, dramatically improving yield. Two clean fractions of 17β-HSD8 protein 
were obtained (Figure 4.37, lanes 2 and 3), with the 6 x His-tagged-MBP protein and 6 x His-tagged-TEV 
protease eluting in later fractions (Figure 4.37, lanes 4-6). 
Figure 4.36. 17β-HSD8 Second Affinity. Following TEV cleavage, the sample was again passed over a Histrap HP 
column, allowing the binding of uncleaved MBP-HSD8, His-Tagged-MBP, His-tagged TEV and any remaining high 
affinity contaminants, leaving clean 17β-HSD8 protein. Lane 1 = Ladder, Lane 2 = Pre-second affinity, Lane 3 = Post 
second affinity. 
 
Figure 4.37. 17β-HSD8 Second Affinity Elution. To elute bound 17β-HSD8 protein following a second affinity step, a 
stepwise increase in imidazole concentration was used, with two clean fractions of 17β-HSD8 protein obtained. Lane 
1 = Ladder, Lanes 2-6 = Elution fractions. 
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Protein containing fractions were pooled, concentrated and loaded onto a pre-equilibrated HiLoad 
Sephadex 75 prep-grade column. Elution fractions were collected periodically with two peaks observed. 
Fractions corresponding to the start, middle and end of each peak were analysed via SDS-PAGE and 
Coomassie Blue staining. A faint high molecular weight band was observed in fractions taken from the 
first peak (Figure 4.37, Lanes 2-4), possibly a multimer of the 17β-HSD8 enzyme. Clean monomeric 17β-
HSD8 protein was observed in fractions corresponding to the second peak (Figure 4.38, Lanes 6-8).  
 
Fractions 6-8 were pooled, concentrated to 2 mg/mL, flash frozen in liquid nitrogen and stored long term 
at -80°C. Protein identity confirmed via mass-spectrometry. 
 
  
Figure 4.38. 17β-HSD8 Gel Filtration. 17β-HSD8 protein was further purified by gel filtration. Fractions were taken 
periodically and those corresponding to the start, middle and end of the two observed peaks were analysed using 
SDS-PAGE and Coomassie Blue staining confirming the presence of pure 17β-HSD8 protein.  Lane 1 = Ladder, Lanes 
2-4 = Start, middle and end of elution peak 1, Lanes 6-8= Start, middle and end of elution peak 2. 
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4.27 Purified Protein Concentration Check: 
The extinction coefficients calculated for the 17β-HSD8, 17β-HSD10 and 17β-HSD14 and subsequently 
used to monitor protein concentration throughout the purification procedure are known to be reasonably 
inaccurate. Using a training set of 116 proteins, the predicted extinction coefficients have been shown to 
vary from the experimental calculated value by an average of 3.17%, however in the absence of 
tryptophan residues, this error can increase to greater than 10%364. As the 17β-HSD8, 17β-HSD10 and 
17β-HSD14 proteins harbour relatively low numbers of tryptophan residues (1, 0 and 2 respectively), there 
is the possibility that the calculated extinction coefficient, and thus the estimated protein concentration, 
may be inaccurate. For compound screening experiments, where enzyme activity is reported as a 
percentage of control, the absolute enzyme concentration is arguably less important than for the 
calculation kinetic constants, where activity is reported per unit enzyme (mg-1). Prior to undertaking a 
kinetics based appraisal of the 17β-HSD8 and 17β-HSD14 enzymes, a check was made to ensure the 
protein concentrations determined via absorbance at 280 nm were reasonably accurate. Samples of 17β-
HSD8, 17β-HSD10 and 17β-HSD14 were diluted to an expected concentration of 0.5 mg/mL and the actual 
protein concentration determined using the BCA assay. In all cases, the protein concentration as 
determined by BCA assay was extremely close to that estimated using absorbance at 280 nm (Figure 4.39).  
 
Figure 4.39. Expected vs actual protein concentration. Samples of purified 17β-HSD8, 17β-HSD10 and 17β-HSD14 
were diluted to an expected 0.5mg/mL concentration, as determined by absorbance at 280 nm. The actual protein 
concentration was determined using the BCA assay. In all cases the protein concentration as determined via 
absorbance at 280 nm was found to be accurate. Values shown are an average taken from one experiment with three 
technical repeats ± SEM. 
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4.3 17β-HSD8 and 17β-HSD14 Recombinant Enzyme Assays: 
4.31 Initial Activity Tests 
An initial test for activity was made using high, saturating concentrations of substrate, β-estradiol, and 
cofactor, NAD+, and varying concentrations of 17β-HSD8 and 17β-HSD14 enzyme. The reported specific 
activity values for the conversion of estradiol to estrone by both 17β-HSD8365 and 17β-HSD14366,367 are 
significantly lower than that observed previously for 17β-HSD10 and acetoacetyl-CoA (section 1.03), being 
in the realms of nmol/min-1/mg-1 as opposed to μmol/min-1/mg-1 and as such, the absorbance assay used 
previously was exchanged for a fluorescence based read-out, giving increased sensitivity. As would be 
expected, with increasing enzyme concentration, a dose dependent increase in the rate of reaction was 
observed (Figures 4.40 and 4.41).  
 
Figure 4.40. 17β-HSD8 enzymatic activity. The rate estadiol conversion to estrone was monitored over time as a 
function of NADH fluorescence in the presence of increasing concentrations of 17β-HSD8 enzyme. Values shown are 
an average of one experiment with three technical ± SEM. 
Figure 4.41. 17β-HSD14 enzymatic activity. The rate estadiol conversion to estrone was monitored over time as a 
function of NADH fluorescence in the presence of increasing concentrations of 17β-HSD14 enzyme. Values shown 
are an average of one experiment with three technical repeats ± SEM. 
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The rate of reaction was determined during the linear period of the progress curve for both the 17β-HSD8 
and 17β-HSD14 enzymes, again confirming a dose dependent increase in activity with increasing enzyme 
concentration (Figures 4.42 and 4.43). Concentrations of 5 μg/mL 17β-HSD8 and 150 μg/mL 17β-HSD14 
were selected for subsequent experiments, ensuring linearity over a suitable time-interval, giving a high 
signal to noise ratio and also conserving protein. 
 
 
 
Figure 4.43. 17β-HSD14 rate of reaction. The rate of the 17β-HSD14 catalysed conversion of estradiol to estrone was 
measured as a function of NADH fluorescence over time. With increasing enzyme concentration, a dose dependent 
increase in the rate of reaction was observed, suggesting the purified 17β-HSD14 enzyme is catalytically active. 
Values are an average taken from one experiment each with three technical repeats ± SEM. 
Figure 4.42. 17β-HSD8 rate of reaction. The rate of the 17β-HSD8 catalysed conversion of estradiol to estrone was 
measured as a function of NADH fluorescence over time. With increasing enzyme concentration, a dose dependent 
increase in the rate of reaction was observed, suggesting the purified 17β-HSD8 enzyme is catalytically active. Values 
are an average taken from one experiment with three technical repeats ± SEM. 
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4.32 Michaelis-Menten Kinetics 
Michaelis-menten kinetics were derived for 17β-HSD8 with respect to substrate, estradiol and cofactor, 
NAD+. A Vmax value of 657.6 ± 28.6 nmol min-1 mg-1 and a Km value of 30.7 ± 3.3 μM were calculated for 
17β-HSD8 with respect to estradiol. With respect to cofactor, NAD+, a Vmax value of 573.5 ± 17.0 nmol min-
1 mg-1 and a Km value of 367.1 ± 27.8 μM were calculated (Figure 4.44). Substrate and cofactor 
concentrations of 50 μM estradiol and 500 μM NAD+ were passed forward into compound screening 
experiments using 17β-HSD8. 
 
Michaelis-Menten kinetics were similarly derived for 17β-HSD14 with respect to substrate, estradiol and 
cofactor, NAD+. A Vmax value of 3.5 ± 0.1 nmol min-1 mg-1 and a Km value of 33.4 ± 2.7 μM were calculated 
for the 17β-HSD14 enzyme with respect to estradiol. With respect to cofactor, NAD+, a Vmax value of 2.4 ± 
0.1 nmol min-1 mg-1 and a Km value of 73.0 ± 7.2 μM were calculated (Figure 4.45). Substrate and cofactor 
Figure 4.44. 17β-HSD8 Michaelis-Menten kinetics. Vmax and Km were calculated with respect to estradiol (top) and 
NAD+ (bottom) for the 17β-HSD8 enzyme. A Vmax value of 657.6 ± 28.6 nmol min-1 mg-1 and a Km value of 30.7 ± 3.3 
μM were calculated with respect to estradiol. A Vmax value of 573.5 ± 17.0 nmol min-1 mg-1 and a Km value of 367.1 ± 
27.8 μM were calculated with respect to NAD+. Values shown are an average of two independent experiments each 
with three technical repeats ± SEM. 
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concentrations of 50μM estradiol and 150 μM NAD+ were passed forward into compound screening 
experiments using 17β-HSD14. 
 
 
 
 
 
 
 
 
 
Figure 4.45. 17β-HSD14 Michaelis-Menten Kinetics. Vmax and Km were calculated with respect to estradiol (top) and 
NAD+ (bottom) for the 17β-HSD8 enzyme. A Vmax value of 657.6 ± 28.6 nmol min-1 mg-1 and a Km value of 30.7 ± 3.3 
μM were calculated with respect to estradiol. A Vmax value of 573.5 ± 17.0 nmol min-1 mg-1 and a Km value of 367.1 ± 
27.8 μM were calculated with respect to NAD+. Values shown are an average of two independent experiments each 
with three technical repeats ± SEM. 
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4.33 Inhibitor Screening 17β-HSD10, 17β-HSD8 and 17β-HSD14 
To give a measure of compound specificity, known inhibitors of the 17β-HSD10 enzyme were screened 
against 17β-HSD8 and 17β-HSD14 at a saturating concentration, as determined previously against 17β-
HSD10 (K690/K691/K1093 = 12.5 μM, 88401= 50 μM, AG18051= 6.25 μM, Chapter 3: Sections 3.05, 3.07, 
3.13). Compound AG18051 was found to be extremely specific resulting in 96.80 ± 0.49% inhibition of 
17β-HSD10, 7.10 ± 3.14% inhibition of 17β-HSD8 and 4.87 ± 5.39% inhibition of 17β-HSD14. Compound 
88401 resulted in a significant and approximately equal decrease in activity of both 17β-HSD10 and 17β-
HSD8, 67.36 ± 1.22% and 63.99 ± 3.26%, respectively. A non-significant decrease in activity of the 17β-
HSD14 enzyme, 11.13 ± 4.52%, was also observed in the presence of this compound. Frentizole derived 
compounds; K690, K691 and K1093 induced a significant decrease in activity of all three enzymes with 
17β-HSD10 showing 57.89 ± 1.71% inhibition, 63.24 ± 5.26% inhibition and 82.09 ± 0.85% inhibition in the 
presence of compounds K690, K691 and K1093, respectively. In the presence of compounds K690, K691 
and K1093, 17β-HSD8 exhibited 66.16 ± 1.49% inhibition, 78.62 ± 2.70% inhibition and 59.00 ± 1.37% 
inhibition respectively whilst 17β-HSD14 showed 25.18 ± 3.28% inhibition, 21.18 ± 2.04% inhibition and 
19.71 ± 2.56% inhibition (Figure 4.46).   
 
Figure 4.46. Inhibitor specificity 17β-HSD10, 17β-HSD8 and 17β-HSD14. Validated 17β-HSD10 inhibitors were 
subsequently screened against 17β-HSD8 and 17β-HSD14 at a saturating concentration (as determined against 17β-
HSD10). Values shown are an average of two independent experiment, each with three technical repeats ± SEM. 
Statistical analysis was performed using a one-way ANOVA with Bonferonni multiple comparisons. * = P ≤ 0.05, ** 
= P ≤ 0.01, *** = P ≤ 0.001, **** = P ≤ 0.0001. 
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Chapter 4 - Discussion: 
A key property of any drug molecule is specificity of action, allowing the therapeutic modulation of a 
protein of interest, whilst sparing closely related homologues and thereby avoiding off-target affects and 
toxicity. The 17β-hydroxysteroid dehydrogenase family, to which 17β-HSD10, our target enzyme belongs, 
contains a further 13 closely related enzymes and thus the likelihood of off-target effects appears high 
and worthy of investigation. On the basis of a structural similarity search, performed using the RCSB 
Protein Data Bank website, two closely related enzymes, 17β-HSD8 and 17β-HSD14, were identified. The 
coding sequence for each enzyme was cloned, proteins purified and activity assays developed allowing a 
measure of inhibitor specificity to be generated. 
The 17β-HSD8 cDNA sequence was custom synthesised using the GeneArt service offered by Thermo 
Fisher and was cloned into our standard peHISTEV expression vector. Protein expressed using the 
resultant peHISTEV-HSD8 construct and BL21(DE3) E. coli was found to be insoluble under all conditions 
tested (Figure 4.23) and thus the 17β-HSD8 cDNA sequence was subcloned into a second pET derived 
expression vector, generating a fusion protein with the solubility enhancing maltose binding protein 
(MBP-HSD8). The MBP-HSD8 fusion protein was soluble and subsequently purified successfully (Section 
4.26).    
The 17β-HSD14 cDNA sequence was reverse transcribed from an mRNA template and cloned into our 
standard peHISTEV expression vector, yielding soluble protein when expressed in Bl21(DE3) E. coli. During 
protein elution from the Ni-NTA affinity column, two bands were observed with both subsequently being 
identified as 17β-HSD14 via mass spectrometry (Figure 4.30). Whilst under ideal conditions, a 
recombinant protein would be expressed in a single homogenous form, this is not always the case. The 
lower molecular weight of the second minor band of 17β-HSD14 protein suggests it may represent a 
truncated isoform of the protein. Due to differing tRNA abundance and the concomitant differential 
codon usage between prokaryotic and eukaryotic organisms, some mammalian proteins can be difficult 
to express using a bacterial system368. The presence of such rare codons can result in premature 
termination of translation, particularly when such residues are present sequentially within the coding 
sequence, potentially explaining the observed secondary minor band of 17β-HSD14.  
A check was made for rare codons within the 17β-HSD14 coding sequence using the Rare Codon 
Calculator369, identifying a number of potentially problematic residues, although not sequentially within 
the coding sequence (see Appendix: E). To circumvent this issue, the cDNA sequence could be codon-
optimised for expression using E. coli, requiring the gene to be custom synthesised, or extensive rounds 
of site directed mutagenesis. A different strain of E. coli could also be utilised in-place of BL21(DE3). Two 
such variants, BL21-Codon Plus and BL21-Rosetta, are engineered to express higher than normal levels of 
these rare tRNA molecules, preventing stalling of the translation machinery and thus resulting in higher 
yields of full length protein. Alternatively, the 6 x His-tag used for Ni-NTA mediated protein purification 
could also be moved from the N-terminus of the protein, to the C-terminus thereby only isolating full 
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length 17β-HSD14. A second explanation for this minor band of 17β-HSD14 protein, relates to the fact 
that the 17β-HSD14 protein is predicted to harbour an internal disulphide bridge (DIANNA webserver370) 
and thus the second band may represent an incompletely reduced isoform of the protein, possibly due to 
the use of old loading dye, resulting in a protein with altered secondary structure and a modified migration 
through the gel. 
To characterise the catalytic properties of the 17β-HSD8 and 17β-HSD14 enzymes, and to guide 
subsequence compound screening experiments, a kinetics based appraisal was undertaken for both 
enzymes. Michaelis-Menten parameters, Vmax and Km, were calculated for both enzymes with respect to 
substrate, estradiol, and cofactor, NAD+. 
The Vmax and Km values calculated here for the 17β-HSD14 enzyme with respect to estradiol, Vmax = 3.47 ± 
0.12 nmol min-1 mg-1, Km = 33.39 ± 2.70 μM, are in line with those previously reported in the literature, 
Vmax = 2.5 ± 1.0 nmol min-1 mg-1 and Km = 5.6 ± 1.2 μM367. However, the values calculated for 17β-HSD8, 
Vmax = 657.6 ± 28.63 nmol min-1 mg-1, Km = 30.70 ± 3.32 μM, are dramatically higher than those reported 
previously, Vmax =0.405 ± 0.046 nmol min-1 mg-1 and Km = 0.110 ± 0.02 μM365. This discrepancy may be 
attributed to a number of experimental differences, or, more likely, a combination of these factors. 
First, the previously reported rate constants were derived from protein generated using the murine 
coding sequence for the 17β-HSD8 enzyme365, as opposed to the human sequence employed here, 
possibly contributing to the observed differences in catalytic activity. However, an alignment of the 
primary sequences for both human and mouse variants of the 17β-HSD8 enzyme reveals a high degree of 
sequence identity (87.1%, Figure 4.47). In addition, the differential amino acids map to non-conserved 
regions outside of the active site and thus it seems unlikely that primary sequence differences are in of 
themselves able to account for the dramatically differing levels of reported enzymatic activity. 
 
 Figure 4.47. Amino acid sequence alignment of human and mouse 17β-HSD8 protein. The primary amino acid 
sequence for human and murine  17β-HSD8 protein were aligned using the ExPASY SIM alignment tool, identifying a 
number of differences. 
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A more likely explanation relates to the protein purification methodologies utilised here and previously 
by Fomitcheva et al.365, which would likely result in preparations of differing purity. Here, a combination 
of Ni-NTA chromatography and size exclusion chromatography were employed and, although somewhat 
unnecessary given the small size of the 6 x His-tag (0.84 kDa), an additional pass over the Ni-NTA column 
was included to remove free 6 x His-tags following TEV cleavage, resulting in a reasonably pure protein 
preparation as indicated by SDS-PAGE and Coomassie Blue staining (Figure 4.38). For the purification of 
the murine homologue of the 17β-HSD8 enzyme, a single chromatography step was employed using a 
GST-tag and a glutathione sepharose column. A single chromatography step is also unlikely to result in a 
pure protein product, as is indicated by the additional bands present in the final preparation (Figure 
4.48)365, likely contributing to the described discrepancies in catalytic efficiency. In addition, following 
thrombin cleavage, no additional step was employed to remove the now free and contaminating GST-
tags365. As the GST-tag and 17β-HSD8 enzyme are comparable in size, 26 kDa and 27 kDa respectively, and 
will be present at a one to one molar ratio, the accurate determination of the concentration of 17β-HSD8 
protein in the final protein preparation will be difficult, if not impossible. 
 
Finally, the 17β-HSD8 enzyme appears to have an intrinsic tendency to fold incorrectly, indicated by the 
formation of inclusion bodies when overexpressed in E. coli, classically considered a marker of protein 
misfolding371 (Figure 4.23). The MBP-tag has been shown to be comparably more effective than the GST-
tag in promoting protein solubility, and presumably correct folding, resulting in preparations of higher 
enzymatic activity372-375. Thus, a higher proportion of the 17β-HSD8 purified here using an MBP-tag may 
be correctly folded and thus relatively more active, per unit mass, than that produced previously using 
the GST-tag.    
 
Figure 4.48. Fomitcheva et al. 17β-HSD8 purification. 17β-HSD8 was purified from crude cell lysate using a single 
GST based chromatography step resulting in an impure final preparation. Lane 1= Ladder, Lane 2= 17β-HSD8-GST 
protein, Lane 3= Thrombin cleaved 17β-HSD8 protein (Top arrow= 17β-HSD8-GST Fusion in Lane 2, Bottom Arrow= 
Thrombin cleaved 17β-HSD8 in Lane 3, Bottom Band in Lane 3= Free GST-tag, Top smear in Lane 3= Unknown). Figure 
reproduced from365. 
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In contrast to our expectation, in terms of inhibitor potency and specificity, compound AG18051 (Figure 
4.49) was found to be by far and away the best, resulting in almost complete inhibition of 17β-HSD10, the 
target enzyme, and no significant decrease in the activity of 17β-HSD8 and 17β-HSD14 (Figure 4.46).  
 
The small molecule inhibitors identified as a result of this investigation; compounds K690, K691, 88401 
and K1093 (Figure 4.50), appear to show specificity for 17β-HSD10 over 17β-HSD14, with compound 
88401 resulting in no significant decrease in activity of 17β-HSD14, whilst compounds K690, K691 and 
K1093 resulted in a significant but comparably small decrease in activity, as compared to that seen with 
17β-HSD10 (Figure 4.46). However, all four compounds were found to induce a large and significant 
decrease in activity of the 17β-HSD8 enzyme (Figure 4.46). 
 
 
 
 
 
 
 
 
 
Whilst the compounds identified herein compare poorly with AG18051, all, with the exception of 
compound K1093, represent initial screening hits and thus are likely to be suboptimal in terms of potency 
and specificity. Compound K1093, with alternate substitution at position 5 of the benzothiazole moiety, 
Figure 4.49. Structure AG18051.  Compound AG18051 was identified as a potent inhibitor of the 17β-HSD10 by 
Kissinger et al. in 2004350. 
 
Figure 4.50. Identified 17β-HSD10 enzyme inhibitors. As a result of this investigation, a number of inhibitors of the 
17β-HSD10 enzyme were identified. K690, K691 and K1093, derived from the Frentizole parent scaffold and 88401 
identified as a result of a large screen of the NCI diversity IV compound library (Sections 3.06 and 3.13) 
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exhibits increased potency against 17β-HSD10 and decreased potency against 17β-HSD8 as compared to 
compounds K690 and K691, suggesting further substitution of the benzothizaole moiety at position 5 may 
be advantageous for subsequent generations of more specific inhibitors. 
The results obtained here again re-emphasise the need for a crystal structure of the 17β-HSD10 enzyme 
and now also the 17β-HSD8 enzyme in complex with inhibitor, allowing the rational design of subsequent 
compound series with improved potency against 17β-HSD10, and specificity as measured against 17β-
HSD8. Whilst previous attempts have been made within the group to generate a crystal structure of the 
17β-HSD10 enzyme, all have failed. All previously published crystal structures of 17β-HSD10 (PDB ID: 2023, 
1SO8, 1U7T) harbour at least one ligand, presumably stabilising the structure of the enzyme and, now 
that the mechanism of inhibition utilised by our Frentizole derived inhibitors is understood (Section 3.08), 
such an approach appears viable for the generation of enzyme-inhibitor-cofactor complexes. In addition, 
now validated, differential scanning fluorimetry may prove of use allowing the rational optimisation of 
buffer composition and the identification of stabilising additives which may further improve the chances 
of crystal formation. To illustrate the point, previous crystal trials were performed at pH values as low as 
4.0, however, using DSF and a three buffer system (citric acid, HEPES, CHES), allowing the effects of buffer 
composition and pH to be delineated, it becomes apparent that below pH 5.5-5.0 the 17β-HSD10 enzyme 
is denatured, indicated by an altered melt profile and increased initial fluorescence (Figure 4.51). As such, 
DSF may be used to narrow the range of conditions trailed in a logical manner, concentrating time and 
resources into the most promising avenues of investigation and thereby increasing the chances of success. 
 
 
 
Figure. 4.51. Differential scanning fluorimetry mediated buffer optimisation.  DSF can be used to rationally alter 
buffer composition, improving protein stability and thereby improving the chances of crystal formation, indicated here 
using a gradient from pH 4-10. Values shown are an average of two independent experiments, each with three 
technical repeats. For clarity, error bars have been omitted. 
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Chapter 5 - Introduction and Aims: 
So far I have developed a highly robust screening assay for our target enzyme 17β-HSD10, leading to the 
identification of a number of novel enzyme inhibitors (Chapter 3). In addition, I have cloned, purified and 
developed screening assays for two close structural homologues of the 17β-HSD10 enzyme, 17β-HSD8 
and 17β-HSD14, allowing a measure of inhibitor specificity to be generated (Chapter 4). Whilst such assays 
are useful as initial explorative screening tools, given their high-throughput and low cost, they do little to 
recapitulate the complex environment found within the cell. Thus, it would be advantageous to develop 
a robust cellular based disease model against which compounds of interest can be tested. Previous work 
performed by Shi du Yan et al. has shown that the co-expression of catalytically active 17β-HSD10 enzyme 
with Aβ results in a marked increase in oxidative stress, whilst the overexpression of a catalytically inactive 
mutant of the 17β-HSD10 enzyme with Aβ does not338, a property which could potentially be exploited to 
generate a cellular screening tool.  
Using site directed mutagenesis, a catalytically inactive mutant of the 17β-HSD10 enzyme would first be 
generated. The wild-type 17β-HSD10 and the catalytically inactive mutant would subsequently be 
introduced into a mammalian cell line alongside Aβ, after which relative levels of oxidative stress would 
be assessed using a commercially available probe. If previous work is correct, treatment with Aβ should 
induce a marked increase in oxidative stress when catalytically active 17β-HSD10 enzyme is present. 
Validated 17β-HSD10 inhibitors would be titrated onto a wild-type 17β-HSD10/Aβ background, hopefully 
showing for the first time a reversal of a disease relevant phenotype and confirming that the direct 
inhibition of 17β-HSD10 activity is of therapeutic merit in treating AD. Cells harbouring a catalytically 
inactive mutant of the 17β-HSD10 enzyme would act as a no-stress control, accounting for intrinsic levels 
of reactive oxygen species and in doing so, defining the window for intervention (illustrated in Figure 
5.01). The aim of this chapter was to develop such an assay. 
Figure 5.01. Hypothetical 17β-HSD10 based cellular disease model. The combined expression of active 17β-HSD10 
with Aβ has been shown to induce a marked increase in oxidative stress, whilst inactive 17β-HSD10 does not. Thus, 
through the use of a reactive oxygen species marker a high throughput screening tool could be generated allowing 
compounds of interest to be tested in a cellular environment. 
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5.1 Mammalian 17β-HSD10 Inhibition 
When producing recombinant protein, a number of expression systems can be utilised; broadly divided 
into prokaryotic, eukaryotic or cell free. Here, a prokaryotic E. coli based system was used, primarily due 
to the facilities available, in-house expertise and ultimately, cost. However, such heterologous expression 
can generate undesirable affects, such as a lack of post-translational modification or incorrect folding of 
a protein of interest, potentially influencing downstream applications. Thus, a check was made to ensure 
that the Frentizole derived 17β-HSD10 enzyme inhibitors, K690 and K691, identified using recombinant 
protein produced in E. coli, remain active against mammalian expressed 17β-HSD10 protein.  
To this end, HEK293 cells were transiently transfected with the pcDNA3-HSD10 construct. 24 hours post 
transfection, cells were treated with a hypotonic buffer, rendering them fragile, and lysates generated 
using a dounce homogeniser. Inhibitors K690, K691 or vehicle (DMSO) were added after which substrate 
(acetoacetyl-CoA) and cofactor (NADH) were spiked in, and the change in absorbance monitored over 
time at 340 nm. A significant decrease in activity was observed in the presence of compounds K690 and 
K691, as compared to vehicle treated 17β-HSD10 (Figure 5.02). Approximately 30-40% residual activity 
was observed in the presence of saturating concentrations of K690 and K691, comparable to previous 
results (Figures 3.15 and 3.16), suggesting there is no difference between prokaryotic and eukaryotic 
expressed enzyme and the results obtained previously are valid. As such, provided they are capable of 
membrane penetration, compounds K690 and K691 should be active in a cellular environment. 
 
Figure 5.02. Inhibition of mammalian expressed 17β-HSD10. 17β-HSD10 expressed in HEK293 cells, after which cells 
were lysed, inhibitors K690 and K691 added, follwed by acetoacetyl-CoA and NADH and activity monitored at 340 
nm. A comparable level of inhibition was with compounds K690 and K691 using both bacterial and mammalian 
expressed 17β-HSD10. Values shown are an average of three independent experiments each with three technical 
repeats ± SEM. Statistical anaylsis was performed using a one-way ANOVA with Bonferroni mutiple comparisons. * 
= P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, **** = P ≤ 0.0001. 
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5.2 Inhibitor Toxicity  
Compounds which are acutely toxic are unlikely to be developed into a successful therapeutic agent. As 
such, a measure of the toxicity of compounds K690 and K691 was made using a lactate dehydrogenase 
assay (LDH) assay. The LDH assay provides a measure of cell death on the basis of enhanced membrane 
permeability and thus serves as a useful indicator for both necrotic and apoptotic cell death376. The assay 
is based around a coupled reaction, in which the lactate dehydrogenase enzyme converts lactate to 
pyruvate using NAD+ as a cofactor, producing NADH. NADH is subsequently used by diaphorase to convert 
iodonitrotetrazolium (INT) to formazan, giving a coloured product which can be measured using 
spectrophotometry via absorbance at 490 nm (Scheme 5.01).  
 
During the LDH assay procedure, compounds of interest are added to the culture media, which is then 
used directly in the assay. As such, there is the potential for compound induced inhibition of either the 
lactate dehydrogenase enzyme or the coupled diaphorase enzyme, possibly leading to false negative 
results.  
Therefore, to ensure that compounds K690 and K691 do not interfere with the LDH assay, an initial trial 
experiment was performed using purified LDH and diaphorase enzymes. The LDH assay was performed in 
the presence of 50 μM K690, K691 or vehicle (DMSO). No significant alteration in signal was observed in 
the presence of either compound, as compared to vehicle (DMSO), indicating compounds K690 and K691 
do not inhibit the LDH or diaphorase enzymes and thus the assay is suitable for assessing compound 
induced cytotoxicity (Figure 5.03). 
Figure 5.03. K690 and K691 induced LDH interference. A check was made to ensure that compounds K690 and K691 
do not interfere with the LDH assay. No signfiicant decrease in signal was apparent in the presence of compound 
K690 or K691. Values shown are an average of three biological repeats each with three technical repeats ± SEM. 
Statistical anaylsis was performed using a one-way ANOVA with Bonferroni mutiple comparisons. 
Scheme 5.01. Lactate dehydrogenase assay. The lactate dehydrogenase enzyme converts lactate to pyruvate, 
generating NADH. NADH is subsequent utilised by diaphorase to convert a tetrazolium salt (INT) to formazan, a 
coloured product which can be measured via absorbance at 490 nm. 
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With the assay validated, HEK293 and SH-SY5Y cells were treated with varying concentrations of 
compounds K690 and K691 for 24 hours, after which cell death was assessed using the LDH assay. In all 
cases, no increase in cell death was observed (Figure 5.04). A high background signal is apparent due to 
the presence of foetal bovine serum in the culture media, which is known to contain LDH376.   
 
 
  
Figure 5.04. K690 and K691 induced cytotoxicity. HEK293 and SH-SY5Y cells were treated with the indicated 
concentrations of compounds K690 and K691 and incubated for 24 hours. Following incubation, a measure of cell 
death was made using the LDH assay. In all cases, no significant increase in cell death was observed following 
incubation with compounds K690 and K691 for 24 hours.  Top= HEK293, Bottom= SH-SY5Y. Values shown are an 
average of three independent experiments, each with three technical repeats ± SEM. . Statistical anaylsis was 
performed using a one-way ANOVA with Bonferroni mutiple comparisons. * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, 
**** = P ≤ 0.0001. 
Chapter 5: A Cellular Disease Model 
188 
 
5.3 17β-HSD10 Site-Directed Mutagenesis: 
In order to develop a 17β-HSD10 centred cellular disease model, a catalytically inactive mutant of the 17β-
HSD10 enzyme was first required. Two such mutations have previously been reported in the literature, 
Q165H320 and Y168G338. The first, Q165H, has been proposed to prevent cofactor binding, thereby 
rendering the enzyme inactive, whilst the Y168G mutation alters a conserved residue within the enzyme 
catalytic triad, again rendering the enzyme catalytically dead.  
Site directed mutagenesis (SDM) was used to introduce both mutations into the coding sequence of the 
17β-HSD10 enzyme, previously cloned into the pcDNA3 vector for mammalian expression (Figure 5.05). 
Previous work conducted by Dr. Margaret Taylor, a past PhD student within the group, has shown that 
the subcellular localisation of the 17β-HSD10 enzyme changes when overexpressed, becoming dispersed 
throughout the cell as opposed to solely mitochondrial, presumably due to the overloading of the cellular 
translocation machinery (unpublished observation). Therefore, the expression construct was previously 
modified to add an N-terminal mitochondrial targeting sequence, taken from the COX8 gene, ensuring 
correct subcellular localisation (Figure 5.05). The COX8 mitochondrial targeting sequence is subsequently 
cleaved from the protein within the mitochondrial matrix, giving wild-type 17β-HSD10 in its native cellular 
location.  
 
 
 
 
 
Figure 5.05. pcDNA3-HSD10 vector map. The 17β-HSD10 coding sequence was cloned into the pcDNA3 mammalian 
expression vector. An N-terminal mitochodrial targeting sequence (MTS) was previously added ensuring the correct 
sub cellular localisation of the expressed 17β-HSD10 enzyme . 
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Q165H Mutant 
Using standard QuickChange style SDM primers the Q165H mutation was successfully introduced into the 
17β-HSD10 coding sequence (Figure 5.06, see Appendix: B for sequencing results). 
Forward Primer: 5'-GGGTCAGGTTGGACAcGCTGCATACTCTGCTTCC-3 
Reverse Primer: 5'-GGAAGCAGAGTATGCAGCgTGTCCAACCTGACCC-3 
 
Y168G Mutant 
Initial attempts to generate the Y168G mutant using standard QuickChange style primers were 
unsuccessful. 
Forward Primer: 5'-GGACAAGCTGCAggCTCTGCTTCCAAGG-3' 
Reverse Primer: 5'-CCTTGGAAGCAGAGccTGCAGCTTGTCC-3' 
 
Whilst additional optimisation would likely have given rise to the desired mutation, an altered, more 
efficient SDM methodology, has been described by Liu & Naismith345. In this case, primers are designed 
with a short extension 5' to the desired mutation and a comparatively long 3' extension thereafter, with 
the result that the produced primers have a higher affinity for the template as compared to one another 
and giving an exponential amplification of product, as opposed to the linear amplification seen with 
QuickChange style primers. Using this style of primer, the Y168G mutation was successfully introduced 
into the 17β-HSD10 cDNA sequence (Figure 5.07, see Appendix: B for sequencing results). 
Liu & Naismith Forward Primer: 5'-GCTGCAggCTCTGCTTCCAAGGGGGGAATAGTGGGC-3' 
Liu & Naismith Reverse Primer: 5'-GCAGAccTGCAGCTTGTCCAACCTGACCCTCG-3' 
Figure 5.06. Q165H site directed mutagenesis. The Q165H mutation was introduced into the coding sequence of the 
17β-HSD10 enzyme, held within the pcDNA3 expression construct, using QuickChange style SDM primers. Lane 1= 
Ladder, Lane 2= Dpn1 Control, Lanes 3-10= Thermal gradient 72 -50°C. 
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5.4:  17β-HSD10 Mutant Characterisation  
5.41 Mutant 17β-HSD10 Expression 
With the putative inactivating mutations successfully introduced into the 17β-HSD10 coding sequence, 
and sequence verified, a check was made to ensure each is expressed equally well to the wild-type 
enzyme. With the introduction of amino acid substitutions into a protein sequence there is the potential 
that the efficiency of translation may be altered, resulting in lower than usual protein levels. Here, such 
an effect would present as an apparent loss of enzymatic activity, when in-fact the effect would be due 
to a decrease in enzyme expression, influencing the validity of subsequent conclusions. 
As such, a check was made to ensure both the Y168G and Q165H mutants are expressed equally well to 
the wild-type enzyme. HEK293 cells were transiently transfected with each construct and 17β-HSD10 
expression assessed via western blot following 24-hours incubation. Following transfection with the 
empty pcDNA3 vector, a faint single band is observed, corresponding to endogenous 17β-HSD10 enzyme 
(Figure 5.08, Lanes 1-3). After transfection with the pcDNA3 vector harbouring either the wild-type 
enzyme, the Q165H mutant or the Y168G mutant, two prominent bands are seen, corresponding to the 
free enzyme (lower band) and MTS-tagged enzyme (upper band) (Figure 5.08, Lanes 4-12).  The intensity 
of the observed bands was found to be comparable with each construct, as determined via densitometry 
based analysis, suggesting the Q165H and Y168G mutants of the 17β-HSD10 enzyme are expressed 
equally well to the wild-type enzyme and thus any changes in activity observed between them can be 
attributed to differences in catalytic efficiency and not simply a lack of enzyme being present. 
 
Figure 5.07. Y168G site directed mutagenesis. The Y168G mutation was introduced into the coding sequence of the 
17β-HSD10 enzyme, held within the pcDNA3 expression construct, using Liu& Naismith style SDM primers345. Lane 1= 
Ladder, Lane 2= Dpn1 Control, Lanes 3-10= Thermal gradient 72 -50°C. 
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5.42 Mutant 17β-HSD10 Enzymatic Activity 
With the Y168G and Q165H mutants of the 17β-HSD10 enzyme confirmed as being expressed equally well 
to the wild-type enzyme, a valid comparison of their relative catalytic efficiencies could now be made. In 
order to confirm that the Q165H and Y168G mutants of the 17β-HSD10 enzyme are indeed catalytically 
inactive, HEK293 cells were again transiently transfected with each construct. 24 hours post transfection, 
cells were treated with a hypotonic buffer rendering them fragile and subsequently lysed using a dounce 
homogeniser. Cellular debris was pelleted via centrifugation and substrate (acetoacetyl-CoA) and 
cofactor, (NADH) spiked into the supernatant. 17β-HSD10 catalytic activity was measured as a function of 
NADH conversion to NAD+, via absorbance at 340 nm. pcDNA3 empty vector transfected cells were used 
as a control, allowing the activity of endogenous levels of 17β-HSD10 and any additional enzymes which 
are capable of catalysing the same reaction to be controlled for. Any increase in activity following 
transfection with each construct could then reliably be attributed to the introduced enzyme. Activity was 
normalised to total protein content using the BCA assay, accounting for any variation in plating density or 
lysis efficiency.  
In contrast to previous reports320, the Q165H mutation was found to reduce the catalytic activity of the 
17β-HSD10 enzyme, but not completely inactivate it (Figure 5.09).  
 
 
 
 
 
 
 
 
Figure 5.08. Expression of wild-type 17β-HSD10, the Q165H mutant and the Y168G mutant. HEK293 cells were 
transiently transfected with the indicated 17β-HSD10 constructs.  24 hours post transfection, the expression of the 
17β-HSD10 enzyme assessed via western blot. Each mutant of the 17β-HSD10 enzyme  was found to be expressed to 
a comparable level as the wild-type. Lanes 1-3= pcDNA3 empty vector, Lanes 4-6= Wild-type 17β-HSD10, Lanes 7-9= 
Q165H, Lanes 10-12= Y168G. 
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As previously reported338, the Y168G mutation was found to completely inactivate the 17β-HSD10 
enzyme, with only background levels of activity observed. 
Figure 5.09. Catalytic activity of the 17β-HSD10-Q165H mutant. HEK293 cells were transiently transfected with the 
empty pcDNA3 vector, wild-type 17β-HSD10 or the Q165H mutant. 24 hours post transfection, cells were lysed and 
enzyme activity measured as a function of NADH conversion to NAD+. The Q165H mutant of the 17β-HSD10 enzyme 
was found to be less active than the wild-type enzyme but not catalytically dead. Values shown are an average of 
three independent experiments each with three technical repeats ± SEM. Statistical anaylsis was performed using a 
one-way ANOVA with Bonferroni mutiple comparisons. * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, **** = P ≤ 0.0001. 
Figure 5.10. Catalytic activity of the 17β-HSD10-Y168G mutant. HEK293 cells were transiently transfected with the 
empty pcDNA3 vector, wild-type 17β-HSD10 or the Y168G mutant. 24 hours post transfection, cells were lysed and 
enzymatic activity measured as a function of NADH conversion to NAD+. The Y168G mutant of the 17β-HSD10 enzyme 
was found to be catalytically dead, as reported previously. Values shown are an average of three independent 
experiments each with three technical repeats ± SEM. Statistical anaylsis was performed using a one-way ANOVA with 
Bonferroni mutiple comparisons. NS = Non-significant, * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, **** = P ≤ 0.0001. 
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5.5 APP Transfection Optimisation 
In cell culture based experiments, the application of amyloid beta-peptide is typically performed using 
one of two methodologies; cells are either dosed with purified recombinant amyloid beta-peptide of the 
desired oligmeric state or transfected with a mutant of the amyloid precursor protein (APP), leading to 
elevated levels of Aβ being generated endogenously.   
Commercially available recombinant amyloid beta-peptide must first be treated with a monomerising 
agent and subsequently incubated under the appropriate conditions to generate the desired oligomerised 
state. The methodologies employed for such steps are divergent in nature with varying efficiencies and 
levels of characterisation358. Previously, in the original paper reporting the 17β-HSD10/Aβ interaction as 
toxic, COS-7 cells were transiently transfected with both APP (V171G), generating increased levels of Aβ1-
42, and 17β-HSD10 resulting in elevated levels of oxidative damage and cell death337,338. As such, cells were 
here transiently transfected with APP harbouring the Swedish mutation (APPswe), generating enhanced 
levels of Aβ1-40 and Aβ1-42 endogenously, the species with which the 17β-HSD10 enzyme interacts338.  
The APPswe gene had previously been cloned into the pcDNA3 mammalian expression vector using the 
HindIII and XbaI restriction sites (Figure 5.11). 
 
In order to optimise the transfection and expression of the APPswe construct, HEK293 cells were 
transiently transfected with the empty pcDNA3 vector or the pcDNA3-APPswe construct. Cell lysates were 
generated 24 and 48 hours post transfection, and the levels of amyloid precursor protein and Aβ assessed 
via western blot. Following transfection with the pcDNA3-APPswe construct, prominent bands 
corresponding to the amyloid-precursor protein and Aβ are apparent at both 24 and 48 hours post 
transfection (Figure 5.12). A 48-hour incubation period post transfection was passed forward into future 
experiments. 
 
Figure 5.11. pcDNA3-APPswe Vector Map. The amyloid precursor protein coding sequence, harbouring the Swedish 
mutation, was cloned into the pcDNA3 vector using the HindIII and XbaI restriction enzyme sites. 
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5.6 HEK293 
5.61 HEK293 17β-HSD10 Stable Cell Line Generation 
Whilst it would be possible to transiently transfect cells with both the 17β-HSD10 and APPswe constructs 
simultaneously, the efficiency of such a dual transfection would likely be low, introducing a large degree 
of variation between repeat experiments. Thus, a decision was made to generate stable cell lines 
expressing pcDNA3 empty vector, the wild-type 17β-HSD10 enzyme, the Q165H mutant or the Y168G 
mutant. The produced cell lines would subsequently be transiently transfected with the pcDNA3 empty 
vector or the pcDNA3-APPswe construct, after which the levels of 4-HNE, a marker of oxidative stress 
employed previously as a measure of 17β-HSD10/Aβ induced oxidative damage 338, would be assessed.  
Wild-type HEK293 cells were transiently transfected with the empty pcDNA3 vector, the wild-type 17β-
HSD10 enzyme, the Q165H mutant or the Y168G mutant. 48 hours post transfection, cells were placed 
into selection media, containing Geneticin, and selection maintained for a sufficient period to kill both 
non-transfected and transiently transfected cells. Stably transfected cells were allowed to propagate in 
maintenance media and the expression of the 17β-HSD10 enzyme confirmed via western blot (Figure 
5.13). Densitometry based analysis revealed an approximate 8-fold upregulation of 17β-HSD10 with each 
expression construct. 
Figure 5.12. APP and Aβ expression at 24-hour and 48-hours post transfection. HEK293 cells were transfected with 
the empty pcDNA3 vector or the pcDNA3-APPswe construct. 24 and 48 hours post transfection, the expression of 
the amyloid precursor protein and Aβ was assessed via western blot. Following transfection with the pcDNA3-
APPswe construct a marked increase in both amyloid precursor protein and Aβ expression can be seen. Lanes 1-3= 
Wild-type cells, Lanes 4-6= pcDNA3 empty vector, Lanes 7-9= pcDNA3-APPswe. 
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5.62 HEK293 17β-HSD10 Stable Cell Lines + APP - 4-HNE Western Blot: 
Previously, immunocytochemistry was used to measure intracellular levels of 4-hydroxynoneal (4-HNE), a 
marker of oxidative stress, in cells expressing catalytically active and inactive 17β-HSD10 enzyme 
alongside Aβ, with enhanced levels of 4-HNE observed in the presence of the active enzyme338. Here, 
western blotting was instead employed. To confirm that the antibody against 4-HNE was indeed capable 
of detecting such an antigen, HEK293 cells were treated with either purified 4-HNE or vehicle (ethanol) 
and cell lysates taken thereafter. The relative levels of 4-HNE modified proteins were subsequently 
assessed via western blot. A marked increase in 4-HNE modified proteins was observed in samples treated 
with purified 4-HNE, as would be expected, confirming that the antibody is capable of detecting this 
antigen (Figure 5.14). 
Figure 5.13. 17β-HSD10 expressing HEK293 stable cell lines. HEK293 cells were stably transfected with the pcDNA3 
empty vector, the 17β-HSD10 enzyme, the Q165H mutant or the Y168G mutant and expression confirmed via western 
blot. Lanes 1-3= pcDNA3 stable expression, Lanes 4-6= Wild-type 17β-HSD10, Lanes 7-9= Q165H mutant, Lanes 10-
12= Y168G mutant. 
Figure 5.14. 4-HNE antibody validation. HEK293 cells were treated with purified 4-HNE, or vehicle and cell lysates 
taken. Levels of 4-HNE modified proteins were assessed via western blot, showing a marked increase in 4-HNE treated 
samples. Lanes 1-3=Vehicle treated, Lanes 4-6= 4-HNE treated.  
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HEK293 cells stably expressing the pcDNA3 empty vector, the wild-type 17β-HSD10 enzyme or the Y168G 
mutant were transiently transfected with the APPswe construct. 48 hours post-transfection, the relative 
levels of 4-HNE modified proteins were assessed via western blot, with the expectation that cells 
expressing the 17β-HSD10 enzyme would show a marked increase in 4-HNE levels. However, no marked 
difference in 4-HNE levels was observed between cells expressing pcDNA3 empty vector, the wild-type 
17β-HSD10 enzyme or the Y168G mutant (Figure 5.15).  
 
5.7 SH-SY5Y Dual Stable Cell Line Generation 
One potential explanation for the discrepancy between the results described herein and those reported 
previously, is the length of incubation post-transfection with the amyloid precursor protein. No time 
interval was reported previously338 raising the possibility that a 48-hour incubation may be too long, in 
which case the cell may compensate, or too short in which case no signal will be apparent.  
In an attempt to produce a more robust phenotype, an alternative strategy was employed. Firstly, a more 
disease relevant cell line, in the form of the neuroblastoma derived SH-SY5Y cell line, was used and, in an 
attempt to maximise phenotypic differences between control and amyloid expressing cells, a decision was 
made to move from the transient transfection of the APPswe gene used previously, to stable expression.  
Chemical transfection reagents are known to show relatively poor efficiency with neuronal derived cell 
lines and so nucleofection was instead used. SH-SY5Y cells were nucleofected with the pcDNA3 empty 
vector, the wild-type 17β-HSD10 enzyme or the catalytically inactive Y168G mutant. 48-hours post 
nucleofection cells were placed into selection media, containing Geneticin, and selection maintained for 
a sufficient length of time to kill both non-transfected and transiently transfected cells. Stably transfected 
cells were allowed to propagate in maintenance media and the expression of the 17β-HSD10 protein 
confirmed via western blot. As expected, a marked increase in 17β-HSD10 expression was observed in 
Figure 5.15. 4-HNE western blot. HEK293 cells stably expressing the pcDNA3 empty vector, the wild-type 17β-HSD10 
enzyme or the Y168G mutant were transiently transfected with the APPswe construct. 48 hours post transfection the 
relative levels of 4-HNE were assessed via western blot. No marked difference was observed. Lanes 1-3 = pcDNA3 
empty vector + APPswe, Lanes 4-6= 17β-HSD10 stable + APPswe, Lanes 7-9= Y168G stable + APPswe. 
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both the wild-type 17β-HSD10 and Y168G mutant expressing cells as compared to the pcDNA3 empty 
vector (Figure 5.16, lanes 4-9). 
 
The 17β-HSD10 and APPswe constructs had both previously been generated using the pcDNA3 vector and 
thus both harbour a Geneticin resistance marker, precluding the sequential selection of dual stable 
transfectants. As such, the APPswe gene was PCR amplified out of the pcDNA3 backbone and 5’HindIII 
and 3’NotI restriction enzyme sites simultaneously added for downstream cloning. 
APPswe Forward: 5'- taagcaAAGCTTATGCTGCCCGGTTTGGCA-3' 
APPswe Rev:erse 5'-tgcttaGCGGCCGCTTACTAGTTCTGCATCTGCTCAAAGAACTTGTAGG-3' 
(Lower case= Spacer sequence, Bold = Restriction Site 
 
To optimise primer annealing temperatures, three small scale PCR reactions were performed with primer 
annealing at 72°C, 65°C and 55°C. Clean product was observed at the expected size, 2.1 kb, at each 
temperature tested (Figure 5.17) and thus a 72°C annealing temperature was used subsequently. 
 
Figure 5.17. APPswe PCR primer check. PCR primers were designed to amplify the APPswe cDNA sequence out of 
the pcDNA3 backbone and simultaneously add 5’HindIII and 3'NotI restriction enzyme sites. To optimise primer 
annealing, three temperatures were trialled. Lane 1= Ladder, Lane 2= 72°C annealing, Lane 3= 65°C annealing, Lane 
4= 55°C annealing. Clean product was observed at each temperature trialled and thus 72°C was used subsequently. 
Figure 5.16. 17β-HSD10 Expressing SH-SY5Y stable cell lines. SH-SY5Y cells were nucleofected with the empty 
pcDNA3 vector, the wild-type 17β-HSD10 enzyme or the Y168G mutant.  Stably expressing cells were selected using 
Geneticin and 17β-HSD10 expression confirmed via western blot. Lanes 1-3= pcDNA3, Lanes 4-6= Wild-type 17β-
HSD10, Lanes 7-9 = Y168G mutant. 
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The PCR amplified APPswe gene was ligated into the pcDNA4/TO vector, harbouring a Zeocin selection 
marker, generating a pcDNA4-APPswe construct (Figure 5.18, see Appendix: B for sequencing results). 
 
The pcDNA4/TO vector comes in multiple variations. The one to hand was designed to add C-terminal myc 
and 6 x His tags, allowing the identification of protein expression using an anti-myc antibody, and 
subsequent protein purification via Ni-NTA affinity chromatography. In this instance neither feature was 
desired and so two stop codons were added to the C-terminal end of the APPswe gene, preventing their 
expression. The pcDNA4/TO vector has an additional advantage, in that it can be used in conjunction with 
the pcDNA6/TR vector to generate a tetracycline inducible expression system. Due to time constraints, a 
decision was made that in the first instance, tetracycline control of APPswe expression would not be 
employed and thus both the 17β-HSD10 enzyme and the APPswe gene would be constitutively expressed. 
However, should this combination prove to be toxic it would be a relatively simple matter to introduce 
tetracycline mediated control of APPswe expression, requiring an additional round of stable selection, this 
time using the pcDNA6/TR vector and Blasticidin.  
Figure 5.18 pcDNA4-APPswe Vector Map. The amyloid precursor protein coding sequence, harbouring the Swedish 
mutation, was cloned into the pcDNA4 vector using the HindIII and NotI restriction enzyme sites. 
Figure 5.19. pcDNA6/TR Vector Map. The pcDNA6/TR vector can be used in conjunction with the pcDNA4/TO vector 
to generate a tetracycline inducible expression system. 
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Stably transfected SH-SH5Y cells, harbouring the empty pcDNA3 vector, the wild-type 17β-HSD10 enzyme 
or the Y168G mutant were subsequently nucleofected with the empty pcDNA4 vector or the pcDNA4-
APPswe construct. 48-hours post nucleofection cells were placed into Zeocin containing media and 
selection maintained for a sufficient period to kill non-transfected and transiently transfected cells. 
Following selection, cells were placed into maintenance media and allowed to propagate.  
The expression of both APPswe and 17β-HSD10 were subsequently confirmed via western blot (Figure 
5.20). Densitometry based analysis revealed approximately equal levels of overexpression for the wild-
type 17β-HSD10 enzyme and Y168G mutant, as compared to empty vector controls (5 to 7-fold 
overexpression). The endogenous levels of APP in pcDNA4-empty vector transfected cell lines were found 
to be almost undetectable, preventing a comparison being made via densitometry, however visual 
inspection of the blots indicates a marked increase in APP expression following transfection with the 
pcDNA4-APPswe construct. 
 
Figure 5.20. 17β-HSD10/17β-HSD10(Y168G) and APPswe dual stable SH-SY5Y cell lines. SH-SY5Y cells were 
nucleofected with the pcDNA3 empty vector, the pcDNA3-HSD10 or pcDNA3-HSD10(Y168G) constructs and stable 
transfectants selected. Subsequently, cells were nucleofected with the pcDNA4 empty vector or pcDNA4-APPswe 
construct and dual stable transfectants selected. Lanes 1-3 = pcDNA3/pcDNA4 empty vector, Lanes 4-6= 
pcDNA3/pcDNA4-APPswe, Lanes 7-8= pcDNA3-HSD10/pcDNA4 empty vector, Lanes 10-12= pcDNA3-
HSD10/pcDNA4-APPswe.  
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The relative levels of 4-HNE modified proteins in the SH-SY5Y pcDNA3 empty-vector/pcDNA4-APPswe, 
pcDNA3-17β-HSD10/pcDNA4-APPswe and pcDNA3-Y168G/pcDNA4-APPswe dual stable cell lines were 
assessed via western blot. No marked difference in 4-HNE levels were observed between the three cell 
lines (Figure 5.21). Identical results were obtained using the generalised reactive oxygen species marker, 
H2DCFDA, and mitochondrial superoxide marker MitoSox (data not shown).  
  
Figure 5.21. Relative levels of 4-HNE modified proteins in SH-SY5Y dual stable cell lines. Lanes 1-3= pcDNA3 empty 
vector/pcDNA4-APPswe, Lanes 4-6= pcDNA3-17β-HSD10/pcDNA4-APPswe, Lanes 7-9= pcDNA3-17β-
HSD10(Y168G)/pcDNA4-APPswe. No marked difference in the level of 4-HNE modified proteins was observed 
between the indicated cell lines. 
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Chapter 5 - Discussion: 
Two publications from the group of Shi du Yan, have shown that the overexpression of the 17β-HSD10 
enzyme alongside Aβ results in a marked increase in oxidative stress and cell death, and through the use 
of an inactive mutant (mutERAB), that this stress is dependent on the catalytic activity of the 17β-HSD10 
enzyme337,338 (Figure 5.22).  
 
Further work has shown that this oxidative stress and cell death is due to a perturbation of mitochondrial 
function340 and translates into a cognitive deficit in mouse models, expressing neuronally targeted mutant 
amyloid precursor protein and 17β-HSD10 enzyme303,339. The administration of a selective agent shown 
to disrupt the 17β-HSD10/Aβ interaction (ABAD-DP) was shown to reverse these effects, suggesting 
causation303,339. Here, I have failed to replicate the aforementioned studies in both the HEK293 and SH-
SY5Y cells, human embryonic kidney and human neuroblastoma cell lines, respectively.  
Two missense mutations, Q165H320 and Y168G338, have been reported in the literature as rendering the 
17β-HSD10 enzyme catalytically inactive. Through the use of site directed mutagenesis, I have generated 
both mutants, and confirmed comparable expression of each in a mammalian cell line (Figure 5.08). 
However, in contrast to previous reports, further characterisation revealed that whilst the Q165H 
mutation reduces the catalytic activity of the 17β-HSD10 enzyme, it does not completely abolish it (Figure 
5.09). This discrepancy between experiments is difficult to reconcile. The Q165H mutation was reported 
to prevent the binding of cofactor NADH/NAD+, as measured using differential scanning fluorimetry, 
thereby preventing activity against all known substrates320. The activity observed herein however suggests 
otherwise. An examination of the crystal structure of the 17β-HSD10 enzyme (PDB: 1U7T) reveals that the 
Q165H amino acid substitution sits far from the cofactor binding site, instead residing in the putative 
substrate binding cleft (Figure 5.23), potentially influencing substrate binding affinity. The enzyme activity 
assay performed previously utilised 2-methyl-3-hydoxybutyryl-CoA as substrate and thus the Q165H 
Figure 5.22. Effect of 17β-HSD10 catalytic activity on 17β-HSD10/Aβ cytotoxicity. Co-transfection of COS-7 cells with 
wild-type 17β-HSD10 (ERAB) and Aβ resulted in a marked increase in 4-hydoxynoneal levels, whilst a catalytically 
inactive mutant of the 17β-HSD10 enzyme (Y168G/K172G, mutERAB) with Aβ did not. Figure reproduced from338.   
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mutation may alter 2-methyl-3-hydoxybutyrl-CoA binding affinity, an effect which may be less apparent 
with acetoacetyl-CoA, explaining the activity observed here and lack thereof. Alternatively, as no 
substrate concentration is reported for the aforementioned activity assay, the Q165H mutation may lower 
affinity such that no significant substrate binding occurred under the conditions utilised previously, whilst 
the 120 μM acetoacetyl-CoA utilised here may be sufficient for binding and catalysis.  
 
In concordance with previous reports338, the Y168G mutation was however found to completely inactivate 
the 17β-HSD10 enzyme (Figure 5.10). However, when HEK293 cells stably expressing either the wild-type 
17β-HSD10 enzyme or the Y168G mutant (Figure 5.13) were transfected with the APPswe construct, giving 
elevated levels of Aβ1-40 and Aβ1-42, the species with which 17β-HSD10 interacts338, no marked increase in 
4-HNE levels were observed, as measured by western blot (Figure 5.15). The previously reported increase 
in 4-HNE levels following transient transfection with the 17β-HSD10 enzyme and Aβ was detected using 
immunocytochemistry and is large, almost 5 fold (Figure 5.22)338, suggesting a signal should have been 
seen even when assessed via a comparatively indirect western blot. The expression constructs generated 
here have been sequence verified, the subsequently produced stable cell lines verified via western blot 
and the antibody against 4-HNE has been shown to be capable of detecting this antigen, as such the cause 
of this discrepancy is not immediately obvious.  
In an attempt to generate a more robust phenotype, dual stable SH-SY5Y cells were generated, expressing 
either the wild-type 17β-HSD10 or the Y168G mutant alongside APPswe (Figure 5.20). However, similar 
results were obtained with no marked increase in 4-HNE levels being observed (Figure 5.21). In addition, 
the generalised ROS probe, H2DCFDA, and the superoxide probe, MitoSox, also showed no increase in 
oxidative stress, although due to time constraints these experiments were not repeated adequately and 
thus provide only anecdotal evidence.  
A number of experimental differences may explain these alternate results. Firstly, the original reports 
regarding the toxic interaction between the 17β-HSD10 enzyme and Aβ reported subcellular localisation 
Figure 5.23. 17β-HSD10 Q165H Mutation. The 17β-HSD10 enzyme was co-crystalised with bound cofactor, NAD+ 
(stick diagram). The Q165H mutation was found to reside outside of the cofactor binding site. 
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of 17β-HSD10 to the endoplasmic reticulum and, upon topical treatment with Aβ, a mobilisation to the 
plasma membrane337. The former result has now categorically been disproven, with the 17β-HSD10 
localised solely to the mitochondria313, whilst the latter has yet to be repeated. However, both of these 
observations correlate with those made by Dr. Margaret Taylor, who noted that upon overexpression the 
localisation of the 17β-HSD10 changes, becoming dispersed throughout the cell and localised to the 
plasma membrane (unpublished observations). Such observations prompted the addition of a N-terminal 
mitochondrial targeting sequence to our 17β-HSD10 overexpression construct, ensuring correct 
subcellular localisation, a plasmid which has become the archetypal mammalian expression construct 
used within the group.  Therefore, the observed cytotoxicity may in fact represent an artefact caused by 
the overexpression methodology utilised. Subsequent work using transgenic mice employed the PDGF-β 
promoter to drive the production of APP and 17β-HSD10, ensuring neuronal expression, but again no 
mitochondrial targeting sequence was used raising the possibility that the same artefact may have been 
propagated303,339,340. Such a theory would be reasonably easy to test, requiring a round of site directed 
mutagenesis to remove the mitochondrial targeting sequence from our expression construct, the 
subsequent overexpression of non-tagged 17β-HSD10 and APPswe, and a second appraisal of toxicity. 
Should toxicity now be apparent, it would suggest such an effect was indeed responsible.  
In which case, a thorough appraisal of the subcellular localisation of the 17β-HSD10 enzyme in the AD 
brain should be undertaken. The expression of the 17β-HSD10 enzyme has been shown to be increased 
in the Alzheimer’s diseased state, 28% in the temporal grey matter and 40% in the hippocampus303, and 
573% in the CSF341. Should the subcellular localisation of the 17β-HSD10 enzyme change in the AD brain 
in a similar manner to that seen in cell culture based experiments, the conclusions derived from the work 
conducted of Shi du Yan et al. would remain valid, and he therapeutic targeting of 17β-HSD10 would 
remain viable. 
 
 
Figure 5.24. 17β-HSD10 upregulation in the AD brain. The expression of the 17β-HSD10 enzyme has been shown to 
increase approximately 28% in the temporal grey matter, and 40% in the hippocampus of patients with AD. Figure 
reproduced from303. 
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An alternative explanation may relate to compensatory mechanisms described previously in both 
transgenic mAPP/17β-HSD10 mice and in the brains of AD patients. In both transgenic mice and brain 
samples derived from Alzheimer’s diseased patients an increase in the level of expression of endophilin I 
and peroxiredoxin II have been reported, linked to cell death and antioxidant activities, respectively342,343.  
 
Following transfection, a marked increase in cell death was apparent in cells harbouring the pcDNA4-
APPswe construct as compared to the pcDNA4 empty vector and as such, the surviving cells may represent 
a subpopulation better able to cope with the elevated levels of stress associated with the 17β-HSD10/Aβ 
interaction. Dead or dying cells would have been lost during the wash steps required for lysate generation, 
biasing results and possibly explaining the lack of 4-HNE signal observed here. Such a theory could be 
tested in two ways, firstly a western blot for peroxiredoxin II could be performed using the lysates derived 
previously, should a significant upregulation be observed in samples transfected with both 17β-HSD10 
and Aβ it would suggest such a compensatory mechanism is at work. Alternatively, the transfections could 
be repeated and an LDH assay performed using culture media derived from each condition, such an assay 
would retain the signal derived from dead and dying cells, giving a more representative appraisal of 
cellular stress. If such an effect were to be observed, it may prove advantageous to generate clonal cell 
lines expressing equal levels of active and inactive 17β-HSD10 enzyme and introduce a tetracycline 
mediated control of APPswe expression, allowing cells to be propagated to a sufficient level prior to 
induction and preventing the selection pressure induced by the constitutive stable expression employed 
here.  
 
 
 
 
Figure 5.25. Peroxiredoxin II upregulation. The expression of the antioxidant enzyme peroxiredoxin II has been 
shown to be elevated in the brains of mAPP/17β-HSD10 transgenic mice (left panel) and in the brains of Alzheimer’s 
diseased patients (right panel). Figures reproduced from342. 
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Chapter 6 - Final Discussion and Future Perspectives 
As a result of this project we now have expression constructs and optimised purification protocols for our 
target enzyme, 17β-HSD10 (Chapter 3), and two related enzymes showing close structural homology, 17β-
HSD8 and 17β-HSD14 (Chapter 4). In addition, we have robust enzyme activity assays developed for each, 
allowing the effect of small molecules of interest on catalytic activity to be assessed in a reasonably high-
throughput manner, currently 96-well format.  
Following small molecule screening experiments conducted herein, we have identified a subset of 
Frentizole derived compounds which appear capable of inhibiting the catalytic activity of the 17β-HSD10 
enzyme (Chapter 3: Section 3.06) and on the basis of a comparatively large screen of the NCI Diversity IV 
library we have a range of inhibitor molecules which are currently in the process of being further 
evaluated (Chapter 3: Section 3.13). In addition, early in 2015, we entered into a collaboration with a large 
European screening initiative, representing a collaboration between academic and industrial partners and 
resulting in the screening of hundreds of thousands of small molecules against our target. A qualified hit-
list of validated inhibitors is expected in the near future. As a small academic institution, our ability to 
characterise such a large number of potential hit compounds is limited, and as such the assays developed 
here will prove vital, allowing the efficient triage on compounds on the basis of potency, specificity, and 
hopefully, with some optimisation, efficacy in a cellular environment, allowing resources to be channelled 
into only the most promising hit molecules. 
One consistent frustration within the group has been the inability to generate crystal structures of the 
17β-HSD10 enzyme in complex with inhibitor, meaning that the design of subsequent compound series 
has up to this point been based on trial and error, and although progress is being made, as evidenced by 
the enhanced potency and solubility seen with compound K1093 (Chapter 3: Figure 3.21) as compared to 
initial hits K690 and K691 (Chapter 3: Figure 3.19), it has been slow. However, we are now working in 
collaboration with the Structural Genomics Consortium in Oxford, renowned for their structural biology 
expertise and who have previously successfully crystallised the 17β-HSD10 enzyme (PDB: 2O23), to 
generate a crystal structure of the 17β-HSD10 in complex with inhibitor. The analysis of such a model will 
hopefully lead to a more detailed understanding of the interactions formed between protein and ligand, 
allowing subsequent series to be designed in a more logical fashion and thereby expediting the 
development process. The results of the kinetic based investigations conducted here (Chapter 3: Section 
3.08) suggested that Frentizole derived inhibitors, K690 and K691, act via a non-competitive mechanism 
and therefore both cofactor and substrate may be of use in stabilising the enzyme-inhibitor complex, likely 
improving the chances of crystal formation, as evidenced by all known crystal structures requiring the 
presence of a co-crystallising ligand. Now optimised, such experiments could be swiftly performed to 
characterise the mechanism of inhibition utilised by other inhibiting molecules identified as a result of the 
NCI Diversity IV screen or as part of the large-scale screen currently being undertaken, guiding subsequent 
crystallography experiments. 
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The lack of correlation between experiments performed here (Chapter 5), demonstrating no enhanced 
toxicity with overexpression of 17β-HSD10 and Aβ, and those conducted previously, where overt toxicity 
was reported337,338, is disconcerting. In my opinion, a detailed appraisal of the cytotoxic effects of the 17β-
HSD10/Aβ complex should be performed as a matter of urgency, simultaneously validating the inhibition 
of the 17β-HSD10 enzyme as a therapeutic strategy in treating Alzheimer’s disease and potentially 
generating an extremely useful screening tool. Several reasons could underlie the aforementioned 
discrepancy, most notably; the altered subcellular localisation of the 17β-HSD10 enzyme upon 
overexpression and the lack of a mitochondrial targeting sequence being used in experiments reporting 
toxicity337,338, the differing methods of assessing toxicity (previously immunocytochemistry and here 
western blotting) and possible compensatory mechanisms as a result of stably overexpressing these toxic 
components (detailed in Chapter 5 – Discussion).  
Should the toxic effects of the 17β-HSD10/Aβ complex be confirmed, the 17β-HSD10 enzyme offers an 
attractive drug target for the treatment of AD. It has been suggested that the failure of plaque clearing 
therapeutics, AN1792, Solaneuzumab and Bapenuzumab, to improve cognitive performance may relate 
to the fact that intervention was made too late in the disease process. Such a theory is supported by 
mouse models expressing ADAD associated mutants of the APP protein, where cognitive defects become 
apparent prior to plaque deposition270-272, and in AD patients where plaque burden does not correlate 
with disease severity and patients with plaque deposition sufficient for a diagnosis of AD, remain 
cognitively normal273,276. Interestingly, soluble oligomeric forms of Aβ, the forms which are known to 
interact with the 17β-HSD10 enzyme338,349, have been suggested as the true disease driving form of Aβ in 
the AD brain, correlating with synapse loss285,292,293, which is in of itself is the strongest correlate for 
cognitive performance274. The formation of oligomeric forms of Aβ has been shown to precede plaque 
deposition and thus the formation of the cytotoxic 17β-HSD10/Aβ may represent an early event in the AD 
brain, driving mitochondrial dysfunction and the synapatic loss characteristic of the disease, making it an 
attractive target for intervention. 
Aside from its potential role in AD, 17β-HSD10 has also been implicated in a range of additional disorders. 
MHBD deficiency is caused by mutations in the gene encoding 17β-HSD10 and, although originally 
attributed to a defect in isoleucine degradation316, it now Instead appears to be related to perturbations 
of a structural role performed by the 17β-HSD10 enzyme in the formation of the mtRNase P complex320, 
with disease causing mutations appearing to affect its ability to interact with and thereby stabilise the 
TRMT10C subunit330,377. One common disease causing mutation, R130C, has been suggested to destabilise 
the 17β-HSD10 enzyme, as evidenced by a time-dependent decrease in activity and a decrease in the level 
of detectable protein in patient fibroblasts320. As a result of work conducted by Xie et al. we know that 
Frentizole, and two derivatives thereof (Figure 6.01) are capable of perturbing the 17β-HSD10/Aβ 
interaction344, and as a result of work conducted here, we know that these molecules are not capable of 
directly inhibiting the catalytic activity of the enzyme, but several derivatives are, suggesting that the 
perturbation of the 17β-HSD10/Aβ interaction is likely due to an interaction with the 17β-HSD10 enzyme 
Chapter 6: Final Discussion and Future Perspectives 
207 
 
as opposed to Aβ (Figures 3.15 and 3.16). In concordance with this one inhibiting derivative, K1093 was 
found to induce a marked stabilisation of the enzyme, as measured using DSF, indicative of a direct 
protein-ligand interaction (Figure 3.30).  
 
As such, it may be interesting to clone and purify the R130C mutant of the 17β-HSD10 enzyme and 
perform differential scanning fluorimetry in the presence of Frentizole derivatives, particularly K1093 
(Figures 3.15 and 3.16) to assess whether any are capable of stabilising the R130C mutant enzyme 
potentially allowing the formation of a functional mtRNase P complex and thereby generating a novel 
therapeutic agent against the currently untreatable MHBD deficiency. Such an effect could be assessed in 
cell culture by introducing the R130C mutation using CRISPR or by culturing patient fibroblasts and 
assessing the ability of such a compound to reverse mutation induced mitochondrial abnormalities using 
electron microscopy, as was done previously320. 
In addition to being implicated in both Alzheimer’s disease and MHDB deficiency, the 17β-HSD10 enzyme 
has also been suggested to play a role in certain forms of cancer. Firstly, an approximately 3-fold 
upregulation of 17β-HSD10 has been reported in epithelial cells derived from malignant prostate tumours, 
resulting in elevated synthesis of DHT, a potent androgen, which may promote tumour growth378. 17β-
HSD10 overexpression has also been shown to promote cell proliferation both in in vitro and, using a 
xenograft based mouse model, in vivo, as well as increasing cellular resistance to oxidative stress379. 
Upregulation of 17β-HSD10 has also been shown in patients with certain forms of osteosarcomas who fail 
to respond to chemotherapy, and was proposed as a potential target for inervention380 and also in 
prostate cancer metastases381. 
On the basis of these observations, it appears that, although a focus has been placed here on Alzheimer’s 
disease, the assays developed and the compounds identified as a result of this project may have far 
Figure 6.01. 17β-HSD10/Aβ interaction perturbing compounds. Frentizole, the parent compound was found to be 
capable of disrupting the interaction between the 17β-HSD10 enzyme and Aβ (IC50>200 μM) derivatives 1 and 2 were 
found to be markedly more potent (IC50<10 μM). Redrawn from344.  
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reaching applications in both the treatment of MHBD deficiency and in the development of novel 
therapeutic agents for the treatment of certain forms of cancer.  
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Appendix:  
Appendix A: Protein Mass Spectrometry 
17β-HSD10 Mass Spectrometry 
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17β-HSD8 Mass Spectrometry 
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17β-HSD14 Mass Spectrometry 
 
 
 
  
Appendix 
230 
 
Appendix B: DNA Construct Sequencing 
pcDNA3-HSD10: 
ATGTCCGTCCTGACGCCGCTGCTGCTGCGGGGCTTGACAGGCTCGGCCCGGCGGCTCCCAGTGCCGCGCGCCAAGATC
CATTCGTTGGGGGATCCACCGGTCGCCGAATTCACCATGGCAGCAGCGTGTCGGAGCGTGAAGGGCCTGGTGGCGGTA
ATAACCGGAGGAGCCTCGGGCCTGGGCCTGGCCACGGCGGAGCGACTTGTGGGGCAGGGAGCCTCTGCTGTGCTTCTG
GACCTGCCCAACTCGGGTGGGGAGGCCCAAGCCAAGAAGTTAGGAAACAACTGCGTTTTCGCCCCAGCCGACGTGACC
TCTGAGAAGGATGTGCAAACAGCTCTGGCTCTAGCAAAAGGAAAGTTTGGCCGTGTGGATGTAGCTGTCAACTGTGCA
GGCATCGCGGTGGCTAGCAAGACGTACAACTTAAAGAAGGGCCAGACCCATACCTTGGAAGACTTCCAGCGAGTTCTT
GATGTGAATCTCATGGGCACCTTCAATGTGATCCGCCTGGTGGCTGGTGAGATGGGCCAGAATGAACCAGACCAGGGA
GGCCAACGTGGGGTCATCATCAACACTGCCAGTGTGGCTGCCTTCGAGGGTCAGGTTGGACAAGCTGCATACTCTGCT
TCCAAGGGGGGAATAGTGGGCATGACACTGCCCATTGCTCGGGATCTGGCTCCCATAGGTATCCGGGTGATGACCATT
GCCCCAGGTCTGTTTGGCACCCCACTGCTGACCAGCCTCCCAGAGAAAGTGTGCAACTTCTTGGCCAGCCAAGTGCCC
TTCCCTAGCCGACTGGGTGACCCTGCTGAGTATGCTCACCTCGTACAGGCCATCATCGAGAACCCATTCCTCAATGGA
GAGGTCATCCGGCTGGATGGGGCCATTCGTATGCAGCCTTGA 
 
 
Orange = MTS-Sequence 
 
 
 
Alignment of Sequence_1:  [HSD10 cDNA Sequence] with  Sequence_2: 
[Patrick_pcDNA3-HSD10_F-T7-150916-03-62(1).seq.xdna]  
 
Similarity : 786/786 (100.00 %) 
 
Seq_1  1     ATGGCAGCAGCGTGTCGGAGCGTGAAGGGCCTGGTGGCGGTAATAACCGGAGGAGCCTCG  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     ATGGCAGCAGCGTGTCGGAGCGTGAAGGGCCTGGTGGCGGTAATAACCGGAGGAGCCTCG  60 
 
 
Seq_1  61    GGCCTGGGCCTGGCCACGGCGGAGCGACTTGTGGGGCAGGGAGCCTCTGCTGTGCTTCTG  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    GGCCTGGGCCTGGCCACGGCGGAGCGACTTGTGGGGCAGGGAGCCTCTGCTGTGCTTCTG  120 
 
 
Seq_1  121   GACCTGCCCAACTCGGGTGGGGAGGCCCAAGCCAAGAAGTTAGGAAACAACTGCGTTTTC  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   GACCTGCCCAACTCGGGTGGGGAGGCCCAAGCCAAGAAGTTAGGAAACAACTGCGTTTTC  180 
 
 
Seq_1  181   GCCCCAGCCGACGTGACCTCTGAGAAGGATGTGCAAACAGCTCTGGCTCTAGCAAAAGGA  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   GCCCCAGCCGACGTGACCTCTGAGAAGGATGTGCAAACAGCTCTGGCTCTAGCAAAAGGA  240 
 
 
Seq_1  241   AAGTTTGGCCGTGTGGATGTAGCTGTCAACTGTGCAGGCATCGCGGTGGCTAGCAAGACG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   AAGTTTGGCCGTGTGGATGTAGCTGTCAACTGTGCAGGCATCGCGGTGGCTAGCAAGACG  300 
 
 
Seq_1  301   TACAACTTAAAGAAGGGCCAGACCCATACCTTGGAAGACTTCCAGCGAGTTCTTGATGTG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   TACAACTTAAAGAAGGGCCAGACCCATACCTTGGAAGACTTCCAGCGAGTTCTTGATGTG  360 
 
 
Seq_1  361   AATCTCATGGGCACCTTCAATGTGATCCGCCTGGTGGCTGGTGAGATGGGCCAGAATGAA  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   AATCTCATGGGCACCTTCAATGTGATCCGCCTGGTGGCTGGTGAGATGGGCCAGAATGAA  420 
 
 
Seq_1  421   CCAGACCAGGGAGGCCAACGTGGGGTCATCATCAACACTGCCAGTGTGGCTGCCTTCGAG  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   CCAGACCAGGGAGGCCAACGTGGGGTCATCATCAACACTGCCAGTGTGGCTGCCTTCGAG  480 
 
 
Seq_1  481   GGTCAGGTTGGACAAGCTGCATACTCTGCTTCCAAGGGGGGAATAGTGGGCATGACACTG  540 
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             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  481   GGTCAGGTTGGACAAGCTGCATACTCTGCTTCCAAGGGGGGAATAGTGGGCATGACACTG  540 
 
 
Seq_1  541   CCCATTGCTCGGGATCTGGCTCCCATAGGTATCCGGGTGATGACCATTGCCCCAGGTCTG  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   CCCATTGCTCGGGATCTGGCTCCCATAGGTATCCGGGTGATGACCATTGCCCCAGGTCTG  600 
 
 
Seq_1  601   TTTGGCACCCCACTGCTGACCAGCCTCCCAGAGAAAGTGTGCAACTTCTTGGCCAGCCAA  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  601   TTTGGCACCCCACTGCTGACCAGCCTCCCAGAGAAAGTGTGCAACTTCTTGGCCAGCCAA  660 
 
 
Seq_1  661   GTGCCCTTCCCTAGCCGACTGGGTGACCCTGCTGAGTATGCTCACCTCGTACAGGCCATC  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  661   GTGCCCTTCCCTAGCCGACTGGGTGACCCTGCTGAGTATGCTCACCTCGTACAGGCCATC  720 
 
 
Seq_1  721   ATCGAGAACCCATTCCTCAATGGAGAGGTCATCCGGCTGGATGGGGCCATTCGTATGCAG  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  721   ATCGAGAACCCATTCCTCAATGGAGAGGTCATCCGGCTGGATGGGGCCATTCGTATGCAG  780 
 
 
Seq_1  781   CCTTGA  786 
             |||||| 
Seq_2  781   CCTTGA  786 
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pcDNA3-HSD10: Q165H Mutation 
ATGGCAGCAGCGTGTCGGAGCGTGAAGGGCCTGGTGGCGGTAATAACCGGAGGAGCCTCGGGCCTGGGCCTGGCCACG
GCGGAGCGACTTGTGGGGCAGGGAGCCTCTGCTGTGCTTCTGGACCTGCCCAACTCGGGTGGGGAGGCCCAAGCCAAG
AAGTTAGGAAACAACTGCGTTTTCGCCCCAGCCGACGTGACCTCTGAGAAGGATGTGCAAACAGCTCTGGCTCTAGCA
AAAGGAAAGTTTGGCCGTGTGGATGTAGCTGTCAACTGTGCAGGCATCGCGGTGGCTAGCAAGACGTACAACTTAAAG
AAGGGCCAGACCCATACCTTGGAAGACTTCCAGCGAGTTCTTGATGTGAATCTCATGGGCACCTTCAATGTGATCCGC
CTGGTGGCTGGTGAGATGGGCCAGAATGAACCAGACCAGGGAGGCCAACGTGGGGTCATCATCAACACTGCCAGTGTG
GCTGCCTTCGAGGGTCAGGTTGGACAcGCTGCATACTCTGCTTCCAAGGGGGGAATAGTGGGCATGACACTGCCCATT
GCTCGGGATCTGGCTCCCATAGGTATCCGGGTGATGACCATTGCCCCAGGTCTGTTTGGCACCCCACTGCTGACCAGC
CTCCCAGAGAAAGTGTGCAACTTCTTGGCCAGCCAAGTGCCCTTCCCTAGCCGACTGGGTGACCCTGCTGAGTATGCT
CACCTCGTACAGGCCATCATCGAGAACCCATTCCTCAATGGAGAGGTCATCCGGCTGGATGGGGCCATTCGTATGCAG
CCTTGA 
Red = Q165H mutation 
 
Alignment of Sequence_1:  [Q165H_2_FW-T7-190815-09-72.seq.xdna] with  
Sequence_2: [HSD10 cDNA Sequence]  
 
Similarity : 785/786 (99.87 %) 
 
             M  A  A  A  C  R  S  V  K  G  L  V  A  V  I  T  G  G  A  S   
Seq_1  1     ATGGCAGCAGCGTGTCGGAGCGTGAAGGGCCTGGTGGCGGTAATAACCGGAGGAGCCTCG  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     ATGGCAGCAGCGTGTCGGAGCGTGAAGGGCCTGGTGGCGGTAATAACCGGAGGAGCCTCG  60 
             M  A  A  A  C  R  S  V  K  G  L  V  A  V  I  T  G  G  A  S   
 
 
             G  L  G  L  A  T  A  E  R  L  V  G  Q  G  A  S  A  V  L  L   
Seq_1  61    GGCCTGGGCCTGGCCACGGCGGAGCGACTTGTGGGGCAGGGAGCCTCTGCTGTGCTTCTG  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    GGCCTGGGCCTGGCCACGGCGGAGCGACTTGTGGGGCAGGGAGCCTCTGCTGTGCTTCTG  120 
             G  L  G  L  A  T  A  E  R  L  V  G  Q  G  A  S  A  V  L  L   
 
 
             D  L  P  N  S  G  G  E  A  Q  A  K  K  L  G  N  N  C  V  F   
Seq_1  121   GACCTGCCCAACTCGGGTGGGGAGGCCCAAGCCAAGAAGTTAGGAAACAACTGCGTTTTC  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   GACCTGCCCAACTCGGGTGGGGAGGCCCAAGCCAAGAAGTTAGGAAACAACTGCGTTTTC  180 
             D  L  P  N  S  G  G  E  A  Q  A  K  K  L  G  N  N  C  V  F   
 
 
             A  P  A  D  V  T  S  E  K  D  V  Q  T  A  L  A  L  A  K  G   
Seq_1  181   GCCCCAGCCGACGTGACCTCTGAGAAGGATGTGCAAACAGCTCTGGCTCTAGCAAAAGGA  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   GCCCCAGCCGACGTGACCTCTGAGAAGGATGTGCAAACAGCTCTGGCTCTAGCAAAAGGA  240 
             A  P  A  D  V  T  S  E  K  D  V  Q  T  A  L  A  L  A  K  G   
 
 
             K  F  G  R  V  D  V  A  V  N  C  A  G  I  A  V  A  S  K  T   
Seq_1  241   AAGTTTGGCCGTGTGGATGTAGCTGTCAACTGTGCAGGCATCGCGGTGGCTAGCAAGACG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   AAGTTTGGCCGTGTGGATGTAGCTGTCAACTGTGCAGGCATCGCGGTGGCTAGCAAGACG  300 
             K  F  G  R  V  D  V  A  V  N  C  A  G  I  A  V  A  S  K  T   
 
 
             Y  N  L  K  K  G  Q  T  H  T  L  E  D  F  Q  R  V  L  D  V   
Seq_1  301   TACAACTTAAAGAAGGGCCAGACCCATACCTTGGAAGACTTCCAGCGAGTTCTTGATGTG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   TACAACTTAAAGAAGGGCCAGACCCATACCTTGGAAGACTTCCAGCGAGTTCTTGATGTG  360 
             Y  N  L  K  K  G  Q  T  H  T  L  E  D  F  Q  R  V  L  D  V   
 
 
             N  L  M  G  T  F  N  V  I  R  L  V  A  G  E  M  G  Q  N  E   
Seq_1  361   AATCTCATGGGCACCTTCAATGTGATCCGCCTGGTGGCTGGTGAGATGGGCCAGAATGAA  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   AATCTCATGGGCACCTTCAATGTGATCCGCCTGGTGGCTGGTGAGATGGGCCAGAATGAA  420 
             N  L  M  G  T  F  N  V  I  R  L  V  A  G  E  M  G  Q  N  E   
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             P  D  Q  G  G  Q  R  G  V  I  I  N  T  A  S  V  A  A  F  E   
Seq_1  421   CCAGACCAGGGAGGCCAACGTGGGGTCATCATCAACACTGCCAGTGTGGCTGCCTTCGAG  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   CCAGACCAGGGAGGCCAACGTGGGGTCATCATCAACACTGCCAGTGTGGCTGCCTTCGAG  480 
             P  D  Q  G  G  Q  R  G  V  I  I  N  T  A  S  V  A  A  F  E   
 
 
             G  Q  V  G  H  A  A  Y  S  A  S  K  G  G  I  V  G  M  T  L   
Seq_1  481   GGTCAGGTTGGACACGCTGCATACTCTGCTTCCAAGGGGGGAATAGTGGGCATGACACTG  540 
             ||||||||||||||#||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  481   GGTCAGGTTGGACAAGCTGCATACTCTGCTTCCAAGGGGGGAATAGTGGGCATGACACTG  540 
             G  Q  V  G  Q  A  A  Y  S  A  S  K  G  G  I  V  G  M  T  L   
 
 
             P  I  A  R  D  L  A  P  I  G  I  R  V  M  T  I  A  P  G  L   
Seq_1  541   CCCATTGCTCGGGATCTGGCTCCCATAGGTATCCGGGTGATGACCATTGCCCCAGGTCTG  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   CCCATTGCTCGGGATCTGGCTCCCATAGGTATCCGGGTGATGACCATTGCCCCAGGTCTG  600 
             P  I  A  R  D  L  A  P  I  G  I  R  V  M  T  I  A  P  G  L   
 
 
             F  G  T  P  L  L  T  S  L  P  E  K  V  C  N  F  L  A  S  Q   
Seq_1  601   TTTGGCACCCCACTGCTGACCAGCCTCCCAGAGAAAGTGTGCAACTTCTTGGCCAGCCAA  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  601   TTTGGCACCCCACTGCTGACCAGCCTCCCAGAGAAAGTGTGCAACTTCTTGGCCAGCCAA  660 
             F  G  T  P  L  L  T  S  L  P  E  K  V  C  N  F  L  A  S  Q   
 
 
             V  P  F  P  S  R  L  G  D  P  A  E  Y  A  H  L  V  Q  A  I   
Seq_1  661   GTGCCCTTCCCTAGCCGACTGGGTGACCCTGCTGAGTATGCTCACCTCGTACAGGCCATC  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  661   GTGCCCTTCCCTAGCCGACTGGGTGACCCTGCTGAGTATGCTCACCTCGTACAGGCCATC  720 
             V  P  F  P  S  R  L  G  D  P  A  E  Y  A  H  L  V  Q  A  I   
 
 
             I  E  N  P  F  L  N  G  E  V  I  R  L  D  G  A  I  R  M  Q   
Seq_1  721   ATCGAGAACCCATTCCTCAATGGAGAGGTCATCCGGCTGGATGGGGCCATTCGTATGCAG  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  721   ATCGAGAACCCATTCCTCAATGGAGAGGTCATCCGGCTGGATGGGGCCATTCGTATGCAG  780 
             I  E  N  P  F  L  N  G  E  V  I  R  L  D  G  A  I  R  M  Q   
 
 
             P  *   
Seq_1  781   CCTTGA  786 
             |||||| 
Seq_2  781   CCTTGA  786 
             P  *   
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pcDNA3-HSD10: Y168G Mutation 
ATGGCAGCAGCGTGTCGGAGCGTGAAGGGCCTGGTGGCGGTAATAACCGGAGGAGCCTCGGGCCTGGGCCTGGCCACG
GCGGAGCGACTTGTGGGGCAGGGAGCCTCTGCTGTGCTTCTGGACCTGCCCAACTCGGGTGGGGAGGCCCAAGCCAAG
AAGTTAGGAAACAACTGCGTTTTCGCCCCAGCCGACGTGACCTCTGAGAAGGATGTGCAAACAGCTCTGGCTCTAGCA
AAAGGAAAGTTTGGCCGTGTGGATGTAGCTGTCAACTGTGCAGGCATCGCGGTGGCTAGCAAGACGTACAACTTAAAG
AAGGGCCAGACCCATACCTTGGAAGACTTCCAGCGAGTTCTTGATGTGAATCTCATGGGCACCTTCAATGTGATCCGC
CTGGTGGCTGGTGAGATGGGCCAGAATGAACCAGACCAGGGAGGCCAACGTGGGGTCATCATCAACACTGCCAGTGTG
GCTGCCTTCGAGGGTCAGGTTGGACAAGCTGCAggCTCTGCTTCCAAGGGGGGAATAGTGGGCATGACACTGCCCATT
GCTCGGGATCTGGCTCCCATAGGTATCCGGGTGATGACCATTGCCCCAGGTCTGTTTGGCACCCCACTGCTGACCAGC
CTCCCAGAGAAAGTGTGCAACTTCTTGGCCAGCCAAGTGCCCTTCCCTAGCCGACTGGGTGACCCTGCTGAGTATGCT
CACCTCGTACAGGCCATCATCGAGAACCCATTCCTCAATGGAGAGGTCATCCGGCTGGATGGGGCCATTCGTATGCAG
CCTTGA 
 
Red = Y168G mutation 
 
Alignment of Sequence_1:  [Y168G _ Forward-T7-090916-01-26.seq.xdna] with  
Sequence_2: [HSD10 cDNA Sequence]  
 
Similarity : 784/786 (99.75 %) 
 
             M  A  A  A  C  R  S  V  K  G  L  V  A  V  I  T  G  G  A  S   
Seq_1  1     ATGGCAGCAGCGTGTCGGAGCGTGAAGGGCCTGGTGGCGGTAATAACCGGAGGAGCCTCG  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     ATGGCAGCAGCGTGTCGGAGCGTGAAGGGCCTGGTGGCGGTAATAACCGGAGGAGCCTCG  60 
             M  A  A  A  C  R  S  V  K  G  L  V  A  V  I  T  G  G  A  S   
 
 
             G  L  G  L  A  T  A  E  R  L  V  G  Q  G  A  S  A  V  L  L   
Seq_1  61    GGCCTGGGCCTGGCCACGGCGGAGCGACTTGTGGGGCAGGGAGCCTCTGCTGTGCTTCTG  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    GGCCTGGGCCTGGCCACGGCGGAGCGACTTGTGGGGCAGGGAGCCTCTGCTGTGCTTCTG  120 
             G  L  G  L  A  T  A  E  R  L  V  G  Q  G  A  S  A  V  L  L   
 
 
             D  L  P  N  S  G  G  E  A  Q  A  K  K  L  G  N  N  C  V  F   
Seq_1  121   GACCTGCCCAACTCGGGTGGGGAGGCCCAAGCCAAGAAGTTAGGAAACAACTGCGTTTTC  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   GACCTGCCCAACTCGGGTGGGGAGGCCCAAGCCAAGAAGTTAGGAAACAACTGCGTTTTC  180 
             D  L  P  N  S  G  G  E  A  Q  A  K  K  L  G  N  N  C  V  F   
 
 
             A  P  A  D  V  T  S  E  K  D  V  Q  T  A  L  A  L  A  K  G   
Seq_1  181   GCCCCAGCCGACGTGACCTCTGAGAAGGATGTGCAAACAGCTCTGGCTCTAGCAAAAGGA  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   GCCCCAGCCGACGTGACCTCTGAGAAGGATGTGCAAACAGCTCTGGCTCTAGCAAAAGGA  240 
             A  P  A  D  V  T  S  E  K  D  V  Q  T  A  L  A  L  A  K  G   
 
 
             K  F  G  R  V  D  V  A  V  N  C  A  G  I  A  V  A  S  K  T   
Seq_1  241   AAGTTTGGCCGTGTGGATGTAGCTGTCAACTGTGCAGGCATCGCGGTGGCTAGCAAGACG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   AAGTTTGGCCGTGTGGATGTAGCTGTCAACTGTGCAGGCATCGCGGTGGCTAGCAAGACG  300 
             K  F  G  R  V  D  V  A  V  N  C  A  G  I  A  V  A  S  K  T   
 
 
             Y  N  L  K  K  G  Q  T  H  T  L  E  D  F  Q  R  V  L  D  V   
Seq_1  301   TACAACTTAAAGAAGGGCCAGACCCATACCTTGGAAGACTTCCAGCGAGTTCTTGATGTG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   TACAACTTAAAGAAGGGCCAGACCCATACCTTGGAAGACTTCCAGCGAGTTCTTGATGTG  360 
             Y  N  L  K  K  G  Q  T  H  T  L  E  D  F  Q  R  V  L  D  V   
 
 
             N  L  M  G  T  F  N  V  I  R  L  V  A  G  E  M  G  Q  N  E   
Seq_1  361   AATCTCATGGGCACCTTCAATGTGATCCGCCTGGTGGCTGGTGAGATGGGCCAGAATGAA  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   AATCTCATGGGCACCTTCAATGTGATCCGCCTGGTGGCTGGTGAGATGGGCCAGAATGAA  420 
             N  L  M  G  T  F  N  V  I  R  L  V  A  G  E  M  G  Q  N  E   
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             P  D  Q  G  G  Q  R  G  V  I  I  N  T  A  S  V  A  A  F  E   
Seq_1  421   CCAGACCAGGGAGGCCAACGTGGGGTCATCATCAACACTGCCAGTGTGGCTGCCTTCGAG  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   CCAGACCAGGGAGGCCAACGTGGGGTCATCATCAACACTGCCAGTGTGGCTGCCTTCGAG  480 
             P  D  Q  G  G  Q  R  G  V  I  I  N  T  A  S  V  A  A  F  E   
 
 
             G  Q  V  G  Q  A  A  G  S  A  S  K  G  G  I  V  G  M  T  L   
Seq_1  481   GGTCAGGTTGGACAAGCTGCAGGCTCTGCTTCCAAGGGGGGAATAGTGGGCATGACACTG  540 
             |||||||||||||||||||||##||||||||||||||||||||||||||||||||||||| 
Seq_2  481   GGTCAGGTTGGACAAGCTGCATACTCTGCTTCCAAGGGGGGAATAGTGGGCATGACACTG  540 
             G  Q  V  G  Q  A  A  Y  S  A  S  K  G  G  I  V  G  M  T  L   
 
 
             P  I  A  R  D  L  A  P  I  G  I  R  V  M  T  I  A  P  G  L   
Seq_1  541   CCCATTGCTCGGGATCTGGCTCCCATAGGTATCCGGGTGATGACCATTGCCCCAGGTCTG  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   CCCATTGCTCGGGATCTGGCTCCCATAGGTATCCGGGTGATGACCATTGCCCCAGGTCTG  600 
             P  I  A  R  D  L  A  P  I  G  I  R  V  M  T  I  A  P  G  L   
 
 
             F  G  T  P  L  L  T  S  L  P  E  K  V  C  N  F  L  A  S  Q   
Seq_1  601   TTTGGCACCCCACTGCTGACCAGCCTCCCAGAGAAAGTGTGCAACTTCTTGGCCAGCCAA  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  601   TTTGGCACCCCACTGCTGACCAGCCTCCCAGAGAAAGTGTGCAACTTCTTGGCCAGCCAA  660 
             F  G  T  P  L  L  T  S  L  P  E  K  V  C  N  F  L  A  S  Q   
 
 
             V  P  F  P  S  R  L  G  D  P  A  E  Y  A  H  L  V  Q  A  I   
Seq_1  661   GTGCCCTTCCCTAGCCGACTGGGTGACCCTGCTGAGTATGCTCACCTCGTACAGGCCATC  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  661   GTGCCCTTCCCTAGCCGACTGGGTGACCCTGCTGAGTATGCTCACCTCGTACAGGCCATC  720 
             V  P  F  P  S  R  L  G  D  P  A  E  Y  A  H  L  V  Q  A  I   
 
 
             I  E  N  P  F  L  N  G  E  V  I  R  L  D  G  A  I  R  M  Q   
Seq_1  721   ATCGAGAACCCATTCCTCAATGGAGAGGTCATCCGGCTGGATGGGGCCATTCGTATGCAG  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  721   ATCGAGAACCCATTCCTCAATGGAGAGGTCATCCGGCTGGATGGGGCCATTCGTATGCAG  780 
             I  E  N  P  F  L  N  G  E  V  I  R  L  D  G  A  I  R  M  Q   
 
 
             P  *   
Seq_1  781   CCTTGA  786 
             |||||| 
Seq_2  781   CCTTGA  786 
             P  *   
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pcDNA4-APPswe 
ATGCTGCCCGGTTTGGCACTGCTCCTGCTGGCCGCCTGGACGGCTCGGGCGCTGGAGGTACCCACTGATGGTAATGCT
GGCCTGCTGGCTGAACCCCAGATTGCCATGTTCTGTGGCAGACTGAACATGCACATGAATGTCCAGAATGGGAAGTGG
GATTCAGATCCATCAGGGACCAAAACCTGCATTGATACCAAGGAAGGCATCCTGCAGTATTGCCAAGAAGTCTACCCT
GAACTGCAGATCACCAATGTGGTAGAAGCCAACCAACCAGTGACCATCCAGAACTGGTGCAAGCGGGGCCGCAAGCAG
TGCAAGACCCATCCCCACTTTGTGATTCCCTACCGCTGCTTAGTTGGTGAGTTTGTAAGTGATGCCCTTCTCGTTCCT
GACAAGTGCAAATTCTTACACCAGGAGAGGATGGATGTTTGCGAAACTCATCTTCACTGGCACACCGTCGCCAAAGAG
ACATGCAGTGAGAAGAGTACCAACTTGCATGACTACGGCATGTTGCTGCCCTGCGGAATTGACAAGTTCCGAGGGGTA
GAGTTTGTGTGTTGCCCACTGGCTGAAGAAAGTGACAATGTGGATTCTGCTGATGCGGAGGAGGATGACTCGGATGTC
TGGTGGGGCGGAGCAGACACAGACTATGCAGATGGGAGTGAAGACAAAGTAGTAGAAGTAGCAGAGGAGGAAGAAGTG
GCTGAGGTGGAAGAAGAAGAAGCCGATGATGACGAGGACGATGAGGATGGTGATGAGGTAGAGGAAGAGGCTGAGGAA
CCCTACGAAGAAGCCACAGAGAGAACCACCAGCATTGCCACCACCACCACCACCACCACAGAGTCTGTGGAAGAGGTG
GTTCGAGTTCCTACAACAGCAGCCAGTACCCCTGATGCCGTTGACAAGTATCTCGAGACACCTGGGGATGAGAATGAA
CATGCCCATTTCCAGAAAGCCAAAGAGAGGCTTGAGGCCAAGCACCGAGAGAGAATGTCCCAGGTCATGAGAGAATGG
GAAGAGGCAGAACGTCAAGCAAAGAACTTGCCTAAAGCTGATAAGAAGGCAGTTATCCAGCATTTCCAGGAGAAAGTG
GAATCTTTGGAACAGGAAGCAGCCAACGAGAGACAGCAGCTGGTGGAGACACACATGGCCAGAGTGGAAGCCATGCTC
AATGACCGCCGCCGCCTGGCCCTGGAGAACTACATCACCGCTCTGCAGGCTGTTCCTCCTCGGCCTCGTCACGTGTTC
AATATGCTAAAGAAGTATGTCCGCGCAGAACAGAAGGACAGACAGCACACCCTAAAGCATTTCGAGCATGTGCGCATG
GTGGATCCCAAGAAAGCCGCTCAGATCCGGTCCCAGGTTATGACACACCTCCGTGTGATTTATGAGCGCATGAATCAG
TCTCTCTCCCTGCTCTACAACGTGCCTGCAGTGGCCGAGGAGATTCAGGATGAAGTTGATGAGCTGCTTCAGAAAGAG
CAAAACTATTCAGATGACGTCTTGGCCAACATGATTAGTGAACCAAGGATCAGTTACGGAAACGATGCTCTCATGCCA
TCTTTGACCGAAACGAAAACCACCGTGGAGCTCCTTCCCGTGAATGGAGAGTTCAGCCTGGACGATCTCCAGCCGTGG
CATTCTTTTGGGGCTGACTCTGTGCCAGCCAACACAGAAAACGAAGTTGAGCCTGTTGATGCCCGCCCTGCTGCCGAC
CGAGGACTGACCACTCGACCAGGTTCTGGGTTGACAAATATCAAGACGGAGGAGATCTCTGAAGTGAAtcTGGATGCA
GAATTCCGACATGACTCAGGATATGAAGTTCATCATCAAAAATTGGTGTTCTTTGCAGAAGATGTGGGTTCAAACAAA
GGTGCAATCATTGGACTCATGGTGGGCGGTGTTGTCATAGCGACATGATCGTCATCACCTTGGTGATGCTGAAGAAGA
AACAGTACACATCCATTCATCATGGTGTGGTGGAGGTTGACGCCGCTGTCACCCCAGAGGAGCGCCACCTGTCCAAGA
TGCAGCAGAACGGCTACGAAAATCCAACCTACAAGTTCTTTGAGCAGAGCAGAACTAG 
Red = Swedish Mutation (KM670/671NL) 
Alignment of Sequence_1:  [pcDNA4_APPswe_F-CMV Fwd-150916-03-64(2).seq.xdna] 
with  Sequence_2: [APP695 cDNA Sequence]  
 
Similarity : 2086/2088 (99.90 %) 
             M  L  P  G  L  A  L  L  L  L  A  A  W  T  A  R  A  L  E  V   
Seq_1  1     ATGCTGCCCGGTTTGGCACTGCTCCTGCTGGCCGCCTGGACGGCTCGGGCGCTGGAGGTA  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     ATGCTGCCCGGTTTGGCACTGCTCCTGCTGGCCGCCTGGACGGCTCGGGCGCTGGAGGTA  60 
             M  L  P  G  L  A  L  L  L  L  A  A  W  T  A  R  A  L  E  V   
 
 
             P  T  D  G  N  A  G  L  L  A  E  P  Q  I  A  M  F  C  G  R   
Seq_1  61    CCCACTGATGGTAATGCTGGCCTGCTGGCTGAACCCCAGATTGCCATGTTCTGTGGCAGA  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    CCCACTGATGGTAATGCTGGCCTGCTGGCTGAACCCCAGATTGCCATGTTCTGTGGCAGA  120 
             P  T  D  G  N  A  G  L  L  A  E  P  Q  I  A  M  F  C  G  R   
 
 
             L  N  M  H  M  N  V  Q  N  G  K  W  D  S  D  P  S  G  T  K   
Seq_1  121   CTGAACATGCACATGAATGTCCAGAATGGGAAGTGGGATTCAGATCCATCAGGGACCAAA  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   CTGAACATGCACATGAATGTCCAGAATGGGAAGTGGGATTCAGATCCATCAGGGACCAAA  180 
             L  N  M  H  M  N  V  Q  N  G  K  W  D  S  D  P  S  G  T  K   
 
 
             T  C  I  D  T  K  E  G  I  L  Q  Y  C  Q  E  V  Y  P  E  L   
Seq_1  181   ACCTGCATTGATACCAAGGAAGGCATCCTGCAGTATTGCCAAGAAGTCTACCCTGAACTG  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   ACCTGCATTGATACCAAGGAAGGCATCCTGCAGTATTGCCAAGAAGTCTACCCTGAACTG  240 
             T  C  I  D  T  K  E  G  I  L  Q  Y  C  Q  E  V  Y  P  E  L   
 
 
             Q  I  T  N  V  V  E  A  N  Q  P  V  T  I  Q  N  W  C  K  R   
Seq_1  241   CAGATCACCAATGTGGTAGAAGCCAACCAACCAGTGACCATCCAGAACTGGTGCAAGCGG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   CAGATCACCAATGTGGTAGAAGCCAACCAACCAGTGACCATCCAGAACTGGTGCAAGCGG  300 
             Q  I  T  N  V  V  E  A  N  Q  P  V  T  I  Q  N  W  C  K  R   
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             G  R  K  Q  C  K  T  H  P  H  F  V  I  P  Y  R  C  L  V  G   
Seq_1  301   GGCCGCAAGCAGTGCAAGACCCATCCCCACTTTGTGATTCCCTACCGCTGCTTAGTTGGT  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   GGCCGCAAGCAGTGCAAGACCCATCCCCACTTTGTGATTCCCTACCGCTGCTTAGTTGGT  360 
             G  R  K  Q  C  K  T  H  P  H  F  V  I  P  Y  R  C  L  V  G   
 
 
             E  F  V  S  D  A  L  L  V  P  D  K  C  K  F  L  H  Q  E  R   
Seq_1  361   GAGTTTGTAAGTGATGCCCTTCTCGTTCCTGACAAGTGCAAATTCTTACACCAGGAGAGG  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   GAGTTTGTAAGTGATGCCCTTCTCGTTCCTGACAAGTGCAAATTCTTACACCAGGAGAGG  420 
             E  F  V  S  D  A  L  L  V  P  D  K  C  K  F  L  H  Q  E  R   
 
 
             M  D  V  C  E  T  H  L  H  W  H  T  V  A  K  E  T  C  S  E   
Seq_1  421   ATGGATGTTTGCGAAACTCATCTTCACTGGCACACCGTCGCCAAAGAGACATGCAGTGAG  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   ATGGATGTTTGCGAAACTCATCTTCACTGGCACACCGTCGCCAAAGAGACATGCAGTGAG  480 
             M  D  V  C  E  T  H  L  H  W  H  T  V  A  K  E  T  C  S  E   
 
 
             K  S  T  N  L  H  D  Y  G  M  L  L  P  C  G  I  D  K  F  R   
Seq_1  481   AAGAGTACCAACTTGCATGACTACGGCATGTTGCTGCCCTGCGGAATTGACAAGTTCCGA  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  481   AAGAGTACCAACTTGCATGACTACGGCATGTTGCTGCCCTGCGGAATTGACAAGTTCCGA  540 
             K  S  T  N  L  H  D  Y  G  M  L  L  P  C  G  I  D  K  F  R   
 
 
             G  V  E  F  V  C  C  P  L  A  E  E  S  D  N  V  D  S  A  D   
Seq_1  541   GGGGTAGAGTTTGTGTGTTGCCCACTGGCTGAAGAAAGTGACAATGTGGATTCTGCTGAT  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   GGGGTAGAGTTTGTGTGTTGCCCACTGGCTGAAGAAAGTGACAATGTGGATTCTGCTGAT  600 
             G  V  E  F  V  C  C  P  L  A  E  E  S  D  N  V  D  S  A  D   
 
 
             A  E  E  D  D  S  D  V  W  W  G  G  A  D  T  D  Y  A  D  G   
Seq_1  601   GCGGAGGAGGATGACTCGGATGTCTGGTGGGGCGGAGCAGACACAGACTATGCAGATGGG  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  601   GCGGAGGAGGATGACTCGGATGTCTGGTGGGGCGGAGCAGACACAGACTATGCAGATGGG  660 
             A  E  E  D  D  S  D  V  W  W  G  G  A  D  T  D  Y  A  D  G   
 
 
             S  E  D  K  V  V  E  V  A  E  E  E  E  V  A  E  V  E  E  E   
Seq_1  661   AGTGAAGACAAAGTAGTAGAAGTAGCAGAGGAGGAAGAAGTGGCTGAGGTGGAAGAAGAA  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  661   AGTGAAGACAAAGTAGTAGAAGTAGCAGAGGAGGAAGAAGTGGCTGAGGTGGAAGAAGAA  720 
             S  E  D  K  V  V  E  V  A  E  E  E  E  V  A  E  V  E  E  E   
 
 
             E  A  D  D  D  E  D  D  E  D  G  D  E  V  E  E  E  A  E  E   
Seq_1  721   GAAGCCGATGATGACGAGGACGATGAGGATGGTGATGAGGTAGAGGAAGAGGCTGAGGAA  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  721   GAAGCCGATGATGACGAGGACGATGAGGATGGTGATGAGGTAGAGGAAGAGGCTGAGGAA  780 
             E  A  D  D  D  E  D  D  E  D  G  D  E  V  E  E  E  A  E  E   
 
 
             P  Y  E  E  A  T  E  R  T  T  S  I  A  T  T  T  T  T  T  T   
Seq_1  781   CCCTACGAAGAAGCCACAGAGAGAACCACCAGCATTGCCACCACCACCACCACCACCACA  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  781   CCCTACGAAGAAGCCACAGAGAGAACCACCAGCATTGCCACCACCACCACCACCACCACA  840 
             P  Y  E  E  A  T  E  R  T  T  S  I  A  T  T  T  T  T  T  T   
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E  S  V  E  E  V  V  R  V  P  T  T  A  A  S  T  P  D  A  V   
Seq_1  841   GAGTCTGTGGAAGAGGTGGTTCGAGTTCCTACAACAGCAGCCAGTACCCCTGATGCCGTT  900 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  841   GAGTCTGTGGAAGAGGTGGTTCGAGTTCCTACAACAGCAGCCAGTACCCCTGATGCCGTT  900 
             E  S  V  E  E  V  V  R  V  P  T  T  A  A  S  T  P  D  A  V   
 
 
             D  K  Y  L  E  T  P  G  D  E  N  E  H  A  H  F  Q  K  A  K   
Seq_1  901   GACAAGTATCTCGAGACACCTGGGGATGAGAATGAACATGCCCATTTCCAGAAAGCCAAA  960 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  901   GACAAGTATCTCGAGACACCTGGGGATGAGAATGAACATGCCCATTTCCAGAAAGCCAAA  960 
             D  K  Y  L  E  T  P  G  D  E  N  E  H  A  H  F  Q  K  A  K   
 
 
             E  R  L  E  A  K  H  R  E  R  M  S  Q  V  M  R  E  W  E  E   
Seq_1  961   GAGAGGCTTGAGGCCAAGCACCGAGAGAGAATGTCCCAGGTCATGAGAGAATGGGAAGAG  
1020 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  961   GAGAGGCTTGAGGCCAAGCACCGAGAGAGAATGTCCCAGGTCATGAGAGAATGGGAAGAG  
1020 
             E  R  L  E  A  K  H  R  E  R  M  S  Q  V  M  R  E  W  E  E   
 
 
             A  E  R  Q  A  K  N  L  P  K  A  D  K  K  A  V  I  Q  H  F   
Seq_1  1021  GCAGAACGTCAAGCAAAGAACTTGCCTAAAGCTGATAAGAAGGCAGTTATCCAGCATTTC  
1080 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1021  GCAGAACGTCAAGCAAAGAACTTGCCTAAAGCTGATAAGAAGGCAGTTATCCAGCATTTC  
1080 
             A  E  R  Q  A  K  N  L  P  K  A  D  K  K  A  V  I  Q  H  F   
 
 
             Q  E  K  V  E  S  L  E  Q  E  A  A  N  E  R  Q  Q  L  V  E   
Seq_1  1081  CAGGAGAAAGTGGAATCTTTGGAACAGGAAGCAGCCAACGAGAGACAGCAGCTGGTGGAG  
1140 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1081  CAGGAGAAAGTGGAATCTTTGGAACAGGAAGCAGCCAACGAGAGACAGCAGCTGGTGGAG  
1140 
             Q  E  K  V  E  S  L  E  Q  E  A  A  N  E  R  Q  Q  L  V  E   
 
 
             T  H  M  A  R  V  E  A  M  L  N  D  R  R  R  L  A  L  E  N   
Seq_1  1141  ACACACATGGCCAGAGTGGAAGCCATGCTCAATGACCGCCGCCGCCTGGCCCTGGAGAAC  
1200 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1141  ACACACATGGCCAGAGTGGAAGCCATGCTCAATGACCGCCGCCGCCTGGCCCTGGAGAAC  
1200 
             T  H  M  A  R  V  E  A  M  L  N  D  R  R  R  L  A  L  E  N   
 
 
             Y  I  T  A  L  Q  A  V  P  P  R  P  R  H  V  F  N  M  L  K   
Seq_1  1201  TACATCACCGCTCTGCAGGCTGTTCCTCCTCGGCCTCGTCACGTGTTCAATATGCTAAAG  
1260 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1201  TACATCACCGCTCTGCAGGCTGTTCCTCCTCGGCCTCGTCACGTGTTCAATATGCTAAAG  
1260 
             Y  I  T  A  L  Q  A  V  P  P  R  P  R  H  V  F  N  M  L  K   
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             K  Y  V  R  A  E  Q  K  D  R  Q  H  T  L  K  H  F  E  H  V   
Seq_1  1261  AAGTATGTCCGCGCAGAACAGAAGGACAGACAGCACACCCTAAAGCATTTCGAGCATGTG  
1320 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1261  AAGTATGTCCGCGCAGAACAGAAGGACAGACAGCACACCCTAAAGCATTTCGAGCATGTG  
1320 
             K  Y  V  R  A  E  Q  K  D  R  Q  H  T  L  K  H  F  E  H  V   
 
 
             R  M  V  D  P  K  K  A  A  Q  I  R  S  Q  V  M  T  H  L  R   
Seq_1  1321  CGCATGGTGGATCCCAAGAAAGCCGCTCAGATCCGGTCCCAGGTTATGACACACCTCCGT  
1380 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1321  CGCATGGTGGATCCCAAGAAAGCCGCTCAGATCCGGTCCCAGGTTATGACACACCTCCGT  
1380 
             R  M  V  D  P  K  K  A  A  Q  I  R  S  Q  V  M  T  H  L  R   
 
 
             V  I  Y  E  R  M  N  Q  S  L  S  L  L  Y  N  V  P  A  V  A   
Seq_1  1381  GTGATTTATGAGCGCATGAATCAGTCTCTCTCCCTGCTCTACAACGTGCCTGCAGTGGCC  
1440 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1381  GTGATTTATGAGCGCATGAATCAGTCTCTCTCCCTGCTCTACAACGTGCCTGCAGTGGCC  
1440 
             V  I  Y  E  R  M  N  Q  S  L  S  L  L  Y  N  V  P  A  V  A   
 
 
             E  E  I  Q  D  E  V  D  E  L  L  Q  K  E  Q  N  Y  S  D  D   
Seq_1  1441  GAGGAGATTCAGGATGAAGTTGATGAGCTGCTTCAGAAAGAGCAAAACTATTCAGATGAC  
1500 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1441  GAGGAGATTCAGGATGAAGTTGATGAGCTGCTTCAGAAAGAGCAAAACTATTCAGATGAC  
1500 
             E  E  I  Q  D  E  V  D  E  L  L  Q  K  E  Q  N  Y  S  D  D   
 
 
             V  L  A  N  M  I  S  E  P  R  I  S  Y  G  N  D  A  L  M  P   
Seq_1  1501  GTCTTGGCCAACATGATTAGTGAACCAAGGATCAGTTACGGAAACGATGCTCTCATGCCA  
1560 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1501  GTCTTGGCCAACATGATTAGTGAACCAAGGATCAGTTACGGAAACGATGCTCTCATGCCA  
1560 
             V  L  A  N  M  I  S  E  P  R  I  S  Y  G  N  D  A  L  M  P   
 
 
             S  L  T  E  T  K  T  T  V  E  L  L  P  V  N  G  E  F  S  L   
Seq_1  1561  TCTTTGACCGAAACGAAAACCACCGTGGAGCTCCTTCCCGTGAATGGAGAGTTCAGCCTG  
1620 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1561  TCTTTGACCGAAACGAAAACCACCGTGGAGCTCCTTCCCGTGAATGGAGAGTTCAGCCTG  
1620 
             S  L  T  E  T  K  T  T  V  E  L  L  P  V  N  G  E  F  S  L   
 
 
             D  D  L  Q  P  W  H  S  F  G  A  D  S  V  P  A  N  T  E  N   
Seq_1  1621  GACGATCTCCAGCCGTGGCATTCTTTTGGGGCTGACTCTGTGCCAGCCAACACAGAAAAC  
1680 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1621  GACGATCTCCAGCCGTGGCATTCTTTTGGGGCTGACTCTGTGCCAGCCAACACAGAAAAC  
1680 
             D  D  L  Q  P  W  H  S  F  G  A  D  S  V  P  A  N  T  E  N   
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             E  V  E  P  V  D  A  R  P  A  A  D  R  G  L  T  T  R  P  G   
Seq_1  1681  GAAGTTGAGCCTGTTGATGCCCGCCCTGCTGCCGACCGAGGACTGACCACTCGACCAGGT  
1740 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1681  GAAGTTGAGCCTGTTGATGCCCGCCCTGCTGCCGACCGAGGACTGACCACTCGACCAGGT  
1740 
             E  V  E  P  V  D  A  R  P  A  A  D  R  G  L  T  T  R  P  G   
 
 
             S  G  L  T  N  I  K  T  E  E  I  S  E  V  N  L  D  A  E  F   
Seq_1  1741  TCTGGGTTGACAAATATCAAGACGGAGGAGATCTCTGAAGTGAATCTGGATGCAGAATTC  
1800 
             ||||||||||||||||||||||||||||||||||||||||||||##|||||||||||||| 
Seq_2  1741  TCTGGGTTGACAAATATCAAGACGGAGGAGATCTCTGAAGTGAAGATGGATGCAGAATTC  
1800 
             S  G  L  T  N  I  K  T  E  E  I  S  E  V  K  M  D  A  E  F   
 
 
             R  H  D  S  G  Y  E  V  H  H  Q  K  L  V  F  F  A  E  D  V   
Seq_1  1801  CGACATGACTCAGGATATGAAGTTCATCATCAAAAATTGGTGTTCTTTGCAGAAGATGTG  
1860 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1801  CGACATGACTCAGGATATGAAGTTCATCATCAAAAATTGGTGTTCTTTGCAGAAGATGTG  
1860 
             R  H  D  S  G  Y  E  V  H  H  Q  K  L  V  F  F  A  E  D  V   
 
 
             G  S  N  K  G  A  I  I  G  L  M  V  G  G  V  V  I  A  T  V   
Seq_1  1861  GGTTCAAACAAAGGTGCAATCATTGGACTCATGGTGGGCGGTGTTGTCATAGCGACAGTG  
1920 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1861  GGTTCAAACAAAGGTGCAATCATTGGACTCATGGTGGGCGGTGTTGTCATAGCGACAGTG  
1920 
             G  S  N  K  G  A  I  I  G  L  M  V  G  G  V  V  I  A  T  V   
 
 
             I  V  I  T  L  V  M  L  K  K  K  Q  Y  T  S  I  H  H  G  V   
Seq_1  1921  ATCGTCATCACCTTGGTGATGCTGAAGAAGAAACAGTACACATCCATTCATCATGGTGTG  
1980 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1921  ATCGTCATCACCTTGGTGATGCTGAAGAAGAAACAGTACACATCCATTCATCATGGTGTG  
1980 
             I  V  I  T  L  V  M  L  K  K  K  Q  Y  T  S  I  H  H  G  V   
 
 
             V  E  V  D  A  A  V  T  P  E  E  R  H  L  S  K  M  Q  Q  N   
Seq_1  1981  GTGGAGGTTGACGCCGCTGTCACCCCAGAGGAGCGCCACCTGTCCAAGATGCAGCAGAAC  
2040 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1981  GTGGAGGTTGACGCCGCTGTCACCCCAGAGGAGCGCCACCTGTCCAAGATGCAGCAGAAC  
2040 
             V  E  V  D  A  A  V  T  P  E  E  R  H  L  S  K  M  Q  Q  N   
 
 
             G  Y  E  N  P  T  Y  K  F  F  E  Q  M  Q  N  *   
Seq_1  2041  GGCTACGAAAATCCAACCTACAAGTTCTTTGAGCAGATGCAGAACTAG  2088 
             |||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  2041  GGCTACGAAAATCCAACCTACAAGTTCTTTGAGCAGATGCAGAACTAG  2088 
             G  Y  E  N  P  T  Y  K  F  F  E  Q  M  Q  N  *   
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peHISTEV-HSD10 
ATGGCAGCAGCGTGTCGGAGCGTGAAGGGCCTGGTGGCGGTAATAACCGGAGGAGCCTCGGGCCTGGGCCTGGCCACG
GCGGAGCGACTTGTGGGGCAGGGAGCCTCTGCTGTGCTTCTGGACCTGCCCAACTCGGGTGGGGAGGCCCAAGCCAAG
AAGTTAGGAAACAACTGCGTTTTCGCCCCAGCCGACGTGACCTCTGAGAAGGATGTGCAAACAGCTCTGGCTCTAGCA
AAAGGAAAGTTTGGCCGTGTGGATGTAGCTGTCAACTGTGCAGGCATCGCGGTGGCTAGCAAGACGTACAACTTAAAG
AAGGGCCAGACCCATACCTTGGAAGACTTCCAGCGAGTTCTTGATGTGAATCTCATGGGCACCTTCAATGTGATCCGC
CTGGTGGCTGGTGAGATGGGCCAGAATGAACCAGACCAGGGAGGCCAACGTGGGGTCATCATCAACACTGCCAGTGTG
GCTGCCTTCGAGGGTCAGGTTGGACAAGCTGCATACTCTGCTTCCAAGGGGGGAATAGTGGGCATGACACTGCCCATT
GCTCGGGATCTGGCTCCCATAGGTATCCGGGTGATGACCATTGCCCCAGGTCTGTTTGGCACCCCACTGCTGACCAGC
CTCCCAGAGAAAGTGTGCAACTTCTTGGCCAGCCAAGTGCCCTTCCCTAGCCGACTGGGTGACCCTGCTGAGTATGCT
CACCTCGTACAGGCCATCATCGAGAACCCATTCCTCAATGGAGAGGTCATCCGGCTGGATGGGGCCATTCGTATGCAG
CCTTGA 
 
 
Alignment of Sequence_1:  [HSD10 cDNA Sequence] with  Sequence_2: [peHISTEV- 
HSD10_F_aug-T7-190916-03-60.seq.xdna]  
 
Similarity : 786/786 (100.00 %) 
 
Seq_1  1     ATGGCAGCAGCGTGTCGGAGCGTGAAGGGCCTGGTGGCGGTAATAACCGGAGGAGCCTCG  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     ATGGCAGCAGCGTGTCGGAGCGTGAAGGGCCTGGTGGCGGTAATAACCGGAGGAGCCTCG  60 
 
 
Seq_1  61    GGCCTGGGCCTGGCCACGGCGGAGCGACTTGTGGGGCAGGGAGCCTCTGCTGTGCTTCTG  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    GGCCTGGGCCTGGCCACGGCGGAGCGACTTGTGGGGCAGGGAGCCTCTGCTGTGCTTCTG  120 
 
 
Seq_1  121   GACCTGCCCAACTCGGGTGGGGAGGCCCAAGCCAAGAAGTTAGGAAACAACTGCGTTTTC  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   GACCTGCCCAACTCGGGTGGGGAGGCCCAAGCCAAGAAGTTAGGAAACAACTGCGTTTTC  180 
 
 
Seq_1  181   GCCCCAGCCGACGTGACCTCTGAGAAGGATGTGCAAACAGCTCTGGCTCTAGCAAAAGGA  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   GCCCCAGCCGACGTGACCTCTGAGAAGGATGTGCAAACAGCTCTGGCTCTAGCAAAAGGA  240 
 
 
Seq_1  241   AAGTTTGGCCGTGTGGATGTAGCTGTCAACTGTGCAGGCATCGCGGTGGCTAGCAAGACG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   AAGTTTGGCCGTGTGGATGTAGCTGTCAACTGTGCAGGCATCGCGGTGGCTAGCAAGACG  300 
 
 
Seq_1  301   TACAACTTAAAGAAGGGCCAGACCCATACCTTGGAAGACTTCCAGCGAGTTCTTGATGTG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   TACAACTTAAAGAAGGGCCAGACCCATACCTTGGAAGACTTCCAGCGAGTTCTTGATGTG  360 
 
 
Seq_1  361   AATCTCATGGGCACCTTCAATGTGATCCGCCTGGTGGCTGGTGAGATGGGCCAGAATGAA  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   AATCTCATGGGCACCTTCAATGTGATCCGCCTGGTGGCTGGTGAGATGGGCCAGAATGAA  420 
 
 
Seq_1  421   CCAGACCAGGGAGGCCAACGTGGGGTCATCATCAACACTGCCAGTGTGGCTGCCTTCGAG  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   CCAGACCAGGGAGGCCAACGTGGGGTCATCATCAACACTGCCAGTGTGGCTGCCTTCGAG  480 
 
 
Seq_1  481   GGTCAGGTTGGACAAGCTGCATACTCTGCTTCCAAGGGGGGAATAGTGGGCATGACACTG  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  481   GGTCAGGTTGGACAAGCTGCATACTCTGCTTCCAAGGGGGGAATAGTGGGCATGACACTG  540 
 
 
Seq_1  541   CCCATTGCTCGGGATCTGGCTCCCATAGGTATCCGGGTGATGACCATTGCCCCAGGTCTG  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   CCCATTGCTCGGGATCTGGCTCCCATAGGTATCCGGGTGATGACCATTGCCCCAGGTCTG  600 
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Seq_1  601   TTTGGCACCCCACTGCTGACCAGCCTCCCAGAGAAAGTGTGCAACTTCTTGGCCAGCCAA  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  601   TTTGGCACCCCACTGCTGACCAGCCTCCCAGAGAAAGTGTGCAACTTCTTGGCCAGCCAA  660 
 
 
Seq_1  661   GTGCCCTTCCCTAGCCGACTGGGTGACCCTGCTGAGTATGCTCACCTCGTACAGGCCATC  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  661   GTGCCCTTCCCTAGCCGACTGGGTGACCCTGCTGAGTATGCTCACCTCGTACAGGCCATC  720 
 
 
Seq_1  721   ATCGAGAACCCATTCCTCAATGGAGAGGTCATCCGGCTGGATGGGGCCATTCGTATGCAG  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  721   ATCGAGAACCCATTCCTCAATGGAGAGGTCATCCGGCTGGATGGGGCCATTCGTATGCAG  780 
 
 
Seq_1  781   CCTTGA  786 
             |||||| 
Seq_2  781   CCTTGA  786 
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peHISTEV-HSD14 
ATGGCTACGGGAACGCGCTATGCCGGGAAGGTGGTGGTCGTGACCGGGGGCGGGCGCGGCATCGGAGCTGGGATCGTG
CGCGCCTTCGTGAACAGCGGGGCCCGAGTGGTTATCTGCGACAAGGATGAGTCTGGGGGCCGGGCCCTGGAGCAGGAG
CTCCCTGGAGCTGTCTTTATCCTCTGTGATGTGACTCAGGAAGATGATGTGAAGACCCTGGTTTCTGAGACCATCCGC
CGATTTGGCCGCCTGGATTGTGTTGTCAACAACGCTGGCCACCACCCACCCCCACAGAGGCCTGAGGAGACCTCTGCC
CAGGGATTCCGCCAGCTGCTGGAGCTGAACCTACTGGGGACGTACACCTTGACCAAGCTCGCCCTCCCCTACCTGCGG
AAGAGTCAAGGGAATGTCATCAACATCTCCAGCCTGGTGGGGGCAATCGGCCAGGCCCAGGCAGTTCCCTATGTGGCC
ACCAAGGGGGCAGTAACAGCCATGACCAAAGCTTTGGCCCTGGATGAAAGTCCATATGGTGTCCGAGTCAACTGTATC
TCCCCAGGAAACATCTGGACCCCGCTGTGGGAGGAGCTGGCAGCCTTAATGCCAGACCCTAGGGCCACAATCCGAGAG
GGCATGCTGGCCCAGCCACTGGGCCGCATGGGCCAGCCCGCTGAGGTCGGGGCTGCGGCAGTGTTCCTGGCCTCCGAA
GCCAACTTCTGCACGGGCATTGAACTGCTCGTGACGGGGGGTGCAGAGCTGGGGTACGGGTGCAAGGCCAGTCGGAGC
ACCCCCGTGGACGCCCCCGATATCCCTTCCTGA 
 
Alignment of Sequence_1:  [HSD14 cDNA Sequence] with  Sequence_2: 
[HSD14_G228A_A440G_3_F-T7-020216-01-37(1).seq.xdna]  
 
Similarity : 813/813 (100.00 %) 
 
             M  A  T  G  T  R  Y  A  G  K  V  V  V  V  T  G  G  G  R  G   
Seq_1  1     ATGGCTACGGGAACGCGCTATGCCGGGAAGGTGGTGGTCGTGACCGGGGGCGGGCGCGGC  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     ATGGCTACGGGAACGCGCTATGCCGGGAAGGTGGTGGTCGTGACCGGGGGCGGGCGCGGC  60 
             M  A  T  G  T  R  Y  A  G  K  V  V  V  V  T  G  G  G  R  G   
 
 
             I  G  A  G  I  V  R  A  F  V  N  S  G  A  R  V  V  I  C  D   
Seq_1  61    ATCGGAGCTGGGATCGTGCGCGCCTTCGTGAACAGCGGGGCCCGAGTGGTTATCTGCGAC  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    ATCGGAGCTGGGATCGTGCGCGCCTTCGTGAACAGCGGGGCCCGAGTGGTTATCTGCGAC  120 
             I  G  A  G  I  V  R  A  F  V  N  S  G  A  R  V  V  I  C  D   
 
 
             K  D  E  S  G  G  R  A  L  E  Q  E  L  P  G  A  V  F  I  L   
Seq_1  121   AAGGATGAGTCTGGGGGCCGGGCCCTGGAGCAGGAGCTCCCTGGAGCTGTCTTTATCCTC  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   AAGGATGAGTCTGGGGGCCGGGCCCTGGAGCAGGAGCTCCCTGGAGCTGTCTTTATCCTC  180 
             K  D  E  S  G  G  R  A  L  E  Q  E  L  P  G  A  V  F  I  L   
 
 
             C  D  V  T  Q  E  D  D  V  K  T  L  V  S  E  T  I  R  R  F   
Seq_1  181   TGTGATGTGACTCAGGAAGATGATGTGAAGACCCTGGTTTCTGAGACCATCCGCCGATTT  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   TGTGATGTGACTCAGGAAGATGATGTGAAGACCCTGGTTTCTGAGACCATCCGCCGATTT  240 
             C  D  V  T  Q  E  D  D  V  K  T  L  V  S  E  T  I  R  R  F   
 
 
             G  R  L  D  C  V  V  N  N  A  G  H  H  P  P  P  Q  R  P  E   
Seq_1  241   GGCCGCCTGGATTGTGTTGTCAACAACGCTGGCCACCACCCACCCCCACAGAGGCCTGAG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   GGCCGCCTGGATTGTGTTGTCAACAACGCTGGCCACCACCCACCCCCACAGAGGCCTGAG  300 
             G  R  L  D  C  V  V  N  N  A  G  H  H  P  P  P  Q  R  P  E   
 
 
             E  T  S  A  Q  G  F  R  Q  L  L  E  L  N  L  L  G  T  Y  T   
Seq_1  301   GAGACCTCTGCCCAGGGATTCCGCCAGCTGCTGGAGCTGAACCTACTGGGGACGTACACC  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   GAGACCTCTGCCCAGGGATTCCGCCAGCTGCTGGAGCTGAACCTACTGGGGACGTACACC  360 
             E  T  S  A  Q  G  F  R  Q  L  L  E  L  N  L  L  G  T  Y  T   
 
 
             L  T  K  L  A  L  P  Y  L  R  K  S  Q  G  N  V  I  N  I  S   
Seq_1  361   TTGACCAAGCTCGCCCTCCCCTACCTGCGGAAGAGTCAAGGGAATGTCATCAACATCTCC  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   TTGACCAAGCTCGCCCTCCCCTACCTGCGGAAGAGTCAAGGGAATGTCATCAACATCTCC  420 
             L  T  K  L  A  L  P  Y  L  R  K  S  Q  G  N  V  I  N  I  S   
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             S  L  V  G  A  I  G  Q  A  Q  A  V  P  Y  V  A  T  K  G  A   
Seq_1  421   AGCCTGGTGGGGGCAATCGGCCAGGCCCAGGCAGTTCCCTATGTGGCCACCAAGGGGGCA  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   AGCCTGGTGGGGGCAATCGGCCAGGCCCAGGCAGTTCCCTATGTGGCCACCAAGGGGGCA  480 
             S  L  V  G  A  I  G  Q  A  Q  A  V  P  Y  V  A  T  K  G  A   
 
 
             V  T  A  M  T  K  A  L  A  L  D  E  S  P  Y  G  V  R  V  N   
Seq_1  481   GTAACAGCCATGACCAAAGCTTTGGCCCTGGATGAAAGTCCATATGGTGTCCGAGTCAAC  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  481   GTAACAGCCATGACCAAAGCTTTGGCCCTGGATGAAAGTCCATATGGTGTCCGAGTCAAC  540 
             V  T  A  M  T  K  A  L  A  L  D  E  S  P  Y  G  V  R  V  N   
 
 
             C  I  S  P  G  N  I  W  T  P  L  W  E  E  L  A  A  L  M  P   
Seq_1  541   TGTATCTCCCCAGGAAACATCTGGACCCCGCTGTGGGAGGAGCTGGCAGCCTTAATGCCA  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   TGTATCTCCCCAGGAAACATCTGGACCCCGCTGTGGGAGGAGCTGGCAGCCTTAATGCCA  600 
             C  I  S  P  G  N  I  W  T  P  L  W  E  E  L  A  A  L  M  P   
 
 
             D  P  R  A  T  I  R  E  G  M  L  A  Q  P  L  G  R  M  G  Q   
Seq_1  601   GACCCTAGGGCCACAATCCGAGAGGGCATGCTGGCCCAGCCACTGGGCCGCATGGGCCAG  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  601   GACCCTAGGGCCACAATCCGAGAGGGCATGCTGGCCCAGCCACTGGGCCGCATGGGCCAG  660 
             D  P  R  A  T  I  R  E  G  M  L  A  Q  P  L  G  R  M  G  Q   
 
 
             P  A  E  V  G  A  A  A  V  F  L  A  S  E  A  N  F  C  T  G   
Seq_1  661   CCCGCTGAGGTCGGGGCTGCGGCAGTGTTCCTGGCCTCCGAAGCCAACTTCTGCACGGGC  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  661   CCCGCTGAGGTCGGGGCTGCGGCAGTGTTCCTGGCCTCCGAAGCCAACTTCTGCACGGGC  720 
             P  A  E  V  G  A  A  A  V  F  L  A  S  E  A  N  F  C  T  G   
 
 
             I  E  L  L  V  T  G  G  A  E  L  G  Y  G  C  K  A  S  R  S   
Seq_1  721   ATTGAACTGCTCGTGACGGGGGGTGCAGAGCTGGGGTACGGGTGCAAGGCCAGTCGGAGC  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  721   ATTGAACTGCTCGTGACGGGGGGTGCAGAGCTGGGGTACGGGTGCAAGGCCAGTCGGAGC  780 
             I  E  L  L  V  T  G  G  A  E  L  G  Y  G  C  K  A  S  R  S   
 
 
             T  P  V  D  A  P  D  I  P  S  *   
Seq_1  781   ACCCCCGTGGACGCCCCCGATATCCCTTCCTGA  813 
             ||||||||||||||||||||||||||||||||| 
Seq_2  781   ACCCCCGTGGACGCCCCCGATATCCCTTCCTGA  813 
             T  P  V  D  A  P  D  I  P  S  *   
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pET-MBP-HSD8 (Codon Optimised) 
ATGGCGAGCCAGCTGCAGAATCGTCTGCGTAGCGCACTGGCACTGGTTACCGGTGCAGGTAGCGGTATTGGTCGTGCA
GTTAGCGTTCGTCTGGCAGGCGAAGGTGCAACCGTTGCAGCATGTGATCTGGATCGTGCAGCAGCACAAGAAACCGTG
CGTCTGCTGGGTGGTCCGGGTAGCAAAGAAGGTCCGCCTCGCGGTAATCATGCAGCATTTCAGGCAGATGTTAGCGAA
GCACGTGCAGCACGTTGTCTGCTGGAACAGGTTCAGGCATGTTTTAGCCGTCCGCCTAGCGTTGTTGTTAGCTGTGCA
GGTATTACCCAGGATGAATTTCTGCTGCATATGAGCGAAGATGATTGGGATAAAGTTATTGCCGTTAATCTGAAAGGC
ACCTTTCTGGTTACCCAGGCAGCAGCCCAGGCCCTGGTTAGCAATGGTTGTCGTGGTAGCATTATTAACATTAGCAGC
ATTGTTGGCAAAGTGGGTAATGTTGGTCAGACCAATTATGCAGCAAGCAAAGCCGGTGTTATTGGCCTGACCCAGACC
GCAGCACGTGAACTGGGTCGTCATGGTATTCGTTGTAATAGCGTTCTGCCTGGTTTTATTGCAACCCCGATGACCCAG
AAAGTTCCGCAGAAAGTTGTTGATAAAATCACCGAAATGATTCCGATGGGTCATCTGGGCGATCCGGAAGATGTTGCA
GATGTTGTTGCATTTCTGGCCAGCGAAGATAGCGGTTATATCACCGGCACCAGCGTTGAAGTGACCGGTGGTCTGTTT
ATGTAA 
 
Alignment of Sequence_1:  [HSD8_MBP_Rev-T7 Term-260416-09-65(1).seq.xdna] with  
Sequence_2: [HSD8_CodonOptimised.fas]  
 
Similarity : 786/786 (100.00 %) 
 
             M  A  S  Q  L  Q  N  R  L  R  S  A  L  A  L  V  T  G  A  G   
Seq_1  1     ATGGCGAGCCAGCTGCAGAATCGTCTGCGTAGCGCACTGGCACTGGTTACCGGTGCAGGT  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     ATGGCGAGCCAGCTGCAGAATCGTCTGCGTAGCGCACTGGCACTGGTTACCGGTGCAGGT  60 
             M  A  S  Q  L  Q  N  R  L  R  S  A  L  A  L  V  T  G  A  G   
 
 
             S  G  I  G  R  A  V  S  V  R  L  A  G  E  G  A  T  V  A  A   
Seq_1  61    AGCGGTATTGGTCGTGCAGTTAGCGTTCGTCTGGCAGGCGAAGGTGCAACCGTTGCAGCA  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    AGCGGTATTGGTCGTGCAGTTAGCGTTCGTCTGGCAGGCGAAGGTGCAACCGTTGCAGCA  120 
             S  G  I  G  R  A  V  S  V  R  L  A  G  E  G  A  T  V  A  A   
 
 
             C  D  L  D  R  A  A  A  Q  E  T  V  R  L  L  G  G  P  G  S   
Seq_1  121   TGTGATCTGGATCGTGCAGCAGCACAAGAAACCGTGCGTCTGCTGGGTGGTCCGGGTAGC  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   TGTGATCTGGATCGTGCAGCAGCACAAGAAACCGTGCGTCTGCTGGGTGGTCCGGGTAGC  180 
             C  D  L  D  R  A  A  A  Q  E  T  V  R  L  L  G  G  P  G  S   
 
 
             K  E  G  P  P  R  G  N  H  A  A  F  Q  A  D  V  S  E  A  R   
Seq_1  181   AAAGAAGGTCCGCCTCGCGGTAATCATGCAGCATTTCAGGCAGATGTTAGCGAAGCACGT  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   AAAGAAGGTCCGCCTCGCGGTAATCATGCAGCATTTCAGGCAGATGTTAGCGAAGCACGT  240 
             K  E  G  P  P  R  G  N  H  A  A  F  Q  A  D  V  S  E  A  R   
 
 
             A  A  R  C  L  L  E  Q  V  Q  A  C  F  S  R  P  P  S  V  V   
Seq_1  241   GCAGCACGTTGTCTGCTGGAACAGGTTCAGGCATGTTTTAGCCGTCCGCCTAGCGTTGTT  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   GCAGCACGTTGTCTGCTGGAACAGGTTCAGGCATGTTTTAGCCGTCCGCCTAGCGTTGTT  300 
             A  A  R  C  L  L  E  Q  V  Q  A  C  F  S  R  P  P  S  V  V   
 
 
             V  S  C  A  G  I  T  Q  D  E  F  L  L  H  M  S  E  D  D  W   
Seq_1  301   GTTAGCTGTGCAGGTATTACCCAGGATGAATTTCTGCTGCATATGAGCGAAGATGATTGG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   GTTAGCTGTGCAGGTATTACCCAGGATGAATTTCTGCTGCATATGAGCGAAGATGATTGG  360 
             V  S  C  A  G  I  T  Q  D  E  F  L  L  H  M  S  E  D  D  W   
 
 
             D  K  V  I  A  V  N  L  K  G  T  F  L  V  T  Q  A  A  A  Q   
Seq_1  361   GATAAAGTTATTGCCGTTAATCTGAAAGGCACCTTTCTGGTTACCCAGGCAGCAGCCCAG  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   GATAAAGTTATTGCCGTTAATCTGAAAGGCACCTTTCTGGTTACCCAGGCAGCAGCCCAG  420 
             D  K  V  I  A  V  N  L  K  G  T  F  L  V  T  Q  A  A  A  Q   
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             A  L  V  S  N  G  C  R  G  S  I  I  N  I  S  S  I  V  G  K   
Seq_1  421   GCCCTGGTTAGCAATGGTTGTCGTGGTAGCATTATTAACATTAGCAGCATTGTTGGCAAA  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   GCCCTGGTTAGCAATGGTTGTCGTGGTAGCATTATTAACATTAGCAGCATTGTTGGCAAA  480 
             A  L  V  S  N  G  C  R  G  S  I  I  N  I  S  S  I  V  G  K   
 
 
             V  G  N  V  G  Q  T  N  Y  A  A  S  K  A  G  V  I  G  L  T   
Seq_1  481   GTGGGTAATGTTGGTCAGACCAATTATGCAGCAAGCAAAGCCGGTGTTATTGGCCTGACC  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  481   GTGGGTAATGTTGGTCAGACCAATTATGCAGCAAGCAAAGCCGGTGTTATTGGCCTGACC  540 
             V  G  N  V  G  Q  T  N  Y  A  A  S  K  A  G  V  I  G  L  T   
 
 
             Q  T  A  A  R  E  L  G  R  H  G  I  R  C  N  S  V  L  P  G   
Seq_1  541   CAGACCGCAGCACGTGAACTGGGTCGTCATGGTATTCGTTGTAATAGCGTTCTGCCTGGT  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   CAGACCGCAGCACGTGAACTGGGTCGTCATGGTATTCGTTGTAATAGCGTTCTGCCTGGT  600 
             Q  T  A  A  R  E  L  G  R  H  G  I  R  C  N  S  V  L  P  G   
 
 
             F  I  A  T  P  M  T  Q  K  V  P  Q  K  V  V  D  K  I  T  E   
Seq_1  601   TTTATTGCAACCCCGATGACCCAGAAAGTTCCGCAGAAAGTTGTTGATAAAATCACCGAA  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  601   TTTATTGCAACCCCGATGACCCAGAAAGTTCCGCAGAAAGTTGTTGATAAAATCACCGAA  660 
             F  I  A  T  P  M  T  Q  K  V  P  Q  K  V  V  D  K  I  T  E   
 
 
             M  I  P  M  G  H  L  G  D  P  E  D  V  A  D  V  V  A  F  L   
Seq_1  661   ATGATTCCGATGGGTCATCTGGGCGATCCGGAAGATGTTGCAGATGTTGTTGCATTTCTG  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  661   ATGATTCCGATGGGTCATCTGGGCGATCCGGAAGATGTTGCAGATGTTGTTGCATTTCTG  720 
             M  I  P  M  G  H  L  G  D  P  E  D  V  A  D  V  V  A  F  L   
 
 
             A  S  E  D  S  G  Y  I  T  G  T  S  V  E  V  T  G  G  L  F   
Seq_1  721   GCCAGCGAAGATAGCGGTTATATCACCGGCACCAGCGTTGAAGTGACCGGTGGTCTGTTT  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  721   GCCAGCGAAGATAGCGGTTATATCACCGGCACCAGCGTTGAAGTGACCGGTGGTCTGTTT  780 
             A  S  E  D  S  G  Y  I  T  G  T  S  V  E  V  T  G  G  L  F   
 
 
             M  *   
Seq_1  781   ATGTAA  786 
             |||||| 
Seq_2  781   ATGTAA  786 
             M  *   
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Appendix C: Compound Synthesis and NMR 
Synthesis Methodology 
Solvents and reagents were purchased from Fluka and Sigma-Aldrich (Czech Republic) and used without 
further puriﬁcation. Reactions were monitored by thin layer chromatography (TLC) performed on 
aluminium sheets pre-coated with silica gel 60 F254 (Merck, Czech Republic), using a mobile phase of ethyl 
acetate/methanol (EtOAc/MeOH; 0-50%) and detected under 254 nm UV light. Melting points were 
measured on a micro heating stage PHMK 05 (VEB KombinatNagema, Radebeul, Germany) and are 
uncorrected. Yields were calculated for the two-step synthesis. 
NMR spectra were generally recorded at Varian Gemini 300 (1H 300 MHz, 13C 75 MHz, Palo Alto CA, USA) 
or Varian S500 (1H 500 MHz, 13C 126 MHz, Palo Alto CA, USA). In all cases, the chemical shift values for 1H 
spectra are reported in ppm (δ) relative to residual CHD2SO2CD3 (δ 2.50), shift values for 13C spectra are 
reported in ppm (δ) relative to solvent peak dimethylsulfoxide-d6 (δ 39.52). 
Mass spectra (MS, respectively, multiple stage MS) were recorded on a LTQ XL linear ion trap mass 
spectrometer and evaluated using Xcalibur v 2.5.0 software (both Thermo Fisher Scientific, San Jose, CA, 
USA). The samples were dissolved in methanol (HPLC grade; Sigma-Aldrich, Prague, Czech Republic) and 
injected continuously (10 µl/min) using a Hamilton syringe into the electrospray ion source. The 
parameters of the electrospray were set up as follows: sheath gas flow rate 20 arbitrary units, aux gas 
flow rate 10 arbitrary units, sweep gas flow rate 0 arbitrary units, spray voltage 4.5 kV, capillary 
temperature 275 °C, capillary voltage 13 V, tube lens 100 V. 
Elemental analysis (EA) was measured at Perkin-Elmer CHN Analyser 2,400 Series II apparatus. 
Initially, 2-amino-6-fluorobenzo[d]thiazole (1 g, 5.95 mmol) was dissolved in a mixture of anhydrous 
dichloromethane (DCM; 60 ml) and anhydrous dimethylformamide (DMF, 10 ml). 1,1’-
carbonyldiimidazole (CDI; 1.16 g, 7.13 mmol) was added and the reaction mixture was vigorously stirred 
at reflux for 16 hours under nitrogen. The resulting precipitate was collected by filtration, washed with 
DCM (30 ml) and dried under reduced pressure to obtain N-(6-fluorobenzo[d]thiazol-2-yl)-1H-imidazole-
1-carboxamide as a white solid (95 % yield). 
In the second step, N-(6-fluorobenzo[d]thiazol-2-yl)-1H-imidazole-1-carboxamide (0.3g, 1.14 mmol) was 
dissolved in a mixture of anhydrous DMF (10 ml) and triethylamine (Et3N; 0.35 ml, 2.51 mmol). 4-
hydroxyaniline (0.14 g, 1.26 mmol) was added and the reaction mixture was stirred at room temperature 
for 16 hours under nitrogen. The reaction mixture was portioned with water (40 ml) or 10 % HCl (40 ml; 
compounds with free carboxylic moiety), solid product was collected by filtration, washed with water (30 
ml), cold MeOH (5 ml) and dried under reduced pressure at 60°C to obtain N-(4-hydroxyphenyl)-N'-(6-
fluorobenzo[d]thiazol-2-yl)urea as a beige solid (95 % yield) 
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Series 1: K684-K711 
K684 
N-(4-hydroxyphenyl)-N'-(6-fluorobenzo[d]thiazol-2-yl)urea 
M.p. 250 °C decomp. Yield 90 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 8.85 (br s, 1H), 7.81 (dd, J = 8.7, 
2.7 Hz, 1H), 7.67 – 7.60 (m, 1H), 7.30 – 7.25 (m, 2H), 7.21 (td, J = 9.1, 2.7 Hz, 1H), 6.76 – 6.71 (m, 2H). 13C 
NMR (126 MHz, DMSO-d6): δ (ppm) 159.64, 158.26 (d, J = 238.9 Hz), 153.51, 151.97, 145.48, 132.62 (d, J 
= 11.0 Hz), 129.65, 121.22, 120.52, 115.37, 113.72 (d, J = 24.3 Hz), 108.03 (d, J = 26.9 Hz). ESI-MS: m/z 304 
[M+H+] (calc. for C14H10FN3O2S: 303.05). EA: calc. C 55.44; H 3.32; N 13.85; S 10.57. Found: C 55.22; H 3.50; 
N 13.55; S 10.48. 
 
K685 
N-(4-hydroxyphenyl)-N'-(6-chlorobenzo[d]thiazol-2-yl)urea 
M.p. 285 °C decomp. Yield 58 %.1H NMR (300 MHz, DMSO-d6): δ (ppm) 9.25 (br s, 1H), 8.83 (br s, 1H), 8.03 
(d, J = 2.1 Hz, 1H), 7.63 (d, J = 8.6 Hz, 1H), 7.39 (dd, J = 8.6, 2.2 Hz, 1H), 7.33 – 7.22 (m, 2H), 6.80 – 6.68 (m, 
2H). 13C NMR (75 MHz, DMSO-d6): δ (ppm) 160.33, 153.55, 151.77, 147.74, 133.15, 129.57, 126.81, 126.16, 
121.21, 120.81, 115.37. ESI-MS: m/z 320 [M+H+] (calc. for C14H10ClN3O2S: 319.02). EA: calc. C 52.59; H 3.15; 
N 13.14; S 10.03. Found: C 52.34; H 3.45; N 12.90; S 9.81. 
 
K686 
N-(3-hydroxyphenyl)-N'-(6-fluorobenzo[d]thiazol-2-yl)urea 
M.p. 298–300 °C.Yield 49 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.45 (br s, 1H), 9.02 (br s, 1H), 7.83 
(dd, J = 8.7, 2.5 Hz, 1H), 7.71 – 7.60 (m, 1H), 7.23 (td, J = 9.1, 2.7 Hz, 1H), 7.14 – 7.06 (m, 2H), 6.84 (d, J = 
8.0 Hz, 1H), 6.47 (dd, J = 8.1, 1.7 Hz, 1H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 158.29 (d, J = 239.0 Hz), 
157.85, 151.41, 145.58, 139.33, 132.60, 129.66, 120.80, 113.80 (d, J = 24.3 Hz), 110.19, 109.45, 108.06 (d, 
J = 26.9 Hz), 105.80. ESI-MS: m/z 304 [M+H+] (calc. for C14H10FN3O2S: 303.05). EA: calc. C 55.44; H 3.32; N 
13.85; S 10.57. Found: C 55.15; H 3.66; N 13.59; S 10.27. 
 
K687 
N-(3-hydroxyphenyl)-N'-(6-chlorobenzo[d]thiazol-2-yl)urea 
M.p. 294–296 °C.Yield 36 %.1H NMR (300 MHz, DMSO-d6): δ (ppm) 9.47 (br s, 1H), 9.05 (br s, 1H), 8.05 (d, 
J = 2.1 Hz, 1H), 7.64 (d, J = 8.7 Hz, 1H), 7.40 (dd, J = 8.7, 2.2 Hz, 1H), 7.18 – 7.03 (m, 2H), 6.85 (d, J = 8.4 Hz, 
1H), 6.47 (dd, J = 8.0, 1.9 Hz, 1H). 13C NMR (75 MHz, DMSO-d6): δ (ppm) 160.21, 157.89, 151.59, 139.33, 
133.09, 129.72, 126.93, 126.24, 121.26, 120.81, 110.26, 109.48, 105.82. ESI-MS: m/z 320 [M+H+] (calc. for 
C14H10ClN3O2S: 319.02). EA: calc. C 52.59; H 3.15; N 13.14; S 10.03. Found: C 52.30; H 3.38; N 12.88; S 
10.32. 
 
K688 
N-(2-hydroxyphenyl)-N'-(6-fluorobenzo[d]thiazol-2-yl)urea 
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M.p. 228–230 °C.Yield 80 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 8.82 (br s, 1H), 8.04 (d, J = 8.0 Hz, 1H), 
7.83 (dd, J = 8.7, 2.4 Hz, 1H), 7.69 – 7.63 (m, 1H), 7.23 (td, J = 9.0, 2.4 Hz, 1H), 6.88 (d, J = 4.3 Hz, 2H), 6.83 
– 6.77 (m, 1H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 159.12, 158.28 (d, J = 238.9 Hz), 151.41, 146.17, 
145.81, 132.74 (d, J = 11.1 Hz), 126.47, 123.11, 120.83, 119.21, 119.05, 114.63, 113.76 (d, J = 24.3 Hz), 
108.04 (d, J = 27.0 Hz). ESI-MS: m/z 304 [M+H+] (calc. for C14H10FN3O2S: 303.05). EA: calc. C 55.44; H 3.32; 
N 13.85; S 10.57. Found: C 55.21; H 3.69; N 13.47; S 10.23. 
 
K689 
N-(2-hydroxyphenyl)-N'-(6-chlorobenzo[d]thiazol-2-yl)urea 
M.p. 216–218 °C.Yield 42 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.30 (br s, 1H), 10.12 (br s, 1H), 8.84 
(br s, 1H), 8.04 (d, J = 1.8 Hz, 1H), 7.99 (d, J = 6.5 Hz, 1H), 7.64 (d, J = 8.6 Hz, 1H), 7.40 (dd, J = 8.6, 2.1 Hz, 
1H), 6.93 – 6.88 (m, 2H), 6.85 – 6.77 (m, 1H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 160.77, 152.24, 
148.09, 146.47, 133.35, 126.67, 126.54, 125.97, 123.13, 121.01, 120.77, 119.28, 119.06, 114.91. ESI-MS: 
m/z 320 [M+H+] (calc. for C14H10ClN3O2S: 319.02). EA: calc. C 52.59; H, 3.15; N 13.14; S 10.03. Found: C 
52.72; H 3.27; N 13.09; S 10.07. 
 
K690 
N-(3-chloro-4-hydroxyphenyl)-N'-(6-fluorobenzo[d]thiazol-2-yl)urea 
M.p. 298–299.5 °C.Yield 74 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.94 (br s, 1H), 8.98 (br s, 1H), 7.82 
(dd, J = 8.6, 2.6 Hz, 1H), 7.69 – 7.61 (m, 1H), 7.59 (d, J = 2.5 Hz, 1H), 7.22 (td, J = 9.1, 2.7 Hz, 1H), 7.18 (dd, 
J = 8.7, 2.5 Hz, 1H), 6.94 (d, J = 8.7 Hz, 1H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 159.42, 158.29 (d, J = 
239.1 Hz), 151.83, 149.05, 145.57, 132.52, 130.60, 120.92, 120.57, 119.59, 119.36, 116.67, 113.80 (d, J = 
24.4 Hz), 108.11 (d, J = 27.0 Hz). ESI-MS: m/z 338 [M+H+] (calc. for C14H9ClFN3O2S: 337.01). EA: calc. C 
49.78; H 2.69; N 12.44; S 9.49. Found: C 47.39; H 2.89; N 12.12; S 9.15. 
 
K691 
N-(3-chloro-4-hydroxyphenyl)-N'-(6-chlorobenzo[d]thiazol-2-yl)urea 
M.p. 283.5–285 °C.Yield 30 %.1H NMR (300 MHz, DMSO-d6): δ (ppm) 9.95 (br s, 1H), 9.01 (br s, 1H), 8.04 
(d, J = 2.1 Hz, 1H), 7.70 – 7.56 (m, 2H), 7.40 (dd, J = 8.6, 2.2 Hz, 1H), 7.19 (dd, J = 8.8, 2.5 Hz, 1H), 6.94 (d, 
J = 8.7 Hz, 1H). 13C NMR (75 MHz, DMSO-d6): δ (ppm) 160.40, 151.93, 149.07, 132.94, 130.55, 126.88, 
126.20, 121.24, 120.93, 119.60, 119.34, 116.66. ESI-MS: m/z 354 [M+H+] (calc. for C14H9Cl2N3O2S: 352.98). 
EA: calc. C 47.47; H 2.56; N 11.86; S 9.05. Found: C 47.12; H 2.96; N 11.49; S 9.33. 
 
K692 
2-hydroxy-5-[3-(6-fluorobenzo[d]thiazol-2-yl)ureido]benzoic acid 
M.p. 304–305 °C.Yield 70 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.13 (br s, 1H), 8.01 (d, J = 2.7 Hz, 1H), 
7.82 (dd, J = 8.7, 2.7 Hz, 1H), 7.69 – 7.61 (m, 1H), 7.58 (dd, J = 8.8, 2.7 Hz, 1H), 7.22 (td, J = 9.1, 2.7 Hz, 1H), 
6.95 (d, J = 8.9 Hz, 1H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 171.60, 159.58, 158.29 (d, J = 239.1 Hz), 
Appendix 
250 
 
157.09, 152.26, 144.93, 132.45 (d, J = 11.3 Hz), 129.97, 127.69, 120.52, 120.42, 117.45, 113.79 (d, J = 24.2 
Hz), 112.65, 108.09 (d, J = 26.9 Hz). ESI-MS: m/z 348 [M+H+] (calc. for C15H10FN3O4S: 347.04). EA: calc. C 
51.87; H 2.90; N 12.10; S 9.23. Found: C 51.52; H 2.66; N 12.02; S 8.99. 
 
K693 
2-hydroxy-5-[3-(6-chlorobenzo[d]thiazol-2-yl)ureido]benzoic acid 
M.p. 285–287 °C.Yield 61 %.1H NMR (300 MHz, DMSO-d6): δ (ppm) 9.10 (br s, 1H), 8.05 (d, J = 2.1 Hz, 1H), 
8.01 (d, J = 2.7 Hz, 1H), 7.63 (d, J = 8.6 Hz, 1H), 7.57 (dd, J = 8.8, 2.5 Hz, 1H), 7.40 (ddd, J = 8.6, 2.2, 0.7 Hz, 
1H), 6.95 (d, J = 8.9 Hz, 1H). 13C NMR (75 MHz, DMSO-d6): δ (ppm) 189.75, 171.62, 160.45, 157.14, 152.28, 
147.04 132.94, 129.93, 127.74, 126.90, 126.22, 121.24, 120.58, 117.47, 112.66. ESI-MS: m/z 364 [M+H+] 
(calc. for C15H10ClN3O4S: 363.01). EA: calc. C 49.53; H 2.77; N 11.55; S 8.81. Found: C 49.39; H 2.89; N 11.40; 
S 8.78. 
 
K694 
N-(4-methoxyphenyl)-N'-(6-fluorobenzo[d]thiazol-2-yl)urea 
M.p. 331–333 °C.Yield 70 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 8.95 (br s, 1H), 7.82 (dd, J = 8.6, 2.4 Hz, 
1H), 7.69 – 7.61 (m, 1H), 7.41 (d, J = 8.9 Hz, 2H), 7.22 (td, J = 9.1, 2.7 Hz, 1H), 6.91 (d, J = 9.0 Hz, 2H), 3.73 
(s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 159.44, 158.26 (d, J = 239.0 Hz), 155.30, 151.85, 145.47, 
132.62, 131.22, 120.82, 120.70, 114.11, 113.75 (d, J = 24.3 Hz), 108.05 (d, J = 26.8 Hz), 55.21. ESI-MS: m/z 
318 [M+H+] (calc. for C15H12FN3O2S: 317.06). EA: calc. C 56.77; H 3.81; N 13.24; S 10.10. Found: C 56.59; H 
3.41; N 12.92; S 9.87. 
 
K695 
N-(4-methoxyphenyl)-N'-(6-chlorobenzo[d]thiazol-2-yl)urea 
M.p. 280–282 °C.Yield 92 %.1H NMR (300 MHz, DMSO-d6): δ (ppm) 8.96 (br s, 1H), 8.04 (d, J = 2.1 Hz, 1H), 
7.63 (d, J = 8.6 Hz, 1H), 7.45 – 7.36 (m, 3H), 6.95 – 6.88 (m, 2H), 3.73 (s, 3H). 13C NMR (75 MHz, DMSO-d6): 
δ (ppm) 160.31, 155.33, 151.83, 147.59, 133.08, 131.18, 126.83, 126.16, 121.19, 120.83, 114.11, 55.21. 
ESI-MS: m/z 334 [M+H+] (calc. for C15H12ClN3O2S: 333.03). EA: calc. C 53.97; H 3.62; N 12.59; S 9.61. Found: 
C 53.71; H3.95; N 12.21; S 9.30. 
 
K696 
N-(3,4-dimethoxyphenyl)-N'-(6-fluorobenzo[d]thiazol-2-yl)urea 
M.p. 280–282 °C.Yield 84 %.1H NMR (300 MHz, DMSO-d6): δ (ppm) 8.97 (br s, 1H), 7.82 (dd, J = 8.7, 2.7 Hz, 
1H), 7.73 – 7.59 (m, 1H), 7.28 – 7.17 (m, 2H), 6.97 (dd, J = 8.6, 2.3 Hz, 1H), 6.91 (d, J = 8.7 Hz, 1H), 3.76 (s, 
3H), 3.73 (s, 3H). 13C NMR (75 MHz, DMSO-d6): δ (ppm) 159.47, 158.29 (d, J = 239.0 Hz), 148.81, 144.91, 
132.53, 131.72, 120.54, 113.79 (d, J = 24.3 Hz), 112.28, 111.11, 108.07 (d, J = 26.9 Hz), 104.46, 55.78, 
55.47. ESI-MS: m/z 348 [M+H+] (calc. for C16H14FN3O3S: 347.07). EA: calc. C 55.32; H 4.06; N 12.10; S 9.23. 
Found: C 54.97; H 4.00; N 11.94; S 8.86. 
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K697 
N-(3,4-dimethoxyphenyl)-N'-(6-chlorobenzo[d]thiazol-2-yl)urea 
M.p. 280–282 °C.Yield 87 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 8.98 (br s, 1H), 8.03 (d, J = 2.1 Hz, 1H), 
7.64 (d, J = 8.6 Hz, 1H), 7.40 (dd, J = 8.6, 2.2 Hz, 1H), 7.20 (d, J = 2.1 Hz, 1H), 6.97 (dd, J = 8.6, 2.3 Hz, 1H), 
6.91 (d, J = 8.7 Hz, 1H), 3.76 (s, 3H), 3.73 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 160.27, 151.78, 
148.80, 147.81, 144.94, 133.06, 131.66, 126.85, 126.18, 121.19, 120.76, 112.28, 111.12, 104.47, 55.78, 
55.47. ESI-MS: m/z 364 [M+H+] (calc. for C16H14ClN3O3S: 363.04). EA: calc. C 52.82; H 3.88; N 11.55; S 8.81. 
Found: C 52.38; H 4.26; N 10.97; S 8.37. 
 
K698 
2-methoxy-5-[3-(6-fluorobenzo[d]thiazol-2-yl)ureido]benzoic acid 
M.p. 278–279 °C.Yield 47 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.13 (br s, 1H), 7.85 – 7.80 (m, 2H), 
7.68 – 7.62 (m, 1H), 7.60 (dd, J = 8.9, 2.8 Hz, 1H), 7.23 (td, J = 9.1, 2.7 Hz, 1H), 7.11 (d, J = 9.0 Hz, 1H), 3.80 
(s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 166.97, 159.56, 158.30 (d, J = 239.0 Hz), 154.11, 152.22, 
144.87, 132.44 (d, J = 12.1 Hz), 130.95, 124.02, 121.71, 121.27, 120.41, 113.80 (d, J = 24.3 Hz), 113.17, 
108.10 (d, J = 26.9 Hz), 56.05. ESI-MS: m/z 362 [M+H+] (calc. for C16H12FN3O4S: 361.05). EA: calc. C 53.18; 
H 3.35; N 11.63; S 8.87. Found: C 52.83; H 2.96; N 11.59; S 8.48. 
 
K699 
2-methoxy-5-[3-(6-chlorobenzo[d]thiazol-2-yl)ureido]benzoic acid 
M.p. 268.5–270.5 °C.Yield 56 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.12 (br s, 1H), 8.05 (d, J = 1.9 Hz, 
1H), 7.82 (d, J = 2.7 Hz, 1H), 7.63 (d, J = 8.6 Hz, 1H), 7.60 (dd, J = 9.0, 2.7 Hz, 1H), 7.40 (dd, J = 8.6, 2.1 Hz, 
1H), 7.11 (d, J = 9.0 Hz, 1H), 3.80 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 166.95, 160.44, 154.13, 
152.22, 132.92, 130.89, 126.89, 126.20, 124.04, 121.74, 121.26, 121.23, 120.49, 113.16, 56.05. ESI-MS: 
m/z 378 [M+H+] (calc. for C16H12ClN3O4S: 377.02). EA: calc. C 50.87; H 3.20; N 11.12; S 8.49. Found: C 50.37; 
H 3.31; N 10.79; S 8.97. 
 
K700 
N-(4-phenoxyphenyl)-N'-(6-fluorobenzo[d]thiazol-2-yl)urea 
M.p. 305–307 °C.Yield 83 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.15 (br s, 1H), 7.82 (dd, J = 8.6, 2.2 Hz, 
1H), 7.69 – 7.62 (m, 1H), 7.53 (d, J = 8.7 Hz, 2H), 7.37 (t, J = 7.8 Hz, 2H), 7.23 (td, J = 9.1, 2.5 Hz, 1H), 7.10 
(t, J = 7.4 Hz, 1H), 7.02 (d, J = 8.8 Hz, 2H), 6.98 (d, J = 8.0 Hz, 2H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 
158.29 (d, J = 238.4 Hz), 151.74, 134.16, 132.54, 129.96, 122.99, 120.79, 120.67, 119.67, 117.87, 113.80 
(d, J = 24.3 Hz), 108.09 (d, J = 27.1 Hz). ESI-MS: m/z 380 [M+H+] (calc. for C20H14FN3O2S: 379.08). EA: calc. 
C 63.31; H 3.72; N 11.08; S 8.45. Found: C 62.89; H 3.40; N 10.70; S 8.05. 
 
K701 
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N-(4-phenoxyphenyl)-N'-(6-chlorobenzo[d]thiazol-2-yl)urea 
M.p. 295–297 °C.Yield 88 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.15 (br s, 1H), 8.05 (d, J = 2.0 Hz, 1H), 
7.64 (d, J = 8.9 Hz, 1H), 7.53 (d, J = 9.2 Hz, 2H), 7.41 (dd, J = 8.6, 2.2 Hz, 1H), 7.40 – 7.35 (m, 2H), 7.11 (t, J 
= 7.4 Hz, 1H), 7.03 (d, J = 8.9 Hz, 2H), 6.98 (d, J = 7.7 Hz, 2H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 
160.31, 157.66, 157.33, 151.78, 150.59, 135.75, 134.12, 133.01, 129.97, 126.90, 126.21, 123.01, 122.73, 
121.24, 120.81, 119.92, 119.79, 119.66, 117.89, 117.57. ESI-MS: m/z 396 [M+H+] (calc. for C20H14ClN3O2S: 
395.05). EA: calc. C 60.68; H 3.56; N 10.61; S 8.10. Found: C 60.33; H 3.94; N 10.30; S 7.85. 
 
K702 
4-[3-(6-fluorobenzo[d]thiazol-2-yl)ureido]benzoic acid 
M.p. 300 °C decomp. Yield 67 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.38 (br s, 1H), 7.91 (d, J = 8.7 Hz, 
2H), 7.84 (dd, J = 8.7, 2.6 Hz, 1H), 7.69 – 7.65 (m, 1H), 7.63 (d, J = 8.8 Hz, 2H), 7.24 (td, J = 9.1, 2.7 Hz, 1H). 
13C NMR (126 MHz, DMSO-d6): δ (ppm) 166.92, 162.31, 159.07, 158.36 (d, J = 239.1 Hz), 152.10, 144.90, 
142.80, 132.50 (d, J = 11.0 Hz), 130.63, 120.57 (d, J = 9.0 Hz), 117.68, 113.89 (d, J = 24.2 Hz), 108.12 (d, J 
= 27.0 Hz). ESI-MS: m/z 332 [M+H+] (calc. for C15H10FN3O3S: 331.04). EA: calc. C 54.38; H 3.04; N 12.68; S 
9.68. Found: C 54.04; H 3.33; N 12.39; S 9.35. 
 
K703 
4-[3-(6-chlorobenzo[d]thiazol-2-yl)ureido]benzoic acid 
M.p. 300 °C decomp. Yield 35 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.76 (br s, 1H), 8.06 (d, J = 2.0 Hz, 
1H), 7.92 (d, J = 8.6 Hz, 2H), 7.70 – 7.59 (m, 3H), 7.41 (dd, J = 8.6, 2.1 Hz, 1H). 13C NMR (126 MHz, DMSO-
d6): δ (ppm) 166.90, 160.24, 152.21, 142.67, 132.81, 130.59, 127.04, 126.30, 124.82, 121.31, 120.48, 
117.90. ESI-MS: m/z 348 [M+H+] (calc. for C15H10ClN3O3S: 347.01). EA: calc. C 51.80; H 2.90; N 12.08; S 
9.22. Found: C 51.41; H 3.13; N 11.80; S 8.91. 
 
K704 
ethyl-[3-(6-fluorobenzo[d]thiazol-2-yl)ureido]benzoate 
M.p. 333–335 °C.Yield 32 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.53 (br s, 1H), 7.99 – 7.79 (m, 3H), 
7.72 – 7.56 (m, 3H), 7.29 – 7.20 (m, 1H), 4.33 – 4.25 (m, 2H), 1.31 (t, J = 6.5 Hz, 3H). 13C NMR (126 MHz, 
DMSO-d6): δ (ppm) 165.30, 158.36 (d, J = 237.5 Hz), 142.93, 130.39, 123.85, 118.02, 117.49, 113.94 (d, J 
= 23.6 Hz), 108.21 (d, J = 26.9 Hz), 60.44, 14.24. ESI-MS: m/z 360 [M+H+] (calc. for C17H14FN3O3S: 359.07). 
EA: calc. C 56.82; H 3.93; N 11.69; S 8.92. Found: C 56.37; H 3.77; N 11.92; S 9.24. 
 
K705 
ethyl-4-[3-(6-chlorobenzo[d]thiazol-2-yl)ureido]benzoate 
M.p. 326–328 °C.Yield 45 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.19 (br s, 1H), 8.08 (s, 1H), 7.97 – 7.86 
(m, 2H), 7.72 – 7.55 (m, 3H), 7.48 – 7.39 (m, 1H), 4.34 – 4.25 (m, 2H), 1.32 (t, J = 6.9 Hz, 3H). 13C NMR (126 
MHz, DMSO-d6): δ (ppm) 165.27, 160.41, 151.78, 142.91, 132.73, 130.37, 127.04, 126.31, 123.86, 121.33, 
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118.03, 117.45, 60.45, 14.24.ESI-MS: m/z 376 [M+H+] (calc. for C17H14ClN3O3S: 375.04). EA: calc. C 54.33; 
H 3.75; N 11.18; S 8.53. Found: C 54.01; H 3.89; N 11.50; S 8.82. 
 
K706 
N-(4-acetylphenyl)-N'-(6-fluorobenzo[d]thiazol-2-yl)urea 
M.p. 308–310 °C.Yield 48 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.53 (br s, 1H), 8.00 – 7.80 (m, 3H), 
7.71 – 7.55 (m, 3H), 7.25 (t, J = 7.8 Hz, 1H), 2.53 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 196.41, 
158.37 (d, J = 235.7 Hz), 151.85, 143.91, 143.02, 132.24, 131.36, 129.67, 120.45, 117.89, 117.38, 113.96 
(d, J = 23.8 Hz), 108.26 (d, J = 27.9 Hz), 26.45. ESI-MS: m/z 330 [M+H+] (calc. for C16H12FN3O2S: 329.06). EA: 
calc. C 58.35; H 3.67; N 12.76; S 9.74. Found: C 57.97; H 3.46; N 13.18; S 10.19. 
 
K707 
N-(4-acetylphenyl)-N'-(6-chlorobenzo[d]thiazol-2-yl)urea 
M.p. 288–290 °C.Yield 38 %.1H NMR (300 MHz, DMSO-d6): δ (ppm) 9.62 (br s, 1H), 8.20 – 7.80 (m, 3H), 
7.66 (d, J = 13.9 Hz, 3H), 7.42 (d, J = 13.3 Hz, 1H), 2.53 (s, 3H). 13C NMR (75 MHz, DMSO-d6): δ (ppm) 196.40, 
160.77, 152.56, 143.05, 132.72, 131.37, 129.63, 126.99, 126.29, 121.32, 120.32, 117.93, 117.38, 26.43. 
ESI-MS: m/z 346 [M+H+] (calc. for C16H12ClN3O2S: 345.03). EA: calc. C 55.57; H 3.50; N 12.15; S 9.27. Found: 
C 55.29; H 3.88; N 12.22; S 9.49. 
 
K708 
N-{4-[3-(6-fluorobenzo[d]thiazol-2-yl)ureido]phenyl}acetamide 
M.p. 335–337 °C.Yield 85 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.88 (br s, 1H), 9.03 (br s, 1H), 7.82 
(dd, J = 8.6, 2.5 Hz, 1H), 7.69 – 7.62 (m, 1H), 7.54 (d, J = 8.9 Hz, 2H), 7.42 (d, J = 8.9 Hz, 2H), 7.23 (td, J = 
9.1, 2.7 Hz, 1H), 2.03 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 167.94, 158.27 (d, J = 239.0 Hz), 
151.64, 145.50, 134.84, 133.37, 132.52, 120.66, 119.60, 119.41, 118.52, 113.76 (d, J = 24.2 Hz), 108.05 (d, 
J = 26.8 Hz), 23.88. ESI-MS: m/z 345 [M+H+] (calc. for C16H13FN4O2S: 344.07). EA: calc. C 55.80; H 3.81; N 
16.27; S 9.31. Found: C 55.53; H 3.77; N 16.71; S 8.95. 
 
K709 
N-{4-[3-(6-chlorobenzo[d]thiazol-2-yl)ureido]phenyl}acetamide 
M.p. 335–337 °C.Yield 89 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 9.89 (br s, 1H), 9.06 (br s, 1H), 8.04 (d, 
J = 1.9 Hz, 1H), 7.64 (d, J = 8.7 Hz, 1H), 7.54 (d, J = 9.2 Hz, 2H), 7.45 – 7.36 (m, 3H), 2.03 (s, 3H). 13C NMR 
(126 MHz, DMSO-d6): δ (ppm) 167.98, 160.25, 151.69, 134.89, 133.34, 126.87, 126.19, 121.21, 120.80, 
119.60, 119.46, 23.90. ESI-MS: m/z 361 [M+H+] (calc. for C16H13ClN4O2S: 360.04). EA: calc. C 53.26; H 3.63; 
N 15.53; S 8.89. Found: C 52.95; H, 3.95; N 15.22; S 8.48. 
 
K710 
methyl-2-hydroxy-5-[3-(6-fluorobenzo[d]thiazol-2-yl)ureido]benzoate 
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M.p. 277–279 °C.Yield 81 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.28 (br s, 1H), 9.09 (br s, 1H), 8.04 
(d, J = 2.6 Hz, 1H), 7.82 (dd, J = 8.7, 2.6 Hz, 1H), 7.68 – 7.60 (m, 1H), 7.55 (dd, J = 8.9, 2.7 Hz, 1H), 7.23 (td, 
J = 9.1, 2.7 Hz, 1H), 6.98 (d, J = 9.0 Hz, 1H), 3.92 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 168.94, 
159.54, 158.29 (d, J = 239.0 Hz), 155.98, 152.11, 132.43, 130.19, 127.59, 120.38, 120.13, 117.80, 113.80 
(d, J = 24.4 Hz), 112.71, 108.09 (d, J = 26.9 Hz), 52.55. ESI-MS: m/z 362 [M+H+] (calc. for C16H12FN3O4S: 
361.05). EA: calc. C 53.18; H 3.35; N 11.63; S 8.87. Found: C 52.90; H 2.96; N 11.28; S 9.15. 
 
K711 
methyl-2-hydroxy-5-[3-(6-chlorobenzo[d]thiazol-2-yl)ureido]benzoate 
M.p. 278–280 °C.Yield 80 %.1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.29 (br s, 1H), 9.11 (br s, 1H), 8.08 – 
8.00 (m, 2H), 7.62 (d, J = 9.0 Hz, 1H), 7.55 (dd, J = 9.6, 2.3 Hz, 1H), 7.39 (dd, J = 9.0, 2.1 Hz, 1H), 6.98 (d, J = 
9.7 Hz, 1H), 3.92 (s, 3H). 13C NMR (126 MHz, DMSO-d6): δ (ppm) 168.94, 160.46, 156.00, 152.24, 147.04, 
132.88, 130.15, 127.59, 126.89, 126.20, 121.21, 120.13, 117.80, 112.69, 52.55. ESI-MS: m/z 378 [M+H+] 
(calc. for C16H12ClN3O4S: 377.02). EA: calc. C 50.87; H 3.20; N 11.12; S 8.49. Found: C 50.57; H 3.47; N 10.88; 
S, 8.52. 
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Series 2: K795-K805 
K795 
1-(6-chlorobenzo[d]thiazol-2-yl)-3-(3-chlorophenyl)urea 
M.p. 351–353 °C; Yield 83 %; 1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.07 (br s, 1H), 9.36 (br s, 1H), 8.04 
(s, 1H), 7.73 (s, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.47 – 7.27 (m, 3H), 7.10 (d, J = 7.3 Hz, 1H); 13C NMR (126 MHz, 
DMSO-d6): δ (ppm) 160.42, 152.17, 146.76, 139.99, 133.28, 132.77, 130.54, 127.04, 126.30, 122.69, 
121.32, 120.54, 118.29, 117.40; ESI-MS: m/z 338 [M+H+] (calc. for C14H9Cl2N3OS: 336.98); EA: calc. C 49.72; 
H 2.68; N12.42; S 9.48. Found: C 49.29; H 2.76; N 12.53; S 9.81. 
K796 
1-(6-chlorobenzo[d]thiazol-2-yl)-3-(4-chlorophenyl)urea 
M.p. 335–337 °C; Yield 86 %; 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.98 (br s, 1H), 9.29 (br s, 1H), 8.04 
(s, 1H), 7.63 (d, J = 8.3 Hz, 1H), 7.55 (d, J = 8.6 Hz, 2H), 7.47 – 7.27 (m, 3H); 13C NMR (126 MHz, DMSO-d6): 
δ (ppm) 160.24, 152.01, 147.33, 137.40, 132.83, 128.79, 126.99, 126.68, 126.26, 121.28, 120.48; ESI-MS: 
m/z 338 [M+H+] (calc. for C14H9Cl2N3OS: 336.98); EA: calc. C 49.72; H 2.68; N 12.42; S 9.48. Found: C 49.67; 
H 2.72; N 12.54; S 9.78. 
K797 
1-(6-chlorobenzo[d]thiazol-2-yl)-3-(3,4-dichlorophenyl)urea 
M.p. 334–336 °C; Yield 85 %; 1H NMR (300 MHz, DMSO-d6): δ (ppm) 11.25 (br s, 1H), 9.47 (br s, 1H), 8.03 
(s, 1H), 7.90 (s, 1H), 7.77 – 7.19 (m, 4H); 13C NMR (75 MHz, DMSO-d6): δ (ppm) 160.70, 152.89, 145.92, 
138.79, 132.47, 131.13, 130.66, 127.05, 126.31, 124.36, 121.35, 120.01, 119.01; ESI-MS: m/z 372 [M+H+] 
(calc. for C14H8Cl3N3OS: 370.95); EA: calc. C 45.12; H 2.16; N 11.28; S 8.60. Found: C 44.91; H 2.20; N 11.39; 
S 9.01. 
K798 
1-(2-chloro-4-hydroxyphenyl)-3-(6-chlorobenzo[d]thiazol-2-yl)urea 
M.p. 283–285 °C; Yield 71 %; 1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.29 (br s, 1H), 9.77 (br s, 1H), 8.74 
(br s, 1H), 8.05 (d, J = 2.4 Hz, 1H), 7.73 (d, J = 8.9 Hz, 1H), 7.65 (d, J = 8.6 Hz, 1H), 7.40 (dd, J = 8.6, 2.4 Hz, 
1H), 6.90 (d, J = 2.6 Hz, 1H), 6.77 (dd, J = 8.9, 2.5 Hz, 1H); 13C NMR (126 MHz, DMSO-d6): δ (ppm) 160.16, 
154.72, 151.80, 147.81, 133.14, 126.94, 126.19, 125.94, 125.42, 125.04, 121.19, 121.00, 115.61, 114.65; 
ESI-MS: m/z 354 [M+H+] (calc. for C14H9Cl2N3O2S: 352.98); EA: calc. C 47.47; H 2.56; N 11.86; S 9.05. Found: 
C 47.10; H 2.74; N 11.90; S 9.17. 
K799 
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1-(3-chloro-4-methoxyphenyl)-3-(6-chlorobenzo[d]thiazol-2-yl)urea 
M.p. 307–309 °C; Yield 93 %; 1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.00 (br s, 1H), 9.12 (br s, 1H), 8.03 
(d, J = 2.2 Hz, 1H), 7.68 (d, J = 2.4 Hz, 1H), 7.62 (d, J = 8.5 Hz, 1H), 7.39 (dd, J = 8.6, 2.2 Hz, 1H), 7.36 (dd, J 
= 8.9, 2.3 Hz, 1H), 7.11 (d, J = 9.0 Hz, 1H), 3.83 (s, 3H); 13C NMR (126 MHz, DMSO-d6): δ (ppm) 160.39, 
152.14, 150.50, 147.12, 132.84, 131.96, 126.90, 126.20, 121.23, 120.86, 120.82, 119.16, 113.04, 56.20; 
ESI-MS: m/z 368 [M+H+] (calc. for C15H11Cl2N3O2S: 366.99); EA: calc. C 48.93; H 3.01; N 11.41; S 8.71. Found: 
C 48.84; H 3.13; N 11.89; S 8.65. 
K800 
2-chloro-4-(3-(6-chlorobenzo[d]thiazol-2-yl)ureido)benzoic acid 
M.p. 324–326 °C; Yield 83 %; 1H NMR (300 MHz, DMSO-d6): δ (ppm) 12.27 (br s, 1H), 9.69 (br s, 1H), 8.05 
(d, J = 1.9 Hz, 1H), 7.92 – 7.77 (m, 2H), 7.62 (d, J = 8.6 Hz, 1H), 7.50 (dd, J = 8.6, 1.6 Hz, 1H), 7.41 (dd, J = 
8.6, 2.0 Hz, 1H); 13C NMR (75 MHz, DMSO-d6): δ (ppm) 166.00, 160.99, 152.98, 145.64, 142.54, 133.30, 
132.53, 132.40, 127.13, 126.40, 124.12, 121.43, 119.90, 119.74, 116.74; ESI-MS: m/z 382 [M+H+] (calc. for 
C15H9Cl2N3O3S: 380.97); EA: calc. C 47.14; H 2.37; N 10.99; S 8.39. Found: C 47.05; H 2.49; N 11.12; S 8.66. 
K801 
1-(6-chlorobenzo[d]thiazol-2-yl)-3-(3,5-dichloro-4-hydroxyphenyl)urea 
M.p. 300 °C decomp.; Yield 69 %; 1H NMR (300 MHz, DMSO-d6): δ (ppm) 10.61 (br s, 1H), 9.19 (br s, 1H), 
8.03 (d, J = 2.1 Hz, 1H), 7.61 (d, J = 8.6 Hz, 1H), 7.55 (s, 2H), 7.39 (dd, J = 8.6, 2.2 Hz, 1H); 13C NMR (75 MHz, 
DMSO-d6): δ (ppm) 160.83, 152.82, 146.07, 144.82, 132.58, 131.55, 126.97, 126.28, 122.42, 121.33, 
120.06, 119.41; ESI-MS: m/z 388 [M+H+] (calc. for C14H8Cl3N3O2S: 386.94); EA: calc. C 43.27; H 2.07; N 
10.81; S 8.25. Found: C 42.92; H 2.32; N 10.60; S 8.09. 
K802 
1-(6-chlorobenzo[d]thiazol-2-yl)-3-(3,5-dichloro-4-methoxyphenyl)urea 
M.p. 290 °C decomp.; Yield 90 %; 1H NMR (500 MHz, DMSO-d6): δ (ppm) 11.26 (br s, 1H), 9.39 (br s, 1H), 
8.02 (d, J = 2.0 Hz, 1H), 7.65 (s, 2H), 7.60 (d, J = 8.6 Hz, 1H), 7.40 (dd, J = 8.7, 2.0 Hz, 1H), 3.79 (s, 3H); 13C 
NMR (126 MHz, DMSO-d6): δ (ppm) 146.74, 135.97, 132.25, 128.14, 127.03, 126.31, 121.36, 119.07, 60.64; 
ESI-MS: m/z 402 [M+H+] (calc. for C15H10Cl3N3O2S: 400.96); EA: calc. C 44.74; H 2.50; N 10.44; S 7.96. Found: 
C 45.10; H 2.58; N 10.90; S 8.26. 
K803 
3-chloro-5-(3-(6-chlorobenzo[d]thiazol-2-yl)ureido)-2-hydroxybenzoic acid 
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M.p. 268–270 °C; Yield 68 %; 1H NMR (300 MHz, DMSO-d6): δ (ppm) 11.34 (br s, 1H), 9.23 (br s, 1H), 8.03 
(d, J = 2.1 Hz, 1H), 7.93 (d, J = 2.6 Hz, 1H), 7.87 (d, J = 2.7 Hz, 1H), 7.61 (d, J = 8.6 Hz, 1H), 7.39 (dd, J = 8.6, 
2.2 Hz, 1H); 13C NMR (75 MHz, DMSO-d6): δ (ppm) 171.37, 160.76, 152.64, 146.45, 132.67, 130.24, 126.97, 
126.73, 126.28, 121.30, 120.47, 119.53, 114.20; ESI-MS: m/z 398 [M+H+] (calc. for C15H9Cl2N3O4S: 396.97); 
EA: calc. C 45.24; H 2.28; N 10.55; S 8.05. Found: C 44.83; H 2.69; N 10.19; S 7.89. 
K804 
3-chloro-5-(3-(6-chlorobenzo[d]thiazol-2-yl)ureido)-2-methoxybenzoic acid 
M.p. 263.6–265 °C; Yield 60%; 1H NMR (500 MHz, DMSO-d6): δ (ppm) 12.10 (br s, 1H), 9.41 (br s, 1H), 8.04 
(d, J = 2.1 Hz, 1H), 7.89 (d, J = 2.7 Hz, 1H), 7.79 (d, J = 2.7 Hz, 1H), 7.61 (d, J = 8.6 Hz, 1H), 7.40 (dd, J = 8.6, 
2.2 Hz, 1H), 3.80 (s, 3H); 13C NMR (126 MHz, DMSO-d6): δ (ppm) 166.11, 160.84, 152.95, 149.82, 145.83, 
135.06, 132.50, 128.18, 128.02, 127.04, 126.31, 123.23, 121.34, 119.79, 61.67; ESI-MS: m/z 412 [M+H+] 
(calc. for C16H11Cl2N3O4S: 410.98); EA: calc. C 46.62; H 2.69; N 10.19; S 7.78. Found: C 46.12; H 3.08; N 9.72; 
S 7.68. 
K805 
1-(6-chlorobenzo[d]thiazol-2-yl)-3-(2,4-dihydroxyphenyl)urea 
M.p. 241–243 °C; Yield 81 %; 1H NMR (500 MHz, DMSO-d6): δ (ppm) 8.60 (br s, 1H), 8.03 (d, J = 2.1 Hz, 1H), 
7.72 – 7.53 (m, 2H), 7.38 (dd, J = 8.6, 2.1 Hz, 1H), 6.42 (d, J = 2.6 Hz, 1H), 6.21 (dd, J = 8.7, 2.5 Hz, 1H); 13C 
NMR (126 MHz, DMSO-d6): δ (ppm) 160.33, 153.99, 151.53, 148.23, 147.76, 133.19, 126.78, 126.16, 
121.37, 121.15, 120.81, 117.75, 105.63, 102.57; ESI-MS: m/z 336 [M+H+] (calc. for C14H10ClN3O3S: 335.01); 
EA: calc. C 50.08; H 3.00; N 12.52; S 9.55. Found: C 49.77; H 3.48; N 12.30; S 9.22. 
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Appendix D: NCI Diversity IV Hits 
NCI Diversity IV hit compounds, ranked on the basis of residual enzyme activity (Top 100 
compounds). 
 
Plate Well NSC Percentage Activity
Control Control 100.00
4784104 G03 120622 0.70
4774104 D09 63001 2.99
4787104 C07 339161 3.77
4774104 F02 33005 4.27
4786104 C07 50650 4.54
4785104 B05 328111 5.54
4770104 C07 17796 6.28
4787104 E08 106231 6.67
4779104 E03 55453 9.00
4788104 A11 73735 9.37
4773104 E08 19063 10.33
4789104 E08 378719 10.54
4788104 F09 8675 10.95
4772104 F08 246415 11.01
4786104 F02 622608 11.80
4771104 E05 67307 12.04
4785104 E09 105827 12.30
4770104 H10 43013 13.22
4779104 C07 88402 13.34
4779104 C08 93945 13.83
4781104 F07 327444 14.53
4783104 D05 69359 14.97
4776104 D03 148170 15.79
4775104 D04 98857 16.22
4782104 A06 9037 16.26
4772104 G03 128068 16.38
4780104 H10 201634 16.70
4775104 G05 106461 16.94
4778104 B08 34875 17.00
4788104 A03 622689 17.14
4781104 D08 343526 17.44
4783104 F07 90749 21.08
4784104 C08 191441 21.80
4787104 F03 191454 22.52
4777104 C02 311727 22.67
4786104 C10 99925 23.60
4785104 H07 371765 24.19
4787104 D03 164991 24.28
4774104 H05 45291 25.18
4779104 C10 108783 25.72
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4784104 D10 217913 26.72
4774104 H03 38042 26.88
4776104 A02 129260 26.92
4787104 D08 88600 28.68
4782104 H04 661221 29.61
4788104 H10 70931 30.00
4782104 B04 637827 30.62
4777104 A02 309971 30.80
4775104 E04 99796 31.35
4783104 A02 44750 31.98
4787104 E06 319435 32.08
4787104 A03 159566 32.33
4787104 H02 156565 32.58
4778104 C09 38007 32.78
4775104 A04 93817 33.69
4779104 A08 92937 35.37
4779104 H08 98938 35.69
4774104 E06 49652 35.85
4775104 H02 88962 35.86
4783104 C09 637359 36.48
4778104 B04 17055 37.03
4788104 E10 55691 37.46
4781104 A11 177866 37.65
4770104 A03 65248 37.69
4773104 G08 19108 37.99
4774104 C08 58907 38.12
4772104 E10 311723 38.55
4783104 A09 99657 39.53
4779104 G05 73753 41.16
4784104 D08 194308 41.91
4783104 H02 48617 43.90
4777104 F10 11624 44.33
4788104 D07 215718 45.40
4782104 E09 33570 45.43
4774104 A03 35676 45.52
4785104 B09 339316 45.54
4775104 G10 42212 46.13
4779104 D08 95909 46.30
4785104 H02 299119 46.49
4773104 G07 15372 46.58
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4775104 H09 126405 46.67
4776104 G09 277806 46.92
4783104 G02 48443 46.95
4782104 C06 12262 47.02
4789104 D03 371178 47.29
4775104 H03 92794 47.39
4777104 F05 379639 47.72
4783104 H06 83497 47.97
4787104 A04 204665 48.18
4782104 H02 400770 48.19
4780104 B07 151262 48.70
4786104 C02 379697 48.87
4772104 G09 288686 49.13
4772104 B07 169566 49.57
4776104 A10 282187 50.53
4770104 F08 29193 50.58
4777104 E09 9782 50.76
4786104 A09 84126 50.98
4789104 F07 645987 51.00
4786104 G04 11668 51.44
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Appendix E: 17β-HSD14 Rare-Codons 
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Appendix F: Publications 
 
Lukas Hroch*, Ondrej Benek*, Patrick Guest*, Laura Aitken* et al., Design, synthesis and in vitro 
evaluation of benzothiazole-based ureas as potential ABAD/17b-HSD10 modulators for Alzheimer’s 
disease treatment (2016). Bioorganic & Medicinal Chemistry Letters (*Co-First Authors). 
 
 
 
 
 
 
